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The U.S has experienced a high prevalence of substance use disorders, fueled largely by the 
recent opioid epidemic. Despite many policy efforts to increase the access to and supply of substance 
use disorder treatment, only 11% of people with a substance use disorder (SUD) access treatment. 
Among those who received SUD treatment in publicly funded facilities, nearly 70% did not complete it. 
While treatments obtained in outpatient settings (TOOS), including pharmacological and psychosocial 
therapies, are considered effective in reducing relapse and recovery outcomes for many substances, the 
use of total abstinence approaches such as self-help groups are commonplace and oftentimes free, yet 
have less evidence supporting their effectiveness when used alone compared to TOOS. As most people 
with SUD are low-income, the lack of stable treatment coverage is a critical barrier to TOOS treatment 
access and retention, making health insurance a likely key predictor of treatment outcomes. Moreover, 
Medicaid expansion, which extended health insurance coverage to millions of low-income adults and 
strengthened the SUD treatment system, should play a significant role in SUD treatment utilization.  
This study aims to examine correlates of access to and outcomes of outpatient SUD treatment. 
Chapter 2: We examined the associations of health insurance coverage and any SUD treatment 
utilization, as well as the use of TOOS versus the use of self-help only. This study used a non-
experimental design that leveraged multiple years of the 2010-2018 National Survey on Drug Use and 
Health. The final analytic samples of people with any SUD, AUD, and OUD were 42,155, 32,352, and 
4,389, respectively. We found that Medicaid insurance coverage was positively associated with any 
SUD treatment utilization, as well as with the use of TOOS treatment across the any SUD and any OUD 
populations. Our findings suggested that those who were uninsured tended to use self-help only as a 







Chapter 3: To investigate the role of Medicaid expansion on referrals to OUD treatment, we used 
a difference- in- difference (DID) with two-way fixed effect (2WFE) approaches to examine the 
associations of Medicaid expansion and referral sources, particularly healthcare provider referrals. Eight 
years of Treatment Episode Data Set- Discharge (TEDS-D) data spanning from 2010 to 2017 were used 
to explore the associations. Our final analysis sample included 382,609 discharges. The findings 
indicated that Medicaid expansion was positively associated with the likelihood of being referred by 
healthcare providers to outpatient treatment for OUD. The findings also suggest that Medicaid 
expansion has the potential to improve timely and effective access to evidence-based outpatient 
treatment for OUD via increasing access to healthcare providers.   
Chapter 4: Beyond issues of access, treatment retention is a key step toward improving long-term 
OUD treatment outcomes. Given that Medicaid expansion under the Affordable Care Act (ACA) should 
play an important role in substance use treatment system improvement, this study used a natural 
experiment to explore the associations of Medicaid expansion under the ACA with OUD treatment 
completion and retention in outpatient settings. Similar to study 2, we employed DID with 2WFE to 
evaluate the effect of Medicaid expansion, using the 2010-2017 TEDS-D data. Our study indicated that 
Medicaid expansion was positively associated with treatment retention for those who were on 
medication for OUD, yet negatively associated with treatment completion in outpatient treatment 
settings. Further research should focus on better understanding the mechanisms by which Medicaid 






Chapter 1 Introduction 
 
The prevalence of substance use disorders (SUD) is a pressing public health concern in the U.S, 
with approximately 20 million people suffering from such disorders.1 According to the Centers for 
Disease Control and Prevention, more than 70,000 people died in 2017 because of drug overdoses, with 
opioid overdoses accounting for more than 42,000 deaths.2 While costs related to SUD in general are 
estimated to be approximately 440 billion dollars annually,  those associated with opioid use disorder 
(OUD) in particular have been estimated to reach over $92 billion (in 2014 U.S dollars).3,4  
Substance use disorders have previously been considered acute medical conditions that were 
addressed through brief treatment episodes aimed at prompting patients to abstain from the substance 
entirely,5  yet relapse rates were high, at more than 80%.6 More recent thinking among an increasing 
number of providers, patients, and medical societies considers SUD a chronic disease,7 and the 
perspective on treatment has changed accordingly. Understanding substance use disorders as a treatable 
chronic disease has made room for the emergence of approaches that rely more on the health care 
system to effectively for manage this disease over an extended period of time.8   
In contrast to treatments obtained in outpatient settings (TOOS), total abstinence approaches 
remain common. The latter is largely represented by self-help groups, which on their own have less 
documented evidence-based support for specific substances (e.g., opioids, alcohol), and are associated 
with high relapse rates and poor recovery outcomes (e.g.,  health status, quality of life).5 TOOS, most 
notably those that use medications for opioid use disorder (MOUD), have been shown to be an effective 
intervention in reducing relapse, opioid use-associated transmissions of infectious diseases, and 
improved recovery outcomes.9,10 Even though there is growing attention among policymakers to 
increase access to SUD treatment, critical gaps remain with  only 11% of people with SUD receiving 






Barriers to substance treatment utilization include lack of stable financial support to participate 
and remain in the substance use treatments (e.g., health insurance coverage), limited availability of 
providers willing to prescribe medication for OUD (MOUD; e.g., methadone, buprenorphine), and 
stigma  toward substance use disorders and treatment.12 In the U.S, where a significant proportion of 
those with OUD have lower income (67%),11 lacking health insurance coverage can be a critical barrier. 
However, little is known about the association between health insurance and substance treatment 
utilization, and no previous study has examined the role of health insurance in accessing TOOS vs. the 
use of total abstinence approaches alone. The extent to which individuals with SUD use self-help only 
groups as a substitute for TOOS when they are uninsured is unknown. Given the importance of evidence 
based TOOS including pharmacological and psychological therapies for improving SUD recovery 
outcomes, studies exploring potential determinants of treatment access such as health insurance, are 
needed.  
The question of whether accessed treatment is TOOS is also critically important. Although there 
remains disagreement about how to define treatment success, treatment completion and treatment 
retention are generally recognized as key indicators of SUD treatment success.13,14 For example, the 
evidence shows that the better treatment outcomes are achieved when patients with OUD, alcohol use 
disorder (AUD) stay longer in the treatment,7 length of stay in the treatment for OUD, AUD is 
increasingly recognized as an important indicator for the treatment success.  
Among many factors affecting treatment access and outcomes, Medicaid expansion, insurance 
coverage and provider referral source are important determinants.15,16 Medicaid expansion should play a 
significant role in treatment participation and retention by improving Medicaid insurance coverage. By 
lowering out-of-pocket payments from patients, health insurance helps patients access long-term 






and effective treatment in healthcare settings, as well as a strong predictor of treatment success.19,20 
However, while many studies have explored the role of Medicaid expansion in access to health care in 
general, far fewer studies have examined the role of insurance coverage in access to care for SUD 
specifically, and there has been a lack of evidence on importance of coverage on substance treatment 
outcomes.  
To address these crucial gaps, this dissertation focuses on the correlates of access and outcomes 
of evidence-based treatments for SUD. The long-term purpose of this project is to inform policy efforts 
to increase access to and improve outcomes of TOOS for SUD in general, and for low-income 
populations specifically. The study aims are: 
Aim 1. To examine associations of health insurance coverage and any SUD treatment utilization as well 
as TOOS versus self-help only, using 2010-2018 National Surveys on Drug Use and Health (NSDUH) 
Hypothesis1A: Having any health insurance is positively associated with access to any SUD 
treatment.   
Hypothesis1B: Those with Medicaid insurance are more likely to access any SUD treatment 
compared to those who are uninsured. 
Hypothesis1C: Individuals with Medicaid insurance are more likely than those who are uninsured 
to use TOOS whereas those who are uninsured are more likely to use self-help groups only. 
Aim 2. To explore associations between Medicaid expansion and referral sources to outpatient treatment 
for OUD, including healthcare provider referral. 
Hypothesis2:  Medicaid expansion increases the likelihood of being referred to outpatient 








Aim 3.1. To examine associations between Medicaid expansion and OUD treatment completion  
Hypothesis3.1: Medicaid expansion increases the likelihood of completing OUD treatment in 
expansion states compared to non-expansion states.  
Aim 3.2. To examine associations between Medicaid expansion and OUD patients’ length of 
stay in treatment.  
Hypothesis3.2: Medicaid expansion increases the likelihood of longer stay in non-intensive 
outpatient treatment for OUD in expansion states compared to non-expansion states. 
 
Given the importance of improving access to evidence-based treatments for reducing the public 
health burden of SUD, studies exploring factors affecting the utilization as well as treatment outcomes 
of TOOS are needed. Results from study 1 are expected to contribute to our understanding of the role of 
insurance coverage in SUD treatment utilization patterns, including TOOS. Study 2 explored the role of 
Medicaid expansion in healthcare provider referral source. The findings are expected to contribute to our 
understanding of correlate of healthcare provider source, which is considered a key factor in timely, 
effective SUD treatment access, and may help to inform coverage expansions to ensure substance use 
treatment access and success. Study 3 explored the role of Medicaid expansion on outpatient treatment 
for OUD. Studies 2 and 3 contribute to solving the endogeneity of health insurance by using a quasi-
experimental difference-in-differences design (DID) to explore the role of Medicaid expansion in both 
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Figure 1 shows the theoretical associations between factors affecting SUD treatments access as 
well the treatment outcomes. We applied a modified Donabedian model to describe the associations 
between structure, process, and outcomes.  
Expansions in coverage for SUD treatment 
Medicaid has been at the forefront of reforming the delivery system for SUD treatment both 
indirectly through Affordable Care Act-related expansions in the number of people eligible for 
Medicaid, and directly via Section 1115 demonstration waivers intended to increase access to SUD 
treatment. By enabling states to extend Medicaid eligibility to low-income adults, Medicaid expansion 
has helped increase insurance coverage to many people with SUD. In addition, states are able to apply to 
the Centers for Medicare and Medicaid Services for the Section 1115 demonstration waivers to allow 
them to use federal resources to offset costs associated with changing how SUD treatment services are 
covered and how providers are reimbursed. By lowering the out-of-pocket expenses faced by patients 
and increasing the supply of SUD treatment providers, such Medicaid policies increase access to SUD 
treatment among low-income individuals. Previous studies found that Medicaid expansion under the 
ACA has helped increase coverage among low-income adults with SUD.21,22 In addition, Medicaid 
expansions resulted in substantial increases in the use of evidence-based pharmacological treatment for 
OUD,23 including increased availability of medications for OUD including methadone and 
buprenorphine.24 Specifically, admissions to substance use treatment among Medicaid beneficiaries 
increased 113% as a result of the expansion without crowding out admissions from individuals with 
other insurance.23 Other evidence has demonstrated that ACA-related Medicaid coverage expansions 
improved rates of SUD treatment utilization among those with OUD.25 






Demographic characteristics affecting SUD treatment access include age, gender, race/ethnicity, 
marital status, educational attainment, and income.11,26 Specifically, adolescents, African Americans, 
and Asian Americans were historically less likely to use opioid treatment.11 Romo and colleagues 
identified that being older than age 35, not being in the labor force and never having been married were 
associated with increased odds of receiving SUD treatment while living in a non-metropolitan county, 
and being in fair/poor health were associated with decreased odds of receiving SUD treatment.26 
Furthermore, many studies examined the associations of demographic characteristics across different 
types of substance use treatment.27–29 One study examined gender differences in inpatient, outpatient, 
and self-help services and found that women tended to use more outpatient treatment services than 
men.27 For inpatient treatment, African Americans were more likely to delay treatment compared to 
whites. Another study found that African Americans with heavy drinking or illicit drug use disorders 
had an increased likelihood of unmet need in substance treatment.28 Prior work suggested that 
individuals with OUD in rural areas were more likely to have difficulty accessing substance use 
treatment.29  
The relationship between SUD treatment utilization and health outcome  
Increasing treatment access, particularly to evidence-based treatment for SUD, is expected to 
increase health outcomes. This is because evidence-based treatments for SUD are effective in helping 
patients medically manage their withdrawal symptoms (as is the case with MOUD), allowing them to 
feel well enough to engage in social and economic activities.30,31 For instance, MOUD alone or 
combined with psychosocial therapies, has been shown to be effective in reducing opioid-related 
withdrawals and mitigating transmission of infectious diseases associated with opioid use.32,33 






Not having health insurance is likely a critical barrier to accessing SUD treatment, with 
insufficient treatment capacity and the stigma of addiction treatment posing additional barriers.17,34 By 
lowering the out-of-pocket costs faced by the consumers, increasing health insurance coverage is 
expected to improve SUD treatment access, particularly among those with low-incomes. Previous 
studies on health insurance coverage and service utilization showed a positive correlation between 
having insurance and SUD treatment access.21,25 Beyond the importance of health insurance in accessing 
any SUD treatment, insurance may relate to access to different types of SUD treatment, specifically 
whether or not it is TOOS or the only use of self-help. Health insurance, particularly Medicaid, is 
expected to increase the use of a more evidence-based approach for OUD (e.g., methadone, 
buprenorphine) over total abstinence approaches such as self-help groups (i.e., Narcotic Anonymous) 
though no evidence exists to date to support this.  
While we did not look at the state characteristics in this study (state identifiers are not available 
in the public-use version of the NSDUH), we used calendar year to control for year fixed effects, 
including changes in SUD prevalence across time. Population characteristics including demographic 
characteristics (e.g., age, gender, race/ethnicity, marital status, education, and income), and needs (e.g., 
SUD, mental health status) are factors affecting the relationship between coverage and treatment access, 
and were accounted for in this study. 
Medicaid expansion under the ACA and referral sources (Study 2) 
Medicaid has been at the forefront of reforming the delivery system for SUD treatment.  It plays 
a significant role in SUD treatment, as it pays for the majority of treatment for individuals with SUD 
nationwide.35 Similar to other recent SUD treatment policies, Medicaid programs across the country 
have emphasized the role of TOOS that include pharmacological therapy sometimes combined with 






Medicaid expansion has helped increase insurance coverage to many people with SUD. Previous studies 
showed the positive effect of Medicaid expansion on increased health insurance coverages, as well as on 
the provision and utilization of medication assisted treatment for OUD (e.g., buprenorphine). 21,24 
Referral source is a key factor in timely and effective treatment as well as a strong predictor of 
treatment success,19,20 likely by influencing access to SUD treatments. For example, previous studies 
showed positive associations of employer and criminal justice referrals with successful treatment 
completion, while self-referrals and healthcare referrals were negatively associated with successful 
completion.16 However, the recent implementation of SUD facilitated policies that emphasize outpatient 
treatment should lead to an increasing role of the healthcare referral system in treatment success. In 
other words, Medicaid expansion is expected to increase referrals to outpatient treatment from 
healthcare providers, which in turn will increase treatment access, as well as increase treatment success.   
The associations of Medicaid expansion and referral sources should also be controlled for 
individual level characteristics that affect a likelihood of being referred by a specific referral source 
(e.g., self-referrals, healthcare provider referrals, other institutional referrals, court/criminal referral). 
These include demographic characteristics (e.g., age, gender, race/ethnicity, education, 
employment)20,36,37 and other characteristics including frequency of opioid use, homeless status, 
psychiatric comorbidities, and poly substance use.20,36,38 
Medicaid expansion under the ACA and SUD treatment (Study 3).  
Like other recent SUD treatment policies, Medicaid programs across the country have 
emphasized the role of outpatient treatment that include pharmacological therapy sometimes combined 
with psychological therapy.8 This emphasis should lead to an increase in the role of the healthcare 






study showed that Medicaid expansion had a positive impact on increasing the supply and utilization of 
medication-assisted treatment (MAT) for OUD.24 
Evidence also showed that demographic characteristics including age, gender, race/ethnicity, 
education attainment, and employment status affected treatment completion and retention.39 
Specifically, younger age, male, African Americans were negatively associated with opioid treatment 
retention.39,40 In addition, at least two studies on buprenorphine treatment retention reported that being 
employed was positively associated with treatment retention.40,41 A higher level of education was found 
to be positively associated with opioid treatment retention.42,43 Poly substance use, homelessness, 
arrests/incarceration, and comorbidities were found to be negatively associated with treatment 
retention.44  
The conceptual framework above offers a visual description of our expectations regarding 
correlates of access to SUD treatment as well as treatment outcomes. This project provides needed 
insights into the key pathways that are described in the conceptual framework by examining the roles of 
health insurance coverage, and Medicaid expansion on different types of SUD treatment utilization and 
outcomes, as well as on healthcare referral source. Specifically, study 1 examined associations of health 
insurance coverage and SUD treatment utilization, as well as TOOS versus the use of self-help group 
only. Study 2 examined influence of Medicaid expansion on referral sources, especially healthcare 
provider referrals. Study 3 explored the role of Medicaid expansion in substance treatment outcomes, 










Given the importance of evidence-based treatments for reducing the public health burden of 
SUD, studies exploring the role of health insurance coverage, particularly Medicaid, in access to 
different treatment pathways are needed. This study will examine the associations of health insurance 
coverages with any SUD treatment, as well as the use of Treatment Obtained in Outpatient Setting 
(TOOS) versus the use of self-help groups alone.  
This study used a non-experimental design combining multiple waves of a nationally 
representative cross-sectional survey. Data from the 2010 to 2018 National Surveys on Drug Use and 
Health (NSDUH) were used to explore associations between health insurance coverage and any SUD 
treatment utilization as well as use of evidence-based treatment. The final analytic samples were people 
aged 18 to 64 with SUD (42,155), AUD (32,352), and OUD (4,389). All analyses used survey weights 
to be representative of the U.S. population and accounted for the NSDUH’s complex survey design. 
Logistic regressions were used to examine the adjusted associations, controlling for predisposing, 
enabling characteristics (i.e., health insurance), need (health status and recent major depressive episode), 
and post Affordable Care Act.  
Compared with no insurance, people with Medicaid insurance were more likely to use any past 
year substance use treatment among those with SUD (AOR 2.1, 95% CI: 1.8-2.4), those with any AUD 
(AOR 1.9, 95% CI:1.5-2.3), and those with any OUD (AOR 2.2, 95% CI: 1.6-2.9). For the any SUD and 
any AUD populations, private health insurance was negatively associated with the past year use of any 
substance use treatment, compared with no insurance. Compared with no insurance, those with Medicaid 
insurance were more likely to use TOOS versus self-help only across the any SUD, any AUD, and any 





more likely to use TOOS only (vs. self-help only) (AOR 2.0, 95% CI: 1.3-3.0) and any TOOS (vs. self-
help only) (AOR 2.1, 95% CI: 1.4-2.9).  
In conclusion, this study shows the important role of Medicaid insurance coverage on not only 
any SUD treatment access but also the use of TOOS approach. The findings also show that those with 
SUD or OUD who were uninsured tended to use a self-help only approach as the substitute to outpatient 
medical treatment approach. Intervention programs should target those groups and refer them to 









































There is a critical gap between the need for and access to SUD treatment in the U.S. According 
to the National Survey on Drug Use and Health (NSDUH) estimates in 2017, more than 20 million 
people had substance use disorder (SUD); however, only 11% of people with SUD received any 
treatment in the past year.1 With regards to opioids, there were more than 2 million individuals with 
OUD,1 yet only 1 in 5 people with OUD received any treatment.11  
Lack of health insurance coverage is one of the primary barriers to SUD treatment utilization,17 
others include insufficient treatment capacity34 and stigmatization towards substance use disorders and 
treatment.45 In the U.S where a significant proportion of people with SUD have low income, including 
67% of those with OUD,11 lack of health insurance coverage is a significant problem.18 By lowering the 
out of pocket payment faced by patients, increasing health insurance coverage is expected to improve 
the receipt of any SUD treatment, particularly for those with low-income.17  
There are few studies examining the role of health insurance in SUD treatment access in general 
and OUD treatment access in particular. What we do know from the studies that exist is that improving 
insurance coverage, as a result of Medicaid expansion under the Affordable Care Act (ACA), increases 
SUD treatment utilization.21,25 Wen and co-authors found that Medicaid expansion improved access to 
behavioral health care among low-income individuals with SUD.21 McKenna’s study more specifically 
suggests that the ACA improved rates of SUD treatment utilization among those with OUD.25  Further, 
one study pointed out that a 5% increase in private insurance was associated with a 7% increase in the 
probability of receiving medication for SUD ,whereas 5% increase in Medicaid was associated with a 





There have been various treatments for SUD, including total abstinence-based approaches (e.g., 
the sole use of self-help groups) and Treatments Obtained in Outpatient Settings (TOOS) approaches. 
The total abstinence approach, which is largely represented by the use of self-help groups only has been 
the most commonly used treatment in the U.S.5,11,47  Self-help groups, including Alcohol Anonymous, 
Narcotics Anonymous, and other 12 step programs, are intended to help individuals with SUD to abstain 
from drugs and alcohol.5 This type of treatment is normally free of charge and widely available in the 
U.S.5  However, dropout and nonattendance rates from the sole use of this approach are high.6 
Humphreys and colleagues pointed out that approximately half of former substance use treatment 
patients had not attended a single 12-step meeting three months after discharge from an inpatient stay.48  
However, the evidence on the effectiveness of this approach when combined with TOOS is more 
positive. 5,48,49  TOOS, particularly those that use medication for OUD (MOUD; e.g., methadone, 
buprenorphine, and naltrexone) have been shown to be an effective intervention32 by increasing 
abstinence from illegal opioids and improving other recovery outcomes.9,10,50 The literature suggests 
TOOS approaches effectively reduce heavy drinking and opioid withdrawal symptoms while increasing 
treatment retention,51 and are related to significant declines in overall healthcare costs.52 However, one 
significant barrier to the access of these evidence-based treatments can be their costs to patients.53,54 
Notably, a prior study showed that lack of insurance posed financial barriers to MOUD access such as 
buprenorphine treatment.55,56   
Studies on health insurance and the utilization of different types of treatments, particularly self-
help groups and TOOS approaches, remain limited. One study pointed out a significant inverse 
association between health insurance and non-medical sector use of self-help. Uninsured individuals had 
a higher likelihood of receiving services from self-help groups than those with private insurance.57 





the 1999 National Household Survey on Drug Abuse. Other evidence shows that among buprenorphine 
patients, sobriety over time was correlated with having private insurance coverage and whether patients 
attended self-help meetings.58 While there has been evidence of  effectiveness in the use of 
pharmacological therapy for OUD, such as methadone, patients using pharmacotherapy have reported 
not feeling welcome at traditional self-help groups that are designed to achieve total abstinence from 
narcotics and other drugs due to the fact that peers in self-help groups perceived methadone as continued 
narcotic use.59  
Given the importance of evidence-based treatments for reducing the public health burden of 
SUD, studies exploring the role of health insurance coverage, particularly Medicaid, in access to 






Conceptual model  
Figure 2. Health insurance and utilization of any past year substance use treatment as well as TOOS versus self-help approaches 
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This study’s theoretical framework was adapted from Andersen’s healthcare utilization model.60 
This framework describes correlations of environment factors, population characteristics and health 
behaviors, and severity (e.g., comorbid SUD)  that affect receipt of health services, particularly for 
vulnerable populations such as substance users.61,62 “Environment factors”, which include substance-
use-related coverage policies (e.g., Medicaid expansion, 1115 Demonstration Waivers) increase 
"enabling resources" by increasing who is covered, what SUD treatment services are covered, and how 
much of these services is covered.21,22,24  As Medicaid programs are “means-tested programs”, many 
"predisposing characteristics" including age, gender, marital status, and income, can determine 
eligibility for public coverage as an enabling resource.11,26  Enabling resources in general and health 
insurance specifically, influence health behaviors, namely increasing utilization of any SUD  treatment 
as well as whether that treatment primarily relies on TOOS versus self-help only.   
This study examined the associations of health insurance coverages with any SUD treatment, as 
well as the use of TOOS treatment versus the use of self-help groups alone. Given that a majority of 
people with SUD are low-income, public insurance like Medicaid insurance under ACA implementation 
should play an important role. This study was particularly looking at the role of Medicaid insurance in 
the use of TOOS versus self-help only.  
Hypotheses 
 
H1: Those with Medicaid insurance will be more likely to access any SUD treatment compared to those 
who are uninsured 
H2: Individuals with Medicaid insurance will be more likely than those who are uninsured to use TOOS, 
whereas those who are uninsured will be more likely to use self-help groups only.  
The study is expected to contribute to the understanding of those factors that affect the utilization 





associated with the use of outpatient treatment compared to the use of self-help only may suggest ways 
to target certain types of patients, for example, those who are uninsured and only used self-help for 
referral to evidence-based medication assisted treatment.   
Methods 
 
Overview of design and data 
 
This study used a non-experimental design combining multiple waves of a nationally 
representative cross-sectional survey. Data from the 2010 to 2018 National Surveys on Drug Use and 
Health (NSDUH) were used to explore associations between health insurance coverage and any SUD 
treatment utilization as well as the use of evidence-based treatment. The NSDUH is a major source of 
national estimates of SUD and treatment use among civilian, non-institutionalized persons aged ≥ 12.63 
It has richly detailed data on substance use and mental health that enabled us to include several 
measurements of SUD diagnosis, treatment, and health insurance coverage, as well as an extensive set of 
controls for predisposing characteristics (e.g., age, gender, race/ethnicity).  
NSDUH included approximately 500,000 persons aged ≥ 12 from 2010 to 2018 (i.e., roughly 
55,000-58,000 respondents per year) who are residents of households and non-institutionalized from 50 
states and the District of Columbia. We restricted our analysis to people aged 18 to 64 years old 
(N=338,811) to focus on working-age adults, who are most likely to be uninsured. Using multiple waves 
of NSDUH data allows for a large sample size to increase statistical power to detect differences among 
otherwise rare events and populations (e.g., detecting differences in OUD treatment across insurance 
status). The average survey response rate for the nine years of NSDUH data included in this study was 







SUD population. Respondents who self-reported either alcohol or any type of illegal drug use in 
the past year were first defined as substance users in the NSDUH. These respondents were then assessed 
on abuse and dependence symptoms based on the Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition (DSM-IV) criteria.64 The classification of substance abuse was based on an 
affirmative response to one of four questions which were derived from the DSM-IV criteria. 
Classification of dependence on a substance was based on a positive response to three out of seven 
questions matching criteria from the DSM-IV. Respondents were defined as having a SUD if they were 
defined as having substance abuse or dependence. The final analytic sample of people with SUD aged 
18 to 64 years old was 42,155 individuals.  
AUD population. Respondents who used alcohol in the past year were assessed on dependence 
and abuse following the DSM-IV criteria. Alcohol dependence or abuse is defined as alcohol use 
disorder (AUD). The final analytic sample of people with AUD aged 18 to 64 years old was 32,352 
individuals. 
OUD population. Respondents who self-reported any non-medical prescription opioid use or 
heroin use during the past year were first defined as opioid users. There have been changes in the 
questions and methods asking about prescription opioid use in NSDUH beginning in 2015. From 2010 
to 2014, non-medical prescription opioid use was defined as the use of prescription pain relievers in the 
NSDUH. Since 2015, non-medical prescription opioid use was defined as the use that was "not directed 
by a doctor".65 Respondents, who reported either non-medical opioid use or heroin use in the past year, 
were assessed for either abuse or dependence symptoms, based on DSM-IV criteria. The classification 
of opioid abuse was based on an affirmative response to one of four questions derived from the DSM-IV 
criteria. Classification of opioid dependence was based on an affirmative response to three out of seven 





use disorders if they were defined either having prescription abuse or dependence. Respondents were 
defined as having heroin use disorder (HUD) if they were defined as either having heroin abuse or 
dependence. Both prescription OUD and HUD were combined into a more comprehensive OUD 
category.  Even though there has been no change in the questions defining abuse or dependence 
throughout the study years 2010-2018, questions on screening prescription opioid use and misuse did 
change (though both indicate the use of prescription not for medical purposes). We conducted a 
sensitivity analysis that examined several measures related to OUD including past 12- month 
prescription opioid abuse or dependence, and past 12- month heroin abuse or dependence (Findings 
were presented in the sensitivity analysis result).  Importantly, categorizations of OUD or SUD indicate 
the need for treatment.11,64 The final analytic sample of people with OUD aged 18 to 64 years old was 
4,389 individuals. 
Measures 
SUD treatment utilization (health behaviors) 
 
Any SUD treatment utilization. NSDUH respondents who used alcohol or illicit drugs in their 
lifetime were asked whether they received any substance use treatment, which refers to treatment or 
counseling for alcohol, drug use, or medical problems associated with the use of alcohol or illicit drugs.  
Those who reported that they received treatment in their lifetime were asked whether they received 
treatment in the past 12 months, with the question " During the past 12 months, that is since [DATE 
FILL] have you received treatment or counseling for your use of alcohol or any drug, not counting 
cigarettes?”.65 The any SUD treatment variable was an indicator for the receipt of any treatment or 
counseling substance use during the past 12 months. The variable received the value of 1 if respondents 





Any OUD treatment utilization. Any opioid treatment was defined as the receipt of treatment or 
counseling for the respondent's use of prescription opioids or heroin in the past 12 months. The self-
reported opioid treatment utilization variable had been used by Wu and co-authors in their study of 
treatment utilization among people with OUD in the U.S.11  
Use of TOOS treatment for SUD.  The second set of study outcomes focused on the type of SUD 
treatment specifying whether that treatment was self-help or TOOS to treat SUD, such as MOUD. 
NSDUH collected information on treatment in specific facilities including hospital, rehabilitation 
facilities, mental health centers, emergency rooms, private doctor's offices, prisons or jails, or self–help 
groups. Self-help treatment was defined as any past year use of self-help groups (e.g., Alcoholics 
Anonymous (AA) or Narcotics Anonymous (NA)) to treat SUD.65  TOOS to treat SUD was defined as 
past year use of outpatient rehabilitation center, mental health center, or private doctor’s office. We 
constructed binary variables for (1) TOOS only versus self-help only, and (2) any TOOS versus self-
help only. The first variable had the value of 1 if respondents used TOOS and did not use self-help in the 
past year, and 0 if they only used self-help without the use of TOOS; those who used both were not 
included.  The second variable had the value of 1 if respondents used any TOOS (i.e., the only use of 
TOOS, both TOOS and self-help), and 0 if respondents used self-help only (no TOOS). 
Health insurance (enabling resources) 
The primary regressors of interest are types of current health insurance coverage. NSDUH allows 
health insurance to be categorized into 5 types - no insurance, Medicare, Medicaid, private insurance, 
and other insurance. With regard to dual-eligibles (i.e., those with more than one type of insurance), we 
used the insurance type that was considered to be the first payer. For example, those covered by 






Post ACA  
While survey years could pick up coverage expansion policies including the implementation of 
the ACA since 2014, we chose post ACA as a covariate variable because of the roles of ACA 
implementation in increasing insurance coverage66 and affecting substance use treatment through 
defining SUD as one of ten essential health benefits.67  The post ACA variable receives the value of 1 if 
the years were from 2015 to 2018, and 0 if the years were from 2010 to 2014.  
Covariates (predisposing characteristics and needs) 
 
Associations of health insurance and utilization of SUD treatment were controlled for education 
(1 if high school graduate and 0 if less than high school), total family income (less than $50,000; 
$50,000-$75,000, and more than $75,000), and other sociodemographic variables including age (18-25, 
26-34, 35-49, 50-64), race/ethnicity (non-Hispanic White, non-Hispanic African American, Hispanic, 
Asian and other), gender (male and female), and urbanicity (large metropolitan, small metropolitan, and 
non-metropolitan) . Education and income were included in the model as they were socioeconomic 
status affecting both if treatment received and the type of treatment received.26,68 Urbanicity or living 
area was included because it associated with the use of substance treatment utilization.26  
The associations were controlled for general health (good health, poor health) and mental health 
status. Past year major depressive episode (MDE) was one psychological factor that was included in the 
conceptual models as a “need” construct that predicts SUD treatment utilization. MDE was a correlate of 
treatment use given the association between major depression and non-medical opioid use.69 Assessment 
of MDE from NSDUH is based on DSM-IV criteria. MDE is defined if participants experienced either 
depressed mood, loss of interest, and four symptoms including sleep, eating problems, concentration, 







All analyses used survey weights to be representative of the U.S. population, and accounted for 
the NSDUH’s complex survey design. Unadjusted associations between SUD treatment and insurance 
status were examined using statistical Z tests. Logistic regressions were used to examine the adjusted 
associations between these measures controlling for predisposing characteristics (age, race/ethnicity, 
education, income, urbanicity), enabling characteristics (health insurance), need (health status and recent 
MDE), and post ACA.   
Specifically, the following regression model was used to fit to the data: 
Yi = β0 + β1 insurancei +β2 agei + β3 genderi + β4 racei + β5educationi + β6incomei + β7 urbanicityi + 
β8healthi + β9MDEi + β10 postACAt + εi (1) 
Yi are the outcomes of interest including any SUD treatment, TOOS only vs. self-help only, any 
TOOS vs. self-help only. The independent variable of interest is insurance. The covariates include age, 
gender, race, urbanicity, income, health, MDE. Logistic regressions were used to examine the adjusted 
associations between health insurance types and SUD treatment utilization. First, we looked at the 
adjusted associations between insurance types and any substance use treatment in the past year. Next, 
we restricted to those who used any substance treatment in the past year and examined the adjusted 
associations between insurance types and any/only TOOS approach (vs. self-help only).  
Sensitivity analysis 
In order to take into account variations in ACA implementation effects on different types of 
health insurance coverage, we ran a sensitivity analysis replacing the covariate post ACA by interactions 
between the post ACA and types of health insurance coverage. This interaction tested whether the ACA 





treatment utilization. For specific types of insurance coverage, the associations between insurance and 
substance use treatment are moderated by the ACA-related policy changes (e.g., Medicaid expansion, 
essential health benefits for private insurance).  
Importantly, type of insurance might be a function of unobserved health status, leading to 
endogeneity bias.70,71This means, for example, that we do not know whether people who anticipate poor 
health purchase more insurance or whether the increased quantity of SUD services observed is because 
insurance lowers the cost of healthcare for patients.  A previous study showed that the magnitude of the 
insurance effect on the utilization of healthcare is bigger when the endogeneity of insurance status was 
considered.70 Thus, ignoring endogeneity was expected to underestimate the association of insurance 
coverage on utilization in my models. In an attempt to resolve this issue, a sensitivity test was performed 
on the results from the model above by using instrumental variables (IV) and selection models. A few 
previous studies used an IV approach to handle the endogeneity of health insurance.70,71 Meer and Rosen 
used an individual’s self-employment status as an IV of health insurance in exploring the association of 
coverage with health care utilization. They found a positive and statistically significant effect of 
insurance on healthcare utilization using the IV model.70 We constructed past year self-employment 
status based on two questions: “Have you been self-employed at any time during the past 12 months?” 
with possible answers of “ Yes or No”;  and “ How many different employers including yourself,  have 
you had in the past 12 months” with possible answers “ One, two, three, four or more”.  The self-
employment variable was binary variable, receiving the value of 1 if the respondents responded “Yes” to 
the first question on self-employment status any time last year and only had one employer in the past 12 
months; and 0 otherwise.  We ran the IV model using self-employment as an instrument for health 
insurance and test the sensitivity of the main results to this alternative specification. Additionally, in 





more likely to purchase or enrol in health insurance (or more generous coverage), we restricted our 
analysis to those who reported they had an alcohol problem or opioid problem for less than a year as we 
might expect these individuals to be less likely to enroll in coverage to seek treatment. Finally, we also 
examined the associations among different SUD subgroups (i.e., any substance abuse, substance 
dependence, alcohol abuse, alcohol dependence, opioid abuse, opioid dependence) to examine the 





Sample characteristics of people with SUD, any AUD, any OUD 
Table 1-2 shows characteristics of the any SUD population (n=42,155) as well as the any AUD 
(n=32,352) and any OUD (n=4,389) sub-populations. Participants’ ages range from 18 to 64 years old. 
For any SUD population, about 11% received any substance use treatment in the past year. Among those 
who received treatment, about 58% of them accessed TOOS only (vs. 42% used self-help only), whereas 
about 80% used any TOOS (vs. 20% used self-help only). Percentages of people with any AUD and any 
OUD who accessed past year substance use treatment were 9% and 36%, respectively. Among those 
who used SUD treatment, those using any TOOS for any AUD and any OUD were 76% and 88 %, 
respectively. Further, 50% of respondents with any AUD used TOOS only, and 67% of any OUD 
population reported TOOS only treatment utilization. 
Most people with SUD (59%) had private insurance, about 15% had Medicaid insurance, while 
more than 20% were uninsured. A majority of people with SUD were under 35 years old (>50%), male 
(64%), non-Hispanic White (66%), completed high school or more (86%), had a total annual family 
income less than $50,000 (55%), and lived in a large metropolitan area (57%). About 85% of people 





with the SUD population, most people with any AUD or any OUD were covered by private insurance, 
followed by Medicaid, and about one-fifth were uninsured.  Also, like those with SUD, a majority of the 
respondents with any AUD or any OUD were under 35 years old, non-Hispanic White, completed high 
school or more, had total annual family income less than $50,000, and lived in a large metropolitan area. 
Almost three-fourths of people with any OUD reported fair/poor health, and one-third suffered from 
MDE.  
Unadjusted associations between health insurance and substance use treatment utilization 
Figure 3 shows unadjusted associations between the type of coverage and any use of substance 
use treatment in the past year, as well as the utilization of TOOS (vs. self-help only) for the SUD 
population, any AUD, and any OUD sub-populations. Compared to those who were uninsured, people 
with Medicaid coverage had a higher percentage of using any substance use treatment in the past year 
(11.7% vs. 21.6%, p<0.001), TOOS only (49.7% vs. 69.4%, p<0.001), and any TOOS (74.6% vs. 
87.0%, p<0.001). Similarly, for any AUD and any OUD sub-populations, people with Medicaid 
coverage were significantly more likely to report substance use treatment, as well as TOOS approach, 
whereas people with no insurance were more likely to use self-help only (p<0.01).  
Substance use treatment utilization and insurance coverage before versus after the ACA 
Table 1-3 shows past year substance use treatment and health insurance coverage before and 
after the ACA among those with SUD, any AUD, and any OUD. After the ACA, the percentages of 
those who received the substance use treatment significantly increased among those with SUD (10.5% 
vs.12.8%, p<0.001), and any OUD (30.6% vs. 43.7%, p<0.001). The past year utilization of any TOOS 
(vs. self-help only) after the ACA was significantly higher than before the ACA among the SUD 
population (77.3% vs. 82.7%, p<0.01) and any OUD (84.8% vs.90.5%, p<0.05). For the past year 





those receiving treatment among SUD and any AUD populations. After the ACA, the percentages of 
people with no insurance decreased (p<0.001), with significant increases in coverage by Medicaid, as 
well as private insurance (except for any OUD sub-population).  
Adjusted associations between health insurance and substance use treatment utilization 
Table 1-4 shows the adjusted associations of SUD treatment utilization and health insurance 
coverage among those with SUD, any AUD, and any OUD. The associations were adjusted for age, 
gender, race/ethnicity, education, income, urbanicity, general health, mental health and post ACA. 
Compared with no insurance, people with Medicaid insurance were more likely to use any past year 
substance use treatment among those with SUD (AOR 2.1, 95% CI: 1.8-2.4), those with any AUD 
(AOR 1.9, 95% CI: 1.5-2.3), and those with any OUD (AOR 2.2, 95% CI: 1.6-2.9). For any SUD and 
any AUD populations, private health insurance was negatively associated with the past year use of any 
substance use treatment, compared with no insurance.  
Table 1-5 shows the adjusted associations of the health insurance coverage and utilization of 
TOOS approach (versus self-help only). Compared with no insurance, those with Medicaid insurance 
were more likely to use TOOS versus self-help only across the any SUD, any AUD, and any OUD 
populations. For example, for any SUD population, those with Medicaid insurance coverage were more 
likely to use TOOS only (vs. self-help only) (AOR 2.0, 95% CI: 1.3-3.0) and any TOOS (vs. self-help 
only) (AOR 2.1, 95% CI: 1.4-2.9).  
Sensitivity analysis results 
 In order to address the endogeneity of health insurance coverage in the use of SUD treatment, we 
used an IV model with self-employment status as an instrument. The results show that self-employment 





populations (F test = 40.2), but a weak instrument among the OUD population( F test = 0.9).  For the 
SUD population, the IV model showed that those who were insured were more likely to use any SUD 
treatment during the past year compared with those who were uninsured, and the magnitudes were 
bigger compared with our main model (AOR 7.4, 95% CI: 1.5-36.9) (Table 1-6). We also saw a larger 
effect in the IV model comparing TOOS approaches to self-help only; however, it was not statistically 
significant. For the AUD population, we did not see the significant associations in the IV model between 
AUD treatment utilization and insurance coverage for any of the outcomes including any SUD 
treatment, TOOS approach versus self-help approach (Table 1-7).  
 In order to further examine selection bias, we tested the sensitivity of our adjusted associations 
by restricting the sample to those who reported that they had an alcohol problem or opioid problem for 
less than a year. We found that all of the AUD population reported having an alcohol problem for less 
than a year. For those reporting OUD for less than one year, we found that those with Medicaid were 
more likely to use any SUD treatment in the past year (AOR 2.3, 95% CI: 1.7-3.2), TOOS only (vs. self-
help) (AOR 3.7, 95% CI: 1.5-9.2), any TOOS (vs. self-help) (AOR 2.7, 95% CI: 1.3-5.5). Those with 
private insurance were also more likely to use any TOOS (vs. self-help) (AOR: 2.7, 95% CI: 1.3-5.5) 
(Table 1-8). 
An alternative adjusted model replacing the covariate post ACA by the interaction of the post 
ACA and type of health insurance shows that our main findings were robust among those with any SUD 
and any OUD.  Specifically, Medicaid insurance was positively associated with the utilization of any 
SUD treatment as well as TOOS approach (vs. self-help only) after allowing the Medicaid association 
with treatment to be moderated by the post ACA policy variable (Appendix Table 1-A1). Additionally, 
we find a larger magnitude of the odds of receiving TOOS approach (vs. self-help only) among those 





ACA policy variable is included as interaction with coverage type (Appendix Table 1-A2). For example, 
those with Medicaid insurance were 5.9 times more likely to use any TOOS (vs. self-help only) 
compared to those who were uninsured, whereas that adjusted odd ratio when controlling for only post 
ACA was 2.4.  
Appendix table 1-B1 to table 1-B6 show the sensitivity analysis results for the associations of 
health insurance coverages and any SUD treatment as well as TOOS versus self-help only across any 
substance abuse (Table 1-B1), substance dependence (Table 1-B2), alcohol abuse (Table 1-B3), alcohol 
dependence (Table 1-B4), opioid abuse (Table 1-B5), and opioid dependence (Table 1-B6). Those with 
Medicaid insurance were more likely to access any SUD treatment past year across any substance abuse, 
substance dependence, alcohol abuse, alcohol dependence, and opioid dependence but not among opioid 
abuse. Among those who used any treatment past year, those with Medicaid coverage were more likely 
to access the TOOS approach (vs. self-help only) across those with substance dependence, alcohol 
dependence, and opioid dependence populations. For example, those with opioid dependence and who 
were covered by Medicaid insurance were more likely to use only TOOS (AOR 2.5, 95% CI: 1.2-5.4), 
any TOOS (AOR 2.4, 95% CI: 1.3-4.7), compared to those who were uninsured (Table 1-B6).  
Another sensitivity analysis was conducted to examine the associations of health insurance types 
and two different measures of OUD, given that questions on opioid prescription have been changed 
since 2015. The two different measures of OUD included any pain reliever use disorder and any heroin 
use disorder. The associations were adjusted for sociodemographic characteristics and post ACA. The 
sensitivity analysis results show that our main findings were largely robust to the measures of OUD 
used. Those with any pain reliever disorders as well as those with any heroin use disorder and covered 
by Medicaid insurance were more likely to use any substance use treatment compared to those who were 





TOOS approach (vs. self-help only), we also find that those with Medicaid insurance were more likely 
to use TOOS approach (vs. self-help only) compared with those who were uninsured. On the other hand, 
we have not found significantly positively associations between Medicaid insurance and the use of the 
TOOS approach (vs. self-help only) among those with any heroin use disorder (Appendix Table 1-C2).  
Discussion 
 
Given that SUD remains a public health concern, studies on the determinants of access to 
evidence-based outpatient medical treatments such as TOOS are critical. Our study was conducted to 
understand the role of health insurance coverage, particularly Medicaid insurance, on SUD treatment 
utilization patterns. We found that those with Medicaid insurance had higher odds of receiving any 
substance use treatment across any SUD, any AUD, and any OUD populations, compared to those who 
were uninsured. Those with Medicaid were also more likely to access the TOOS approach, while those 
who were uninsured were more likely to use self-help approach only. On the other hand, those with 
private insurance were less likely to use any substance use treatment compared to those who were 
uninsured, among any SUD or any AUD populations.  
Our main findings on the positive association between Medicaid insurance and any past year 
SUD treatment were consistent with the results from the sensitivity analysis that interacted post ACA 
and health insurance types, and the sensitivity analysis that restricted to those who had a substance 
problem for less than a year. Similarly, the main findings on the positive association between Medicaid 
insurance and utilization of TOOS approaches (vs. self-help) were consistent with the results from the 
sensitivity analysis that interacted health insurance type and the post ACA indicator among those with 
SUD or OUD; however, the main findings were not consistent among those with AUD. In addition, for 
the OUD population, we saw a higher magnitude in the adjusted odd ratios in the sensitivity analysis 





compared to the main findings. This could be due to the positive effect of the Medicaid insurance 
expansion under the ACA on the availability of medications for OUD (e.g., buprenorphine) in outpatient 
settings, which are increasingly being used by Medicaid programs to treat OUD and are considered an 
effective treatment.9,10,24 However, we did not find a significant association among those with AUD. 
This may be because self-help group approaches, including Alcoholics Anonymous, maybe a preferred 
form of treatment for those with AUD. 
Our study contributes to the literature in several ways. First, our findings aligned with prior work 
finding the positive association of Medicaid insurance and substance use treatment.21,23 Our study 
population was also similar to previous study populations. A majority of people with substance use 
disorders were males, non-Hispanic Whites, completed high school or more, low-income, lived in a 
large metropolitan area, and suffered from psychiatric problems.11,26 Compared with before the ACA, 
there were significantly higher percentages of  SUD treatment utilization as well as any TOOS (vs. self-
help only) among those with any SUD and any OUD after the ACA implementation.  This might be 
caused by the ACA or other factors including increased awareness of SUD and OUD in states, which 
requires further research. We also found significant increases in Medicaid insurance coverage among 
those with any SUD and any OUD after the ACA implementation compared to before the ACA. 
Importantly, the finding on the positive association of Medicaid insurance and substance use treatment 
utilization emphasizes the role of Medicaid programs on improving access to substance use treatment. 
Indeed, Medicaid has been the single largest payer for substance use disorder treatment.73 The important 
role of Medicaid in the treatment of substance use disorders has increased with the ACA 
implementation. The ACA defined SUD as one of ten essential health benefits that must be covered and 
should be covered with parity with other physical health conditions.67 Additionally, a growing number 





The Medicaid expansion under the ACA and the Section 1115 Demonstration waiver have resulted in 
more Medicaid recipients and greater access to evidence-based treatment options for SUD and OUD.25,74 
The enhancement of treatment options includes increased medication availability for OUD and 
integration of care for physical health and SUD.67,75,76 The finding on positive role of Medicaid 
insurance and SUD treatment utilization informs policy makers and Medicaid programs to continue their 
effort in extending Medicaid insurance coverage to treat SUD.  
Beyond the association between health insurance types and any substance use treatment 
utilization, our study contributes to the understanding of health insurance types and SUD treatment 
patterns. Specifically, the adjusted associations pointed out that Medicaid insurance was also positively 
associated with the use of medical outpatient treatments such as TOOS, whereas uninsured people with 
SUD or OUD were more likely to use self-help only. While self-help groups have been the most 
commonly used treatment in the U.S,11 our results also suggest that those with SUD or OUD who were 
uninsured used self-help only as a potentially lower cost substitute to more evidence-based outpatient 
treatments. Evidence shows that the effectiveness of self-help approach is more positive when combined 
with evidence-based outpatient treatments than self-help alone.48,58 Our study finding provides a 
suggestion for intervention programs in general and Medicaid programs in particular to target uninsured 
people in self-help groups, referring them to more evidence-based outpatient treatments for their SUD, 
especially OUD.  
Our study findings, however, show that those with any SUD or any AUD and who were privately 
insured had lower odds of receiving any substance use treatment in the past year compared to those who 
were uninsured. While our study indicated that a majority of people with any SUD, any AUD, or any 
OUD were covered by private insurance (Table 1-2), our adjusted association results pointed out that 





in general, at least when comparing with no insurance, or Medicaid. We suppose this finding is in 
contrast to previous work highlighting the importance of private insurance in access to SUD 
medications, especially for OUD treatment such as buprenorphine.46 Rather, our study findings suggest 
that people with private insurance had less severe SUD (Appendix 1-D), and thus, were less likely to get 
substance use treatment.  
Limitations 
This study has several limitations. First, the results were based on a cross-sectional NSDUH 
survey; therefore, we could not draw a causal interpretation. Second, health insurance coverage, 
substance use history, and utilization of SUD treatment were self-reported. They might be measured 
with errors. However, NSDUH has a number of strengths for addressing the examined associations 
including large nationally representative sample, comprehensive, detailed sociodemographic, health, 
different types of treatment utilization related information. Importantly, NSDUH data was collected 
using highly private and confidential mode (e.g., computer-assisted self-interviewing) for sensitive 
topics such as substance use.77 Third, type of insurance might be a function of unobserved health status, 
resulting to endogeneity bias in the estimate of association of health insurance and SUD treatment 
utilization.70,71 A few previous studies used an instrumental variable (IV) approach to handle the 
endogeneity of health insurance 70,71 found a positive and statistically significant effect of insurance on 
healthcare utilization.70 When taking into account the endogeneity of insurance status, the magnitude of 
the insurance effect on the SUD treatment utilization increased. In this regard, our study findings only 
suggest the direction, but not the possible magnitude of the associations.  
Conclusion 
This study shows the important role of Medicaid insurance coverage on any SUD treatment 
access and the use of TOOS approach. Specially, the findings also show that those with SUD or OUD 





medical treatment approach. This could be an opportunity for intervention programs that typically refer 
to self-help groups for SUD treatment to shift referrals towards a more evidence-based medical 
outpatient treatment, particularly for OUD treatment. Further studies should include more detailed 
measures of treatment supply and other environmental factors that might impede or facilitate SUD 
treatment access in general and OUD treatment access in particular. For example, further studies should 
include treatment supply, economic indicators, and substance use prevalence indicators at the state level 
from the restricted NSDUH dataset. Subsequent studies also should look for additional instrumental 
variables or other approaches to address the endogeneity of health insurance, to ensure estimates of the 
association between insurance and treatment outcomes are internally valid and consistent. Our study 
findings suggest that SUD treatment policies should continue to expand Medicaid insurance coverage to 






Table 1-1. Treatment utilization in specific facilities, NSDUH 2010-2018 














Any treatment past year 4,430 2867 1424 
 11.3% (0.25) 9.4% (0.27) 35.7% (1.16) 
    Any self-help      2613    1699    938 
     62.6% (1.14)    64.3% (1.42)    67.8% (1.84) 
   Any TOOS     2,828    1,691    1,071 
    70.8% (1.11)    66.4% (1.47)    81.9% (1.58) 
         Outpatient rehabilitation       
         center 
      69.7% (1.44)       66.9% (1.93)        76.3% (2.08) 
         Mental health center       50.4% (1.50)       50.6% (1.98)        48.1% (2.28) 
         Private doctor offices       38.8% (1.50)       37.3% (2.00)        46.5% (2.30) 
    
   Others treatment services     1991     1263    817 
     50.5% (1.24)     51.1% (1.57)    63.2% (1.96) 
         Inpatient rehabilitation center       70.8% (1.57)       69.6% (2.04)       76.8% (2.19) 
         Inpatient, hospital       62.7% (1.64)       64.7% (2.08)       65.8% (2.41) 
         Emergency room       44.1% (1.74)       46.2% (2.25)       45.8% (2.59) 
         Jail/prison       21.5% (1.41)       21.2% (1.81)       20.7% (2.05) 
   Any TOOS versus self-help only    N=3,523    N=2,195 N=1,239 
         Any TOOS    2828       1691    1071 
    79.7% (1.06)        76.0% (1.45)    87.6% (1.41) 
   TOOS only versus self-help 
only 
   N=1,741    N=1,100 N=509 
         TOOS only         1046        596    341 
















Table 1-2. Sample characteristics  
 Any SUD Any AUD Any OUD 
Sample size, unweighted 42,155 32,352 4,389 
Weighted % 9.7% 7.6% 1.0% 
 %(SE) %(SE) %(SE) 
Any substance use treatment 
utilization 
   
   Yes 11.3 (0.25) 9.4 (0.27) 35.7 (1.16) 
TOOS only vs. Self-help only N=3,523 N=2,195 N=1,239 
   TOOS only    57.5 (1.88)    50.1 (2.44)    67.2 (3.20) 
   Self-help only    42.5 (1.88)    49.9 (2.44)    32.8 (3.20) 
Any TOOS vs. Self-help only N=1,741 N=1,100 N=509 
    Any TOOS     79.7 (1.06)    76.0 (1.45)    87.6 (1.41) 
    Self-help only    20.3 (1.06)    24.0 (1.45)    12.4 (1.41) 
Health insurance types    
   None 21.1 (0.32) 20.4 (0.36) 26.6 (1.06) 
   Medicaid  14.8 (0.26) 12.1 (0.27) 28.9 (1.06) 
   Private 58.8 (0.38) 62.2 (0.43) 38.4 (1.12) 
Medicare and other insurance 5.3 (0.17) 5.25 (0.19) 6.03 (0.64) 
Age in years    
   18-25 30.9 (0.29) 28.9 (0.32) 26.9 (0.81) 
   26-34 25.5 (0.34) 25.4 (0.38) 30.2 (1.07) 
   35-49 26.0 (0.35) 27.2 (0.40) 24.9 (0.99) 
   50-64 17.6 (0.40) 18.6 (0.45) 18.0 (1.22) 
Sex    
   Male 64 (0.36) 64.2 (0.42) 59.7 (1.14) 
Race    
   Non-Hispanic Whites 66.1 (0.37) 66.4 (0.42) 72.8 (1.10) 
   Non- Hispanic African Americans 11.7 (0.24) 10.6 (0.26) 9.91 (0.81) 
   Hispanic 16.1 (0.30) 16.8 (0.35) 12.1 (0.83) 
   Other race/ethnicity 6.1 (0.17) 6.1 (0.19) 5.2 (0.46) 
Education    
   High school or more 86.4 (0.27) 86.7 (0.30) 78.6 (0.94) 
Total annual family income    
    < $50,000 54.7 (0.39) 52.0 (0.45) 65.4 (1.12) 
   $ 50,000-74,999 14.6 (0.27) 15.2 (0.32) 13.4 (0.79) 
   75,000 or more 30.7 (0.37) 32.8 (0.43) 21.2 (0.99) 
Urbanicity     
   Large metropolitan 57.1 (0.37) 57.4 (0.43) 53.5 (1.15) 
   Small metropolitan 30.0 (0.34) 30.0 (0.39) 31.1 (1.05) 
   Non-metropolitan 12.9 (0.23) 12.7 (0.26) 15.4 (0.78) 
Health status     
  Good health 14.7 (0.29) 13.4 (0.32) 25.3 (1.08) 
Major Depression Episode (MDE)    














































































Health insurance coverage and SUD treatment utilization  





Table 1-3. Treatment utilization and health insurance coverage before and after ACA 
 Any SUD Any AUD Any OUD 
Sample size 42,155 32,352 4,389 
Population size 169,434,078 133,338,166 17,756,770 
 Pre ACA Post ACA Pre ACA Post 
ACA 
Pre ACA Post ACA 















      














only   
      















      














      
Type of health 
insurance 
 p<0.001  p<0.001  p<0.001 





























































Table 1-4. Adjusted associations of any treatment utilization past year and different types of health 
insurance coverage, controlling for sociodemographic characteristics and post ACA.  
 Any SUD Any AUD Any OUD 
Sample size 39,130 30,219 3,897 
Population size 154,810,987 123,018,127 15,166,167 
 Any SUD treatment 
past year 
Any SUD treatment past 
year 








Health insurance     
   No insurance = 
reference 
   
   Medicaid 2.07*** 1.87*** 2.18*** 
 (1.78 - 2.40) (1.54 - 2.27) (1.63 - 2.91) 
   Private 0.64*** 0.71*** 1.03 
 (0.55 - 0.73) (0.60 - 0.85) (0.78 - 1.36) 
   Medicare and others 1.29* 1.43** 1.55 
 (1.03 - 1.61) (1.09 - 1.87) (0.94 - 2.57) 
Age in years    
   18-25= reference    
   26-34 1.31*** 1.18* 1.09 
 (1.17 - 1.47) (1.02 - 1.37) (0.87 - 1.36) 
   35-49 1.51*** 1.48*** 1.19 
 (1.35 - 1.70) (1.28 - 1.71) (0.93 - 1.54) 
   50-64 1.49*** 1.53*** 1.07 
 (1.22 - 1.81) (1.21 - 1.92) (0.69 - 1.66) 
Sex    
   Female= reference    
   Male 1.32*** 1.50*** 1.22 
 (1.18 - 1.47) (1.30 - 1.72) (0.98 - 1.53) 
Race    
   Non-Hispanic Whites= 
ref 
   
   Non- Hispanic African 
Americans 
0.67*** 0.86 0.75 
 (0.57 - 0.79) (0.71 - 1.05) (0.51 - 1.12) 
   Hispanic 0.63*** 0.72** 0.66* 
 (0.53 - 0.75) (0.59 - 0.88) (0.47 - 0.95) 
   Other race/ethnicity 0.75** 0.89 0.43*** 
 (0.61 - 0.92) (0.71 - 1.13) (0.27 - 0.66) 
Education    
   High school or less=ref    
   High school or more 0.79*** 0.71*** 1.13 
 (0.68 - 0.91) (0.59 - 0.85) (0.87 - 1.46) 
Total annual family 
income 
   
    < $50,000= ref    
   $ 50,000-74,999 0.95 0.99 1.01 
 (0.81 - 1.11) (0.82 - 1.21) (0.74 - 1.39) 





 (0.60 - 0.81) (0.55 - 0.80) (0.53 - 0.95) 
Urbanicity     
   Large metropolitan= 
ref 
   
   Small metropolitan 0.99 1.08 0.76* 
 (0.88 - 1.11) (0.93 - 1.24) (0.60 - 0.96) 
   Non-metropolitan 0.95 0.93 0.67** 
 (0.82 - 1.09) (0.78 - 1.12) (0.51 - 0.89) 
Health status     
   Fair/poor= ref    
   Good health  0.83* 0.80* 1.17 
 (0.72 - 0.96) (0.66 - 0.96) (0.89 - 1.53) 
Major Depression 
Episode (MDE) 
   
   No= ref    
   Yes 2.14*** 2.60*** 1.51*** 
 (1.89 - 2.42) (2.24 - 3.02) (1.18 - 1.92) 
Post ACA    
 1.24*** 1.14* 1.65*** 
 (1.11 - 1.38) (1.00 - 1.31) (1.33 - 2.05) 





























Table 1-5. Adjusted associations of TOOS utilization (versus self-help) and different types of health 
insurance coverage, controlling for sociodemographic characteristics and post ACA. 
 Any SUD Any AUD Any OUD 
Sample size 1,696 3,406  1,069 2,125 494 1,191 
Population size 6,732,414 14,029,360 4,353,406 9,058,392 1,795,907 4,728,784 













Health insurance        
   No insurance = 
reference 
      
   Medicaid 1.97** 2.05*** 1.90* 1.86** 2.45* 2.38** 
 (1.30 - 3.00) (1.44 - 2.92) (1.10 - 3.30) (1.18 - 2.93) (1.18 - 5.10) (1.29 - 4.38) 
   Private 1.16 1.18 1.23 1.15 1.71 2.02 
 (0.78 - 1.72) (0.84 - 1.65) (0.77 - 1.99) (0.77 - 1.71) (0.79 - 3.73) (1.00 - 4.10) 
   Medicare and others 0.77 0.93 1.04 0.94 0.52 0.84 
 (0.41 - 1.46) (0.52 - 1.65) (0.48 - 2.27) (0.48 - 1.86) (0.14 - 1.95) (0.25 - 2.88) 
Age in years       
   18-25= reference       
   26-34 0.91 1.03 0.81 0.97 1.52 1.71 
 (0.63 - 1.29) (0.75 - 1.41) (0.52 - 1.26) (0.66 - 1.42) (0.75 - 3.07) (0.88 - 3.34) 
   35-49 0.72 0.85 0.63* 0.82 1.41 1.18 
 (0.50 - 1.03) (0.63 - 1.16) (0.40 - 0.99) (0.57 - 1.17) (0.68 - 2.95) (0.60 - 2.32) 
   50-64 0.86 1.16 0.88 1.29 3.92 5.14* 
 (0.48 - 1.53) (0.71 - 1.89) (0.45 - 1.73) (0.73 - 2.27) (0.85 - 18.00) (1.16 - 22.71) 
Sex       
   Female= reference       
   Male 0.67* 0.75* 0.77 0.79 0.72 0.78 
 (0.48 - 0.94) (0.56 - 1.00) (0.51 - 1.15) (0.55 - 1.13) (0.40 - 1.28) (0.44 - 1.36) 
Race       
   Non-Hispanic 
Whites= ref 
      
   Non- Hispanic 
African Americans 
0.99 1.27 1.40 1.61 1.20 2.55 
 (0.59 - 1.65) (0.83 - 1.95) (0.74 - 2.65) (0.97 - 2.68) (0.38 - 3.78) (0.77 - 8.43) 
   Hispanic 0.74 0.81 0.94 0.89 0.72 1.09 
 (0.46 - 1.19) (0.55 - 1.18) (0.53 - 1.65) (0.56 - 1.40) (0.28 - 1.82) (0.48 - 2.44) 
   Other race/ethnicity 0.77 0.83 1.38 1.29 1.13 1.08 





Education       
   High school or 
less=ref 
      
   High school or more 1.10 0.92 1.19 0.86 1.06 0.79 
 (0.76 - 1.61) (0.67 - 1.27) (0.72 - 1.95) (0.58 - 1.29) (0.52 - 2.17) (0.41 - 1.54) 
Total annual family 
income 
      
    < $50,000= ref       
   $ 50,000-74,999 1.11 1.12 1.35 1.16 1.33 1.30 
 (0.69 - 1.77) (0.73 - 1.71) (0.78 - 2.33) (0.71 - 1.90) (0.62 - 2.87) (0.62 - 2.73) 
   75,000 or more 1.53 1.25 1.68 1.24 1.54 1.56 
 (1.00 - 2.36) (0.87 - 1.79) (1.00 - 2.84) (0.82 - 1.89) (0.66 - 3.60) (0.76 - 3.21) 
Urbanicity        
   Large metropolitan= 
ref 
      
   Small metropolitan 1.25 1.05 1.33 1.04 1.58 1.41 
 (0.89 - 1.75) (0.79 - 1.41) (0.88 - 2.01) (0.74 - 1.48) (0.80 - 3.12) (0.75 - 2.63) 
   Non-metropolitan 1.41 1.15 1.72* 1.29 1.80 1.48 
 (0.94 - 2.13) (0.82 - 1.62) (1.02 - 2.90) (0.85 - 1.97) (0.89 - 3.64) (0.80 - 2.73) 
Health status        
   Fair/poor= ref       
   Good health  0.59** 0.76 0.54* 0.76 0.96 1.09 
 (0.39 - 0.87) (0.53 - 1.09) (0.32 - 0.90) (0.50 - 1.16) (0.47 - 1.95) (0.55 - 2.14) 
Major Depression 
Episode (MDE) 
      
   No= ref       
   Yes 0.93 1.31 0.73 1.17 1.05 1.49 
 (0.66 - 1.30) (0.97 - 1.78) (0.49 - 1.08) (0.83 - 1.66) (0.55 - 1.99) (0.84 - 2.64) 
Post ACA       
 1.35 1.23 1.42 1.17 1.04 1.20 
 (0.99 - 1.85) (0.94 - 1.61) (0.96 - 2.11) (0.84 - 1.63) (0.58 - 1.89) (0.73 - 1.99) 
***p<0.001, **p<0.01, *p<0.05 
AOR= Adjusted Odd Ratios, CI= Confidence Interval. Ref= Reference 
TOOS only= TOOS, no self-help versus self-help, no TOOS 







Table 1-6. IV models for associations between health insurance coverage and any SUD treatment utilization 






IV model  
TOOS only 
vs. self -help 
only 
TOOS only 
vs. self- help 









        














       
Insured 1.05 7.37* 1.52** 5.79 1.40** 10.06 
 (0.92 - 1.20) 
(1.47 - 
36.94) 
(1.16 - 1.98) 
(0.35 - 
96.13) 
(1.11 - 1.77) 
(0.97 - 
104.42) 
Residual1  0.12*     
  (0.02 - 0.63)     
Residual 2   
 0.22   
  
 
 (0.01 - 3.66)   
Residual 3      0.12 
      (0.01 - 1.29) 
Age in years   





    
   26-34 1.42*** 1.60*** 1 0.94 1.03 0.98 
 (1.27 - 1.60) (1.32 - 1.93) (0.77 - 1.31) (0.69 - 1.30) (0.81 - 1.30) (0.74 - 1.29) 
35-49 1.60*** 1.58*** 0.73* 0.72* 0.83 0.83 
 (1.42 - 1.80) (1.37 - 1.83) (0.57 - 0.95) (0.53 - 0.98) (0.67 - 1.04) (0.64 - 1.07) 
50-64 1.58*** 1.31* 0.57** 0.53* 0.72* 0.65* 
 (1.31 - 1.91) (1.01 - 1.69) (0.39 - 0.84) (0.32 - 0.89) (0.53 - 0.99) (0.43 - 0.97) 
Sex       
Female= 
reference 
      
 1.22*** 1.53*** 0.79 1.08 0.83 1.09 
 (1.10 - 1.36) (1.27 - 1.85) (0.62 - 1.02) (0.77 - 1.52) (0.67 - 1.04) (0.83 - 1.44) 
Total annual 
family 
income       
    < 
$50,000= ref 
      
   $ 50,000-
74,999 
0.73*** 0.57*** 1.06 0.96 0.96 0.82 







0.50*** 0.37*** 1.18 0.98 0.94 0.64 
 (0.43 - 0.58) (0.26 - 0.52) (0.85 - 1.65) (0.47 - 2.04) (0.71 - 1.24) (0.36 - 1.16) 
Race/ethnici
ty 









0.80** 0.79* 1.17 1.31 1.44* 1.48* 
 (0.68 - 0.93) (0.63 - 0.98) (0.78 - 1.74) (0.80 - 2.15) (1.03 - 2.00) (1.00 - 2.20) 
Hispanics 0.69*** 0.8 0.76 0.89 0.88 1.14 
 (0.58 - 0.81) (0.61 - 1.05) (0.53 - 1.08) (0.52 - 1.52) (0.66 - 1.18) (0.74 - 1.78) 
Other 
race/ethnicity 
0.82 0.73** 1.04 1.16 1.15 1.12 
 (0.68 - 1.01) (0.59 - 0.92) (0.64 - 1.68) (0.67 - 2.00) (0.77 - 1.72) (0.72 - 1.72) 
Education       
High school 
or less= ref 
      
High school 
or more 
0.67*** 0.45*** 1.03 0.87 0.99 0.7 
 (0.58 - 0.77) (0.32 - 0.63) (0.77 - 1.36) (0.51 - 1.50) (0.78 - 1.27) (0.44 - 1.11) 




      
Small 
metropolitan 
1.01 1.02 1.19 1.24 0.99 1.02 
 (0.90 - 1.13) (0.90 - 1.16) (0.92 - 1.54) (0.93 - 1.66) (0.80 - 1.24) (0.80 - 1.31) 
Non-
metropolitan 
0.99 1.1 1.41* 1.79** 1.12 1.43* 
 (0.86 - 1.14) (0.94 - 1.30) (1.00 - 1.98) (1.20 - 2.68) (0.83 - 1.51) (1.01 - 2.03) 
Health 
status 
      
Fair/poor = 
ref 
      
Good health 0.70*** 0.63*** 0.48*** 0.49*** 0.60*** 0.58** 
 (0.60 - 0.80) (0.52 - 0.76) (0.35 - 0.66) (0.32 - 0.75) (0.45 - 0.79) (0.40 - 0.82) 
MDE       





   Yes 2.19*** 2.26*** 1.05 1.03 1.47** 1.43* 
 (1.94 - 2.47) (1.97 - 2.60) (0.79 - 1.39) (0.74 - 1.45) (1.14 - 1.90) (1.08 - 1.91) 
Post ACA       
 1.31*** 1.1 1.37* 1.24 1.30* 1.18 
  (1.18 - 1.45) (0.93 - 1.30) (1.08 - 1.76) (0.86 - 1.80) (1.06 - 1.60) (0.89 - 1.57) 
Adjusted Wald test (instrumental test) found that self-employment variable was strong with F = 41.77 (p<0.001)  
***p<0.001, **p<0.01, *p<0.05 







Table 1-7. IV models for associations between health insurance coverage and any SUD treatment utilization 





















        














       
Insured 1.05 5.94 1.41 28.60 1.31 14.87 
 (0.89 - 1.23) (0.92 - 38.48) (0.93 - 2.15) (0.21 - 
3,948.78) 
(0.92 - 1.89) (0.28 - 
778.29) 
Residual1  0.16     
  (0.02 - 1.07)     
Residual 2   
 0.05   
  
 
 (0.00 - 6.31)   
Residual 3      0.09 
      (0.00 - 4.84) 
Age in years   





    
   26-34 1.25** 1.37** 0.87 0.94 1.02 0.98 
 (1.08 - 1.45) (1.10 - 1.72) (0.56 - 1.34) (0.50 - 1.77) (0.70 - 1.48) (0.58 - 1.66) 
35-49 1.54*** 1.52*** 0.67 0.75 0.86 0.95 
 (1.33 - 1.78) (1.27 - 1.81) (0.43 - 1.05) (0.43 - 1.29) (0.60 - 1.23) (0.63 - 1.43) 
50-64 1.61*** 1.41* 0.89 0.88 1.33 1.23 
 (1.29 - 2.02) (1.05 - 1.89) (0.45 - 1.75) (0.35 - 2.18) (0.76 - 2.35) (0.57 - 2.64) 
Sex       
Female= 
reference 
      
 1.42*** 1.79*** 0.74 0.98 0.75 0.87 
 (1.24 - 1.63) (1.44 - 2.22) (0.50 - 1.11) (0.54 - 1.78) (0.53 - 1.08) (0.52 - 1.43) 
Total annual 
family 
income       
    < 
$50,000= ref 
      
   $ 50,000-
74,999 
0.81* 0.62** 1.26 0.95 1.07 0.86 







0.51*** 0.37*** 1.50 0.81 1.10 0.63 
 (0.42 - 0.61) (0.25 - 0.56) (0.91 - 2.48) (0.24 - 2.75) (0.74 - 1.66) (0.26 - 1.57) 
Race/ethnici
ty 









1.00 1.06 1.53 1.82 1.69* 2.06 
 (0.82 - 1.21) (0.80 - 1.41) (0.80 - 2.91) (0.67 - 4.95) (1.02 - 2.79) (0.96 - 4.38) 
Hispanics 0.77* 0.97 0.96 1.34 0.92 1.15 
 (0.63 - 0.94) (0.69 - 1.36) (0.55 - 1.68) (0.58 - 3.11) (0.58 - 1.44) (0.60 - 2.18) 
Other 
race/ethnicity 
0.98 0.95 1.32 1.50 1.30 1.24 
 (0.77 - 1.23) (0.73 - 1.23) (0.65 - 2.68) (0.67 - 3.39) (0.73 - 2.32) (0.65 - 2.36) 
Education       
High school 
or less= ref 
      
High school 
or more 
0.62*** 0.44*** 1.14 0.53 0.83 0.43* 
 (0.52 - 0.75) (0.29 - 0.66) (0.70 - 1.86) (0.20 - 1.43) (0.56 - 1.23) (0.19 - 0.94) 




      
Small 
metropolitan 
1.09 1.13 1.35 1.31 1.06 1.02 
 (0.94 - 1.25) (0.96 - 1.33) (0.89 - 2.04) (0.80 - 2.12) (0.75 - 1.51) (0.68 - 1.52) 
Non-
metropolitan 
0.96 1.09 1.72* 1.91* 1.31 1.44 
 (0.80 - 1.15) (0.89 - 1.34) (1.02 - 2.90) (1.06 - 3.45) (0.86 - 1.99) (0.89 - 2.31) 
Health 
status 
      
Fair/poor = 
ref 
      
Good health 0.69*** 0.68** 0.53* 0.44* 0.73 0.64 
 (0.58 - 0.83) (0.53 - 0.86) (0.32 - 0.88) (0.21 - 0.91) (0.48 - 1.13) (0.37 - 1.09) 





   No=ref       
   Yes 2.66*** 2.65*** 0.69 0.74 1.14 1.07 
 (2.30 - 3.09) (2.24 - 3.13) (0.46 - 1.03) (0.48 - 1.14) (0.81 - 1.63) (0.72 - 1.58) 
Post ACA       
 1.18* 1.02 1.46 1.01 1.20 0.96 
  (1.04 - 1.35) (0.83 - 1.26) (0.98 - 2.17) (0.51 - 1.98) (0.86 - 1.67) (0.60 - 1.52) 
Adjusted Wald test found that self-employment variable was strong with F = 40.21 (p<0.001) 
***p<0.001, **p<0.01, *p<0.05 








































Table 1-8. Adjusted associations of treatment utilization and different types of health insurance coverage, 
controlling for sociodemographic characteristics and post ACA, among people with OUD and used opioid 
less than a year 
 Any SUD treatment TOOS only Any TOOS  







Health insurance     
   No insurance = reference    
   Medicaid 2.31*** 3.66** 2.69** 
 (1.66 - 3.21) (1.46 - 9.20) (1.32 - 5.47) 
   Private 1.11 2.06 2.65** 
 (0.81 - 1.52) (0.88 - 4.84) (1.28 - 5.47) 
   Medicare and others 1.49 0.57 1.58 
 (0.85 - 2.63) (0.12 - 2.75) (0.35 - 7.18) 
Age in years    
   18-25= reference    
   26-34 1.04 1.36 1.78 
 (0.81 - 1.33) (0.61 - 3.05) (0.86 - 3.68) 
   35-49 1.11 0.97 0.87 
 (0.83 - 1.47) (0.42 - 2.22) (0.41 - 1.84) 
   50-64 0.95 1.68 3.85 
 (0.54 - 1.65) (0.23 - 12.37) (0.65 - 22.83) 
Sex    
   Female= reference    
   Male 1.29* 0.70 0.96 
 (1.00 - 1.67) (0.36 - 1.37) (0.52 - 1.75) 
Race    
   Non-Hispanic Whites= 
ref 
   
   Non- Hispanic African 
Americans 
0.69 1.31 3.27 
 (0.45 - 1.07) (0.33 - 5.21) (0.85 - 12.54) 
   Hispanic 0.54** 0.45 0.71 
 (0.37 - 0.78) (0.16 - 1.32) (0.27 - 1.87) 
   Other race/ethnicity 0.30*** 0.53 0.59 
 (0.18 - 0.49) (0.14 - 2.03) (0.20 - 1.73) 
Education    
   High school or less=ref    
   High school or more 1.15 1.31 0.76 
 (0.86 - 1.53) (0.55 - 3.10) (0.36 - 1.63) 
Total annual family 
income 
   
    < $50,000= ref    
   $ 50,000-74,999 1.06 1.26 0.92 





   75,000 or more 0.71* 1.84 1.42 
 (0.52 - 0.97) (0.72 - 4.73) (0.67 - 3.02) 
Urbanicity     
   Large metropolitan= ref    
   Small metropolitan 0.77* 2.61* 2.05 
 (0.59 - 1.00) (1.09 - 6.26) (0.92 - 4.54) 
   Non-metropolitan 0.66** 2.34* 1.70 
 (0.49 - 0.90) (1.07 - 5.10) (0.85 - 3.38) 
Health status     
   Fair/poor= ref    
   Good health  1.00 0.75 0.88 
 (0.74 - 1.36) (0.33 - 1.69) (0.41 - 1.93) 
Major Depression 
Episode (MDE) 
   
   No= ref    
   Yes 1.44** 0.91 1.18 
 (1.11 - 1.87) (0.45 - 1.85) (0.66 - 2.14) 
Post ACA    
 1.41** 0.73 1.07 
 (1.10 - 1.81) (0.38 - 1.43) (0.62 - 1.84) 
***p<0.001, **p<0.01, *p<0.05 
AOR= Adjusted Odd Ratios, CI= Confidence Interval 
TOOS only= TOOS, no self-help versus self-help, no TOOS 








Table 1-9. Summary table for the adjusted associations between health insurance types and any past year 
SUD treatment utilization 







Main results    
   No insurance = reference    
   Medicaid 2.07*** 1.87*** 2.18*** 
 (1.78 – 2.40) (1.54 – 2.27) (1.63 – 2.91) 
   Private 0.64*** 0.71*** 1.03 
 (0.55 – 0.73) (0.60 – 0.85) (0.78 – 1.36) 
   Medicare and others 1.29* 1.43** 1.55 
 (1.03 – 1.61) (1.09 – 1.87) (0.94 – 2.57) 
Sensitivity analysis  
with interaction 
   
   No insurance = reference    
   Medicaid 1.98*** 1.97*** 1.76** 
 (1.62 - 2.43) (1.52 - 2.54) (1.20 - 2.59) 
   Private 0.68*** 0.74** 1.11 
 (0.57 - 0.81) (0.60 - 0.92) (0.79 - 1.55) 
   Medicare and others 1.35* 1.42* 1.54 
 (1.00 - 1.82) (1.00 - 2.02) (0.82 - 2.89) 
Post ACA 1.33* 1.28 1.50 
 (1.07 - 1.66) (0.97 - 1.68) (0.95 - 2.38) 
Post ACA* Uninsured = ref    
    
Post ACA * Medicaid 1.06 0.86 1.56 
 (0.79 - 1.42) (0.58 - 1.26) (0.86 - 2.80) 
Post ACA * Private 0.84 0.86 0.86 
 (0.64 - 1.10) (0.62 - 1.21) (0.49 - 1.51) 
Post ACA * Medicare and 
other 
0.87 0.98 1.03 
 (0.56 - 1.35) (0.58 - 1.66) (0.37 - 2.89) 
    
Sensitivity analysis for those 
with substance problem less 
than a year 
   
   No insurance = reference    
   Medicaid N/A 1.87*** 2.31*** 
  (1.54 – 2.27) (1.66 - 3.21) 
   Private N/A 0.71*** 1.11 
  (0.60 – 0.85) (0.81 - 1.52) 
   Medicare and others N/A 1.43** 1.49 
  (1.09 – 1.87) (0.85 - 2.63) 
Note: All of people with AUD in the final analytic sample had alcohol problem less than a year  





Table 1-10. Summary table for the adjusted associations between health insurance types and any past 
year utilization of TOOS approach (vs. self-help) 
 Any SUD Any AUD Any OUD 













Main results       
   No insurance = 
ref 
      
   Medicaid 1.97** 2.05*** 1.90* 1.86** 2.45* 2.38** 
 (1.30 - 3.00) (1.44 - 2.92) (1.10 - 3.30) (1.18 - 2.93) (1.18 - 5.10) (1.29 - 4.38) 
   Private 1.16 1.18 1.23 1.15 1.71 2.02 
 (0.78 - 1.72) (0.84 - 1.65) (0.77 - 1.99) (0.77 - 1.71) (0.79 - 3.73) (1.00 - 4.10) 
   Medicare and 
others 
0.77 0.93 1.04 0.94 0.52 0.84 




      
No insurance = 
ref 
      
   Medicaid 2.60** 2.51*** 2.06 1.86 5.18** 5.94** 
 (1.44 - 4.68) (1.50 - 4.18) (1.00 - 4.26) (1.00 - 3.47) (1.61 - 16.68) (2.03 - 
17.42) 
   Private 1.01 1.00 1.00 0.91 2.15 1.94 
 (0.61 - 1.66) (0.66 - 1.51) (0.55 - 1.79) (0.56 - 1.48) (0.84 - 5.51) (0.88 - 4.28) 
   Medicare and 
others 
0.44 0.65 0.55 0.63 0.26 0.60 
 (0.19 - 1.04) (0.32 - 1.31) (0.19 - 1.58) (0.27 - 1.45) (0.05 - 1.36) (0.15 - 2.39) 
Post ACA 1.17 0.97 0.94 0.71 1.55 1.48 
 (0.65 - 2.13) (0.60 - 1.57) (0.44 - 2.01) (0.38 - 1.29) (0.54 - 4.39) (0.60 - 3.63) 
PostACA* 
Uninsured= ref 
      
Post ACA* 
Medicaid 
0.66 0.78 0.96 1.20 0.30 0.25 
 (0.28 - 1.53) (0.38 - 1.60) (0.31 - 2.98) (0.49 - 2.98) (0.06 - 1.46) (0.06 - 1.05) 
Post ACA* 
Private 
1.42 1.62 1.80 2.10 0.59 1.07 









 (1.23 - 
14.82) 













than a year 
      
   No insurance = 
ref 
      
   Medicaid N/A N/A 1.90* 1.86** 3.66** 2.69** 
   (1.10 - 3.30) (1.18 - 2.93) (1.46 - 9.20) (1.32 - 5.47) 
   Private N/A N/A 1.23 1.15 2.06 2.65** 
   (0.77 - 1.99) (0.77 - 1.71) (0.88 - 4.84) (1.28 - 5.47) 
   Medicare and 
others 
N/A N/A 1.04 0.94 0.57 1.58 
   (0.48 - 2.27) (0.48 - 1.86) (0.12 - 2.75) (0.35 - 7.18) 
Note: All of people with AUD in the final analytic sample had alcohol problem less than a year  
***p<0.001, **p<0.01, *p<0.05 
AOR= Adjusted Odd Ratios, CI= Confidence Interval. Ref= Reference 
TOOS only= TOOS, no self-help versus self-help, no TOOS 










Despite dramatic increases in opioid-related overdoses in recent years and the predominant role 
Medicaid plays in paying for medically managed opioid use disorder treatment, there is a lack of 
research documenting the relationship between Medicaid coverage and healthcare provider referrals to 
outpatient treatment. This study uses a natural experiment to evaluate whether Medicaid expansion 
under the Affordable Care Act (ACA) increases healthcare provider referrals to outpatient treatment for 
opioid use disorder (OUD). 
This study uses a two ways fixed effects model (2WFE), a modification to a simple difference-
in-difference (DID) model that is more flexible in allowing states to expand Medicaid in different years 
throughout the study period, to identify the effect of Medicaid coverage on provider referrals to OUD 
treatment. As a sensitivity test, a simple DID model was also run including only states that expanded in 
2014 and states that did not expand by 2017. Data include eight years of Treatment Episode Data Set- 
Discharge (TEDS-D) dataset spanning 2010 to 2017 representing 382,609 individuals with outpatient 
OUD treatment. Regression models controlled for state and year fixed effects, medication assisted 
treatment for OUD, and other covariates including demographic characteristics, having a psychiatric 
comorbidity, and polysubstance use.  
Results from the two-way fixed effects (2WFE) model suggest that Medicaid expansion states 
were significantly more likely to have outpatient OUD discharges that were referred by healthcare 
providers (versus self-referred) compared to non-Medicaid expansion states (AOR 1.2, 95% CI: 1.1-
1.3). The simple DID estimates (AOR 1.2, 95% CI: 1.1-1.3) were consistent with the 2WFE results. 
This study found that Medicaid expansion under the ACA has a positive impact on the likelihood 





Medicaid expansion has the potential to improve timely and effective access to evidence-based 








The U.S. has experienced an unprecedented opioid epidemic with 1.6 million people having an 
opioid addiction in 2017.77 According to the Centers for Disease Control and Prevention, overdose 
deaths in 2019 increased six times compared to 1999 and about two-thirds of all drug overdose deaths 
were attributed to opioid overdose.78 In 2019, nearly 50,000 people died due to such overdose.78 Annual 
opioid costs related to crime, lost work productivity and healthcare were estimated to be more than 78 
billion dollars, with 26 billion related to healthcare.79 The epidemic has negatively impacted American 
families and communities, affecting rich and poor, both urban and rural communities.80 More recently, 
an increasing number of providers, patients, and medical societies considers OUD a chronic disease,7 
and the perspective on substance use treatment has changed accordingly. Understanding OUD as a 
treatable chronic disease has made room for the emergence of approaches that rely more on the health 
care system to effectively  manage this disease over an extended period of time.8  Although effective 
treatments for opioid use disorder (OUD) including pharmacological and/or psychological therapies 
exist, more than 80% of those with OUD do not access  substance use disorder (SUD) treatment.11    
For these reasons, a better understanding of what factors may increase access to substance use 
treatment is needed.  To date, the evidence suggests access-related predictors for OUD treatment include 
financial barriers, stigma toward substance use,12 and the extent to which patients understand the health 
care delivery system and OUD treatment options.  Given the shift towards outpatient treatment for 
OUD, referral sources may also be a critical determinant of timely and effective SUD treatment as well 
as a strong predictor for treatment success.19,20 For example, previous studies demonstrated positive 
associations of employer and criminal justice referrals with successful treatment completion, while self-
referrals and healthcare referrals were negatively associated with successful completion.16 Recent 





emphasize treatment obtained in outpatient settings are expected to lead to an increasing role of the 
healthcare system in SUD treatment success. This highlights the potential importance of provider 
referrals to improving outpatient treatment access and outcomes.  
Medicaid expansion represents a significant policy shift both because it has increased health 
insurance coverage for so many individuals with SUD (Medicaid pays for a majority of individuals with 
SUD35) and because it has increased the supply of treatment providers.24 Thus, Medicaid expansion has 
been instrumental in reforming the U.S. delivery system for SUD treatment and increase access to SUD 
treatment.66 By enabling states to expand Medicaid eligibility to low-income adults up to 138% of FPL81 
under the Patient Protection Affordable Care Act (ACA), insurance coverage among individuals with 
SUD has increased in 37 states as of 2020.82  Importantly, the ACA also defined SUD as one of ten 
essential health benefits that must be covered and should be covered on parity with other medical 
conditions;67 however, this benefit could vary by state as the ACA did not specify which SUD services 
must be included. Prior to the ACA, most low-income people who are in need of medication-assisted 
treatment (MAT) for OUD were left untreated.83 Evidence suggests that Medicaid expansion has 
narrowed the treatment gap through increased  insurance coverage and other delivery system 
changes.84,85 Indeed, previous studies found that Medicaid expansion has helped reduce the rates of 
being uninsured among low-income adults with SUD from 36% to 27%. 21,22 Additionally, admissions to 
SUD treatment among Medicaid beneficiaries increased 113% as a result of expansion without crowding 
out admissions from individuals with other types of insurance.23 Medicaid expansion has also resulted in 
substantial increases in the use of pharmacological therapy for opioid use disorder (OUD), including 
methadone and buprenorphine.22–24  
Medicaid policies have emphasized the role of evidence-based outpatient treatment for OUD that 





to an increased role of healthcare providers in referring patients to SUD treatment, particularly 
outpatient treatment, and in the 26 states with Institutions for Mental Diseases (IMD) 1115 
demonstration waivers in 2019, to residential treatment.86 In other words, Medicaid expansion is 
expected to increase SUD treatment referrals to health care facilities from healthcare providers, which in 
turn is expected to increase treatment access, treatment completion, and therefore treatment success.  
Referral source is thus considered a key factor in timely and effective SUD treatment.19,20 However, the 
existing literature on referral source mostly focused on its role in substance use treatment completion. 
These studies have found that substance use treatment completion rates differ by referral sources.15,16 
Employer and criminal justice referral pathways were associated with higher likelihood of successful 
treatment completion, while self-referrals and healthcare referrals were found to be associated with 
lower likelihood of successful completion.16 While referral source plays a significant role in substance 
use treatment and retention, there is a dearth of studies exploring factors affecting referral sources in 
general, and healthcare provider referrals specifically.  
Despite the evidence that Medicaid expansion has played an important role in reforming the 
delivery system for SUD treatment, to date we are unaware of any study examining associations 





Conceptual model  
Figure 4. Conceptual model of Medicaid expansion and referral source 
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 The conceptual model above is adapted from the Donabedian framework that describes the 
associations of structure, process, and outcomes in the healthcare system (figure 1).87 “Structure” 
includes substance use related coverage policies (e.g., Medicaid expansion, ACA, 1115 Demonstration 
Waivers). Referral source is considered “process” that is influenced by the structure factors such as 
Medicaid expansion. The “structure” and “process” influence outcomes including OUD treatment access 
and utilization. The conceptual model above suggests that Medicaid expansion should increase the 
likelihood of being referred to outpatient OUD treatment by healthcare providers. 
 
Study aim 
To explore associations between Medicaid expansion and referral sources to outpatient treatment 
for OUD, including healthcare provider referral. 
Hypothesis   
Medicaid expansion increases the likelihood of being referred to outpatient treatment for OUD 
by healthcare providers in expansion states compared to non-expansion states. 
Methods 
 
Overview of design and data 
 
This study uses a quasi-experimental difference-in-differences (DID) with two-ways fixed 
effects (2WFE) approaches to explore the relationships between Medicaid expansion and referral 
sources.21,24 Data were obtained from the publicly available TEDS-D, a national data system of annual 
discharges from publicly funded substance treatment facilities. They included the following types of 
facilities and services: (1) 24 hour per day medical acute care services in hospital settings, (2) 24 hour 
per day services in non-hospital settings, (3) rehabilitation in hospital settings, (4) short-term residential 
rehabilitation, (5) long-term residential rehabilitation, (6) intensive outpatient/ambulatory care, (7) non-





 The TEDS-D surveys were conducted by both the federal government and state agencies to 
collect information on SUD treatment programs, providing detailed information on the demographic 
characteristics of those who accessed treatment including age, gender, race/ethnicity, education, 
employment; information on drug use history, MAT (e.g., the use of opioid medications such as 
methadone, buprenorphine, naltrexone), homeless status, number of arrests, and referral source. TEDS 
surveys collected information on SUD treatment from publicly-funded facilities which accounted for 
more than 50% of SUD treatment facilities nationally.88 TEDS-D had 12 waves of data (from 2006 to 
2017; not counting for the year 2018 which has just been released), enabling researchers to combine 
many waves of data to increase statistical power and policy relevance. This study used 2010-2017 
TEDS-D data to assess the impact of Medicaid expansion under the ACA on referral sources. Data from 
2010-2017 were chosen in order to have 4 years (2010-2013) of data before ACA implementation 




OUD population. The OUD population included all discharges from the 2010-2017 TEDS-D 
whose primary substance use at admission had been opioids. This resulted in a sample of 3,628,633 
observations. We first excluded discharges from Puerto Rico (n = 3,025) given that the Medicaid 
expansion operates differently in the territories (e.g., Puerto Rico) as well as the differences between 
territories and the states in demographic, health status, and economic indicators.89 The sample age range 
was limited to 18-64 years since expanded Medicaid under the ACA was aimed to increase coverage for 
low-income working-age adults.90 This resulted in a sample of 3,502,661 observations.  Further, as has 





excluded as there was no way to link multiple discharges to a unique patient identifier. Further, 
discharges due to incarceration, or death, or that were missing were also excluded (n=47,916). 
Additionally, as this study focuses on the role of Medicaid expansion on referrals to outpatient 
OUD treatment, all discharges other than non-intensive outpatient were excluded (i.e., excluding the 
discharges from 24 hour per day medical acute care services in hospital setting, 24 hour per day services 
in non-hospital setting; residential rehabilitation in hospital, residential rehabilitation, short-term; 
residential rehabilitation, long term; ambulatory, intensive outpatient) (n=764,885) ( Table 2-1) . This 
resulted an analytic sample of 382,609 discharges aged 18-64 years old, with no prior admission in their 
lifetime with non-intensive outpatient treatment for OUD (For a sample flow chart, see Appendix 2-A). 
Table 2-1. Service types at admissions for opioid treatment 
Service types at admission Frequency Percent 
      
(1) 24 hour per day medical acute care services in hospital settings 117,940 10.28 
(2) 24 hour per day services in non-hospital settings 333,324 29.05 
(3) Rehabilitation in hospital settings 4,013 0.35 
(4) Short-term residential rehabilitation 104,094 9.07 
(5) Long term residential rehabilitation 59,914 5.22 
(6) Intensive outpatient/ambulatory care 104,358 9.09 
(7) Non-intensive outpatient/ambulatory care 382,609 33.34 
(8) Outpatient/ambulatory detoxification. 41,242 3.59 




Referral source (Process) 
 
This variable of interest was constructed as a four-level categorical variable: self-referral, care 
provider, other institutional referral, court/criminal justice referral. Self-referral was defined as an 
individual who referred him/herself to the substance use treatment (52.7%).  The healthcare provider 





healthcare providers (8.3%). The other institutional referral source category (10.1%) combined referrals 
from school (0.2%), employers (0.3%), and community services (9.6%). The category court/criminal 
justice referral/DUI/DWI included discharges who were referred by court or criminal justice (22.2%). 
About 1.8% discharges were defined as missing/unknown/not collected/invalid and are excluded from 
the analyses that follow.  
Medicaid expansion (Structure) 
 
As is described in more detail below, the effect of Medicaid expansion on the source of referrals 
to outpatient OUD treatment was tested with two different empirical approaches – a two-way fixed 
effects (2WFE) model and a difference-in-difference (DID).  Each of these approaches necessitates a 
slightly different empirical definition of the Medicaid expansion policy variables. For the two-ways 
fixed effects model, the key independent variable of interest was defined as whether the state 
implemented Medicaid expansion under the ACA in a given survey year. For each survey year, we 
constructed a binary variable receiving the value of 1 if discharges were from states that adopted 
Medicaid expansion in that year, and 0 if discharges were from a state that did not expand Medicaid in 
that year. As of 2017, 31 states and District of Columbia expanded Medicaid expansion in which 27 
states and District of Columbia expanded the Medicaid in 2014 (early expansion) and 5 states expanded 
between 2015 and 2017, the last year of TEDS-D data included in these analyses (late expansion) (See 
Appendix Table 1 for summary of Medicaid expansion).92 This approach allowed us to assess the impact 
of Medicaid expansion on the referral sources, taking into account the fact that states expanded 
Medicaid in different years.93    
 In the second empirical approach, the simple DID model, the independent variable of interest for 
DID was the interaction whether the discharge was from a facility located in a state with Medicaid 





Medicaid.  In this approach, only early expansion, those that expanded Medicaid in 2014, were included 




The association between Medicaid expansion and referral source was adjusted for state fixed 
effects and year fixed effects to capture unobserved state heterogeneity and national secular trends in 
access to SUD treatment (e.g., the prevalence of opioid use).21,24 Demographic characteristics that are 
available in TEDS-D and used as covariates included age (18-29, 30-44, 45-64 years old), gender (male, 
female), race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, other), education (less than 
high school, high school or higher), employment status (employed,  not employed).  
In addition,  we controlled for whether patients used MAT (yes/no), frequency of opioid use (no 
use in the past month, some use, daily use), homeless at the time of admission (yes/no), number of times 
arrested in the 30 days prior to admission (no, one, two or more),  psychiatric comorbidity (i.e., whether 
patient had psychiatric problem in addition to their substance use) (yes/no), and polysubstance use (no 




We first ran a 2WFE model to examine the impact of Medicaid expansion on referral sources 
using multinomial logit model to account for the fact that the states expanded Medicaid expansion under 
the ACA in different years.  
Y = β0 + β1Medexpst + βX + S +T + ε.    (1) 
Where Y is the outcome of interest, which is a categorical variable including self-referral, healthcare 
provider referral, other institutional referral, court/criminal justice referral. Medexpst is the independent 





otherwise, X represents a matrix of individual-level control variables, S represents state fixed effects, 
and T represents year fixed effects.  
We then restricted the analysis sample to states that adopted Medicaid expansion in 2014 and 
states that did not adopt Medicaid expansion as of 2017.  For estimating associations between Medicaid 
expansion and the referral source, we used a standard DID design with state and year effects. We used 
the state fixed effect in order to account for unobserved state heterogeneity, whereas we used year fixed 
effect to account for the national secular trends that might be systematically correlated with Medicaid 
expansion.  
 
Y = β0 + β1Exps + β2 PostExpansiont + β3 Exps* PostExpansiont + βX + S +T + ε.     (2) 
 
Again, Y is the referral source outcome of interest, including referred by healthcare provider, Exps is the 
independent variable, equal to 1 if the discharges were from the early expansion states and 0 otherwise; 
PostExpansiont is a binary variable indicating the period after early Medicaid expansion (year 2014); 
Exps* PostExpansiont is the interaction of Medicaid expansion and PostExpansion, with X representing 




For valid identification of the effect of Medicaid expansion on referral sources, the DID design 
has several assumptions that should be met.94 Particularly, if the comparison groups have different 
trends in the outcome of interest prior to the policy change, then the DID design is not necessarily an 
appropriate design as it violates the parallel trend assumption that may lead to biased estimate of causal 





2013), which allows us to test the parallel trend assumption.95 The assumption of DID approach is that 
the trends in referral source among the expansion and non-expansion groups is parallel in the time prior 
to the expansion implementation date ( year 2014). We tested the assumption by assessing interactions 
of expansion status and year variable in the pre-expansion period, we created line graphs to visualize the 
outcomes of interest (i.e., trends in self-referrals, healthcare provider referrals, institutional referrals, 
court/criminal justice referrals) over time. Furthermore, in order to correct for the within serial 
correlation in a DID context, we clustered the standard errors at the state level.  
As non-intensive outpatient treatments service settings may include MAT and non-MAT (e.g., 
individual, family and/or group services), we ran a sensitivity analysis of the associations between 
Medicaid expansion and referral sources stratified by MAT.  
In addition, the associations were also adjusted for variables directly affecting the supply of and 
demand for opioids at the state level that vary over time including prescription drug monitoring program 
(PDMP) implementation, and economic conditions including unemployment rates for each state, which 
was obtained from the Bureau of Labor Statistics’ Local Area Unemployment Statistics. We collected 
effective dates of PDMP implementation and verify via different sources including PDMP websites, the 
Prescription Drug Abuse Policy System. We conducted sensitivity analysis to estimate the associations 
and account for the economic conditions and prescription drug monitoring program implementation. 
Further, given that the Section 1115 Demonstration waivers also play a significant role in improving 
SUD delivery system and coverage,21 we also checked the robustness of the main finding by including 
indicator variables states with Section 1115 waiver in a given survey year. We also checked the 
robustness of the main findings by re-estimating the association by including one-year lag after 





those with more than one treatment episodes as it is common that many of those with OUD experienced 




Sample characteristics  
 
Table 2-2 shows characteristics of discharges from non-intensive outpatient treatment for opioids 
from 2010 to 2017, TEDS-D (N= 382,609). Most discharges were self-referred (more than 50%), 
followed by court/criminal justice referral (23%), and healthcare provider referral (13%). More than one 
third of the discharges included MAT services. More than half of individuals discharged used opioids 
daily before accessing outpatient treatment. With regards to demographic characteristics, a majority of 
individuals were 30-44 years old, male, non-Hispanic White, with high school education or higher, had 
not been arrested, and were employed. About one-third suffered from a psychiatric comorbidity. More 
than half used at least one more substance in addition to opioids. 
Figure 5 shows the change in numbers of discharges by referral sources from 2010-2017 TEDS-
D. Overall, there was an increase of 67 % in number of discharges in outpatient treatment for opioids 
from 39,699 discharges in 2010 to 65,793 discharges in 2017. Notably, there was a sudden increase in 
discharges from 2014-2017 (+23,203 discharges), compared to 2010 to 2014 (+3,000 discharges). We 
also saw the increases in discharges that were referred by all referral sources except for court/criminal 
justice referrals.  
 
Trends in referral sources across Medicaid expansion states versus non-expansion states 
Figure 6 presents trends in referral sources including self-referral, healthcare provider referral, 
other institutional referral, and court/criminal justice referral, for non-intensive outpatient treatment for 





versus non-expansion states. Line graphs were created to visualize the parallel assumption. The 
assumption of DID approach is met if the trends in discharges by referral source (i.e., self-referrals, 
healthcare provider referrals) among the expansion and non-expansion groups are parallel in the time 
prior to the expansion implementation date (i.e., Medicaid expansion under ACA in 2014). Overall, for 
all referral sources, higher numbers of discharges were reported from early expansion states than non-
expansion states. Before ACA implementation, trends in self-referred discharges and healthcare provider 
discharges were similar across both early expansion and non-expansion states. After ACA 
implementation, there was an increase in the number of discharges in both self-referral and healthcare 
provider referral in early expansion states but a decrease in non-expansion states, except in the year 
2017, when we observed discharges with self- or provider referral increasing in non-expansion states. 
On the other hand, trends in self-referred discharges and healthcare provider referred discharges for late 
expansion states seemed to violate the parallel assumption. 
Adjusted association results from 2WFE and DID models  
Table 2-3 presents the adjusted estimates from the 2WFE model taking into account the fact that 
states expanded their Medicaid expansion in different times. The results showed that Medicaid 
expansion states were significantly more likely to have discharges that were referred by healthcare 
provider (versus self-referred) compared to non-Medicaid expansion states (Relative Risk Ratio (RRR) 
1.2, 95% CI: 1.1-1.3). Compared with non-expansion states, Medicaid expansion states also were more 
likely to have discharges that were referred by other institution (RRR: 2.3, 95%CI: 2.1-2.4) and 
court/criminal justice (RRR: 1.3, 95% CI: 1.2-1.4) compared to self-referrals.  
Table 2-4 presents the adjusted estimates from DID model, using multinomial logistic regression 
comparing healthcare provider referral, other institutional, court/ criminal justice referral sources, with 





estimate indicated that state implementation of Medicaid expansion in 2014 was associated with an 
increase in likelihood of being referred by healthcare provider (vs. self-referral) (RRR 1.2, 95% CI: 1.1-
1.3), as was observed in the two-way fixed effects model. The Medicaid expansion was also positively 
associated with the likelihood of being referred by other institutional referrals (RRR 2.4, 95% CI: 2.2-
2.6) and court/criminal justice referral (RRR 1.3, 95% CI: 1.2-1.4), again consistent with the results 
from the two-way fixed effects specification described above.  
Table 2-5 presents the adjusted estimates from the 2WFE model among non-MAT, non-intensive 
outpatient treatment for OUD. The results showed that compared with non-expansion states, Medicaid 
expansion states were more likely to have discharges that were referred by healthcare provider (versus 
self-referred) (RRR 1.2, 95% CI: 1.1-1.2). Compared with non-expansion states, Medicaid expansion 
states also were more likely to have discharges that were referred by other institution (RRR: 2.4, 95% 
CI: 2.2-2.5) or court/criminal justice (RRR: 1.3, 95% CI: 1.2-1.3). 
Table 2-6 presents the adjusted estimates from the 2WFE model among individuals receiving 
MAT and in non-intensive outpatient treatment for OUD using logit models. The adjusted two-ways 
fixed effect model suggests that Medicaid expansion was not significantly associated with an increase in 
likelihood of being referred by healthcare providers (vs. self-referral). 
Table 2-7 presents the adjusted estimates from DID model for non-MAT, non-intensive 
outpatient treatment for OUD. The adjusted DID estimate indicated that state implementation of 
Medicaid expansion in 2014 was associated with an increase in likelihood of being referred by 
healthcare provider (vs. self-referral) (RRR 1.2, 95% CI: 1.1-1.3). The Medicaid expansion was also 
positively associated with the likelihood of being referred by other institutional referrals (RRR 2.5, 95% 
CI: 2.3-2.7) or court/criminal justice referral (RRR 1.3, 95% CI: 1.2-1.3). 





treatment for OUD. The adjusted DID estimate indicated that state implementation of Medicaid 
expansion in 2014 was positively associated with the likelihood of being referred by other institutional 
referrals (RRR 2.2, 95% CI: 1.8-2.7) and court/criminal justice referrals (RRR 1.3, 95% CI: 1.01-1.7). 
However, the adjusted DID estimate indicated that state implementation of Medicaid expansion in 2014 
was not significantly associated with an increase in likelihood of being referred by healthcare provider 
(vs. self-referral). 
 
Sensitivity analysis results 
Table 2-C shows the sensitivity analysis results when we added states’ unemployment rates and 
PMDP policies in the 2WFE model (Table 2-C1) and from DID model (Table 2-C2). Compared with 
non-expansion states, the adjusted 2WFE estimates showed that Medicaid expansion states were 
positively associated with increased likelihood of being referred by healthcare providers (RRR 1.1, 95% 
CI: 1.1-1.2), other institutions (RRR: 2.1, 95% CI: 2.0-2.3), court/ criminal justice (RRR: 1.3, 95% CI: 
1.2-1.4) compared to self-referrals.  These results were consistent with the main model results (Table 2-
3), as well as the sensitivity results from the DID model (Table 2C-2).  
Table 2-D presents the sensitivity analysis results from lagged DID model. Medicaid expansion 
had a positive effect in the likelihood of being referred by healthcare providers (vs. self-referrals) in year 
2 of the expansion (RRR 1.2, 95% CI: 1.06-1.33), and year 3 of the expansion (RRR 1.2, 95% CI: 1.04-
1.27). On the other hand, Medicaid expansion had a positive effect in year 3 of the expansion for 
institutional referrals (RRR 1.4, 95% CI: 1.19-1.54), court/criminal justice referrals (RRR 1.5, 95% CI: 
1.37- 1.65).  
Tables 2-E1 to 2-E6 show the sensitivity analysis results for discharges with more than one 





sample and MAT or non-MAT stratification. Medicaid expansion was negatively associated with the 
likelihood of being referred by healthcare providers (RRR 0.9, 95 % CI: 0.88-0.95) but positively 
associated with the likelihood of being referred by institutional referrals (RRR 1.3, 95% CI: 1.3-1.4) 
(Table 2-E1). These were consistent with the DID model results (Table 2-E2) and stratified by MAT 
(Tables 2E3 and 2E4). In addition, we also saw the positive effect of Medicaid expansion on the 
likelihood of being referred by court/criminal justice referrals among those who used MAT in their 
outpatient treatment (Table 2-E4). The sensitivity analysis results for discharges with one more episode 
of treatment with regards to Medicaid expansion and likelihood of being referred by healthcare 
providers were not consistent with the results from main model for non-prior treatment episode 
discharges.  
Appendix 2-F shows the sensitivity analysis results when we added indicators states’ 1115 
Waiver Demonstrations for SUD. The adjusted estimates from 2 WFE showed Medicaid expansion was 
positively associated with the likelihood of being referred by healthcare providers (vs. self-referrals) 
(RRR 1.2, 95% CI: 1.1-1.2), institutional referrals (RRR 2.3, 95% CI: 2.1-2.4), and court/criminal 
justice (RRR 1.3, 95% CI: 1.2- 1.4) (Table 2F-1). These results were consistent with the main model 
results (Table 2-3) as well as the sensitivity analysis results from the DID model (Table 2-F2). 
Additionally, we saw a higher likelihood of being referred by healthcare providers, institutional 
referrals, and court/criminal justice referrals (vs. self-referrals) compared to states that did not 
implement the 1115 Waivers; however, the associations were not significant, except for institutional 
referrals (RRR 1.2, 95% CI 1.1-1.4) (Table 2-F1).  
 
Summary of adjusted associations between key covariates and referral sources 
 





a psychiatric comorbidity, being homeless, no history of arrest were positively associated with the 
likelihood of being referred by healthcare providers while males were negatively associated with the 
likelihood of being referred by healthcare providers (vs. self-referred). For example, discharges with 
psychiatric comorbidity were associated with 48% increase (95% CI: 1.4-1.5) in the likelihood of being 
referred by healthcare providers in non-intensive outpatient treatment for OUD (Table 2-3). However, 
having a psychiatric disorder, being employed, being homeless were less likely to be referred by 





This study explored whether Medicaid expansion under the ACA was associated with changes in 
referral sources to OUD treatment, specifically whether expansion increased the likelihood of being 
referred by healthcare providers to outpatient treatment. Using TEDS-D data from the year 2010 to 2017 
when many states started to implement Medicaid expansion and expanded access to evidence-based 
treatments for OUD, we found that Medicaid expansion was positively associated with the likelihood of 
healthcare provider referrals (versus self-referrals) to non-intensive outpatient treatment for OUD.  
These results provide the first empirical evidence of the positive impact of Medicaid expansions 
under the ACA on healthcare provider referral to outpatient treatment for OUD. Specifically, we found 
expansion was associated with an 18% increase (95% CI: 1.1-1.3) in the likelihood of referral to 
outpatient OUD treatment by a healthcare provider.  The main findings were consistent between the 
2WFE model and the simple DID model with regards to the magnitude, direction, and compactness of 
the estimated likelihood of being referred to outpatient treatment by healthcare provider (vs. self-





Alaska, Indiana, and Pennsylvania) excluded in the DID model, only accounted for an exclusion of 
9,875 observations out of 382,609 observations included in the 2WFE model. Specifically, the 9,875 
observation that were deleted were from Louisiana (n=1,295), Montana (n=837), Alaska (n=675), 
Indiana (3,415), and Pennsylvania (n=3,653). Thus, the removal of the 5 late expansion states (with a 
small number of observations) in the DID model did not appear to substantially change the Medicaid 
expansion estimates observed in the 2WFE model. Our main results were robust and were consistent 
with the sensitivity analysis results for non-MAT subpopulation, additional covariates (i.e., 
unemployment rates and PDMP), and sensitivity analysis that added section 1115 Demonstration 
Waiver. Even though we saw a positive effect of Medicaid expansion on the increased likelihood of 
being referred by healthcare providers for those who received MAT in non-intensive outpatient 
treatment, we have not found a statistically significantly association. This was probably due to a smaller 
sample size for those who received MAT only, who accounted for about one third of those who used 
non-intensive outpatient treatment. In addition, Medicaid policy probably takes time to have an effect on 
the referral system including healthcare provider system.  
Findings from this study add to the literature on the role of Medicaid expansion on the OUD 
treatment delivery system, by highlighting its impact on the likelihood of healthcare provider referrals to 
outpatient treatment. Previous studies on the effects of Medicaid expansion on OUD treatment mostly 
focused on its impact via increasing health insurance coverage, and increasing access to and use of 
medications for OUD, such as buprenorphine.21,24,96,97 Our study emphasizes the role of Medicaid 
expansion on the referral system through increasing the likelihood of being referred by healthcare 
providers who should play significant role in opioid use disorder treatment. A previous study pointed out 
that referrals to substance use treatment by healthcare providers were associated with more accurate 





appropriate level of care.98 The current study suggests that Medicaid expansion has the potential to 
improve the referral system and increase access to timely and effective evidence-based treatments for 
OUD. Ongoing Medicaid expansion efforts should focus on further documenting and supporting 
healthcare providers’ role in accurately diagnosing OUD and referring patients to an appropriate level of 
care.  
The finding on the positive association of Medicaid expansion on healthcare provider referral 
offers some interesting insights into the role of Medicaid expansion on the referral system where 
healthcare providers should play an important role in referring individuals in need of treatment to 
evidence-based treatments for OUD. In addition, referrals from healthcare providers suggests better 
opportunity for screening and referrals to treatment needed given that many of those with OUD also 
suffered from other health conditions including psychiatric problems, chronic diseases, and other 
infection diseases such as HIV/AIDS and Hepatitis C.99,100 In addition, Phillip and his colleagues found 
that healthcare providers referrals to MAT were associated with a decreased risk of discharges due to 
incarceration, compared to criminal justice referrals as well as self-referrals.38 Our study found that 
healthcare provider referrals were not the most common referral source; instead, most patients were 
either self-referred (more than 50%) or referred by the court/criminal justice (more than 30%). However, 
we saw an increasing number of discharges that were referred by healthcare providers over time. 
Furthermore, our study findings were consistent with previous studies that mostly focused on the 
court/criminal justice referral source with regards to the associations between key characteristics and 
referral sources. Further, our study findings indicated key characteristics that were associated with the 
increased likelihood of being referred by healthcare providers. These characteristics included being 







This study’s finding should be interpreted with some caution. First, the generalizability of this 
study may only apply to a specific population that is accessing substance use treatment for the first time, 
aged 18 to 64 years old, in non-intensive outpatient treatment for OUD, and only those receiving 
treatment in a publicly funded facility. A previous study comparing National Survey of Substance Abuse 
Treatment (N-SSATS) and TEDS pointed out that TEDS was a subset of the facilities that reported to N-
SSATS. Specifically, facilities in TEDS accounted for about 50% of all SUD treatment facilities 
nationwide.101 Given that privately funded SUD treatment increased substantially in recent years, 
especially under the ACA’s Medicaid expansion,102 the omission of this treatment type may limit the 
generalizability of this study’s findings. In addition, TEDS-D does not include all community health 
centers, half of which offer SUD treatment services. Previous studies that examined the association 
between Medicaid expansion and community health centers also showed the positive role of Medicaid 
expansion on capacity of community health centers.103,104 In addition, some states (e.g., West Virginia, 
Georgia, Oregon) did not report data in the years 2015 to 2017, which could affect the generalizability 
of our estimates. Furthermore, TEDS-D does not have information on dates of discharges, so including 
discharges that occurred earlier in the year a state expanded Medicaid could result in a conservative bias. 
In addition, it takes time for substance use-related policies to improve the treatment system including the 
referral system.96,105 Thus, we anticipate seeing more significant improvement over time in the 
likelihood of discharges that were referred by healthcare providers in outpatient treatment setting. 
This study’s finding should also be interpreted in consideration of the advantages and limitations 
of TEDS-D. One advantage of using TEDS-D is that it is a large national dataset and representative of 
publicly funded outpatient treatment for opioid use disorder in real-world treatment settings. TEDS-D 
also has comprehensive information on demographic characteristics, substance use history, referral 





DID model as well as incorporate state level information (e.g., unemployment rates and PDMP). 
However, TEDS-D also has several limitations. The first limitation is that TEDS-D is a discharge-level 
dataset and does not have identifiable information to link different discharges of the same individual. 
Including multiple discharges from the same individual in an analytic sample could lead to biased 
estimates. We limited this bias by restricting our analysis sample to only discharges with no prior 
admissions in their lifetime; however, exclusion of discharges with multiple episodes of treatment 
should be acknowledged as an important limitation, particularly as those with multiple discharges in a 
year may represent patients with the highest need. Second, TEDS-D data collection process is based on 
reports from individual programs across different states. The variables might be defined differently 
across individual programs. In addition, some states did not report in certain years. For example, data 
was not available for Georgia (non-expansion state), Oregon (expansion state), and West Virginia 
(expansion state) from 2015 to 2017, which could potentially affect the generalizability of our estimates. 
The missing data (for example, 60% of health insurance information is missing) also limited further 
analysis of the roles of different types of health insurance coverage on referral sources, though such 
analyses would likely be plagued by endogeneity further highlighting the value of leveraging the 




This study found that Medicaid expansion under the ACA had a positive impact on the 
likelihood of being referred by healthcare providers in outpatient treatment for OUD. Our study findings 
suggest that Medicaid expansion has the potential to improve the referral system through healthcare 
provider referrals. Ongoing Medicaid expansion under the ACA should focus on the healthcare provider 






Table 2-2. Sample characteristics 
 Frequency Percent 
Total  N= 382, 609 % 
Referral sources  N=375, 583  
   Self-referral  201,632 53.7 
   Healthcare provider referral  50,465 13.4 
   Other institutional referral  38,631 10.3 
   Court/criminal justice referral 84,855 22.6 
MAT  N= 375,051  
   Yes 133,787 35.7 
Frequency of use  N= 369,848  
   No use in the past month 106,921 28.9 
   Some use 71,499 19.3 
   Daily use  191,428 51.8 
Age  N= 382, 609  
   18-29 127,141 33.2 
   30-44 179,390 46.9 
   45-64 76,078 19.9 
Gender N= 382,525  
   Male  209,602 54.8 
Race/ethnicity  N= 375,376  
   Non-Hispanic White 289,016 77.0 
   Non-Hispanic Black 31,413 8.4 
   Hispanic  40,542 10.8 
   Other 14,405 3.8 
Education  372, 826  
   Highschool or higher 271,923 72.9 
Number of arrests  N= 364, 417  
   None 340, 071  
   1 19, 430 5.3 
   2 or more 4, 916 1.4 
Employment status  N= 376, 639  
     Employed 275, 672 73.2 
Comorbidity N=333, 487  
   Yes  103, 207  
Homeless N= 371, 037  
  Yes 20, 687 5.6 
Polysubstance use  N= 304, 655  
    No 128,782 42.3 
    One more 104,430 34.3 












































2010 2011 2012 2013 2014 2015 2016 2017
Number of discharges by referral sources






Figure 6. Trends in referral sources across Medicaid expansion and non-expansion states, in non-
intensive outpatient opioid treatments, TEDS-D 2010-2017. The vertical line represents the Medicaid 













2010 2011 2012 2013 2014 2015 2016 2017
Self-referral





2010 2011 2012 2013 2014 2015 2016 2017
Healthcare provider referral





2010 2011 2012 2013 2014 2015 2016 2017
Other institutional referral 




2010 2011 2012 2013 2014 2015 2016 2017
Court/criminal justice referral












     
N 231,025 231,025 231,025 
 RRR RRR RRR 
 (95%CI) (95%CI) (95%CI) 
Medicaid expansion        
  Yes  1.18*** 2.28*** 1.31*** 
 (1.11 - 1.24) (2.13 - 2.44) (1.24 - 1.38) 
MAT (No= ref)     
   Yes 0.64*** 0.34*** 0.14*** 
  (0.62 - 0.66) (0.33 - 0.36) (0.13 - 0.14) 
Frequency of use (No 
past month use= ref)  
   
   Some use 0.64*** 0.66*** 0.39*** 
 (0.62 - 0.67) (0.63 - 0.68) (0.37 - 0.40) 
   Daily use 0.51*** 0.37*** 0.16*** 
 (0.50 - 0.53) (0.36 - 0.38) (0.16 - 0.17) 
Age (18-29= ref)     
   30-44 1.00 1.01 0.99 
 (0.97 - 1.03) (0.97 - 1.04) (0.97 - 1.02) 
   45-64 1.11*** 0.81*** 0.87*** 
 (1.07 - 1.15) (0.78 - 0.85) (0.84 - 0.90) 
Gender (Female=ref)    
   Male 0.88*** 0.62*** 1.32*** 
 (0.86 - 0.90) (0.61 - 0.64) (1.29 - 1.35) 
Race/ethnicity (non-
Hispanic White=ref) 
   
   Non-Hispanic Black 1.01 1.35*** 1.19*** 
 (0.96 - 1.07) (1.27 - 1.44) (1.13 - 1.26) 
   Hispanic 0.89*** 1.30*** 1.21*** 
 (0.85 - 0.95) (1.23 - 1.37) (1.15 - 1.27) 
   Other 0.87*** 1.03 0.96 
 (0.81 - 0.94) (0.95 - 1.11) (0.90 - 1.03) 
Education (Less than 
high school= ref)  
   
   Highschool or higher 0.96** 0.79*** 0.77*** 
 (0.93 - 0.99) (0.76 - 0.81) (0.75 - 0.79) 
Number of arrests (0= 
ref) 





   1 0.85*** 1.18*** 2.71*** 
 (0.80 - 0.91) (1.10 - 1.26) (2.58 - 2.85) 
   2 or more 0.86** 0.96 1.09 
 (0.77 - 0.96) (0.83 - 1.11) (0.99 - 1.20) 
Employment status 
(Not employed= ref)  
   
     Employed 
1.32*** 1.15*** 0.94*** 
 (1.28 - 1.36) (1.11 - 1.19) (0.92 - 0.97) 
Comorbidity (No= ref)     
   Yes 1.48*** 0.91*** 0.65*** 
 (1.44 - 1.52) (0.89 - 0.94) (0.63 - 0.67) 
Homeless (No= ref)     
  Yes 1.31*** 1.37*** 0.61*** 
 (1.25 - 1.38) (1.29 - 1.45) (0.57 - 0.65) 
Polysubstance use 
(no= ref)   
   
    One more 0.99 1.03 0.85*** 
 (0.96 - 1.02) (0.99 - 1.06) (0.83 - 0.88) 
    Two or more 0.98 1.07*** 0.95** 
 (0.95 - 1.01) (1.03 - 1.11) (0.92 - 0.98) 
* p<0.05, ** p<0.01, *** p<0.001 
Reference group for multinomial regression is self-referral. Relative Risk Ratio = RRR. Confidence 
Interval = CI.  

































    
N 225,272 225,272 225,272 
 RRR RRR RRR 
 (95%CI) (95%CI) (95%CI) 
    
Expansion 0.84 0.94 1.06 
    (0.52 - 1.35) (0.58 - 1.52) (0.64 - 1.75) 
Post expansion  0.70*** 0.42*** 0.82*** 
    (0.66 - 0.75) (0.39 - 0.45) (0.78 - 0.87) 
Expansion * Post expansion  1.18*** 2.39*** 1.32*** 
    (1.12 - 1.25) (2.23 - 2.56) (1.25 - 1.39) 
MAT (No= ref)     
   Yes 0.65*** 0.34*** 0.14*** 
 (0.63 - 0.67) (0.32 - 0.35) (0.13 - 0.14) 
Frequency of use     
   Some use 0.64*** 0.66*** 0.39*** 
 (0.62 - 0.67) (0.64 - 0.69) (0.37 - 0.40) 
   Daily use  0.51*** 0.38*** 0.16*** 
 (0.50 - 0.53) (0.36 - 0.39) (0.16 - 0.17) 
Age (18-29= ref)     
   30-44 1.00 1.00 0.99 
 (0.97 - 1.03) (0.97 - 1.03) (0.97 - 1.02) 
   45-64 1.11*** 0.81*** 0.87*** 
 (1.07 - 1.15) (0.77 - 0.85) (0.84 - 0.90) 
Gender    
   Male  0.88*** 0.62*** 1.32*** 
 (0.86 - 0.90) (0.60 - 0.64) (1.29 - 1.35) 
Race/ethnicity     
   Non-Hispanic Black 1.02 1.36*** 1.19*** 
 (0.96 - 1.07) (1.28 - 1.45) (1.13 - 1.26) 
   Hispanic  0.89*** 1.31*** 1.21*** 
 (0.85 - 0.94) (1.24 - 1.39) (1.15 - 1.27) 
   Other 0.88*** 1.04 0.98 
 (0.82 - 0.95) (0.96 - 1.12) (0.92 - 1.06) 
Education     
   Highschool or higher 0.96* 0.81*** 0.78*** 
 (0.94 - 0.99) (0.78 - 0.84) (0.76 - 0.80) 
Number of arrests (0=ref)    
   1 0.83*** 1.20*** 2.73*** 
 (0.78 - 0.89) (1.12 - 1.28) (2.60 - 2.87) 
   2 or more 0.86* 0.96 1.08 





Employment status     
     Employed 1.33*** 1.14*** 0.93*** 
 (1.29 - 1.37) (1.10 - 1.18) (0.91 - 0.96) 
Comorbidity    
   Yes  1.50*** 0.91*** 0.65*** 
 (1.46 - 1.54) (0.88 - 0.94) (0.63 - 0.67) 
Homeless    
  Yes 1.33*** 1.35*** 0.61*** 
 (1.26 - 1.40) (1.27 - 1.43) (0.57 - 0.65) 
Polysubstance use     
    One more 1.00 1.02 0.85*** 
 (0.97 - 1.03) (0.98 - 1.05) (0.82 - 0.87) 
    Two or more 0.99 1.06** 0.94*** 
 (0.95 - 1.02) (1.02 - 1.10) (0.91 - 0.97) 
* p<0.05, ** p<0.01, *** p<0.001 
Reference group for multinomial regression is self-referral. Relative Risk Ratio = RRR. Confidence Interval = CI.  









































N 169,449 169,449 169,449 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Medicaid expansion     
  Expanded 1.17*** 2.36*** 1.25*** 
 (1.10 - 1.24) (2.19 - 2.54) (1.18 - 1.32) 
Frequency of use (No 
past month use= ref)  
   
   Some use 0.67*** 0.67*** 0.40*** 
 (0.64 - 0.70) (0.64 - 0.70) (0.38 - 0.41) 
   Daily use 0.59*** 0.41*** 0.18*** 
 (0.57 - 0.61) (0.39 - 0.43) (0.17 - 0.19) 
Age (18-29= ref)     
   30-44 1.03 1.00 0.98 
 (0.99 - 1.06) (0.96 - 1.03) (0.96 - 1.01) 
   45-64 1.21*** 0.82*** 0.91*** 
 (1.16 - 1.27) (0.78 - 0.86) (0.88 - 0.95) 
Gender (Female=ref)    
   Male 0.91*** 0.60*** 1.33*** 
 (0.88 - 0.93) (0.58 - 0.62) (1.29 - 1.36) 
Race/ethnicity (non-
Hispanic White=ref) 
   
   Non-Hispanic Black 1.14*** 1.56*** 1.30*** 
 (1.07 - 1.22) (1.45 - 1.67) (1.23 - 1.37) 
   Hispanic 1.02 1.55*** 1.33*** 
 (0.95 - 1.09) (1.45 - 1.66) (1.26 - 1.41) 
   Other 0.90* 1.05 0.97 
 (0.82 - 0.98) (0.96 - 1.14) (0.90 - 1.04) 
Education (Less than high 
school= ref)  
   
   Highschool or higher 0.94*** 0.76*** 0.75*** 
 (0.91 - 0.97) (0.74 - 0.79) (0.73 - 0.77) 
Number of arrests (0= 
ref) 





   1 0.79*** 1.13** 2.48*** 
 (0.73 - 0.85) (1.05 - 1.22) (2.36 - 2.62) 
   2 or more 0.69*** 0.93 0.93 
 (0.61 - 0.78) (0.79 - 1.09) (0.84 - 1.04) 
Employment status (Not 
employed= ref)  
   
     Employed 1.30*** 1.12*** 0.92*** 
 (1.25 - 1.35) (1.08 - 1.16) (0.90 - 0.95) 
Comorbidity (No= ref)     
   Yes 1.57*** 0.85*** 0.62*** 
 (1.52 - 1.62) (0.82 - 0.88) (0.60 - 0.64) 
Homeless (No= ref)     
  Yes 1.31*** 1.25*** 0.57*** 
 (1.23 - 1.39) (1.16 - 1.33) (0.53 - 0.61) 
Polysubstance use (no= 
ref)   
   
    One more 0.99 0.92*** 0.78*** 
 (0.95 - 1.02) (0.89 - 0.96) (0.76 - 0.81) 
    Two or more 0.91*** 0.93*** 0.84*** 
 (0.88 - 0.95) (0.89 - 0.97) (0.82 - 0.87) 
* p<0.05, ** p<0.01, *** p<0.001 
Reference group for multinomial regression is self-referral. Relative Risk Ratio = RRR. Confidence 
Interval = CI.  































N 53,295 48,302 
 AOR AOR 
  (95%CI) (95%CI) 
   
Medicaid expansion    
  Expanded 1.10 1.31 
 (0.97 - 1.25) (1.00 - 1.71) 
Frequency of use (No past month use= ref)    
   Some use 0.58*** 0.36*** 
 (0.53 - 0.63) (0.32 - 0.40) 
   Daily use 0.38*** 0.15*** 
 (0.36 - 0.41) (0.13 - 0.16) 
Age (18-29= ref)    
   30-44 0.91** 0.99 
 (0.86 - 0.96) (0.91 - 1.08) 
   45-64 0.86*** 0.58*** 
 (0.80 - 0.93) (0.51 - 0.66) 
Gender (Female=ref)   
   Male 0.81*** 1.14*** 
 (0.77 - 0.85) (1.06 - 1.24) 
Race/ethnicity (non-Hispanic White=ref)   
   Non-Hispanic Black 0.87** 0.99 
 (0.79 - 0.95) (0.85 - 1.17) 
   Hispanic 0.81*** 0.81** 
 (0.73 - 0.89) (0.69 - 0.93) 
   Other 0.83* 0.91 
 (0.71 - 0.97) (0.71 - 1.15) 
Education (Less than high school= ref)    
   Highschool or higher 0.97 0.87*** 
 (0.92 - 1.02) (0.80 - 0.94) 





   1 0.98 5.34*** 
 (0.86 - 1.13) (4.69 - 6.08) 
   2 or more 1.45** 2.01*** 
 (1.11 - 1.90) (1.38 - 2.93) 
Employment status (Not employed= ref)    
     Employed 1.37*** 0.98 
 (1.29 - 1.46) (0.90 - 1.07) 
Comorbidity (No= ref)    
   Yes 1.20*** 1.01 
 (1.14 - 1.27) (0.93 - 1.10) 
Homeless (No= ref)    
  Yes 1.31*** 0.82* 
 (1.18 - 1.44) (0.68 - 0.98) 
Polysubstance use (no= ref)     
    One more 0.93** 1.57*** 
 (0.88 - 0.98) (1.43 - 1.72) 
    Two or more 1.09* 2.23*** 
 (1.02 - 1.16) (2.02 - 2.46) 
* p<0.05, ** p<0.01, *** p<0.001 
Reference group for multinomial regression is self-referral. Relative Risk Ratio = RRR. Confidence Interval = CI.  




























Other institutional Court/criminal justice 
referral Referral 
    
N 164,420 164,420 164,420 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Expansion 0.91 0.71 1.14 
    (0.41 - 2.01) (0.37 - 1.38) (0.60 - 2.16) 
Post expansion  0.68*** 0.34*** 0.75*** 
    (0.64 - 0.73) (0.32 - 0.37) (0.70 - 0.80) 
Expansion * Post expansion  1.18*** 2.50*** 1.25*** 
    (1.10 - 1.25) (2.31 - 2.69) (1.18 - 1.32) 
Frequency of use (No 
past month use= ref)  
   
   Some use 0.67*** 0.67*** 0.40*** 
 (0.64 - 0.70) (0.65 - 0.70) (0.38 - 0.41) 
   Daily use 0.59*** 0.41*** 0.18*** 
 (0.57 - 0.61) (0.40 - 0.43) (0.17 - 0.19) 
Age (18-29= ref)     
   30-44 1.02 1.00 0.98 
 (0.99 - 1.06) (0.96 - 1.03) (0.96 - 1.01) 
   45-64 1.21*** 0.82*** 0.91*** 
 (1.16 - 1.27) (0.78 - 0.86) (0.87 - 0.95) 
Gender (Female=ref)    
   Male 0.91*** 0.59*** 1.32*** 
 (0.88 - 0.94) (0.57 - 0.61) (1.29 - 1.36) 
Race/ethnicity (non-
Hispanic White=ref) 
   
   Non-Hispanic Black 1.16*** 1.56*** 1.30*** 
 (1.08 - 1.23) (1.45 - 1.68) (1.22 - 1.37) 
   Hispanic 1.02 1.56*** 1.34*** 
 (0.95 - 1.10) (1.46 - 1.68) (1.26 - 1.42) 
   Other 0.90* 1.06 0.99 
 (0.83 - 0.99) (0.97 - 1.16) (0.92 - 1.07) 
Education (Less than high 
school= ref)  
   





 (0.91 - 0.98) (0.74 - 0.80) (0.73 - 0.78) 
Number of arrests (0= 
ref) 
   
   1 0.77*** 1.13** 2.48*** 
 (0.71 - 0.84) (1.05 - 1.22) (2.36 - 2.62) 
   2 or more 0.71*** 0.92 0.92 
 (0.62 - 0.80) (0.78 - 1.08) (0.83 - 1.03) 
Employment status (Not 
employed= ref)  
   
     Employed 1.31*** 1.12*** 0.92*** 
 (1.27 - 1.36) (1.08 - 1.16) (0.90 - 0.95) 
Comorbidity (No= ref)     
   Yes 1.59*** 0.85*** 0.62*** 
 (1.54 - 1.64) (0.82 - 0.88) (0.60 - 0.64) 
Homeless (No= ref)     
  Yes 1.34*** 1.24*** 0.56*** 
 (1.26 - 1.42) (1.15 - 1.32) (0.52 - 0.60) 
Polysubstance use (no= 
ref)   
   
    One more 1.00 0.92*** 0.78*** 
 (0.96 - 1.03) (0.88 - 0.95) (0.75 - 0.80) 
    Two or more 0.92*** 0.93*** 0.83*** 
 (0.89 - 0.96) (0.89 - 0.96) (0.80 - 0.86) 
* p<0.05, ** p<0.01, *** p<0.001 
Reference group for multinomial regression is self-referral. Relative Risk Ratio = RRR. Confidence Interval = CI.  

























Other institutional  Court/criminal 
justice referral Referral  
    
N 60,852 60,852 60,852 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Expansion 0.79 1.17 0.47 
    (0.43 - 1.44) (0.54 - 2.54) (0.18 - 1.18) 
Post expansion  0.71*** 0.51*** 1.18 
    (0.62 - 0.82) (0.42 - 0.62) (0.89 - 1.57) 
Expansion * Post expansion  1.12 2.22*** 1.33* 
    (0.99 - 1.28) (1.83 - 2.69) (1.02 - 1.74) 
Frequency of use (No past 
month use= ref)  
   
   Some use 0.58*** 0.69*** 0.35*** 
 (0.53 - 0.63) (0.62 - 0.76) (0.32 - 0.39) 
   Daily use 0.38*** 0.40*** 0.15*** 
 (0.35 - 0.41) (0.37 - 0.44) (0.13 - 0.16) 
Age (18-29= ref)     
   30-44 0.92** 0.95 1.02 
 (0.87 - 0.98) (0.88 - 1.02) (0.94 - 1.11) 
   45-64 0.91* 0.69*** 0.61*** 
 (0.84 - 0.98) (0.62 - 0.77) (0.54 - 0.69) 
Gender (Female=ref)    
   Male 0.82*** 0.73*** 1.21*** 
 (0.78 - 0.86) (0.68 - 0.78) (1.12 - 1.30) 
Race/ethnicity (non-Hispanic 
White=ref) 
   
   Non-Hispanic Black 0.88** 1.04 0.97 
 (0.80 - 0.96) (0.91 - 1.19) (0.82 - 1.13) 
   Hispanic 0.82*** 0.93 0.80** 
 (0.74 - 0.90) (0.82 - 1.05) (0.69 - 0.92) 
   Other 0.85* 1.03 0.93 
 (0.73 - 0.99) (0.85 - 1.24) (0.73 - 1.17) 
Education (Less than high 
school= ref)  
   





 (0.93 - 1.03) (0.85 - 0.98) (0.83 - 0.98) 
Number of arrests (0= ref)    
   1 0.99 1.29** 5.07*** 
 (0.86 - 1.14) (1.09 - 1.52) (4.47 - 5.75) 
   2 or more 1.44** 0.84 2.35*** 
 (1.10 - 1.89) (0.53 - 1.32) (1.64 - 3.38) 
Employment status (Not 
employed= ref)  
   
     Employed 1.40*** 1.21*** 1.00 
 (1.32 - 1.49) (1.12 - 1.31) (0.92 - 1.09) 
Comorbidity (No= ref)     
   Yes 1.21*** 1.26*** 1.07 
 (1.14 - 1.28) (1.18 - 1.35) (0.99 - 1.16) 
Homeless (No= ref)     
  Yes 1.34*** 1.62*** 0.92 
 (1.21 - 1.48) (1.44 - 1.82) (0.77 - 1.10) 
Polysubstance use (no= ref)      
    One more 0.93** 1.36*** 1.59*** 
 (0.88 - 0.98) (1.26 - 1.47) (1.46 - 1.74) 
    Two or more 1.07* 1.47*** 2.15*** 
 (1.00 - 1.14) (1.34 - 1.60) (1.95 - 2.37) 
* p<0.05, ** p<0.01, *** p<0.001 
Reference group for multinomial regression is self-referral. Relative Risk Ratio = RRR. Confidence Interval = CI.  















     
 RRR RRR RRR 
 (95%CI) (95%CI) (95%CI) 
Medicaid expansion        
  Yes  1.18*** 2.28*** 1.31*** 
 (1.11 - 1.24) (2.13 - 2.44) (1.24 - 1.38) 
Among non-MAT    
Medicaid expansion  RRR RRR RRR 
  Yes 1.17*** 2.36*** 1.25*** 
 (1.10 – 1.24) (2.19 – 2.54) (1.18 – 1.32) 
Among MAT     
Medicaid expansion  AOR  AOR 
  Yes 1.10  1.31 
 (0.97 - 1.25)  (1.00 - 1.71) 
Sensitivity analysis with 
additional covariates 
   
Medicaid expansion  RRR RRR RRR 
  Yes  1.10** 2.11*** 1.28*** 
 (1.04 - 1.16) (1.97 - 2.27) (1.22 - 1.35) 
Sensitivity analysis with 
added Section 1115 
Waiver 
   
Medicaid expansion  RRR RRR RRR 
  Yes  1.17*** 2.26*** 1.31*** 
 (1.11 - 1.24) (2.11 - 2.42) (1.24 - 1.38) 
    
* p<0.05, ** p<0.01, *** p<0.001 
Reference group for multinomial regression is self-referral. Relative Risk Ratio = RRR. Confidence Interval = CI.  






Chapter 4 Medicaid expansion’s role in opioid use disorder treatment completion and length of stay 




Along with expanded access, treatment retention is a key step towards improving long-term 
opioid use disorder (OUD) treatment outcomes. However, there is a dearth of studies examining 
associations between Medicaid expansion and OUD treatment outcomes in outpatient treatment settings, 
which is surprising, given that Medicaid expansion under the ACA has played a significant role in 
improving the substance use treatment system. This study explores the role of Medicaid expansion in 
OUD treatment completion and retention in outpatient settings.  
This study used a two-way fixed effects (2WFE) model to examine the effect of Medicaid 
expansion on treatment outcomes.  A simple difference-in-differences (DID) model that only included 
states that expanded Medicaid in 2014 and states that did not expand by 2017 was used as a sensitivity 
test. Data were 2010-2017 Treatment Episode Data Set- Discharge (TEDS-D) in non-intensive 
outpatient treatment for OUD (N= 382,609). Logistic regression models controlled for state and year 
fixed effects, Medication-Assisted Treatment (MAT) for OUD, and other covariates including 
demographic characteristics, psychiatric comorbidity, and poly substance use were included as 
covariates. The adjusted associations were stratified by MAT, as non-intensive outpatient treatment 
could include both MAT and non-MAT, while treatment outcome expectation could be different 
between these two strategies (e.g., treatment retention is expected as a positive outcome for MAT).  
Patients in Medicaid expansion states were less likely to stay in non-intensive outpatient 
treatment longer than 90 days (AOR 0.9, 95% CI: 0.89-0.97), compared with those in non-expansion 
states. However, patients from Medicaid expansion states receiving MAT were more likely to stay in 





(AOR 1.2, 95%; CI: 1.08-1.30). Findings from the 2WFE were consistent with the findings from the 
DID model. 
Our study indicated that Medicaid expansion was positively associated with treatment retention 
in medication for OUD in outpatient treatment setting, but negatively associated with treatment 
completion in non-MAT treatment. We suggest a renewed focus on the role of insurance coverage 
policies such as Medicaid program on treatment retention in opioid treatment. Further research should 
address state variations in Medicaid policy components for a better understanding of mechanisms of the 


































 Only one in ten individuals in the U.S. with a substance use disorder (SUD), and only one in 
five of those with opioid use disorder (OUD) receive any type of treatment.1,11 Beyond issues of access, 
treatment completion is a key step towards improving long-term SUD treatment outcomes (e.g., 
sustained abstinence/recovery, improved health, social, and economic outcomes13,14). In a study on 
treatment completion among publicly-funded substance use treatment facilities, only 28% of patients 
completed their treatment.14 As a majority of individuals with OUD are low income (more than 60%),11 
lack of financial support for these patients to participate and remain in treatment is one key barrier. 
Other barriers include the limited availability of providers and stigma toward substance use treatment.12 
Further, the ability of the health care delivery system to refer individuals with SUD in need of treatment 
to appropriate, evidence-based treatments is lacking,19 which likely influences treatment completion and 
retention.19,20  
Medicaid expansion represents a significant policy shift both because it has increased health 
insurance coverage for so many individuals with SUD (Medicaid pays for a majority of individuals with 
SUD35) and because it has increased the supply of treatment providers.24 Thus, Medicaid expansion has 
been instrumental in reforming the U.S. delivery system for SUD treatment and increasing access to 
such treatment.66 By enabling states to expand Medicaid eligibility to low-income adults up to 138% of 
FPL 81 Medicaid expansion under the Patient Protection Affordable Care Act (ACA) has increased 
insurance coverage among individuals with SUD in 37 states as of 2020.82  Importantly, the ACA also 
defined SUD as one of ten essential health benefits that must be covered and should be covered on parity 
with other medical conditions;67 however, this benefit can vary by state as the ACA did not specify 
which SUD services must be included. Prior to the ACA, most low-income people who were in need of 





expansion has narrowed the treatment gap through increased insurance coverage and delivery system 
changes.84,85 Indeed, previous studies found that Medicaid expansion has helped reduce the percentage 
of uninsured low-income adults with SUD from 36% to 27%.21,22 Additionally, admissions to SUD 
treatment among Medicaid beneficiaries increased 113% as a result of expansion, without crowding out 
admissions from individuals with other types of insurance.23 Medicaid expansion has also resulted in 
substantial increases in the use of pharmacological therapy, including methadone and buprenorphine, for 
OUD.22–24  
Although there have been many interpretations of how best to define treatment success, 
treatment completion and treatment retention are considered key indicators for positive treatment 
outcomes for substance use treatment.13,14 Brorson and co-authors asserted that treatment completion is 
one of the most widely used proximal measures of  SUD treatment effectiveness.13 In their study, 
treatment completion was defined as successfully completing treatment goals. The authors particularly 
pointed out that individuals who completed substance use treatment were more likely to remain 
abstinent, had fewer relapses, and were in better health.13 In addition, previous studies only focused on 
substance treatment completion in general, whereas opioid treatment completion could be different. 
There has been a shift from rapid detoxification to long-term treatment for OUD given that OUD has 
been considered a chronic disease.106–108 Medication-assisted treatment (MAT) for OUD — methadone, 
buprenorphine, and naltrexone — have been approved by the Food and Drug Administration to be 
effective in reducing drug use and overdose.109 Evidence also indicated that longer stay in MAT led to 
better outcomes. Indeed, the NIDA Clinical Trials Network on opioid treatment over time indicated that 
long-term MAT for recovery is considered best practice.108  
  Medicaid expansion under the ACA has played the significant role in SUD treatment delivery 





associations with substance use treatment access instead of substance use treatment completion and 
retention. No study has examined the relationship between Medicaid expansion and outpatient treatment 
for OUD. Furthermore, previous studies used data collected before the ACA implementation in 2014, 
which did not capture post ACA and Medicaid policies that facilitated improving access to SUD 
treatments. To fill this critical knowledge gap, this study explored the role of Medicaid expansion in 





Conceptual model  
Figure 7. Conceptual model of Medicaid expansion, referral source, and OUD treatment access and outcomes 
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 The conceptual model above was adapted from the Donabedian framework that describes the 
associations of structure, process, and outcomes in the healthcare system (figure 1).87 “Structure” 
includes substance use related coverage policies (e.g., Medicaid expansion, ACA, 1115 Demonstration 
Waivers). A referral source is considered a “process” that is influenced by structural factors such as 
Medicaid expansion. The “structure” and “process” influence outcomes including OUD treatment access 
and utilization. Based on the conceptual model, the Medicaid expansion under the ACA should improve 
positive OUD treatment outcomes, including treatment completion, and retention in MAT (e.g., 
buprenorphine, methadone).  
Study aims and hypotheses 
Aim 3.1 
To examine associations between Medicaid expansion and OUD treatment completion  
Hypothesis 
 Medicaid expansion increases the likelihood of completing OUD treatment in expansion states 
compared to non-expansion states.  
Aim 3.2.  
To examine associations between Medicaid expansion and OUD length of stay in the treatment.  
Hypothesis 
 Medicaid expansion increases the likelihood of longer stays in non-intensive outpatient 




Overview of design and data 
 
This study used a quasi-experimental difference-in-differences (DID) with two-way fixed effects 





retention.21,24 Data were obtained from the publicly available TEDS-D, a national data system of annual 
discharges from publicly funded substance treatment facilities. They included the following types of 
facilities and services: (1) 24 hour per day medical acute care services in hospital settings, (2) 24 hour 
per day services in non-hospital settings, (3) rehabilitation in hospital settings, (4) short-term residential 
rehabilitation, (5) long term residential rehabilitation, (6) intensive outpatient/ambulatory care, (7) non-
intensive outpatient/ambulatory care, and (8) outpatient/ambulatory detoxification.  
The TEDS-D surveys were conducted by both the federal government and state agencies to 
collect information on SUD treatment programs, providing detailed information on the demographic 
characteristics of those who accessed treatment including their age, gender, race/ethnicity, education, 
and employment; information on drug use history, MAT (e.g., the use of opioid medications such as 
methadone, buprenorphine, and naltrexone), homeless status, number of arrests, and referral source. 
TEDS-D had 12 waves of data (from 2006 to 2017, not counting for year 2018, which has just been 
released), enabling researchers to combine many waves to increase statistical power and policy 
relevance. This study used 2010-2017 TEDS-D data to assess the impact of Medicaid expansion under 
the ACA on SUD treatment outcomes. Data from 2010 to 2017 were chosen in order to have four years 
(2010-2013) of data from before the ACA implementation (2014) and four years (2014-2017) of data 
from after the implementation.  
Sample 
 
This study uses the same analytic sample as study 2 (which was presented in the Chapter 3) - 
TEDS-D discharges aged 18 to 64 years old, with no prior admission, in ambulatory, non-intensive 
outpatient treatment for OUD. A description of the sample is included again below for completeness. 
OUD population. The OUD population included all discharges from the 2010-2017 TEDS-D 





observations. We first excluded discharges from Puerto Rico (n = 3,025) given that the Medicaid 
expansion operates differently in the territories (e.g., Puerto Rico) as well as the differences between 
territories and the states in demographic, health status, and economic indicators.89 We then limited the 
sample to discharges aged 18-64 years old because the expanded Medicaid under the ACA was aimed to 
increase coverage for this specific population with low-income.90 This resulted in a sample of 3,502,661 
observations.  Further, as has been done in previous work,91 discharges with a prior admission in the past 
year (n=2,279,678) were excluded because each patient could have many discharges but there was no 
encoded identity of an individual in the TEDS-D. Additionally, as this study focuses on the role of 
Medicaid expansion on referrals to outpatient OUD treatment, all discharges other than non-intensive 
outpatient were excluded (i.e., excluding the discharges from 24 hour per day medical acute care 
services in hospital setting, 24 hour per day services in non-hospital setting; residential rehabilitation in 
hospital, residential rehabilitation, short-term; residential rehabilitation, long term; ambulatory, intensive 
outpatient) (n=792,458).  Further, discharges due to incarceration, or death, or that were missing were 
also excluded (n=47,916). This resulted an analytic sample of 382,609 discharges aged 18-64 years old, 
with no prior admission in the current year, with non-intensive outpatient treatment for OUD (For a 
sample flow chart, see Appendix 3-A). 
 
Measures 
OUD treatment success (outcomes) 
 
Substance use treatment outcomes included treatment completion and length of stay in the 
treatment for OUD. First, the treatment completion variable was constructed as a binary variable, 
receiving the value of 1 if the participant completed the treatment or was transferred to another 





As opioid dependence is increasingly considered to be a chronic disease that could be 
successfully managed with evidence-based, effective pharmacological treatment,8 the length of 
treatment is also a measure of treatment success.8 For this study, length of stay in the opioid treatment 
was constructed as a binary variable, receiving the value of 1 if length of stay was equal to or greater 
than 90 days and 0 if length of stay was less than 90 days.91  
Medicaid expansion (Structure) 
 
As is described in more detail below, the effect of Medicaid expansion on the treatment 
outcomes in outpatient OUD treatment was tested with two different empirical approaches – a two-way 
fixed effects (2WFE) model and a difference-in-difference (DID). Each of these approaches necessitates 
a slightly different empirical definition of the Medicaid expansion policy variables. For the two-ways 
fixed effects model, the key independent variable of interest is defined as whether the state implemented 
Medicaid expansion under the ACA in a given survey year. For each survey year, we constructed a 
binary variable receiving the value of 1 if discharges are from states that adopted Medicaid expansion in 
that year, and 0 if a discharge was from a state that did not expand Medicaid in that year. As of 2017, 31 
states and the District of Columbia had expanded Medicaid of which 27 states and the District of 
Columbia had expanded Medicaid in 2014 (early expansion) and 5 states had expanded after 2014 (late 
expansion) (See Appendix Table 1 for summary of Medicaid expansion).92 This approach allows us to 
assess the impact of Medicaid expansion on treatment outcomes, taking into account the fact that states 
expanded Medicaid in different years.93    
 In the second empirical approach, the DID model, the independent variable of interest for DID 
was the interaction whether the discharge was from a facility located in a state with Medicaid expansion 





approach, only early expansion, those that expanded Medicaid in 2014, were included and compared to 
states that never expanded Medicaid as of 2017.  
Referral source (Process) 
 
This variable was constructed as a four-level categorical variable: self-referral, care provider, 
other institutional referral, court/criminal justice referral. Self-referral was defined as an individual who 
referred him/herself to the substance use treatment (52.7%).  The healthcare provider referral category 
(13.2%) combined referrals from alcohol/ drug care providers (4.9%) and other healthcare providers 
(8.3%). The other institutional referral source category (10.1%) combined referrals from school (0.2%), 
employers (0.3%), and community services (9.6%). The category court/criminal justice 
referral/DUI/DWI included discharges who were referred by court or criminal justice (22.2%). About 
1.8% discharges are defined as missing/unknown/not collected/invalid and are excluded from the 
analyses that follow.  
Covariates  
 
The associations between Medicaid expansion and treatment outcomes were adjusted for state 
fixed effects and year fixed effects to capture unobserved state heterogeneity and national secular trends 
in access to SUD treatment ( e.g., the opioid use prevalence).21,24 Demographic characteristics that were 
available in TEDS-D and were also included as covariates included age (18-29, 30-44, 45-64 years old), 
gender (male, female), race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, other), 
education (less than high school, high school or higher), employment status (employed,  not employed).  
In addition,  we controlled for whether patients used MAT (yes/no), frequency of opioid use (no 
use in the past month, some use, daily use), homeless at the time of admission (yes/no), number of times 





patient had psychiatric problem in addition to their substance use) (yes/no), and polysubstance use (no 
other substance, one more substance other than opioids, two or more substances other than opioids. 38,91  
Statistical analysis 
 
We first ran a 2WFE model to examine the impact of Medicaid expansion on treatment outcomes 
using logit model to account for the fact that the states expanded Medicaid expansion under the ACA in 
a different year.  
Y = β0 + β1Medexpst + βX + S +T + ε.    (1) 
Where Yist is the outcome of interest, which is a categorical variable including self-referral, healthcare 
provider, other institutional referral, court/criminal justice. Medexpst is the independent variable, equals 
to 1 if discharges were from the states that expanded Medicaid in year t and 0 otherwise, X represents a 
matrix of individual-level control variables, Ss represents state fixed effects, and Tt represents year fixed 
effects.  
We then restricted the sample to states that adopted Medicaid expansion in 2014 and states that 
did not adopt Medicaid expansion as of 2017. For estimating associations between Medicaid expansion 
and the treatment outcomes, we used the standard DID design with state and year fixed effects. We 
controlled for the state fixed effect in order to account for unobserved state heterogeneity. We controlled 
the year fixed effect to control for national secular trend in substance use treatment that might be 
systematically correlated with Medicaid expansion (e.g., substance use prevalence).  
 
Y = β0 + β1Exps + β2 PostExpansiont + β3 Exps* PostExpansiont + βX + S +T + ε.     (2) 
 
Where Y is the outcome of interest, including treatment completion and length of stay, Exps is the 
independent variable, equal to 1 if the discharges were from the early expansion states and 0 otherwise; 





2014); Expst* PostExpansionst is the interaction of Medicaid expansion and PostExpansion, with X 
representing a matrix of individual-level control variables,  S denoting state fixed effects, and T 
denoting year fixed effects.  
 
Sensitivity analyses  
To identify the effect of Medicaid expansion on treatment outcomes, the DID design has several 
assumptions that should be met.94 Particularly, if the comparison groups have different trends in the 
outcome of interest prior to the policy change, then the DID design is not necessarily an appropriate 
design as it violates the parallel trend assumption that may lead to biased estimate of causal effect. To 
mitigate this concern, we included multiple waves of data in the pre-expansion period (2010-2013), 
which allowed us to test the parallel trend assumption.95 The assumption of DID approach is that the rate 
of our outcomes among the expansion and non-expansion groups is parallel in the time prior the 
expansion implementation date, which is the Medicaid expansion under the ACA or the year 2014. We 
tested the assumption by assessing interactions of expansion status and year variable in the pre-
expansion period, we created line graphs to visualize the outcomes of interest (i.e., treatment completion 
and length of stay) over time. Furthermore, in order to correct for the within serial correlation in a 
difference in differences context, we clustered the standard errors at the state level.  
We ran a sensitivity analysis of the associations stratified by MAT given that non-intensive 
outpatient treatments service setting may include MAT and non-MAT (e.g., individual, family and/or 
group services) and that expectation on treatment outcomes from MAT may be different with non-MAT. 
For example, we would expect longer stay in MAT for better recovery outcomes.39,108  In addition, from 
paper 2 findings, Medicaid expansion was significantly associated with referral sources and that referral 





completion and length of stay.  We conducted another sensitivity analysis that removing referral source 
variable in the adjusted associations using DID model.  
In addition, the association was also adjusted for variables directly affecting substance market at 
state level including prescription drug monitoring program (PDMP) implementation, and economic 
conditions including unemployment rates for each state, which were obtained from the Bureau of Labor 
Statistics’ Local Area Unemployment Statistics. We collected effective dates of PDMP implementation 
and verify via different sources including PDMP websites, the Prescription Drug Abuse Policy System. 
We conducted sensitivity analysis to estimate the associations and account for the economic conditions 
and prescription drug monitoring program implementation.  
Further, given that the Section 1115 Demonstration waivers also play a significant role in 
improving SUD delivery system and coverage,21 we also checked the robustness of the main finding by 
including indicator variables states with Section 1115 waivers in a given survey year.  We also checked 
the robustness of the main findings by re-estimating the association by including one-year lag after 




Sample characteristics  
 
Table 3-1 shows characteristics of discharges from non-intensive outpatient treatment for opioids 
from 2010 to 2017, TEDS-D (N= 382,609). About 52% of those with OUD completed the treatment. 
About 44% of those with OUD stayed in the treatment longer than 90 days. Most discharges were self-
referred (more than 50%), followed by referrals from court/criminal justice (23%), healthcare providers 
(13%). More than one-third of the discharges included medication assisted treatment. More than half of 





characteristics, a majority of the discharges were 30-44 years old, male, non-Hispanic White, with high 
school completion or higher, had never been arrested, and were employed. About one-third suffered 
from a comorbid condition. More than half used at least one more substance besides the primary 
substance (i.e., opioids). 
 
Trends in OUD treatment outcomes across Medicaid expansion states versus non-expansion states 
Figures 8 and 9 shows line graphs presenting trends in treatment outcomes across non-expansion, 
early expansion, and late expansion states from 2010 to 2017, with the vertical lines representing ACA 
implementation in 2014.The line graphs were created to inspect the parallel trends assumption for the 
DID model. Figure 8 presents trends in treatment length of stay in non-intensive outpatient treatment for 
opioids for Medicaid expansion states versus non-expansion states. Before the ACA implementation in 
2014, trends in length of stay were increasing in non-expansion states and decreasing in expansion 
states. After the ACA implementation, there was an increase in length of stay in expansion states, but a 
decrease in non-expansion states. For late expansion states, the trend in length of stay varied before the 
ACA implementation and decreased after the ACA implementation. The trend in treatment outcomes for 
late expansion states seemed to violate the parallel trends assumption.  
Figure 9 presents trends in treatment completion in non-intensive outpatient treatment for opioids 
for Medicaid expansion states versus non-expansion states. Before ACA implementation in 2014, trends 
in treatment completion were decreasing in non-expansion states and increasing in early expansion 
states. After ACA implementation, there was an increase in treatment completion in early expansion 
states and non-expansion states. For late expansion states, the trend in treatment completion fluctuated 







Adjusted associations of Medicaid expansion and treatment length of stay 
Table 3-2 presents the adjusted estimates from the two-way fixed effects model and stratified by 
MAT, using adjusted logistic regressions for associations between Medicaid expansion and treatment 
length of stay. Compared with those in non-expansion states, discharges from Medicaid expansion states 
were less likely to stay in non-intensive outpatient treatment longer than 90 days (AOR 0.9, 95% CI: 
0.89-0.97). Non-MAT discharges from Medicaid expansion states were also less likely to stay in 
treatment longer than 90 days compared to those in non-expansion states (AOR 0.9, 95% CI: 0.88-0.97). 
However, outpatient discharges on MAT in Medicaid expansion states were more likely to stay in 
treatment longer than 90 days, compared to non-expansion states (AOR 1.2, 95% CI: 1.08-1.30). These 
results were consistent with the results from the standard DID model that presents the adjusted estimates 
and stratified by MAT, using adjusted logistic regressions for associations between Medicaid expansion 
and treatment length of stay (Table 3-3).  
 
Sensitivity analysis results for the adjusted associations of Medicaid expansion and treatment length of 
stay 
Table 3-C1 presents the adjusted estimates from the sensitivity analysis using a DID model in 
which we removed the referral source covariate since Medicaid expansion was expected to influence 
referrals to SUD treatment (findings from Chapter 3). After the covariate was removed, we found that 
those discharges who received MAT in Medicaid expansion states were more likely to stay in opioid 
treatment longer than 90 days compared to those in non-expansion states (AOR 1.2, 95% CI: 1.1-1.3), 
which was also consistent with the main DID model.  





rates and state PDMP covariates were added to the 2WFE model. The results were consistent with the 
main 2WFE in that those who were discharged and received MAT in Medicaid expansion states were 
more likely to stay in non-intensive outpatient opioid treatment longer than 90 days (AOR 1.2, 95% CI: 
1.1-1.3). Similarly, the results of the sensitivity analysis with the additional unemployment and PDMP 
covariates were consistent with the main DID model results (Table 3-D2).  
Table 3-E2 presents the results from the sensitivity analysis with lagged expansion effects in the 
DID model. Medicaid expansion started to have its positive effect on the opioid treatment length of stay 
(i.e., longer than 90 days) in year 1 for pooled model (AOR 2.5, 95% CI: 2.3-2.7), non-MAT (AOR 3.0, 
95% CI: 2.7-3.3), and MAT (AOR 1.5, 95% CI: 1.2-1.8); but not in year 2. A positive expansion effect 
was observed in year 3 for both the pooled model (AOR 1.3, 95% CI: 1.2-1.4) and MAT only model 
(AOR 3.6, 95% CI: 3.0-4.2).  
Table 3-F1 shows the sensitivity analysis results from the 2WFE model that added indicators for 
each state for 1115 Demonstration waivers. Again, the results were consistent with the main 2WFE 
model in that those discharges who received MAT from Medicaid expansion states were more likely to 
stay longer than 90 days in outpatient opioid treatment, compared to those in non-expansion states (AOR 
1.2, 95 % CI: 1.1-1.3).  
We also conducted a sensitivity analysis that examined the associations among discharges with 
more than one treatment episode in their lifetime (Tables 3-G1 and 3-G2) and found that discharges on 
MAT in Medicaid expansion states were more likely to stay longer than 90 days in outpatient opioid 
treatment (AOR 1.1, 95% CI: 1.1-1.2) compared to those in non-expansion states.  
 
Adjusted associations of Medicaid expansion and treatment completion 





stratified by MAT, using adjusted logistic regressions for examining associations between Medicaid 
expansion and treatment completion. The two-way fixed effect model considers the fact that states 
expanded their Medicaid expansion at different times. The results showed that discharges from Medicaid 
expansion states were less likely to complete the treatment in non-intensive outpatient treatment 
compared to those in non-expansion states (AOR 0.8, 95% CI: 0.8-0.9). When stratified by MAT, those 
discharges from Medicaid expansion states who received MAT were also less likely to complete non-
intensive outpatient treatment, compared to discharges on MAT in non-expansion states (AOR 0.5, 95% 
CI: 0.4-0.5). These results were consistent with the standard DID model that only included early 
expansion states and non-expansion states (Table 3-5).   
 
Sensitivity analysis results for the adjusted associations of Medicaid expansion and treatment 
completion 
Table 3-C2 presents the adjusted estimates from the sensitivity analysis using the DID model in 
which we removed the referral source covariate, since Medicaid expansion was also expected to affect 
referral sources. The results were consistent with the main 2WFE model except that non-MAT 
discharges in Medicaid expansion states were more likely to complete treatment compared to those in 
non-expansion states (AOR 1.1, 95 % CI: 1.3-1.5).  
Table 3-D3 presents the results from the sensitivity analysis in which annual state unemployment 
rates and an indicator for states having a PDMP were added to the 2WFE model as covariates. The 
results were consistent with the main 2WFE, such that those discharged in Medicaid expansion states 
were less likely to complete non-intensive outpatient opioid treatment in the pooled model (AOR 0.8, 
95% CI: 0.8-0.9) and for those who were on MAT model (AOR 0.5, 95% CI: 0.4-0.5). Similarly, the 





model results (Table 3-D4).  
Table 3-E2 presents the results from the sensitivity analysis with a lagged expansion effect for 
the DID model. Medicaid expansion seems to have its positive effect on opioid treatment completion in 
the expansion year (AOR 1.6, 95% CI: 1.5-1.7); however, it has a negative effect on opioid treatment 
completion one year after expansion (AOR 0.7, 95% CI: 0.6-0.8), two years after expansion (AOR 0.7, 
95% CI: 0.6-0.8), and three years after expansion (AOR 0.6, 95% CI: 0.5-0.6).  
Table 3-F2 shows the sensitivity analysis results from the 2WFE model that added the 1115 
Demonstration waiver indicators for each state in each year. Again, the results were consistent with the 
main 2WFE model, showing that in the pooled model, those discharges from Medicaid expansion were 
less likely to complete opioid treatment compared to those in non-expansion states (AOR 0.9, 95 % CI: 
0.8-0.9).  
We also conducted the sensitivity analysis among those discharges with more than one episode 
of treatment (Table 3-G3), and found that discharges in Medicaid expansion states were less likely to 
complete treatment in the pooled model ( AOR 0.9, 95 % CI: 0.86-0.92) and MAT (AOR 0.5, 95 % CI: 
0.5-0.6) compared to those in non-expansion states; however, discharges who were on non-MAT in 
Medicaid expansion states were more likely to complete the treatment ( AOR 1.1, 95% CI: 1.1-1.2) 
compared to those in non-expansion states.  
 
Summary of adjusted associations between key covariates and treatment completion and retention 
The adjusted estimates from the 2WFE showed young age, male, being non-Hispanic Black, 
having psychiatric comorbidities, being homeless, and polysubstance use were negatively associated 
with the likelihood of treatment retention. However, we found that being employed was associated with 





higher education was associated with being less likely to stay longer than 90 days in MAT treatment in 
non-intensive outpatient treatment for OUD. The results were consistent with the results from the DID 
model. We also found that young age, male, being non-Hispanic Black, and having psychiatric 
comorbidities were associated with being less likely to complete treatment while having higher 
education and being employed were associated with being more likely to complete non-intensive 




This study provides the first empirical evidence of the impact of Medicaid expansions under the 
ACA on the treatment completion and length of stay in non-intensive outpatient treatments for OUD. 
We found that the Medicaid expansion under the ACA was positively associated with longer stay in 
treatment (at least, more than 90 days) for MAT in non-intensive outpatient treatment. On the other 
hand, we found that the implementation of Medicaid expansion under the ACA was negatively 
associated with treatment completion in non-intensive outpatient treatment overall and stratified by 
MAT. The main findings from the 2WFE model were consistent with the findings from the standard 
DID model that only included non-expansion states and states that expanded the Medicaid in 2014. 
Our main study results on the positive association of Medicaid expansion and treatment length of 
stay were consistent with the sensitivity analysis results that removed the referral source covariate, the 
sensitivity analysis results that added state-level variables affecting the substance market (i.e., annual 
unemployment rates and PDMP implementation), and the sensitivity analysis results that added Section 
1115 Demonstration waiver. On the other hand, the main result on the negative association of Medicaid 
expansion and treatment completion was not robust when the referral source covariate was removed, due 





the inclusion of the referral source covariate might result in a biased estimate. This sensitivity analysis 
indicated that Medicaid expansion was negatively associated with treatment completion in the pooled 
model and among those who used MAT, but positively associated with treatment completion in non-
MAT, non-intensive outpatient treatment for opioids. In addition, there might be a more complicated 
mechanism that affects the association between Medicaid programs and treatment completion in non-
intensive outpatient treatment. For example, even though the ACA required Medicaid programs to cover 
SUD treatment, there have been variations in coverage for individual services among states. For 
example, many states did not cover methadone or a full range of services needed for better treatment 
recovery outcomes.111 Further research should explore associations of Medicaid expansion policy 
components for better understanding of Medicaid policy and SUD treatment outcomes.  
Our study contributes to the literature in certain ways. First, it adds to the literature on the role of 
Medicaid expansion in improving the substance use treatment system by increasing access to treatment 
and suggests some improvements in treatment outcomes for patients on MAT in outpatient settings. 
Previous studies on Medicaid expansion mostly focused on its role in health insurance coverage, as well 
as in the supply and utilization of medication for OUD including buprenorphine.21,24,96 These studies 
found that Medicaid expansion had a positive impact on the increased health insurance coverage, 
especially for those with low-incomes,21 as well as the increased provision of medication for OUD such 
as buprenorphine.24 Our study further demonstrated the positive influence of Medicaid expansion on 
opioid treatment retention in outpatient settings with MAT. This finding is important, as treatment 
retention has been considered a positive treatment outcome in medication treatment for OUD.39,108  
Our study also adds to the literatures on factors affecting MAT treatment retention, which are of 
particular importance as OUD has been increasingly considered a chronic disease that requires long-





and improving  health).112,113 Furthermore, there is growing evidence that treatment retention is 
considered the key quality indicator for OUD treatment.108 Previous studies on opioid treatment 
retention indicated factors that were negatively associated with reduced treatment retention including 
younger age, polysubstance use, being arrested.39–41 In addition, Mennis and his colleagues in their 
studies on outpatient treatment completion for SUD indicated the influence of race/ethnicity on 
treatment completion.91 They found that African Americans and Hispanics were more likely to drop out 
of treatment compared to Whites. Our studies further highlight the role of OUD treatment related 
policies such as the Medicaid expansion on evidence-based treatment outcomes.  
The adjusted estimates from our study were consistent with previous studies with regards to 
other factors affecting OUD treatment retention. We also found that younger age, male, being non-
Hispanic Black, having psychiatric comorbidities, homeless, and previous arrests/incarceration were 
negatively associated with treatment retention.39–41,44 However, our study also showed that discharges 
with employment, and higher education were less likely to stay in the outpatient OUD treatment longer 
than 90 days, which is different from the results of previous studies on OUD treatment retention. We 




This study has several limitations. First, we restricted the sample to discharges aged 18 to 64 
years old, with no prior admission, and who received ambulatory, non-intensive outpatient treatment for 
OUD from publicly-funded substance use programs. Therefore, the generalizability of this study may 
only apply to this specific population. Second, Medicaid expansion might change the likelihood that 
SUD treatment facilities reported to TEDS-D. Third, we noticed that even though the ACA required 





specific SUD services covered, including different types and durations of outpatient treatment and 
medications for OUD.111 Lack of coverage for effective OUD medications (e.g., certain state Medicaid 
programs did not cover for methadone),111 as well of the full range SUD services might increase the 
likelihood patients accessing treatment in inappropriate settings,114 which could result in poor treatment 
retention.   
Other limitations relate to the utilization of TEDS-D to examine the association between 
Medicaid expansion and the treatment outcomes. First, TEDS-D is discharge-level data instead of 
patient-level data, which means that one patient could have many discharges in a given year. It may 
therefore result in biased estimates. We limited this potential bias by restricting our sample to discharges 
with no prior admissions; however, exclusion of multiple discharges should be acknowledged as an 
important limitation, particularly as those with multiple discharges in a year may represent patients with 
highest need. However, as described above, we performed a sensitivity analysis among those with more 
than one treatment episode. Second, TEDS-D data collection was based on reports from individual 
programs across different states which may have missing data and variables that were defined differently 
across different programs. The missing data (for example, 60% of health insurance information is 
missing) limited further analysis of the roles of different types of health insurance coverage on treatment 
outcomes, though such analyses would likely be plagued by endogeneity. Third, TEDS-D length of stay 
variable was encoded categorically for durations over 30 days; therefore, we could only construct length 
of stay as a binary variable with a threshold of 90 days. This limited the use of linear or count data 
models in examining the association between Medicaid expansion and length of stay in opioid treatment. 
 
Conclusion  
The strength of this study is that the analyses were based on a large national TEDS-D dataset that 





role of Medicaid expansion in treatment retention (at least, more than 90 days) in MAT, non-intensive 
outpatient treatment for opioid use disorder. Given that treatment completion is considered a positive 
treatment outcome, especially in non-intensive outpatient treatments without medications (e.g., 
psychosocial therapies), the study finding on the negative effect of Medicaid expansion on those 
treatments need to be addressed. Medicaid policy makers might consider policies facilitating those 






Table 3-1. Sample characteristics  
  Frequency Percent 
Total  N= 382,609 % 
Treatment completion N=271,306  
   Completed (187, 837) 51.9 
Length of stay  N= 382,609  
   90 days or more  166, 533 43.5 
Referral sources  N=375, 583 
 
   Self-referral 201,632 53.7 
   Healthcare provider referral 
50,465 13.4 
   Other institutional referral 
38,631 10.3 
   Court/criminal justice referral 
84,855 22.6 
MAT  N= 375,051  
   Yes 133,787 35.7 
Frequency of use  N= 369,848 
 
   No use in the past month 
106,921 28.9 
   Some use 71,499 19.3 
   Daily use 191,428 51.8 
Age  N= 382, 609 
 
   18-29 127,141 33.2 
   30-44 179,390 46.9 
   45-64 76,078 19.9 
Gender N= 382,525 
 
   Male 209,602 54.8 
Race/ethnicity  N= 375,376 
 
   Non-Hispanic White 289,016 77.0 
   Non-Hispanic Black 31,413 8.4 
   Hispanic  40,542 10.8 
   Other 14,405 3.8 
Education  372, 826 
 
   Highschool or higher 271,923 72.9 
Number of arrests  N= 364, 417 
 
   None 340, 071 93.3 





   2 or more 4, 916 1.4 
Employment status  N= 376, 639 
 
     Employed 275, 672 73.2 
Comorbidity N=333, 487 
 
   Yes 103, 207 30.9 
Homeless N= 371, 037 
 
  Yes 20, 687 5.6 
Polysubstance use  N= 304, 655 
 
    No 128,782 42.3 
    One more 104,430 34.3 
































Figure 8. Trends in length of stay across Medicaid expansion and non-expansion states, in non-intensive 
outpatient opioid treatments, TEDS-D 2010-2017. The vertical line represents the Medicaid expansion 





Figure 9. Trends in treatment completion across Medicaid expansion and non-expansion states, in non-
intensive outpatient opioid treatments, TEDS-D 2010-2017. The vertical line represents the Medicaid 
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Table 3-2. 2WFE model for the adjusted associations between Medicaid expansion and length of stay   
  
2 ways fixed effect 
pooled model 
2 ways fixed effect 
Non-MAT 
2 ways fixed effect 
MAT 
     
N 231,025 169,449 61,573 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Medicaid expansion     
    Expansion  0.93*** 0.92** 1.19*** 
 (0.89 - 0.97) (0.88 - 0.97) (1.08 - 1.30) 
MAT (No= ref)     
   Yes 2.22***   
 (2.16 - 2.27)   
Referral sources    
   Healthcare provider 
referral 
0.93*** 1.01 0.87*** 
 (0.90 - 0.96) (0.97 - 1.04) (0.83 - 0.92) 
   Institutional referral 1.04* 1.21*** 0.78*** 
 (1.01 - 1.08) (1.17 - 1.26) (0.72 - 0.84) 
   Court/criminal justice 1.87*** 2.14*** 0.74*** 
 (1.82 - 1.92) (2.07 - 2.20) (0.69 - 0.81) 
Frequency of use (No 
past month use= ref)  
   
   Some use 0.72*** 0.70*** 0.85*** 
 (0.70 - 0.74) (0.68 - 0.73) (0.79 - 0.91) 
   Daily use 0.67*** 0.62*** 0.84*** 
 (0.66 - 0.69) (0.60 - 0.64) (0.80 - 0.89) 
Age (18-29= ref)     
   30-44 1.07*** 1.07*** 1.09*** 
 (1.05 - 1.09) (1.04 - 1.10) (1.04 - 1.13) 
   45-64 1.31*** 1.32*** 1.31*** 
 (1.27 - 1.34) (1.27 - 1.36) (1.25 - 1.38) 
Gender (Female=ref)    
   Male 0.90*** 0.89*** 0.92*** 
 (0.88 - 0.91) (0.87 - 0.91) (0.89 - 0.95) 
Race/ethnicity (non-
Hispanic White=ref) 





   Non-Hispanic Black 0.94** 0.94** 0.93* 
 (0.91 - 0.98) (0.89 - 0.98) (0.87 - 0.98) 
   Hispanic 1.01 0.94* 1.09** 
 (0.98 - 1.05) (0.90 - 0.99) (1.03 - 1.16) 
   Other 1.00 1.00 0.99 
 (0.95 - 1.06) (0.94 - 1.06) (0.88 - 1.10) 
Education (Less than 
high school= ref)  
   
   Highschool or higher 0.98 1.00 0.96* 
 (0.96 - 1.00) (0.98 - 1.03) (0.92 - 0.99) 
Number of arrests (0= 
ref) 
   
   1 0.97 1.04 0.79*** 
 (0.93 - 1.01) (0.99 - 1.09) (0.73 - 0.86) 
   2 or more 1.18*** 1.17*** 0.88 
 (1.09 - 1.28) (1.07 - 1.27) (0.73 - 1.06) 
Employment status 
(Unemployed= ref)  
   
     Employed 0.79*** 0.78*** 0.83*** 
 (0.77 - 0.81) (0.76 - 0.80) (0.80 - 0.87) 
Comorbidity (No= ref)     
   Yes 0.88*** 0.90*** 0.89*** 
 (0.86 - 0.90) (0.87 - 0.92) (0.85 - 0.92) 
Homeless (No= ref)     
  Yes 0.74*** 0.77*** 0.70*** 
 (0.70 - 0.77) (0.73 - 0.81) (0.65 - 0.76) 
Polysubstance use (no= 
ref)   
   
    One more 0.80*** 0.80*** 0.86*** 
 (0.78 - 0.81) (0.78 - 0.82) (0.82 - 0.89) 
    Two or more 0.73*** 0.76*** 0.76*** 
 (0.71 - 0.74) (0.73 - 0.78) (0.72 - 0.80) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  
* p<0.05, ** p<0.01, *** p<0.001 











Table 3-3. DID model for the adjusted associations between Medicaid expansion and treatment length of 
stay  





    
N 225,272 164,420 60,849 
 AOR AOR AOR 
 (95%CI) (95%CI) (95%CI) 
     
Treat 2.91*** 2.09** 3.25*** 
   Expansion states (2.07 - 4.10) (1.26 - 3.46) (2.05 - 5.15) 
       
Expansion  0.97 1.33*** 0.51*** 
   After the ACA 
implementation (2014)  
(0.93 - 1.02) (1.26 - 1.41) (0.46 - 0.56) 
    
Medicaid expansion     
    Medicaid expansion  0.94** 0.94** 1.19*** 
 (0.90 - 0.98) (0.89 - 0.98) (1.08 - 1.31) 
MAT (No= ref)     
   Yes 2.23***   
 (2.18 - 2.29)   
Referral sources    
   Healthcare provider referral 0.93*** 1.01 0.88*** 
 (0.90 - 0.96) (0.97 - 1.05) (0.83 - 0.92) 
   Institutional referral 1.05** 1.22*** 0.79*** 
 (1.02 - 1.09) (1.17 - 1.26) (0.74 - 0.85) 
   Court/criminal justice 1.88*** 2.16*** 0.74*** 
 (1.83 - 1.94) (2.10 - 2.23) (0.68 - 0.80) 
Frequency of use (No past 
month use= ref)  
   
   Some use 0.72*** 0.70*** 0.84*** 
 (0.69 - 0.74) (0.68 - 0.72) (0.78 - 0.90) 
   Daily use 0.67*** 0.62*** 0.84*** 
 (0.65 - 0.69) (0.60 - 0.64) (0.79 - 0.89) 
Age (18-29= ref)     
   30-44 1.07*** 1.07*** 1.09*** 
 (1.05 - 1.10) (1.05 - 1.10) (1.04 - 1.14) 
   45-64 1.30*** 1.32*** 1.31*** 
 (1.27 - 1.34) (1.27 - 1.37) (1.24 - 1.38) 
Gender (Female=ref)    





 (0.88 - 0.92) (0.87 - 0.92) (0.89 - 0.96) 
Race/ethnicity (non-
Hispanic White=ref) 
   
   Non-Hispanic Black 0.94** 0.94* 0.93* 
 (0.91 - 0.98) (0.89 - 0.99) (0.87 - 0.99) 
   Hispanic 1.01 0.94** 1.09** 
 (0.97 - 1.05) (0.89 - 0.98) (1.02 - 1.16) 
   Other 1.01 1.01 0.99 
 (0.96 - 1.07) (0.94 - 1.08) (0.88 - 1.10) 
Education (Less than high 
school= ref)  
   
   Highschool or higher 0.98 1.00 0.96* 
 (0.96 - 1.00) (0.98 - 1.03) (0.92 - 0.99) 
Number of arrests (0= ref)    
   1 0.96 1.04 0.79*** 
 (0.92 - 1.00) (0.99 - 1.09) (0.72 - 0.86) 
   2 or more 1.20*** 1.18*** 0.88 
 (1.11 - 1.30) (1.08 - 1.30) (0.73 - 1.06) 
Employment status 
(Unemployed= ref)  
   
     Employed 0.80*** 0.79*** 0.84*** 
 (0.78 - 0.82) (0.77 - 0.81) (0.80 - 0.87) 
Comorbidity (No= ref)     
   Yes 0.88*** 0.89*** 0.89*** 
 (0.86 - 0.90) (0.87 - 0.92) (0.85 - 0.92) 
Homeless (No= ref)     
  Yes 0.73*** 0.76*** 0.70*** 
 (0.70 - 0.76) (0.72 - 0.81) (0.64 - 0.75) 
Polysubstance use (no= ref)      
    One more 0.79*** 0.79*** 0.85*** 
 (0.77 - 0.81) (0.77 - 0.81) (0.82 - 0.89) 
    Two or more 0.72*** 0.75*** 0.76*** 
 (0.70 - 0.74) (0.73 - 0.77) (0.73 - 0.80) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  
* p<0.05, ** p<0.01, *** p<0.001 












Table 3-4. 2WFE model for the adjusted associations between Medicaid expansion and treatment 
completion   
  
2 ways fixed effect 
pooled model 
Non-MAT MAT 
     
N 231,021 169,447 61,571 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Medicaid expansion  0.84*** 1.02 0.48*** 
    Expansion  (0.80 - 0.87) (0.97 - 1.06) (0.43 - 0.54) 
    
MAT (No= ref)     
   Yes 0.86***   






   Healthcare provider 
referral 
1.07*** 1.05** 1.14*** 
 (1.04 - 1.10) (1.02 - 1.09) (1.08 - 1.21) 
   Institutional referral 1.30*** 1.32*** 1.15*** 
 (1.26 - 1.34) (1.27 - 1.37) (1.07 - 1.24) 
   Court/criminal justice 2.03*** 2.00*** 1.89*** 
 (1.98 - 2.09) (1.94 - 2.06) (1.73 - 2.06) 
Frequency of use (No 
past month use= ref)  
   
   Some use 0.74*** 0.76*** 0.70*** 
 (0.71 - 0.76) (0.73 - 0.78) (0.65 - 0.76) 
   Daily use 0.77*** 0.85*** 0.59*** 
 (0.75 - 0.79) (0.83 - 0.88) (0.55 - 0.62) 
Age (18-29= ref)     
   30-44 1.06*** 1.07*** 1.04 
 (1.04 - 1.09) (1.04 - 1.09) (0.99 - 1.08) 
   45-64 1.14*** 1.23*** 0.99 
 (1.11 - 1.18) (1.19 - 1.27) (0.93 - 1.05) 
Gender (Female=ref)    
   Male 0.93*** 0.97** 0.81*** 







   
   Non-Hispanic Black 0.82*** 0.94* 0.68*** 
 (0.79 - 0.86) (0.90 - 0.99) (0.63 - 0.73) 
   Hispanic 0.85*** 0.92*** 0.81*** 
 (0.82 - 0.89) (0.88 - 0.97) (0.75 - 0.86) 
   Other 0.73*** 0.76*** 0.69*** 
 (0.69 - 0.77) (0.72 - 0.81) (0.61 - 0.78) 
Education (Less than 
high school= ref)  
   
   Highschool or higher 1.19*** 1.17*** 1.20*** 
 (1.16 - 1.21) (1.14 - 1.20) (1.15 - 1.25) 
Number of arrests (0= 
ref) 
   
   1 1.15*** 1.19*** 1.04 
 (1.10 - 1.20) (1.13 - 1.24) (0.94 - 1.14) 
   2 or more 0.84*** 0.89* 1.03 
 (0.78 - 0.91) (0.81 - 0.97) (0.83 - 1.29) 
Employment status 
(Unemployed= ref)  
   
     Employed 1.03* 1.06*** 0.97 
 (1.01 - 1.05) (1.03 - 1.09) (0.93 - 1.02) 
Comorbidity (No= ref)     
   Yes 0.89*** 0.87*** 0.95* 
 (0.88 - 0.91) (0.85 - 0.89) (0.91 - 0.99) 
Homeless (No= ref)     
  Yes 1.10*** 1.14*** 1.02 
 (1.06 - 1.15) (1.08 - 1.20) (0.94 - 1.12) 
Polysubstance use (no= 
ref)   
   
    One more 1.12*** 1.13*** 1.02 
 (1.10 - 1.14) (1.11 - 1.16) (0.98 - 1.07) 
    Two or more 1.21*** 1.22*** 1.07* 
 (1.18 - 1.24) (1.18 - 1.25) (1.01 - 1.13) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  
* p<0.05, ** p<0.01, *** p<0.001 
















DID model  
  MAT 
    
N 225,268 164,418 60,847 
 AOR AOR AOR 
 (95%CI) (95%CI) (95%CI) 
        
Treat    
   Expansion states 1.58*** 1.45*** 2.12*** 
    (1.51 - 1.65) (1.38 - 1.52) (1.89 - 2.39) 
Expansion     
   After the ACA implementation (2014)  2.00*** 1.78* 3.01*** 
 (1.42 - 2.82) (1.09 - 2.91) (1.85 - 4.91) 
Medicaid expansion     
    Expansion  0.83*** 1.02 0.48*** 
 (0.80 - 0.87) (0.97 - 1.07) (0.43 - 0.54) 
MAT (No= ref)     
   Yes 0.87***   
 (0.85 - 0.89)   
Referral sources    
   Healthcare provider referral 1.07*** 1.06*** 1.15*** 
 (1.04 - 1.10) (1.02 - 1.09) (1.09 - 1.22) 
   Institutional referral 1.30*** 1.32*** 1.16*** 
 (1.26 - 1.34) (1.27 - 1.37) (1.07 - 1.25) 
   Court/criminal justice 2.05*** 2.03*** 1.89*** 
 (2.00 - 2.11) (1.97 - 2.09) (1.73 - 2.07) 
Frequency of use (No past month use= 
ref)  
   
   Some use 0.74*** 0.77*** 0.70*** 
 (0.72 - 0.76) (0.74 - 0.79) (0.65 - 0.75) 
   Daily use 0.79*** 0.87*** 0.58*** 
 (0.77 - 0.81) (0.85 - 0.90) (0.55 - 0.62) 
Age (18-29= ref)     
   30-44 1.06*** 1.07*** 1.03 
 (1.04 - 1.08) (1.04 - 1.09) (0.98 - 1.08) 
   45-64 1.11*** 1.22*** 0.91** 
 (1.08 - 1.14) (1.18 - 1.27) (0.86 - 0.96) 
Gender (Female=ref)    
   Male 0.92*** 0.96*** 0.80*** 







   
   Non-Hispanic Black 0.82*** 0.94* 0.68*** 
 (0.79 - 0.86) (0.90 - 0.99) (0.63 - 0.73) 
   Hispanic 0.85*** 0.92** 0.80*** 
 (0.82 - 0.88) (0.88 - 0.97) (0.75 - 0.86) 
   Other 0.74*** 0.78*** 0.68*** 
 (0.70 - 0.78) (0.73 - 0.83) (0.60 - 0.77) 
Education (Less than high school= ref)     
   Highschool or higher 1.19*** 1.17*** 1.20*** 
 (1.16 - 1.21) (1.14 - 1.20) (1.15 - 1.25) 
Number of arrests (0= ref)    
   1 1.16*** 1.20*** 1.03 
 (1.11 - 1.21) (1.14 - 1.26) (0.94 - 1.14) 
   2 or more 0.84*** 0.89* 1.04 
 (0.77 - 0.91) (0.81 - 0.97) (0.83 - 1.30) 
Employment status (Unemployed= ref)     
     Employed 1.03* 1.06*** 0.97 
 (1.01 - 1.05) (1.04 - 1.09) (0.93 - 1.02) 
Comorbidity (No= ref)     
   Yes 0.89*** 0.87*** 0.95* 
 (0.87 - 0.91) (0.85 - 0.89) (0.91 - 0.99) 
Homeless (No= ref)     
  Yes 1.11*** 1.15*** 1.02 
 (1.06 - 1.16) (1.09 - 1.21) (0.94 - 1.12) 
Polysubstance use (no= ref)      
    One more 1.13*** 1.14*** 1.02 
 (1.10 - 1.15) (1.11 - 1.17) (0.98 - 1.07) 
    Two or more 1.22*** 1.22*** 1.07* 
 (1.19 - 1.25) (1.19 - 1.26) (1.01 - 1.13) 
   2017 - - - 
 
   
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  
* p<0.05, ** p<0.01, *** p<0.001 






Table 3-6. Summary table for the adjusted associations between Medicaid expansion and length of stay 




2WFE Non-MAT 2WFE MAT 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
Main results    
    Medicaid expansion  0.93*** 0.92** 1.19*** 
 (0.89 - 0.97) (0.88 - 0.97) (1.08 - 1.30) 
Sensitivity analysis with 
additional covariates 
(unemployment rates and 
PDMP)  
   
   Medicaid expansion 0.94** 0.95 1.15** 
 (0.90 - 0.98) (0.91 - 1.00) (1.04 - 1.26) 
Sensitivity analysis with 
added Section 1115 
Demonstration Waiver 
   
   Medicaid expansion  0.93** 0.93** 1.15** 
 (0.90 - 0.98) (0.89 - 0.98) (1.05 - 1.27) 
Sensitivity analysis for one 
more treatment episode 
   
   Medicaid Expansion  0.96* 0.89*** 1.11** 
 (0.93 - 1.00) (0.85 - 0.93) (1.04 - 1.19) 
Sensitivity analysis 
removing referral source 
covariate 
DID pooled model DID Non-MAT DID MAT 
    
   Expansion states 2.96*** 2.09** 3.35*** 
    (2.10 - 4.15) (1.27 - 3.45) (2.12 - 5.30) 
   Post expansion  0.98 1.30*** 0.52*** 
    (0.93 - 1.02) (1.23 - 1.37) (0.47 - 0.58) 
   Medicaid expansion     0.96 0.96 1.17*** 
 (0.92 - 1.00) (0.92 - 1.01) (1.07 - 1.29) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  








Table 3-7. Summary table for the adjusted associations between Medicaid expansion and treatment 




2WFE Non-MAT 2WFE MAT 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
Main results    
    Medicaid expansion  0.84*** 1.02 0.48*** 
 (0.80 - 0.87) (0.97 - 1.06) (0.43 - 0.54) 
Sensitivity analysis with 
additional covariates 
(unemployment rates and 
PDMP)  
   
   Medicaid expansion 0.84*** 1.03 0.47*** 
 (0.81 - 0.88) (0.99 - 1.09) (0.42 - 0.52) 
Sensitivity analysis with 
added Section 1115 
Demonstration Waiver 
   
   Medicaid expansion  0.85*** 1.02 0.49*** 
 (0.81 - 0.88) (0.97 - 1.07) (0.44 - 0.54) 
Sensitivity analysis for 
one more treatment 
episode 
   
   Medicaid Expansion  0.87*** 1.10*** 0.52*** 
 (0.84 - 0.90) (1.06 - 1.15) (0.48 - 0.55) 
Sensitivity analysis 
removing referral source 
covariate 
DID pooled model DID Non-MAT DID MAT 
    
   Expansion states 2.02*** 1.78* 3.00*** 
    (1.43 - 2.84) (1.09 - 2.91) (1.84 - 4.87) 
   Expansion  1.56*** 1.40*** 2.14*** 
    (1.50 - 1.64) (1.33 - 1.47) (1.90 - 2.40) 
   Medicaid expansion     0.87*** 1.06* 0.49*** 
 (0.83 - 0.91) (1.01 - 1.11) (0.44 - 0.55) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  






Chapter 5 Conclusions and Implications 
 
Despite many policy efforts to increase access to and supply of substance use disorder treatment, 
only 11% of people with SUD, and nearly 20% of those with OUD accessed SUD treatment. Beyond 
issues of access, SUD treatment retention is also concerning as 70% of individuals failed to stay in 
treatment long enough, likely limiting treatment effectiveness. To contribute to the evidence on 
improving access to care and treatment retention, our studies were conducted to more fully characterize 
the role of insurance coverage on access to and outcomes of SUD treatment, by using both individual 
coverage variables and natural experiments arising from state and year variation in Medicaid expansion.  
These studies also focus on the role of coverage in the SUD treatment referral system, and particularly 
how coverage relates to healthcare provider referrals to outpatient treatment settings.  
Our first study used a representative national survey on drug use and found that Medicaid 
insurance coverage was positively associated with the use of any SUD treatment in the past year across 
any SUD, AUD, or OUD populations. Among those who accessed any SUD treatment, we further 
explored the role of health insurance in the pattern of SUD treatment utilization and found that those 
with any SUD or any OUD who were covered by Medicaid were more likely to use outpatient treatment, 
whereas those who were uninsured were more likely to use self-help only as a substitute for outpatient 
treatment. However, we did not find a statistically significant positive associations between Medicaid 
insurance and outpatient treatment utilization among those with AUD. This could be due to the 
significant role that self-help programs, like Alcoholics Anonymous, plays in the treatment for AUD. 
Our second study used a large national SUD treatment discharge data set to examine the association of 
Medicaid expansion with healthcare provider referrals to outpatient SUD treatment, given that provider 
referrals are considered a key factor in timely and effective SUD treatment utilization. We particularly 





the healthcare sector in evidence-based treatment that emphasizes the use of effective medications for 
OUD. By using a natural experiment to examine the associations of Medicaid expansion and different 
referral sources that utilized DID and 2WFE approaches, we found that Medicaid expansion was 
positively associated with the likelihood of being referred by a healthcare provider in outpatient settings 
of publicly-funded SUD treatment programs. Beyond the issue of access, we again used a national data 
set of SUD treatment discharges from publicly funded facilities to evaluate the effect of Medicaid 
expansion on OUD treatment outcomes in outpatient settings. We found a negative association of 
Medicaid expansion and OUD treatment completion; however, we found a positive association of 
Medicaid expansion and treatment completion among those who were not on MAT during their 
outpatient treatment. This might be caused by the variations in the definitions of the treatment 
completion variable across different states, as well as by a complicated mechanism that Medicaid 
coverage influenced treatment completion among those with first time treatment experience. 
Importantly, we found that Medicaid expansion had a positive effect on treatment retention of at least 90 
days for those who were on MAT during their outpatient treatment episode.  
While one of key advantages of using TEDS-D is that it is the largest national survey of SUD 
treatment episodes in publicly funded programs, the study findings in papers 2 and 3 should be 
interpreted with caution. First, TEDS-D only represents about 50% of all SUD treatment discharges 
nationwide; the omission of privately funded SUD treatment settings might affect the generalizability of 
our estimates. Another key limitation of using TEDS-D arises from missing data (e.g., 60% missing of 
health insurance type information). This prevented us from conducting further analysis to better 
understand mechanisms that Medicaid expansion under the ACA influenced the SUD treatment 





with many sensitivity analyses, confirmed the robustness of our findings, at least for those with OUD 
and who had their first treatment experience in an outpatient, publicly-funded facility.  
Our study findings contribute to the understanding of the role of health insurance coverage in 
patterns of SUD treatment utilization. The first finding, besides emphasizing the positive role of 
Medicaid expansion on outpatient treatment access, also suggests that those who were uninsured used 
self-help only approaches to substitute for outpatient treatment. This finding points to the importance of 
coverage policies and interventions that target self-help groups to increase access to evidence-based 
treatments, such as medications for OUD alone or in combination with psychological therapies. Next, 
given that the healthcare sector should play a significant role in SUD treatment, and healthcare provider 
referral is increasingly important for timely and effective treatment, our findings suggest a renewed 
focus in Medicaid policy on healthcare provider referrals as an important link to evidence-based 
treatment for OUD. While previous studies indicated certain factors affecting treatment retention, our 
study emphasizes the role of Medicaid coverage in treatment retention particularly for those who were 
on MAT in outpatient treatment for OUD. On the other hand, our finding that Medicaid expansion was 
negatively associated with outpatient treatment completion in general suggests more evidence is needed 
to better understand the mechanisms by which Medicaid coverage expansions influence treatment 
completion.  In summary, this study emphasizes the renewed focus of Medicaid policy on access to, and 
referrals to, as well as outcomes of SUD treatment. Looking ahead, future work examining the role of 
insurance coverage in SUD treatment access and outcomes should explore state-level variations in 
Medicaid policy components (e.g., variations in medication coverage, individual services covered) and 
SUD treatment access and outcomes.  
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Appendix 1-A  
 
Table 1-A1. Adjusted associations of any treatment utilization past year and different types of health insurance 
coverage, controlling for sociodemographic characteristics and interaction of the post ACA and insurance types. 
 Any SUD Any AUD Any OUD 
Sample size 39,130 30,219 3,897 
Population size 154,810,987 123,018,127 15,166,167 
 Any SUD treatment 
past year 
Any SUD treatment 
past year 








Health insurance     
   No insurance = reference    
   Medicaid 1.98*** 1.97*** 1.76** 
 (1.62 - 2.43) (1.52 - 2.54) (1.20 - 2.59) 
   Private 0.68*** 0.74** 1.11 
 (0.57 - 0.81) (0.60 - 0.92) (0.79 - 1.55) 
   Medicare and others 1.35* 1.42* 1.54 
 (1.00 - 1.82) (1.00 - 2.02) (0.82 - 2.89) 
Age in years    
   18-25= reference    
   26-34 1.31*** 1.18* 1.09 
 (1.17 - 1.47) (1.02 - 1.37) (0.87 - 1.37) 
   35-49 1.51*** 1.48*** 1.20 
 (1.35 - 1.70) (1.28 - 1.71) (0.93 - 1.54) 
   50-64 1.49*** 1.53*** 1.09 
 (1.22 - 1.81) (1.22 - 1.92) (0.70 - 1.70) 
Sex    
   Female= reference    
   Male 1.32*** 1.50*** 1.22 
 (1.18 - 1.47) (1.30 - 1.72) (0.97 - 1.53) 
Race    
   Non-Hispanic Whites= 
ref 
   
   Non- Hispanic African 
Americans 
0.67*** 0.86 0.75 
 (0.57 - 0.79) (0.71 - 1.05) (0.51 - 1.12) 
   Hispanic 0.63*** 0.72** 0.66* 
 (0.53 - 0.75) (0.59 - 0.88) (0.47 - 0.95) 
   Other race/ethnicity 0.75** 0.89 0.43*** 
 (0.61 - 0.92) (0.71 - 1.13) (0.27 - 0.66) 
Education    
   High school or less=ref    
   High school or more 0.79*** 0.71*** 1.13 





Total annual family 
income 
   
    < $50,000= ref    
   $ 50,000-74,999 0.94 0.99 1.01 
 (0.81 - 1.10) (0.82 - 1.21) (0.74 - 1.39) 
   75,000 or more 0.70*** 0.66*** 0.72* 
 (0.60 - 0.81) (0.55 - 0.80) (0.54 - 0.95) 
Urbanicity     
   Large metropolitan= ref    
   Small metropolitan 0.99 1.08 0.76* 
 (0.88 - 1.11) (0.93 - 1.24) (0.60 - 0.96) 
   Non-metropolitan 0.95 0.93 0.67** 
 (0.82 - 1.09) (0.78 - 1.12) (0.51 - 0.89) 
Health status     
   Fair/poor= ref    
   Good health  0.83* 0.80* 1.17 
 (0.72 - 0.96) (0.66 - 0.96) (0.89 - 1.53) 
Major Depression 
Episode (MDE) 
   
   No= ref    
   Yes 2.14*** 2.60*** 1.51*** 
 (1.89 - 2.42) (2.24 - 3.02) (1.18 - 1.92) 
Post ACA    
 1.33* 1.28 1.50 
 (1.07 - 1.66) (0.97 - 1.68) (0.95 - 2.38) 
Post ACA* health 
insurance types 
   
   Post ACA* Uninsured = 
ref 
   
    
   Post ACA * Medicaid 1.06 0.86 1.56 
 (0.79 - 1.42) (0.58 - 1.26) (0.86 - 2.80) 
   Post ACA * Private 0.84 0.86 0.86 
 (0.64 - 1.10) (0.62 - 1.21) (0.49 - 1.51) 
   Post ACA * Medicare 
and other 
0.87 0.98 1.03 
 (0.56 - 1.35) (0.58 - 1.66) (0.37 - 2.89) 
***p<0.001, **p<0.01, *p<0.05 














Table 1-A2. Adjusted associations of TOOS utilization (versus self-help) and different types of health insurance 
coverage, controlling for sociodemographic characteristics and interaction of post ACA and health insurance 
types 
 Any SUD Any AUD Any OUD 
Sample size 1,696 3,406  1,069 2,125 494 1,191 
Population size 6,732,414 14,029,360 4,353,406 9,058,392 1,795,907 4,728,784 













Health insurance        
   No insurance = 
reference 
      
   Medicaid 2.60** 2.51*** 2.06 1.86 5.18** 5.94** 
 (1.44 - 4.68) (1.50 - 4.18) (1.00 - 4.26) (1.00 - 3.47) (1.61 - 16.68) (2.03 - 17.42) 
   Private 1.01 1.00 1.00 0.91 2.15 1.94 
 (0.61 - 1.66) (0.66 - 1.51) (0.55 - 1.79) (0.56 - 1.48) (0.84 - 5.51) (0.88 - 4.28) 
   Medicare and 
others 
0.44 0.65 0.55 0.63 0.26 0.60 
 (0.19 - 1.04) (0.32 - 1.31) (0.19 - 1.58) (0.27 - 1.45) (0.05 - 1.36) (0.15 - 2.39) 
Age in years       
   18-25= reference       
   26-34 0.88 1.02 0.79 0.97 1.47 1.62 
 (0.61 - 1.27) (0.75 - 1.41) (0.50 - 1.25) (0.66 - 1.43) (0.72 - 3.03) (0.83 - 3.17) 
   35-49 0.70 0.85 0.60* 0.80 1.46 1.16 
 (0.48 - 1.01) (0.62 - 1.15) (0.38 - 0.96) (0.56 - 1.15) (0.70 - 3.03) (0.60 - 2.27) 
   50-64 0.85 1.15 0.88 1.27 3.62 4.69* 
 (0.48 - 1.52) (0.70 - 1.87) (0.45 - 1.71) (0.73 - 2.23) (0.76 - 17.29) (1.06 - 20.84) 
Sex       
   Female= 
reference 
      
   Male 0.69* 0.75 0.81 0.81 0.75 0.79 
 (0.50 - 0.96) (0.56 - 1.01) (0.54 - 1.20) (0.56 - 1.16) (0.42 - 1.33) (0.45 - 1.39) 
Race       
   Non-Hispanic 
Whites= ref 
      
   Non- Hispanic 
African Americans 
0.95 1.26 1.38 1.62 1.09 2.49 
 (0.58 - 1.57) (0.82 - 1.93) (0.74 - 2.54) (0.97 - 2.69) (0.35 - 3.41) (0.76 - 8.17) 
   Hispanic 0.73 0.80 0.98 0.90 0.65 0.98 
 (0.46 - 1.18) (0.54 - 1.18) (0.55 - 1.74) (0.57 - 1.43) (0.27 - 1.60) (0.44 - 2.17) 
   Other 
race/ethnicity 
0.77 0.83 1.40 1.33 1.12 1.03 





Education       
   High school or 
less=ref 
      
   High school or 
more 
1.10 0.93 1.22 0.87 0.96 0.78 
 (0.75 - 1.61) (0.67 - 1.27) (0.74 - 2.00) (0.59 - 1.30) (0.47 - 1.97) (0.41 - 1.48) 
Total annual 
family income 
      
    < $50,000= ref       
   $ 50,000-74,999 1.10 1.11 1.35 1.14 1.21 1.21 
 (0.68 - 1.78) (0.72 - 1.70) (0.78 - 2.35) (0.69 - 1.87) (0.55 - 2.66) (0.57 - 2.58) 
   75,000 or more 1.52 1.22 1.66 1.21 1.32 1.51 
 (0.99 - 2.33) (0.86 - 1.75) (0.99 - 2.78) (0.80 - 1.84) (0.54 - 3.22) (0.73 - 3.12) 
Urbanicity        
   Large 
metropolitan= ref 
      
   Small 
metropolitan 
1.21 1.05 1.30 1.04 1.42 1.40 
 (0.87 - 1.69) (0.78 - 1.41) (0.86 - 1.96) (0.74 - 1.48) (0.71 - 2.83) (0.75 - 2.58) 
   Non-
metropolitan 
1.37 1.13 1.65 1.27 1.68 1.36 
 (0.90 - 2.07) (0.81 - 1.59) (0.97 - 2.82) (0.83 - 1.92) (0.81 - 3.48) (0.75 - 2.48) 
Health status        
   Fair/poor= ref       
   Good health  0.57** 0.75 0.52* 0.75 0.93 1.03 
 (0.38 - 0.86) (0.53 - 1.07) (0.31 - 0.87) (0.49 - 1.13) (0.44 - 1.94) (0.53 - 2.00) 
Major Depression 
Episode (MDE) 
      
   No= ref       
   Yes 0.92 1.31 0.72 1.17 1.13 1.51 
 (0.65 - 1.28) (0.97 - 1.77) (0.48 - 1.07) (0.82 - 1.66) (0.58 - 2.19) (0.84 - 2.72) 
Post ACA       
 1.17 0.97 0.94 0.71 1.55 1.48 
 (0.65 - 2.13) (0.60 - 1.57) (0.44 - 2.01) (0.38 - 1.29) (0.54 - 4.39) (0.60 - 3.63) 
Post ACA* health 
insurance types  
      
PostACA* 
Uninsured 
      
Post ACA* 
Medicaid 
0.66 0.78 0.96 1.20 0.30 0.25 
 (0.28 - 1.53) (0.38 - 1.60) (0.31 - 2.98) (0.49 - 2.98) (0.06 - 1.46) (0.06 - 1.05) 
Post ACA* Private 1.42 1.62 1.80 2.10 0.59 1.07 
 (0.65 - 3.08) (0.85 - 3.06) (0.69 - 4.70) (0.97 - 4.56) (0.14 - 2.61) (0.31 - 3.71) 
Post ACA* 
Medicare and other 





 (1.23 - 
14.82) 
(1.13 - 9.55) (1.20 - 23.10) (1.12 - 13.48) (0.25 - 178.36) (0.30 - 60.52) 
***p<0.001, **p<0.01, *p<0.05 
AOR= Adjusted Odd Ratios, CI= Confidence Interval 
TOOS only= TOOS, no self-help versus self-help, no TOOS 























































Table 1-B1. Adjusted associations of any treatment utilization past year, TOOS (vs. self-help) and different 
types of health insurance coverage, among people with substance abuse 
  Any treatment Only TOOS Any TOOS  





Health insurance     
   No insurance = 
reference 
   
   Medicaid 1.91*** 2.22 1.95 
 (1.41 - 2.60) (0.99 - 5.01) (0.97 - 3.92) 
   Private 0.56*** 1.31 1.08 
 (0.43 - 0.73) (0.62 - 2.76) (0.59 - 1.99) 
   Medicare and others 1.32 1.05 1.07 
 (0.88 - 2.00) (0.33 - 3.34) (0.43 - 2.68) 
Age in years    
   18-25= reference    
   26-34 1.08 0.67 0.61 
 (0.86 - 1.36) (0.35 - 1.30) (0.35 - 1.08) 
   35-49 1.28* 0.94 0.83 
 (1.02 - 1.61) (0.46 - 1.92) (0.46 - 1.51) 
   50-64 0.94 0.31 0.68 
 (0.62 - 1.42) (0.09 - 1.07) (0.24 - 1.90) 
Sex    
   Female= reference    
   Male 1.48*** 0.92 0.84 
 (1.20 - 1.82) (0.50 - 1.68) (0.48 - 1.46) 
Race    
   Non-Hispanic Whites= 
ref 
   
   Non- Hispanic African 
Americans 
1.19 0.80 0.79 
 (0.88 - 1.60) (0.33 - 1.93) (0.39 - 1.59) 
   Hispanic 0.78 1.15 0.96 
 (0.58 - 1.05) (0.52 - 2.53) (0.50 - 1.83) 
   Other race/ethnicity 1.08 0.72 0.69 
 (0.72 - 1.64) (0.22 - 2.34) (0.26 - 1.82) 
Education    





   High school or more 0.55*** 1.28 0.85 
 (0.43 - 0.71) (0.65 - 2.55) (0.48 - 1.50) 
Total annual family 
income 
   
    < $50,000= ref    
   $ 50,000-74,999 0.88 2.37 1.63 
 (0.64 - 1.21) (0.86 - 6.50) (0.66 - 4.03) 
   75,000 or more 0.81 0.91 0.72 
 (0.61 - 1.08) (0.45 - 1.82) (0.39 - 1.32) 
Urbanicity     
   Large metropolitan= 
ref 
   
   Small metropolitan 1.34** 1.12 0.86 
 (1.07 - 1.67) (0.57 - 2.16) (0.49 - 1.50) 
   Non-metropolitan 1.17 1.84 1.06 
 (0.88 - 1.55) (0.86 - 3.93) (0.57 - 1.98) 
Health status     
  Fair/poor= ref    
  Good health 0.76 0.52 0.49 
 (0.56 - 1.04) (0.23 - 1.18) (0.22 - 1.12) 
Major Depression 
Episode (MDE) 
   
   No= ref    
   Yes 1.33* 0.89 1.44 
 (1.02 - 1.74) (0.40 - 1.98) (0.70 - 2.96) 
Post ACA    
 0.92 1.10 0.87 
  (0.74 - 1.15) (0.60 - 2.03) (0.50 - 1.51) 
***p<0.001, **p<0.01, *p<0.05 
AOR= Adjusted Odd Ratios, CI= Confidence Interval 
TOOS only= TOOS, no self-help versus self-help, no TOOS 


















Table 1-B2. Adjusted associations of any treatment utilization past year, TOOS (vs. self-help) and different 
types of health insurance coverage, among people with substance dependence. 
 Any treatment Only TOOS Any TOOS 





Health insurance     
   No insurance = 
reference 
   
   Medicaid 2.10*** 1.90** 2.07*** 
 (1.77 - 2.48) (1.18 - 3.04) (1.39 - 3.10) 
   Private 0.73*** 1.05 1.11 
 (0.62 - 0.86) (0.66 - 1.65) (0.76 - 1.64) 
   Medicare and others 1.35* 0.74 0.89 
 (1.04 - 1.75) (0.37 - 1.49) (0.46 - 1.72) 
Age in years    
   18-25= reference    
   26-34 1.30*** 0.99 1.19 
 (1.14 - 1.49) (0.66 - 1.50) (0.82 - 1.72) 
   35-49 1.53*** 0.66 0.85 
 (1.34 - 1.75) (0.43 - 1.00) (0.60 - 1.20) 
   50-64 1.67*** 0.96 1.30 
 (1.34 - 2.08) (0.51 - 1.81) (0.75 - 2.26) 
Sex    
   Female= reference    
   Male 1.35*** 0.65* 0.77 
 (1.19 - 1.52) (0.45 - 0.94) (0.55 - 1.08) 
Race    
   Non-Hispanic Whites= 
ref 
   
   Non- Hispanic African 
Americans 
0.60*** 1.08 1.59 
 (0.50 - 0.72) (0.60 - 1.97) (0.95 - 2.64) 
   Hispanic 0.61*** 0.68 0.80 
 (0.50 - 0.74) (0.39 - 1.18) (0.51 - 1.24) 
   Other race/ethnicity 0.67*** 0.92 1.00 
 (0.54 - 0.83) (0.45 - 1.88) (0.56 - 1.80) 
Education    
   High school or less=ref    
   High school or more 0.88 1.11 1.02 





Total annual family 
income 
   
    < $50,000= ref    
   $ 50,000-74,999 0.99 1.16 1.14 
 (0.83 - 1.18) (0.71 - 1.89) (0.73 - 1.80) 
   75,000 or more 0.72*** 1.96* 1.62* 
    
Urbanicity     
   Large metropolitan= 
ref 
   
   Small metropolitan 0.91 1.30 1.13 
 (0.80 - 1.03) (0.90 - 1.89) (0.82 - 1.56) 
   Non-metropolitan 0.92 1.37 1.20 
 (0.78 - 1.08) (0.86 - 2.19) (0.82 - 1.77) 
Health status     
  Fair/poor= ref    
  Good health 0.91 0.57* 0.80 
 (0.77 - 1.06) (0.37 - 0.88) (0.54 - 1.17) 
Major Depression 
Episode (MDE) 
   
   No= ref    
   Yes 2.03*** 0.88 1.17 
 (1.77 - 2.32) (0.61 - 1.26) (0.85 - 1.61) 
Post ACA    
 1.17* 1.46* 1.28 
  (1.04 - 1.32) (1.03 - 2.09) (0.95 - 1.73) 
***p<0.001, **p<0.01, *p<0.05 
AOR= Adjusted Odd Ratios, CI= Confidence Interval 
TOOS only= TOOS, no self-help versus self-help, no TOOS 




















Table 1-B3. Adjusted associations of any treatment utilization past year, TOOS (vs. self-help) and different 
types of health insurance coverage, among people with alcohol abuse 
  Any treatment Only TOOS Any TOOS  





Health insurance     
   No insurance = reference    
   Medicaid 1.82*** 2.32 1.73 
 (1.30 - 2.55) (0.92 - 5.89) (0.80 - 3.77) 
   Private 0.60*** 2.09 1.73 
 (0.44 - 0.81) (0.93 - 4.66) (0.88 - 3.40) 
   Medicare and others 1.27 1.59 1.81 
 (0.81 - 1.99) (0.47 - 5.37) (0.67 - 4.89) 
Age in years    
   18-25= reference    
   26-34 0.94 0.82 0.76 
 (0.73 - 1.20) (0.37 - 1.80) (0.40 - 1.46) 
   35-49 1.21 1.02 1.02 
 (0.94 - 1.54) (0.47 - 2.21) (0.55 - 1.92) 
   50-64 0.61 0.68 0.75 
 (0.37 - 1.00) (0.16 - 2.86) (0.23 - 2.48) 
Sex    
   Female= reference    
   Male 1.58*** 0.85 0.72 
 (1.25 - 1.99) (0.41 - 1.78) (0.40 - 1.31) 
Race    
   Non-Hispanic Whites= ref    
   Non- Hispanic African 
Americans 
1.16 0.71 0.67 
 (0.83 - 1.61) (0.25 - 2.07) (0.30 - 1.47) 
   Hispanic 0.82 1.45 1.09 
 (0.59 - 1.12) (0.66 - 3.19) (0.55 - 2.15) 
   Other race/ethnicity 1.03 1.27 1.02 
 (0.67 - 1.59) (0.39 - 4.13) (0.37 - 2.83) 
Education    
   High school or less=ref    
   High school or more 0.53*** 1.05 0.65 
 (0.40 - 0.71) (0.47 - 2.35) (0.34 - 1.26) 
Total annual family income    





   $ 50,000-74,999 1.41** 1.04 0.82 
 (1.11 - 1.78) (0.51 - 2.13) (0.45 - 1.51) 
   75,000 or more 1.13 1.48 0.99 
 (0.83 - 1.55) (0.64 - 3.40) (0.48 - 2.04) 
Urbanicity     
   Large metropolitan= ref    
   Small metropolitan 1.41** 1.04 0.82 
 (1.11 - 1.78) (0.51 - 2.13) (0.45 - 1.51) 
   Non-metropolitan 1.13 1.48 0.99 
 (0.83 - 1.55) (0.64 - 3.40) (0.48 - 2.04) 
Health status     
  Fair/poor= ref    
  Good health 0.68* 0.46 0.37* 
 (0.49 - 0.95) (0.18 - 1.17) (0.15 - 0.94) 
Major Depression Episode 
(MDE) 
   
   No= ref    
   Yes 1.39* 1.25 2.37* 
 (1.05 - 1.85) (0.55 - 2.82) (1.12 - 5.01) 
Post ACA    
 1.27* 0.92 0.87 
  (1.02 - 1.59) (0.47 - 1.79) (0.51 - 1.51) 
***p<0.001, **p<0.01, *p<0.05 
AOR= Adjusted Odd Ratios, CI= Confidence Interval 
TOOS only= TOOS, no self-help versus self-help, no TOOS 




























Table 1-B4. Adjusted associations of any treatment utilization past year, TOOS (vs. self-help) and different 
types of health insurance coverage, among people with alcohol dependence 
  Any treatment Only TOOS Any TOOS  





Health insurance     
   No insurance = reference    
   Medicaid 1.90*** 1.60 2.01* 
 (1.50 - 2.41) (0.81 - 3.15) (1.12 - 3.59) 
   Private 0.83 0.92 0.93 
 (0.67 - 1.03) (0.50 - 1.69) (0.57 - 1.51) 
   Medicare and others 1.52* 1.01 0.84 
 (1.09 - 2.12) (0.42 - 2.44) (0.38 - 1.83) 
Age in years    
   18-25= reference    
   26-34 1.24* 0.77 1.00 
 (1.03 - 1.49) (0.44 - 1.36) (0.62 - 1.61) 
   35-49 1.51*** 0.51* 0.73 
 (1.26 - 1.80) (0.28 - 0.93) (0.47 - 1.14) 
   50-64 1.92*** 0.90 1.25 
 (1.48 - 2.49) (0.43 - 1.89) (0.66 - 2.38) 
Sex    
   Female= reference    
   Male 1.55*** 0.78 0.88 
 (1.31 - 1.83) (0.47 - 1.27) (0.57 - 1.36) 
Race    
   Non-Hispanic Whites= ref    
   Non- Hispanic African 
Americans 
0.74* 2.45* 3.50*** 
 (0.58 - 0.94) (1.10 - 5.44) (1.74 - 7.02) 
   Hispanic 0.68** 0.68 0.80 
 (0.52 - 0.89) (0.31 - 1.48) (0.45 - 1.44) 
   Other race/ethnicity 0.81 1.38 1.38 
 (0.61 - 1.06) (0.55 - 3.44) (0.69 - 2.77) 
Education    
   High school or less=ref    





 (0.66 - 1.06) (0.62 - 2.27) (0.63 - 1.69) 
Total annual family income    
    < $50,000= ref    
   $ 50,000-74,999 0.99 1.54 1.22 
 (0.78 - 1.26) (0.85 - 2.77) (0.69 - 2.14) 
   75,000 or more 0.66*** 2.45* 1.81* 
 (0.52 - 0.84) (1.22 - 4.90) (1.03 - 3.17) 
Urbanicity     
   Large metropolitan= ref    
   Small metropolitan 0.98 1.43 1.15 
 (0.82 - 1.17) (0.88 - 2.33) (0.76 - 1.76) 
   Non-metropolitan 0.90 1.82 1.45 
 (0.72 - 1.13) (0.96 - 3.45) (0.87 - 2.43) 
Health status     
  Fair/poor= ref    
  Good health 0.87 0.55 0.89 
 (0.70 - 1.09) (0.30 - 1.00) (0.55 - 1.43) 
Major Depression Episode 
(MDE) 
   
   No= ref    
   Yes 2.68*** 0.67 0.98 
 (2.25 - 3.19) (0.42 - 1.06) (0.65 - 1.46) 
Post ACA    
 1.03 1.78* 1.28 
  (0.87 - 1.21) (1.09 - 2.92) (0.86 - 1.91) 
***p<0.001, **p<0.01, *p<0.05 
AOR= Adjusted Odd Ratios, CI= Confidence Interval 
TOOS only= TOOS, no self-help versus self-help, no TOOS 




















Table 1-B5. Adjusted associations of any treatment utilization past year, TOOS (vs. self-help) and different 
types of health insurance coverage, among people with opioid abuse 
  Any treatment Only TOOS Any TOOS  





Health insurance     
   No insurance = reference    
   Medicaid 1.67 1.78 4.07 
 (0.71 - 3.89) (0.16 - 19.69) (0.76 - 21.70) 
   Private 0.51 0.14 1.80 
 (0.24 - 1.10) (0.01 - 3.02) (0.26 - 12.40) 
   Medicare and others 1.11 0.59 0.67 
 (0.39 - 3.18) (0.04 - 9.47) (0.08 - 5.97) 
Age in years    
   18-25= reference    
   26-34 1.26 3.21 1.71 
 (0.64 - 2.46) (0.17 - 62.00) (0.28 - 10.26) 
   35-49 1.18 0.59 0.49 
 (0.61 - 2.28) (0.03 - 13.19) (0.08 - 2.93) 
   50-64 0.47 
  
 (0.14 - 1.62) 
  
Sex    
   Female= reference    
   Male 2.24** 1.74 1.68 
 (1.26 - 3.98) (0.22 - 13.78) (0.51 - 5.47) 
Race    
   Non-Hispanic Whites= ref    
   Non- Hispanic African 
Americans 
0.78 4.41 2.67 
 (0.30 - 2.05) (0.13 - 155.28) (0.17 - 41.57) 
   Hispanic 0.32* 0.65 1.51 
 (0.12 - 0.82) (0.04 - 9.79) (0.22 - 10.44) 
   Other race/ethnicity 0.40* 0.50 0.89 
 (0.16 - 0.97) (0.02 - 13.93) (0.07 - 11.10) 
Education    
   High school or less=ref    
   High school or more 1.09 0.38 0.55 
 (0.55 - 2.13) (0.03 - 4.92) (0.05 - 5.74) 
Total annual family income    





   $ 50,000-74,999 1.63 1.83 0.39 
 (0.61 - 4.35) (0.06 - 57.83) (0.04 - 3.56) 
   75,000 or more 1.19 1.94 4.72 
 (0.63 - 2.27) (0.15 - 25.46) (0.51 - 43.87) 
Urbanicity     
   Large metropolitan= ref    
   Small metropolitan 0.83 2.78 2.85 
 (0.43 - 1.62) (0.26 - 30.15) (0.53 - 15.44) 
   Non-metropolitan 0.97 2.04 1.13 
 (0.48 - 1.94) (0.15 - 28.06) (0.15 - 8.46) 
Health status     
  Fair/poor= ref    
  Good health 0.49* 1.60 1.20 
 (0.25 - 0.97) (0.04 - 61.02) (0.29 - 4.92) 
Major Depression Episode 
(MDE) 
   
   No= ref    
   Yes 2.31** 0.20 0.53 
 (1.24 - 4.29) (0.02 - 2.37) (0.13 - 2.20) 
Post ACA    
 0.89 0.49 1.00 
  (0.49 - 1.61) (0.06 - 3.88) (0.27 - 3.74) 
***p<0.001, **p<0.01, *p<0.05 
AOR= Adjusted Odd Ratios, CI= Confidence Interval 
TOOS only= TOOS, no self-help versus self-help, no TOOS 




























Table 1-B6. Adjusted associations of any treatment utilization past year, TOOS (vs. self-help) and different 
types of health insurance coverage, among people with opioid dependence 
  Any treatment Only TOOS Any TOOS  





Health insurance     
   No insurance = reference    
   Medicaid 2.40*** 2.52* 2.43** 
 (1.78 - 3.25) (1.18 - 5.42) (1.26 - 4.70) 
   Private 1.25 1.90 2.04 
 (0.92 - 1.68) (0.86 - 4.20) (0.97 - 4.29) 
   Medicare and others 1.78* 0.89 1.38 
 (1.01 - 3.14) (0.20 - 3.85) (0.34 - 5.59) 
Age in years    
   18-25= reference    
   26-34 1.06 1.44 1.66 
 (0.83 - 1.35) (0.70 - 2.95) (0.82 - 3.35) 
   35-49 1.19 1.48 1.30 
 (0.90 - 1.58) (0.67 - 3.24) (0.63 - 2.72) 
   50-64 1.13 3.62 4.39* 
 (0.72 - 1.77) (0.76 - 17.18) (1.01 - 19.06) 
Sex    
   Female= reference    
   Male 1.17 0.73 0.86 
 (0.92 - 1.48) (0.39 - 1.34) (0.48 - 1.55) 
Race    
   Non-Hispanic Whites= ref    
   Non- Hispanic African 
Americans 
0.90 1.10 2.27 
 (0.59 - 1.39) (0.33 - 3.65) (0.65 - 7.88) 
   Hispanic 0.87 0.76 1.01 
 (0.60 - 1.25) (0.28 - 2.07) (0.43 - 2.37) 
   Other race/ethnicity 0.43*** 1.22 1.13 
 (0.26 - 0.70) (0.35 - 4.27) (0.43 - 2.96) 
Education    
   High school or less=ref    
   High school or more 1.02 1.15 0.83 
 (0.78 - 1.33) (0.53 - 2.51) (0.40 - 1.72) 





    < $50,000= ref    
   $ 50,000-74,999 0.92 1.20 1.17 
 (0.66 - 1.28) (0.54 - 2.65) (0.55 - 2.49) 
   75,000 or more 0.66** 1.35 1.34 
 (0.48 - 0.90) (0.57 - 3.18) (0.64 - 2.80) 
Urbanicity     
   Large metropolitan= ref    
   Small metropolitan 0.76* 1.39 1.25 
 (0.59 - 0.97) (0.69 - 2.79) (0.65 - 2.39) 
   Non-metropolitan 0.64** 1.82 1.46 
 (0.47 - 0.86) (0.85 - 3.86) (0.75 - 2.84) 
Health status     
  Fair/poor= ref    
  Good health 1.35* 0.76 0.86 
 (1.01 - 1.79) (0.35 - 1.64) (0.42 - 1.77) 
Major Depression Episode 
(MDE) 
   
   No= ref    
   Yes 1.43** 1.22 1.75 
 (1.12 - 1.84) (0.61 - 2.44) (0.91 - 3.36) 
Post ACA    
 1.82*** 1.04 1.10 
  (1.44 - 2.29) (0.57 - 1.92) (0.66 - 1.86) 
***p<0.001, **p<0.01, *p<0.05 
AOR= Adjusted Odd Ratios, CI= Confidence Interval 
TOOS only= TOOS, no self-help versus self-help, no TOOS 



























Table 1-C1.  Adjusted associations among those with any pain reliver, any heroin use disorders 
 Any pain reliver use disorder Any heroin use disorder 
Sample size 3,293 1,071 
Population size 12,977,145 3,959,977 





Health insurance    
   No insurance = reference   
   Medicaid 1.86*** 3.21*** 
 (1.34 - 2.58) (1.95 - 5.27) 
   Private 0.98 2.53*** 
 (0.72 - 1.34) (1.56 - 4.10) 
   Medicare and others 1.20 4.13*** 
 (0.67 - 2.15) (1.88 - 9.08) 
Age in years   
   18-25= reference   
   26-34 0.97 1.30 
 (0.75 - 1.25) (0.88 - 1.93) 
   35-49 1.17 2.29** 
 (0.88 - 1.54) (1.33 - 3.94) 
   50-64 1.07 3.35* 
 (0.66 - 1.74) (1.08 - 10.39) 
Sex   
   Female= reference   
   Male 1.21 0.90 
 (0.94 - 1.56) (0.61 - 1.33) 
Race   
   Non-Hispanic Whites= ref   
   Non- Hispanic African Americans 0.73 0.53 
 (0.46 - 1.13) (0.23 - 1.24) 
   Hispanic 0.56** 1.07 
 (0.37 - 0.86) (0.60 - 1.89) 
   Other race/ethnicity 0.39*** 0.47 
 (0.24 - 0.63) (0.20 - 1.09) 
Education   
   High school or less=ref   
   High school or more 1.16 1.11 
 (0.87 - 1.54) (0.72 - 1.72) 
Total annual family income   
    < $50,000= ref   
   $ 50,000-74,999 0.96 1.83* 
 (0.68 - 1.37) (1.04 - 3.20) 
   75,000 or more 0.70* 0.91 
 (0.51 - 0.97) (0.56 - 1.48) 
Urbanicity    
   Large metropolitan= ref   
   Small metropolitan 0.82 0.61* 
 (0.63 - 1.06) (0.40 - 0.93) 
   Non-metropolitan 0.82 0.52* 





Health status    
  Fair/poor= ref   
  Good health 1.19 1.47 
 (0.88 - 1.62) (0.95 - 2.28) 
Major Depression Episode (MDE)   
   No= ref   
   Yes 1.47** 2.60*** 
 (1.12 - 1.91) (1.69 - 4.01) 
Post ACA   
 1.50** 2.00*** 
 (1.17 - 1.92) (1.36 - 2.94) 
***p<0.001, **p<0.01, *p<0.05 
AOR= Adjusted Odd Ratios, CI= Confidence Interval 
TOOS only= TOOS, no self-help versus self-help, no TOOS 







































Table 1-C2. Adjusted associations of TOOS (vs self-help only) and insurance types among those with any pain 
reliever, heroin use disorders 
 Any pain reliever use disorder Any heroin use disorder 
Sample size 366 867  203 551 
Population size 1,403,641 3,507,654 689,798.78 2,019,958 









Health insurance      
   No insurance = reference     
   Medicaid 3.51** 2.97** 1.77 1.93 
 (1.43 - 8.60) (1.46 - 6.05) (0.57 - 5.53) (0.78 - 4.81) 
   Private 2.15 2.38* 0.73 1.45 
 (0.87 - 5.34) (1.10 - 5.18) (0.22 - 2.43) (0.57 - 3.64) 
   Medicare and others 0.51 0.98 0.51 0.81 
 (0.12 - 2.29) (0.25 - 3.77) (0.10 - 2.59) (0.18 - 3.63) 
Age in years     
   18-25= reference     
   26-34 1.77 1.97 1.31 1.16 
 (0.69 - 4.54) (0.84 - 4.64) (0.53 - 3.23) (0.50 - 2.70) 
   35-49 1.59 1.06 0.52 0.67 
 (0.70 - 3.62) (0.50 - 2.21) (0.18 - 1.51) (0.27 - 1.71) 
   50-64 2.85 4.00 - - 
 (0.59 - 13.77) (0.93 - 17.23) - - 
Sex     
   Female= reference     
   Male 0.94 0.98 0.46 0.48 
 (0.47 - 1.86) (0.52 - 1.83) (0.18 - 1.18) (0.21 - 1.09) 
Race     
   Non-Hispanic Whites= 
ref 
    
   Non- Hispanic African 
Americans 
2.20 4.14* 0.31 2.10 
 (0.45 - 10.91) (1.10 - 15.60) (0.05 - 1.95) (0.21 - 20.67) 
   Hispanic 0.89 1.10 0.56 1.35 
 (0.25 - 3.10) (0.40 - 3.06) (0.15 - 2.11) (0.41 - 4.43) 
   Other race/ethnicity 1.16 0.91 0.38 0.78 
 (0.26 - 5.21) (0.29 - 2.85) (0.05 - 2.60) (0.18 - 3.40) 
Education     





   High school or more 0.78 0.62 1.74 0.95 
 (0.34 - 1.78) (0.31 - 1.24) (0.54 - 5.58) (0.34 - 2.65) 
Total annual family 
income 
    
    < $50,000= ref     
   $ 50,000-74,999 1.51 1.09 1.30 1.95 
 (0.66 - 3.43) (0.50 - 2.37) (0.30 - 5.56) (0.70 - 5.45) 
   75,000 or more 1.99 1.78 1.16 1.47 
 (0.70 - 5.63) (0.78 - 4.05) (0.37 - 3.65) (0.57 - 3.80) 
Urbanicity      
   Large metropolitan= ref     
   Small metropolitan 1.62 1.62 2.22 1.30 
 (0.66 - 3.97) (0.75 - 3.46) (0.83 - 5.90) (0.61 - 2.77) 
   Non-metropolitan 2.25* 1.93 3.10 1.87 
 (1.02 - 4.95) (0.94 - 3.93) (0.91 - 10.48) (0.69 - 5.06) 
Health status      
   Fair/poor= ref     
   Good health  0.87 1.02 1.10 1.48 
 (0.39 - 1.93) (0.49 - 2.10) (0.33 - 3.61) (0.60 - 3.61) 
Major Depression 
Episode (MDE) 
    
   No= ref     
   Yes 0.89 1.29 1.25 1.52 
 (0.44 - 1.83) (0.70 - 2.36) (0.39 - 3.96) (0.64 - 3.64) 
Post ACA     
 0.85 1.12 1.73 1.69 
 (0.43 - 1.68) (0.64 - 1.95) (0.64 - 4.66) (0.83 - 3.46) 
***p<0.001, **p<0.01, *p<0.05 
AOR= Adjusted Odd Ratios, CI= Confidence Interval 
TOOS only= TOOS, no self-help versus self-help, no TOOS 
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Appendix 2-B  
Table 2-B. Summary of Medicaid Expansion and Section 1115 Demonstrations across states as of 2017 
State Expansion status  Section 1115 
Demonstrations: 
Substance Use Disorders 
Alabama Not adopted  
Florida Not adopted  
Kansas Not adopted  
Mississippi Not adopted  
Missouri Not adopted  
North Carolina Not adopted (11/1/2019) 
Oklahoma Not adopted  
South Carolina Not adopted  
South Dakota Not adopted  
Tennessee Not adopted  
Texas Not adopted  
Wisconsin Not adopted 1/1/2014 
Wyoming Not adopted  
Georgia Not adopted 
 (later adopted on 12/1/20)  
 
Nebraska Not adopted  
(later adopted on 10/1/20) 
(7/1/2019) 
Idaho Not adopted  
(later adopted on 1/1/20 
(4/17/2020) 
Utah Not adopted  
(later adopted on 1/1/20)  
7/1/2002 
Maine Not adopted  
(later adopted on 1/10/19)  
 
Virginia Not adopted  
(later adopted on 1/1/19)  
4/1/2017 
Louisiana 7/1/16 (2/1/2018) 
Montana 1/1/16  
Alaska 9/1/15 (1/1/2019) 
Indiana 2/1/15 2/1/2015 
Pennsylvania 1/1/15 10/1/2017 
New Hampshire 8/15/14 (7/10/2018) 
Michigan 4/1/14  
Arizona 1/1/14  
Arkansas 1/1/14 1/1/2013 





Colorado 1/1/14  
Connecticut 1/1/14  
Delaware 1/1/14 1/1/1996 
District of Columbia 1/1/14 (1/1/2020) 
Hawaii 1/1/14  
Illinois 1/1/14  
Iowa 1/1/14  
Kentucky 1/1/14 (4/1/2019) 
Maryland 1/1/14 7/1/1997 
Massachusetts 1/1/14 7/1/1997 
Minnesota 1/1/14 (10/1/2019) 
Nevada 1/1/14  
New Jersey 1/1/14 10/2/2012 
New Mexico 1/1/14 (1/1/2019) 
New York 1/1/14 (10/1/2019) 
North Dakota 1/1/14  
Ohio 1/1/14 (10/1/2019) 
Oregon 1/1/14  
Rhode Island 1/1/14 7/1/2009 
Vermont 1/1/14 10/1/2005 
Washington 1/1/14 1/9/2017 
























Appendix 2-C  
Sensitivity analyses with additional covariates 
 








     
N 231,025 231,025 231,025 
 RRR RRR RRR 
 (95%CI) (95%CI) (95%CI) 
Medicaid expansion        
  Yes  1.10** 2.11*** 1.28*** 
 (1.04 - 1.16) (1.97 - 2.27) (1.22 - 1.35) 
MAT (No= ref)     
   Yes 0.64*** 0.34*** 0.14*** 
  (0.62 - 0.66) (0.33 - 0.35) (0.13 - 0.14) 
Frequency of use (No 
past month use= ref)  
   
   Some use 0.64*** 0.65*** 0.39*** 
 (0.62 - 0.67) (0.63 - 0.68) (0.37 - 0.40) 
   Daily use 0.51*** 0.37*** 0.16*** 
 (0.50 - 0.53) (0.36 - 0.38) (0.16 - 0.17) 
Age (18-29= ref)     
   30-44 1.00 1.00 0.99 
 (0.97 - 1.03) (0.96 - 1.03) (0.96 - 1.01) 
   45-64 1.11*** 0.77*** 0.85*** 
 (1.07 - 1.15) (0.74 - 0.81) (0.82 - 0.88) 
Gender (Female=ref)    
   Male 0.88*** 0.62*** 1.31*** 
 (0.85 - 0.90) (0.60 - 0.64) (1.28 - 1.35) 
Race/ethnicity (non-
Hispanic White=ref) 
   
   Non-Hispanic Black 
1.01 1.36*** 1.19*** 
 (0.96 - 1.07) (1.28 - 1.44) (1.14 - 1.26) 
   Hispanic 0.90*** 1.30*** 1.21*** 
 (0.85 - 0.95) (1.23 - 1.38) (1.15 - 1.27) 
   Other 0.88*** 1.04 0.96 
 (0.82 - 0.95) (0.96 - 1.12) (0.90 - 1.03) 
Education (Less than 
high school= ref)  





   Highschool or higher 
0.96** 0.80*** 0.78*** 
 (0.93 - 0.99) (0.78 - 0.83) (0.76 - 0.80) 
Number of arrests (0= 
ref) 
   
   1 0.85*** 1.19*** 2.73*** 
 (0.79 - 0.91) (1.12 - 1.28) (2.60 - 2.86) 
   2 or more 0.83** 0.96 1.10 
 (0.74 - 0.93) (0.83 - 1.11) (1.00 - 1.21) 
Employment status (Not 
employed= ref)  
   
     Employed 
1.32*** 1.14*** 0.93*** 
 (1.28 - 1.36) (1.10 - 1.18) (0.91 - 0.96) 
Comorbidity (No= ref)     
   Yes 1.49*** 0.93*** 0.65*** 
 (1.45 - 1.53) (0.90 - 0.96) (0.63 - 0.67) 
Homeless (No= ref)     
  Yes 1.31*** 1.35*** 0.61*** 
 (1.25 - 1.38) (1.28 - 1.44) (0.58 - 0.65) 
Polysubstance use (no= 
ref)   
   
    One more 
0.99 1.02 0.85*** 
 (0.96 - 1.01) (0.99 - 1.05) (0.83 - 0.88) 
    Two or more 
0.97 1.06** 0.95** 
 (0.94 - 1.01) (1.02 - 1.10) (0.92 - 0.98) 
Unemployment rate    
   Unemployed rate 1.08*** 1.11*** 1.03* 
 (1.05 - 1.11) (1.08 - 1.15) (1.01 - 1.06) 
PMDP (No=ref)    
   Yes 1.24*** 1.44*** 0.84*** 
 (1.13 - 1.36) (1.31 - 1.59) (0.78 - 0.91) 
* p<0.05, ** p<0.01, *** p<0.001 
Reference group for multinomial regression is self-referral. Relative Risk Ratio = RRR. Confidence 
Interval = CI.  

























    
N 225,272 225,272 225,272 
 AOR AOR AOR 
 (95%CI) (95%CI) (95%CI) 
    
Expansion 0.92 1.04 1.07 
    (0.57 - 1.48) (0.64 - 1.68) (0.64 - 1.76) 
Post expansion  1.09 0.64*** 1.00 
    (0.91 - 1.31) (0.53 - 0.78) (0.84 - 1.18) 
Expansion * Post expansion  1.11*** 2.25*** 1.29*** 
    (1.04 - 1.17) (2.09 - 2.41) (1.23 - 1.37) 
MAT (No= ref)     
   Yes 0.65*** 0.33*** 0.14*** 
 (0.63 - 0.67) (0.32 - 0.35) (0.13 - 0.14) 
Frequency of use     
   Some use 0.64*** 0.66*** 0.38*** 
 (0.62 - 0.67) (0.63 - 0.69) (0.37 - 0.40) 
   Daily use  0.51*** 0.37*** 0.16*** 
 (0.50 - 0.53) (0.36 - 0.39) (0.16 - 0.17) 
Age (18-29= ref)     
   30-44 1.00 0.99 0.99 
 (0.97 - 1.03) (0.96 - 1.02) (0.96 - 1.01) 
   45-64 1.11*** 0.77*** 0.84*** 
 (1.07 - 1.15) (0.74 - 0.81) (0.81 - 0.88) 
Gender    
   Male  0.88*** 0.62*** 1.31*** 
 (0.86 - 0.90) (0.60 - 0.63) (1.28 - 1.35) 
Race/ethnicity     
   Non-Hispanic Black 1.02 1.36*** 1.19*** 
 (0.97 - 1.07) (1.28 - 1.45) (1.13 - 1.26) 
   Hispanic  0.90*** 1.32*** 1.21*** 
 (0.85 - 0.95) (1.24 - 1.40) (1.15 - 1.27) 
   Other 0.89** 1.04 0.98 
 (0.82 - 0.96) (0.96 - 1.13) (0.92 - 1.06) 
Education     
   Highschool or higher 0.96* 0.81*** 0.78*** 
 (0.94 - 0.99) (0.78 - 0.84) (0.76 - 0.80) 
Number of arrests (0=ref)    
   1 0.83*** 1.20*** 2.73*** 
 (0.78 - 0.89) (1.12 - 1.28) (2.60 - 2.87) 
   2 or more 0.85** 0.96 1.09 





Employment status     
     Employed 1.33*** 1.14*** 0.93*** 
 (1.29 - 1.37) (1.10 - 1.18) (0.91 - 0.96) 
Comorbidity    
   Yes  1.51*** 0.92*** 0.65*** 
 (1.47 - 1.55) (0.89 - 0.95) (0.63 - 0.67) 
Homeless    
  Yes 1.33*** 1.35*** 0.61*** 
 (1.27 - 1.40) (1.27 - 1.43) (0.57 - 0.65) 
Polysubstance use     
    One more 0.99 1.01 0.85*** 
 (0.97 - 1.02) (0.98 - 1.05) (0.82 - 0.87) 
    Two or more 0.98 1.05** 0.94*** 
 (0.95 - 1.02) (1.02 - 1.09) (0.91 - 0.97) 
Unemployment rate     
   Unemployed rate 1.08*** 1.09*** 1.03* 
 (1.05 - 1.11) (1.06 - 1.12) (1.00 - 1.06) 
PMDP ( No= ref)     
   Yes 1.24*** 1.50*** 0.85*** 
 (1.13 - 1.36) (1.36 - 1.65) (0.78 - 0.92) 
* p<0.05, ** p<0.01, *** p<0.001 
Reference group for multinomial regression is self-referral. Relative Risk Ratio = RRR. Confidence Interval = 
CI.  






























Appendix 2-D  
Sensitivity analysis with lagged model 
 









    
N 225,272 225,272 225,272 
 AOR AOR AOR 
 (95%CI) (95%CI) (95%CI) 
    
Expansion 0.84 0.91 1.03 
    (0.52 - 1.35) (0.57 - 1.48) (0.62 - 1.71) 
Post expansion year 2014  0.91* 0.44*** 1.16*** 
    (0.84 - 0.98) (0.39 - 0.49) (1.07 - 1.26) 
Expansion * Post expansion 
Year 0 (or year 2014)   
1.03 1.78*** 1.04 
    (0.94 - 1.13) (1.57 - 2.01) (0.96 - 1.13) 
Post expansion year 1 1.08 1.09 0.88* 
 (0.98 - 1.20) (0.94 - 1.27) (0.80 - 0.97) 
Expansion* Post expansion year 1 0.98 1.04 1.12 
 (0.87 - 1.10) (0.88 - 1.23) (1.00 - 1.25) 
Post expansion year 2 0.74*** 0.87* 1.00 
 (0.67 - 0.82) (0.76 - 1.00) (0.91 - 1.10) 
Expansion* Post expansion year 2 1.19** 1.26** 1.02 
 (1.06 - 1.33) (1.08 - 1.48) (0.91 - 1.14) 
Post expansion year 3 0.90** 0.83** 0.67*** 
 (0.83 - 0.97) (0.74 - 0.93) (0.62 - 0.72) 
Expansion* Post expansion year 3 1.15** 1.35*** 1.50*** 
 (1.04 - 1.27) (1.19 - 1.54) (1.37 - 1.65) 
MAT (No= ref)     
   Yes 0.65*** 0.33*** 0.14*** 
 (0.63 - 0.67) (0.32 - 0.34) (0.13 - 0.14) 
Frequency of use     
   Some use 0.64*** 0.66*** 0.38*** 
 (0.62 - 0.67) (0.63 - 0.69) (0.37 - 0.40) 
   Daily use  0.51*** 0.38*** 0.16*** 
 (0.50 - 0.53) (0.36 - 0.39) (0.16 - 0.17) 
Age (18-29= ref)     
   30-44 1.00 0.99 0.99 
 (0.97 - 1.03) (0.96 - 1.03) (0.96 - 1.01) 
   45-64 1.11*** 0.77*** 0.84*** 
 (1.07 - 1.15) (0.74 - 0.81) (0.81 - 0.88) 
Gender    
   Male  0.88*** 0.62*** 1.31*** 
 (0.85 - 0.90) (0.60 - 0.63) (1.28 - 1.35) 
Race/ethnicity     





 (0.97 - 1.07) (1.29 - 1.46) (1.14 - 1.26) 
   Hispanic  0.89*** 1.31*** 1.21*** 
 (0.84 - 0.94) (1.24 - 1.39) (1.14 - 1.27) 
   Other 0.87*** 1.02 0.97 
 (0.81 - 0.94) (0.95 - 1.11) (0.91 - 1.04) 
Education     
   Highschool or higher 0.96* 0.81*** 0.78*** 
 (0.94 - 0.99) (0.79 - 0.84) (0.76 - 0.80) 
Number of arrests (0=ref)    
   1 0.83*** 1.20*** 2.74*** 
 (0.78 - 0.89) (1.12 - 1.28) (2.61 - 2.87) 
   2 or more 0.86* 0.97 1.09 
 (0.77 - 0.97) (0.83 - 1.12) (0.99 - 1.20) 
Employment status     
     Employed 1.33*** 1.14*** 0.93*** 
 (1.29 - 1.37) (1.10 - 1.18) (0.91 - 0.96) 
Comorbidity    
   Yes  1.50*** 0.91*** 0.65*** 
 (1.46 - 1.54) (0.89 - 0.94) (0.63 - 0.67) 
Homeless    
  Yes 1.33*** 1.35*** 0.61*** 
 (1.27 - 1.41) (1.27 - 1.43) (0.57 - 0.65) 
Polysubstance use     
    One more 1.00 1.02 0.85*** 
 (0.97 - 1.03) (0.99 - 1.06) (0.83 - 0.88) 
    Two or more 0.99 1.07*** 0.95** 
 (0.96 - 1.03) (1.03 - 1.11) (0.92 - 0.98) 
* p<0.05, ** p<0.01, *** p<0.001 
Reference group for multinomial regression is self-referral. Relative Risk Ratio = RRR. Confidence Interval = 
CI.  























Sensitivity analysis for discharges with many episodes 
 







     
N 518,154 518,154 518,154 
 RRR RRR RRR 
 (95%CI) (95%CI) (95%CI) 
Medicaid expansion        
  Yes  0.91*** 1.34*** 0.96 
 (0.88 - 0.95) (1.26 - 1.42) (0.92 - 1.01) 
MAT (No= ref)     
   Yes 0.53*** 0.29*** 0.13*** 
  (0.52 - 0.54) (0.28 - 0.30) (0.13 - 0.13) 
Frequency of use (No 
past month use= ref)  
   
   Some use 0.52*** 0.57*** 0.36*** 
 (0.51 - 0.53) (0.55 - 0.58) (0.35 - 0.37) 
   Daily use 0.49*** 0.38*** 0.19*** 
 (0.49 - 0.50) (0.37 - 0.39) (0.19 - 0.20) 
Age (18-29= ref)     
   30-44 0.94*** 1.04** 0.90*** 
 (0.92 - 0.95) (1.02 - 1.07) (0.88 - 0.92) 
   45-64 0.92*** 0.86*** 0.67*** 
 (0.89 - 0.94) (0.84 - 0.89) (0.65 - 0.69) 
Gender (Female=ref)    
   Male 0.96*** 0.74*** 1.40*** 
 (0.94 - 0.97) (0.72 - 0.75) (1.37 - 1.42) 
Race/ethnicity (non-
Hispanic White=ref) 
   
   Non-Hispanic Black 1.22*** 1.36*** 1.01 
 (1.18 - 1.25) (1.31 - 1.42) (0.97 - 1.04) 
   Hispanic 0.90*** 1.24*** 1.11*** 
 (0.87 - 0.92) (1.20 - 1.28) (1.08 - 1.14) 
   Other 0.80*** 0.84*** 0.87*** 
 (0.77 - 0.84) (0.80 - 0.89) (0.83 - 0.91) 
Education (Less than 
high school= ref)  
   
   Highschool or higher 1.00 0.83*** 0.86*** 





Number of arrests (0= 
ref) 
   
   1 0.79*** 1.11*** 2.35*** 
 (0.76 - 0.82) (1.06 - 1.17) (2.27 - 2.43) 
   2 or more 0.67*** 0.77*** 1.33*** 
 (0.62 - 0.73) (0.69 - 0.87) (1.24 - 1.44) 
Employment status 
(Not employed= ref)  
   
     Employed 
1.32*** 1.24*** 0.95*** 
 (1.29 - 1.35) (1.21 - 1.27) (0.93 - 0.97) 
Comorbidity (No= ref)     
   Yes 1.22*** 0.97** 0.76*** 
 (1.20 - 1.24) (0.95 - 0.99) (0.75 - 0.77) 
Homeless (No= ref)     
  Yes 1.07*** 1.39*** 0.65*** 
 (1.04 - 1.11) (1.34 - 1.44) (0.63 - 0.68) 
Polysubstance use 
(no= ref)   
   
    One more 1.00 1.11*** 1.06*** 
 (0.98 - 1.01) (1.09 - 1.14) (1.04 - 1.08) 
    Two or more 1.06*** 1.24*** 1.18*** 
 (1.04 - 1.08) (1.21 - 1.27) (1.15 - 1.20) 
* p<0.05, ** p<0.01, *** p<0.001 
Reference group for multinomial regression is self-referral. Adjusted Odds Ratio = AOR. 
Confidence Interval = CI.  

































    
N 225,272 225,272 225,272 
 RRR RRR RRR 
 (95%CI) (95%CI) (95%CI) 
    
Expansion 0.86 2.32** 0.82 
    (0.55 - 1.33) (1.30 - 4.16) (0.54 - 1.24) 
Post expansion  0.78*** 0.79*** 1.42*** 
    (0.74 - 0.83) (0.73 - 0.85) (1.33 - 1.51) 
Expansion * Post expansion  0.90*** 1.36*** 0.93** 
    (0.86 - 0.94) (1.28 - 1.44) (0.88 - 0.97) 
MAT (No= ref)     
   Yes 0.54*** 0.29*** 0.13*** 
 (0.53 - 0.55) (0.29 - 0.30) (0.13 - 0.14) 
Frequency of use     
   Some use 0.52*** 0.57*** 0.36*** 
 (0.50 - 0.53) (0.56 - 0.59) (0.35 - 0.37) 
   Daily use  0.49*** 0.39*** 0.19*** 
 (0.49 - 0.50) (0.38 - 0.39) (0.19 - 0.20) 
Age (18-29= ref)     
   30-44 0.94*** 1.07*** 0.91*** 
 (0.92 - 0.96) (1.04 - 1.09) (0.89 - 0.93) 
   45-64 0.94*** 0.96** 0.68*** 
 (0.92 - 0.96) (0.93 - 0.99) (0.67 - 0.70) 
Gender    
   Male  0.95*** 0.75*** 1.40*** 
 (0.94 - 0.97) (0.73 - 0.76) (1.37 - 1.42) 
Race/ethnicity     
   Non-Hispanic Black 1.10*** 1.04 0.86*** 
 (1.05 - 1.14) (0.98 - 1.10) (0.81 - 0.90) 
   Hispanic  0.99 1.00 1.13*** 
 (0.95 - 1.03) (0.95 - 1.05) (1.08 - 1.18) 
   Other 0.73*** 0.75*** 0.82*** 
 (0.69 - 0.78) (0.70 - 0.81) (0.77 - 0.87) 
Education     
   Highschool or higher 1.00 0.81*** 0.86*** 
 (0.98 - 1.02) (0.79 - 0.83) (0.84 - 0.88) 
Number of arrests (0=ref)    
   1 0.79*** 1.12*** 2.35*** 
 (0.76 - 0.82) (1.06 - 1.17) (2.27 - 2.43) 
   2 or more 0.68*** 0.77*** 1.34*** 
 (0.62 - 0.74) (0.68 - 0.87) (1.24 - 1.44) 
Employment status     
     Employed 1.33*** 1.27*** 0.96*** 





Comorbidity    
   Yes  1.21*** 0.96*** 0.76*** 
 (1.19 - 1.23) (0.94 - 0.98) (0.75 - 0.78) 
Homeless    
  Yes 1.08*** 1.42*** 0.65*** 
 (1.05 - 1.12) (1.37 - 1.47) (0.63 - 0.68) 
Polysubstance use     
    One more 1.00 1.11*** 1.04*** 
 (0.98 - 1.02) (1.08 - 1.14) (1.02 - 1.07) 
    Two or more 1.07*** 1.24*** 1.17*** 
 (1.05 - 1.09) (1.21 - 1.27) (1.14 - 1.19) 
* p<0.05, ** p<0.01, *** p<0.001 
Reference group for multinomial regression is self-referral. Relative Risk Ratio = RRR. Confidence Interval = 
CI.  















































N 169,449 169,449 169,449 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Medicaid expansion     
  Expanded 0.89*** 1.26*** 0.86*** 
 (0.85 - 0.94) (1.17 - 1.35) (0.82 - 0.91) 
Frequency of use (No 
past month use= ref)  
   
   Some use 0.58*** 0.59*** 0.38*** 
 (0.57 - 0.60) (0.57 - 0.61) (0.37 - 0.39) 
   Daily use 0.70*** 0.42*** 0.23*** 
 (0.68 - 0.71) (0.41 - 0.44) (0.22 - 0.23) 
Age (18-29= ref)     
   30-44 0.96*** 1.11*** 0.94*** 
 (0.93 - 0.98) (1.08 - 1.14) (0.92 - 0.96) 
   45-64 1.00 0.94** 0.76*** 
 (0.97 - 1.03) (0.91 - 0.98) (0.74 - 0.78) 
Gender (Female=ref)    
   Male 0.98* 0.71*** 1.39*** 
 (0.96 - 1.00) (0.70 - 0.73) (1.36 - 1.41) 
Race/ethnicity (non-
Hispanic White=ref) 
   
   Non-Hispanic Black 1.40*** 1.48*** 1.06** 
 (1.35 - 1.46) (1.41 - 1.56) (1.02 - 1.10) 
   Hispanic 1.02 1.45*** 1.25*** 
 (0.99 - 1.06) (1.39 - 1.51) (1.20 - 1.29) 
   Other 0.83*** 0.86*** 0.87*** 
 (0.79 - 0.88) (0.80 - 0.92) (0.83 - 0.92) 
Education (Less than high 
school= ref)  
   
   Highschool or higher 0.96*** 0.78*** 0.82*** 
 (0.94 - 0.98) (0.76 - 0.80) (0.80 - 0.83) 
Number of arrests (0= 
ref) 
   
   1 0.72*** 1.07* 1.96*** 
 (0.69 - 0.76) (1.02 - 1.13) (1.89 - 2.04) 





 (0.53 - 0.65) (0.61 - 0.79) (1.03 - 1.22) 
Employment status (Not 
employed= ref)  
   
     Employed 1.38*** 1.24*** 0.95*** 
 (1.35 - 1.42) (1.21 - 1.28) (0.93 - 0.97) 
Comorbidity (No= ref)     
   Yes 1.20*** 0.85*** 0.70*** 
 (1.18 - 1.23) (0.83 - 0.88) (0.68 - 0.71) 
Homeless (No= ref)     
  Yes 1.10*** 1.43*** 0.61*** 
 (1.05 - 1.14) (1.37 - 1.50) (0.58 - 0.64) 
Polysubstance use (no= 
ref)   
   
    One more 0.92*** 1.02 0.96*** 
 (0.89 - 0.94) (0.99 - 1.05) (0.94 - 0.98) 
    Two or more 0.94*** 1.09*** 1.03** 
 (0.91 - 0.96) (1.06 - 1.12) (1.01 - 1.06) 
* p<0.05, ** p<0.01, *** p<0.001 
Reference group for multinomial regression is self-referral. Relative Risk Ratio = RRR. 
Confidence Interval = CI.  











































N 166,400 141,859 141,885 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Medicaid expansion     
  Expanded 0.88** 1.59*** 1.15* 
 (0.81 - 0.95) (1.38 - 1.82) (1.01 - 1.32) 
Frequency of use (No past month 




   Some use 0.42*** 0.61*** 0.39*** 
 (0.41 - 0.44) (0.58 - 0.65) (0.37 - 0.41) 
   Daily use 0.32*** 0.41*** 0.19*** 
 (0.31 - 0.33) (0.39 - 0.43) (0.18 - 0.20) 
Age (18-29= ref)     
   30-44 0.91*** 0.91*** 0.74*** 
 (0.88 - 0.94) (0.87 - 0.96) (0.70 - 0.77) 
   45-64 0.81*** 0.75*** 0.44*** 
 (0.78 - 0.84) (0.71 - 0.80) (0.42 - 0.47) 
Gender (Female=ref)    
   Male 0.93*** 0.81*** 1.45*** 






   Non-Hispanic Black 0.95* 1.18*** 0.99 
 (0.91 - 1.00) (1.11 - 1.26) (0.92 - 1.07) 
   Hispanic 0.83*** 1.05 0.83*** 
 (0.79 - 0.86) (0.99 - 1.12) (0.77 - 0.88) 
   Other 0.74*** 0.83*** 0.95 
 (0.68 - 0.79) (0.75 - 0.92) (0.84 - 1.07) 





   Highschool or higher 1.03* 0.91*** 1.01 
 (1.00 - 1.06) (0.87 - 0.95) (0.97 - 1.06) 
Number of arrests (0= ref)  
 
 
   1 0.88*** 1.05 4.31*** 





   2 or more 0.85 0.91 2.64*** 
 (0.71 - 1.00) (0.72 - 1.16) (2.20 - 3.17) 
Employment status (Not 




     Employed 1.25*** 1.29*** 0.99 
 (1.21 - 1.29) (1.23 - 1.36) (0.94 - 1.04) 
Comorbidity (No= ref)     
   Yes 1.15*** 1.23*** 1.01 
 (1.12 - 1.18) (1.18 - 1.28) (0.97 - 1.05) 
Homeless (No= ref)     
  Yes 1.05* 1.32*** 0.82*** 
 (1.00 - 1.10) (1.24 - 1.41) (0.76 - 0.90) 
Polysubstance use (no= ref)    
 
 
    One more 1.10*** 1.25*** 1.29*** 
 (1.06 - 1.13) (1.19 - 1.31) (1.23 - 1.35) 
    Two or more 1.27*** 1.45*** 1.61*** 
 (1.23 - 1.31) (1.37 - 1.52) (1.52 - 1.69) 
* p<0.05, ** p<0.01, *** p<0.001 
Reference group for multinomial regression is self-referral. Adjusted Odds Ratio = AOR. Confidence Interval = 
CI.  

































Other institutional Court/criminal justice 
referral Referral 
    
N 313,253 313,253 313,253 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Expansion 0.45* 1.39 0.61 
    (0.20 - 0.99) (0.54 - 3.56) (0.31 - 1.21) 
Post expansion  0.77*** 0.70*** 1.15*** 
    (0.72 - 0.81) (0.65 - 0.76) (1.09 - 1.22) 
Expansion * Post expansion  0.87*** 1.29*** 0.82*** 
    (0.83 - 0.92) (1.20 - 1.38) (0.78 - 0.86) 
Frequency of use (No 
past month use= ref)  
   
   Some use 0.58*** 0.59*** 0.37*** 
 (0.56 - 0.60) (0.57 - 0.61) (0.36 - 0.38) 
   Daily use 0.70*** 0.43*** 0.22*** 
 (0.69 - 0.72) (0.42 - 0.44) (0.22 - 0.23) 
Age (18-29= ref)     
   30-44 0.96*** 1.12*** 0.95*** 
 (0.94 - 0.98) (1.09 - 1.15) (0.93 - 0.97) 
   45-64 0.99 0.97 0.76*** 
 (0.96 - 1.02) (0.93 - 1.00) (0.74 - 0.78) 
Gender (Female=ref)    
   Male 0.98 0.72*** 1.38*** 
 (0.96 - 1.00) (0.70 - 0.74) (1.35 - 1.41) 
Race/ethnicity (non-
Hispanic White=ref) 
   
   Non-Hispanic Black 1.43*** 1.47*** 1.06** 
 (1.37 - 1.48) (1.40 - 1.55) (1.02 - 1.10) 
   Hispanic 1.03 1.45*** 1.25*** 
 (0.99 - 1.07) (1.39 - 1.51) (1.21 - 1.29) 
   Other 0.86*** 0.86*** 0.89*** 
 (0.81 - 0.91) (0.80 - 0.92) (0.84 - 0.94) 
Education (Less than high 
school= ref)  
   
   Highschool or higher 0.96*** 0.78*** 0.82*** 
 (0.93 - 0.98) (0.76 - 0.81) (0.80 - 0.84) 
Number of arrests (0= 
ref) 





   1 0.72*** 1.08** 1.95*** 
 (0.68 - 0.76) (1.02 - 1.14) (1.87 - 2.02) 
   2 or more 0.60*** 0.68*** 1.11* 
 (0.54 - 0.67) (0.59 - 0.78) (1.02 - 1.20) 
Employment status (Not 
employed= ref)  
   
     Employed 1.40*** 1.26*** 0.96*** 
 (1.37 - 1.44) (1.22 - 1.30) (0.94 - 0.99) 
Comorbidity (No= ref)     
   Yes 1.21*** 0.86*** 0.70*** 
 (1.18 - 1.24) (0.84 - 0.88) (0.68 - 0.71) 
Homeless (No= ref)     
  Yes 1.10*** 1.43*** 0.61*** 
 (1.06 - 1.15) (1.36 - 1.50) (0.58 - 0.64) 
Polysubstance use (no= 
ref)   
   
    One more 0.91*** 1.01 0.94*** 
 (0.89 - 0.94) (0.98 - 1.04) (0.92 - 0.96) 
    Two or more 0.94*** 1.08*** 1.01 
 (0.92 - 0.97) (1.05 - 1.12) (0.99 - 1.04) 
* p<0.05, ** p<0.01, *** p<0.001 
Reference group for multinomial regression is self-referral. Relative Risk Ratio = RRR. Confidence Interval = 
CI.  































Other institutional  Court/criminal 
justice referral Referral  
    
N 60,852 60,852 60,852 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Expansion 1.28 2.68* 0.40** 
    (0.68 - 2.41) (1.15 - 6.28) (0.21 - 0.78) 
Post expansion  0.86*** 0.77*** 1.37*** 
    (0.79 - 0.94) (0.66 - 0.89) (1.18 - 1.59) 
Expansion * Post expansion  0.89** 1.61*** 1.17* 
    (0.82 - 0.96) (1.40 - 1.85) (1.02 - 1.35) 
Frequency of use (No past 
month use= ref)  
   
   Some use 0.42*** 0.62*** 0.39*** 
 (0.40 - 0.44) (0.58 - 0.65) (0.37 - 0.41) 
   Daily use 0.31*** 0.41*** 0.19*** 
 (0.30 - 0.32) (0.39 - 0.43) (0.18 - 0.20) 
Age (18-29= ref)     
   30-44 0.91*** 0.91*** 0.74*** 
 (0.88 - 0.94) (0.87 - 0.95) (0.71 - 0.78) 
   45-64 0.81*** 0.75*** 0.44*** 
 (0.78 - 0.84) (0.71 - 0.80) (0.42 - 0.47) 
Gender (Female=ref)    
   Male 0.92*** 0.81*** 1.45*** 
 (0.90 - 0.95) (0.78 - 0.84) (1.39 - 1.51) 
Race/ethnicity (non-Hispanic 
White=ref) 
   
   Non-Hispanic Black 0.96 1.18*** 0.99 
 (0.91 - 1.00) (1.11 - 1.26) (0.92 - 1.07) 
   Hispanic 0.83*** 1.06 0.82*** 
 (0.79 - 0.86) (0.99 - 1.12) (0.77 - 0.88) 
   Other 0.74*** 0.82*** 0.96 
 (0.68 - 0.79) (0.74 - 0.91) (0.85 - 1.07) 
Education (Less than high 
school= ref)  
   
   Highschool or higher 1.03* 0.91*** 1.02 
 (1.00 - 1.06) (0.87 - 0.95) (0.97 - 1.06) 





   1 0.88*** 1.05 4.29*** 
 (0.82 - 0.94) (0.95 - 1.16) (4.02 - 4.58) 
   2 or more 0.84 0.94 2.67*** 
 (0.71 - 1.00) (0.74 - 1.19) (2.22 - 3.21) 
Employment status (Not 
employed= ref)  
   
     Employed 1.25*** 1.30*** 0.99 
 (1.21 - 1.30) (1.23 - 1.37) (0.95 - 1.04) 
Comorbidity (No= ref)     
   Yes 1.14*** 1.22*** 1.00 
 (1.11 - 1.18) (1.17 - 1.27) (0.96 - 1.04) 
Homeless (No= ref)     
  Yes 1.05* 1.33*** 0.82*** 
 (1.00 - 1.10) (1.24 - 1.42) (0.76 - 0.90) 
Polysubstance use (no= ref)      
    One more 1.09*** 1.25*** 1.28*** 
 (1.06 - 1.12) (1.19 - 1.31) (1.22 - 1.35) 
    Two or more 1.27*** 1.45*** 1.61*** 
 (1.23 - 1.31) (1.38 - 1.53) (1.52 - 1.69) 
* p<0.05, ** p<0.01, *** p<0.001 
Reference group for multinomial regression is self-referral. Relative Risk Ratio = RRR. Confidence Interval = 
CI.  




























Sensitivity analysis that added Section 1115 Demonstration Waiver 
 
Table 2-F1. Sensitivity analysis that added Waiver 1115 Demonstrations: 2WFE model for non-intensive 







     
N 231,025 231,025 231,025 
 RRR RRR RRR 
 (95%CI) (95%CI) (95%CI) 
Medicaid expansion        
  Yes  1.17*** 2.26*** 1.31*** 
 (1.11 - 1.24) (2.11 - 2.42) (1.24 - 1.38) 
Waiver 1115 
Demonstrations 
   
   Yes  1.04 1.21* 1.03 
 (0.88 - 1.23) (1.04 - 1.41) (0.89 - 1.18) 
MAT (No= ref)     
   Yes 0.64*** 0.34*** 0.14*** 
  (0.62 - 0.66) (0.33 - 0.35) (0.13 - 0.14) 
Frequency of use (No 
past month use= ref)  
   
   Some use 0.64*** 0.65*** 0.39*** 
 (0.62 - 0.67) (0.63 - 0.68) (0.37 - 0.40) 
   Daily use 0.51*** 0.37*** 0.16*** 
 (0.50 - 0.53) (0.36 - 0.38) (0.16 - 0.17) 
Age (18-29= ref)     
   30-44 1.00 1.00 0.99 
 (0.97 - 1.03) (0.97 - 1.03) (0.96 - 1.01) 
   45-64 1.11*** 0.77*** 0.85*** 
 (1.07 - 1.15) (0.74 - 0.81) (0.82 - 0.88) 
Gender (Female=ref)    
   Male 0.88*** 0.62*** 1.31*** 
 (0.85 - 0.90) (0.60 - 0.64) (1.28 - 1.35) 
Race/ethnicity (non-
Hispanic White=ref) 
   
   Non-Hispanic Black 1.01 1.35*** 1.19*** 
 (0.96 - 1.07) (1.27 - 1.44) (1.13 - 1.26) 
   Hispanic 0.89*** 1.30*** 1.21*** 
 (0.85 - 0.95) (1.22 - 1.37) (1.15 - 1.27) 
   Other 0.87*** 1.03 0.96 





Education (Less than 
high school= ref)  
   
   Highschool or higher 0.96** 0.80*** 0.78*** 
 (0.93 - 0.99) (0.78 - 0.83) (0.76 - 0.80) 
Number of arrests (0= 
ref) 
   
   1 0.85*** 1.19*** 2.73*** 
 (0.79 - 0.91) (1.11 - 1.27) (2.60 - 2.86) 
   2 or more 0.85** 0.97 1.09 
 (0.76 - 0.95) (0.84 - 1.12) (0.99 - 1.20) 
Employment status 
(Not employed= ref)  
   
     Employed 
1.32*** 1.14*** 0.93*** 
 (1.28 - 1.36) (1.10 - 1.18) (0.91 - 0.96) 
Comorbidity (No= ref)     
   Yes 1.49*** 0.92*** 0.65*** 
 (1.45 - 1.53) (0.89 - 0.95) (0.63 - 0.67) 
Homeless (No= ref)     
  Yes 1.31*** 1.35*** 0.61*** 
 (1.25 - 1.38) (1.28 - 1.43) (0.58 - 0.65) 
Polysubstance use 
(no= ref)   
   
    One more 0.99 1.02 0.85*** 
 (0.96 - 1.02) (0.99 - 1.06) (0.83 - 0.88) 
    Two or more 0.98 1.07*** 0.95** 
 (0.95 - 1.01) (1.03 - 1.11) (0.92 - 0.98) 
* p<0.05, ** p<0.01, *** p<0.001 
Reference group for multinomial regression is self-referral. Adjusted Odds Ratio = AOR. 
Confidence Interval = CI.  



















Table 2-F2 Sensitivity analysis that added Waiver 1115 Demonstrations: DID model for non-intensive 








    
N 225,272 225,272 225,272 
 RRR RRR RRR 
 (95%CI) (95%CI) (95%CI) 
    
Expansion 0.84 0.94 1.06 
    (0.52 - 1.36) (0.58 - 1.52) (0.64 - 1.75) 
Post expansion  0.70*** 0.42*** 0.82*** 
    (0.66 - 0.74) (0.39 - 0.45) (0.77 - 0.87) 
Expansion * Post expansion  1.18*** 2.38*** 1.31*** 
    (1.12 - 1.24) (2.22 - 2.54) (1.25 - 1.38) 
Waiver 1115 Demonstrations    
   Yes 1.21 1.16 1.02 
 (0.97 - 1.50) (0.98 - 1.36) (0.88 - 1.19) 
MAT (No= ref)     
   Yes 0.65*** 0.33*** 0.14*** 
 (0.63 - 0.67) (0.32 - 0.35) (0.13 - 0.14) 
Frequency of use     
   Some use 0.64*** 0.66*** 0.38*** 
 (0.62 - 0.67) (0.63 - 0.69) (0.37 - 0.40) 
   Daily use  0.51*** 0.38*** 0.16*** 
 (0.50 - 0.53) (0.36 - 0.39) (0.16 - 0.17) 
Age (18-29= ref)     
   30-44 1.00 0.99 0.99 
 (0.97 - 1.03) (0.96 - 1.03) (0.96 - 1.01) 
   45-64 1.11*** 0.77*** 0.84*** 
 (1.07 - 1.15) (0.74 - 0.81) (0.81 - 0.88) 
Gender    
   Male  0.88*** 0.62*** 1.31*** 
 (0.85 - 0.90) (0.60 - 0.63) (1.28 - 1.35) 
Race/ethnicity     
   Non-Hispanic Black 1.02 1.36*** 1.19*** 
 (0.96 - 1.07) (1.28 - 1.45) (1.13 - 1.26) 
   Hispanic  0.89*** 1.31*** 1.21*** 
 (0.84 - 0.94) (1.24 - 1.39) (1.15 - 1.27) 
   Other 0.88*** 1.04 0.98 
 (0.82 - 0.95) (0.96 - 1.12) (0.92 - 1.06) 
Education     
   Highschool or higher 0.96* 0.81*** 0.78*** 
 (0.94 - 0.99) (0.78 - 0.84) (0.76 - 0.80) 
Number of arrests (0=ref)    
   1 0.83*** 1.20*** 2.73*** 
 (0.78 - 0.89) (1.12 - 1.28) (2.60 - 2.87) 





 (0.77 - 0.97) (0.83 - 1.12) (0.98 - 1.20) 
Employment status     
     Employed 1.33*** 1.14*** 0.93*** 
 (1.29 - 1.37) (1.10 - 1.18) (0.91 - 0.96) 
Comorbidity    
   Yes  1.50*** 0.91*** 0.65*** 
 (1.46 - 1.54) (0.89 - 0.94) (0.63 - 0.67) 
Homeless    
  Yes 1.33*** 1.35*** 0.61*** 
 (1.26 - 1.40) (1.27 - 1.43) (0.57 - 0.65) 
Polysubstance use     
    One more 1.00 1.02 0.85*** 
 (0.97 - 1.03) (0.98 - 1.05) (0.82 - 0.87) 
    Two or more 0.99 1.06** 0.94*** 
 (0.95 - 1.02) (1.02 - 1.10) (0.91 - 0.97) 
* p<0.05, ** p<0.01, *** p<0.001 
Reference group for multinomial regression is self-referral. Relative Risk Ratio = RRR. Confidence Interval = 
CI.  



























Appendix 3-B  
Summary of Medicaid expansion and Section 1115 Demonstration Waiver 
 
Table 3-B. Summary of Medicaid Expansion across states as of 2017 
State Expansion status  Section 1115 
Demonstrations: 
Substance Use Disorders 
Alabama Not adopted  
Florida Not adopted  
Kansas Not adopted  
Mississippi Not adopted  
Missouri Not adopted  
North Carolina Not adopted (11/1/2019) 
Oklahoma Not adopted  
South Carolina Not adopted  
South Dakota Not adopted  
Tennessee Not adopted  
Texas Not adopted  
Wisconsin Not adopted 1/1/2014 
Wyoming Not adopted  
Georgia Not adopted 
 (later adopted on 12/1/20)  
 
Nebraska Not adopted  
(later adopted on 10/1/20) 
(7/1/2019) 
Idaho Not adopted  
(later adopted on 1/1/20 
(4/17/2020) 
Utah Not adopted  
(later adopted on 1/1/20)  
7/1/2002 
Maine Not adopted  
(later adopted on 1/10/19)  
 
Virginia Not adopted  
(later adopted on 1/1/19)  
4/1/2017 
Louisiana 7/1/16 (2/1/2018) 
Montana 1/1/16  
Alaska 9/1/15 (1/1/2019) 
Indiana 2/1/15 2/1/2015 
Pennsylvania 1/1/15 10/1/2017 
New Hampshire 8/15/14 (7/10/2018) 
Michigan 4/1/14  
Arizona 1/1/14  





California 1/1/14 9/1/2005 
Colorado 1/1/14  
Connecticut 1/1/14  
Delaware 1/1/14 1/1/1996 
District of Columbia 1/1/14 (1/1/2020) 
Hawaii 1/1/14  
Illinois 1/1/14  
Iowa 1/1/14  
Kentucky 1/1/14 (4/1/2019) 
Maryland 1/1/14 7/1/1997 
Massachusetts 1/1/14 7/1/1997 
Minnesota 1/1/14 (10/1/2019) 
Nevada 1/1/14  
New Jersey 1/1/14 10/2/2012 
New Mexico 1/1/14 (1/1/2019) 
New York 1/1/14 (10/1/2019) 
North Dakota 1/1/14  
Ohio 1/1/14 (10/1/2019) 
Oregon 1/1/14  
Rhode Island 1/1/14 7/1/2009 
Vermont 1/1/14 10/1/2005 
Washington 1/1/14 1/9/2017 
























Sensitivity analysis that removing referral source covariate 
 
 
Table 3-C1. DID model for the adjusted associations between Medicaid expansion and length of stay (without 
controlling for referral sources) 
  DID pooled model DID Non-MAT DID MAT 
    
N 228,239 166,465 61,771 
 AOR AOR AOR 
 (95%CI) (95%CI) (95%CI) 
     
Treat    
   Expansion states 2.96*** 2.09** 3.35*** 
    (2.10 - 4.15) (1.27 - 3.45) (2.12 - 5.30) 
Expansion  0.98 1.30*** 0.52*** 
   After the ACA 
implementation (2014)  
(0.93 - 1.02) (1.23 - 1.37) (0.47 - 0.58) 
    
Medicaid expansion     
    Expansion  0.96 0.96 1.17*** 
 (0.92 - 1.00) (0.92 - 1.01) (1.07 - 1.29) 
MAT (No= ref)     
   Yes 1.95***   
 (1.90 - 1.99)   
Frequency of use (No past 
month use= ref)  
   
   Some use 0.65*** 0.61*** 0.87*** 
 (0.63 - 0.66) (0.59 - 0.63) (0.81 - 0.93) 
   Daily use 0.57*** 0.49*** 0.88*** 
 (0.55 - 0.58) (0.48 - 0.51) (0.84 - 0.93) 
Age (18-29= ref)     
   30-44 1.06*** 1.06*** 1.09*** 
 (1.04 - 1.09) (1.04 - 1.09) (1.05 - 1.14) 
   45-64 1.27*** 1.28*** 1.33*** 
 (1.24 - 1.31) (1.24 - 1.32) (1.26 - 1.40) 
Gender (Female=ref)    
   Male 0.93*** 0.93*** 0.93*** 
 (0.91 - 0.95) (0.91 - 0.95) (0.89 - 0.96) 
Race/ethnicity (non-Hispanic 
White=ref) 
   
   Non-Hispanic Black 0.96 0.97 0.93* 
 (0.93 - 1.00) (0.93 - 1.02) (0.88 - 0.99) 
   Hispanic 1.03 0.97 1.09** 





   Other 1.01 1.01 0.97 
 (0.96 - 1.07) (0.95 - 1.08) (0.87 - 1.09) 
Education (Less than high 
school= ref)  
   
   Highschool or higher 0.96*** 0.97** 0.96* 
 (0.94 - 0.98) (0.94 - 0.99) (0.92 - 1.00) 
Number of arrests (0= ref)    
   1 1.07*** 1.20*** 0.75*** 
 (1.03 - 1.12) (1.14 - 1.25) (0.69 - 0.82) 
   2 or more 1.21*** 1.17*** 0.86 
 (1.12 - 1.31) (1.07 - 1.28) (0.71 - 1.04) 
Employment status 
(Unemployed= ref)  
   
     Employed 0.79*** 0.78*** 0.83*** 
 (0.77 - 0.81) (0.76 - 0.80) (0.80 - 0.87) 
Comorbidity (No= ref)     
   Yes 0.83*** 0.82*** 0.88*** 
 (0.82 - 0.85) (0.80 - 0.84) (0.85 - 0.92) 
Homeless (No= ref)     
  Yes 0.70*** 0.72*** 0.68*** 
 (0.67 - 0.73) (0.68 - 0.76) (0.63 - 0.74) 
Polysubstance use (no= ref)      
    One more 0.78*** 0.77*** 0.85*** 
 (0.76 - 0.80) (0.75 - 0.79) (0.81 - 0.88) 
    Two or more 0.72*** 0.74*** 0.75*** 
 (0.70 - 0.74) (0.72 - 0.76) (0.72 - 0.79) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  























Table 3C-2. DID model for the adjusted associations of Medicaid expansion and treatment completion (without 
controlling for referral sources)  
  DID pooled model DID non-MAT DID MAT 
    
N 228,235 166,463 61,769 
 AOR AOR AOR 
 (95%CI) (95%CI) (95%CI) 
     
Treat    
   Expansion states 2.02*** 1.78* 3.00*** 
    (1.43 - 2.84) (1.09 - 2.91) (1.84 - 4.87) 
Expansion  1.56*** 1.40*** 2.14*** 
   After the ACA 
implementation (2014)  
(1.50 - 1.64) (1.33 - 1.47) (1.90 - 2.40) 
    
Medicaid expansion     
    Expansion  0.87*** 1.06* 0.49*** 
 (0.83 - 0.91) (1.01 - 1.11) (0.44 - 0.55) 
MAT (No= ref)     
   Yes 0.74***   
 (0.72 - 0.76)   
Frequency of use (No past 
month use= ref)  
   
   Some use 0.67*** 0.69*** 0.66*** 
 (0.65 - 0.69) (0.67 - 0.71) (0.62 - 0.71) 
   Daily use 0.65*** 0.71*** 0.53*** 
 (0.63 - 0.66) (0.70 - 0.73) (0.50 - 0.56) 
Age (18-29= ref)     
   30-44 1.06*** 1.06*** 1.03 
 (1.04 - 1.08) (1.04 - 1.09) (0.99 - 1.08) 
   45-64 1.12*** 1.20*** 0.98 
 (1.09 - 1.15) (1.16 - 1.25) (0.93 - 1.04) 
Gender (Female=ref)    
   Male 0.95*** 0.99 0.81*** 
 (0.94 - 0.97) (0.97 - 1.02) (0.78 - 0.85) 
Race/ethnicity (non-Hispanic 
White=ref) 
   
   Non-Hispanic Black 0.84*** 0.97 0.68*** 
 (0.81 - 0.87) (0.92 - 1.01) (0.63 - 0.73) 
   Hispanic 0.86*** 0.94* 0.78*** 
 (0.83 - 0.89) (0.90 - 0.99) (0.73 - 0.84) 
   Other 0.74*** 0.77*** 0.68*** 
 (0.70 - 0.78) (0.73 - 0.82) (0.60 - 0.77) 
Education (Less than high 
school= ref)  





   Highschool or higher 1.16*** 1.13*** 1.19*** 
 (1.13 - 1.18) (1.10 - 1.16) (1.14 - 1.24) 
Number of arrests (0= ref)    
   1 1.28*** 1.33*** 1.11* 
 (1.23 - 1.34) (1.27 - 1.39) (1.01 - 1.23) 
   2 or more 0.84*** 0.87** 1.08 
 (0.77 - 0.91) (0.79 - 0.95) (0.87 - 1.34) 
Employment status 
(Unemployed= ref)  
   
     Employed 1.02 1.05*** 0.98 
 (1.00 - 1.04) (1.02 - 1.07) (0.94 - 1.02) 
Comorbidity (No= ref)     
   Yes 0.85*** 0.81*** 0.95* 
 (0.83 - 0.87) (0.79 - 0.83) (0.91 - 0.99) 
Homeless (No= ref)     
  Yes 1.08** 1.09** 1.02 
 (1.03 - 1.12) (1.04 - 1.15) (0.94 - 1.12) 
Polysubstance use (no= ref)      
    One more 1.11*** 1.11*** 1.03 
 (1.08 - 1.13) (1.08 - 1.14) (0.99 - 1.08) 
    Two or more 1.21*** 1.20*** 1.10*** 
 (1.18 - 1.24) (1.16 - 1.23) (1.04 - 1.16) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  









Sensitivity analysis with additional covariates 
 
 
Table 3D-1. Sensitivity analysis with added covariates for the 2WFE model for the adjusted associations 
between Medicaid expansion and length of stay   
  
2 ways fixed effect 
pooled model 
2 ways fixed effect 
Non-MAT 
2 ways fixed effect 
MAT 
     
N 231,025 169,449 61,573 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Medicaid expansion     
    Expansion  0.94** 0.95 1.15** 
 (0.90 - 0.98) (0.91 - 1.00) (1.04 - 1.26) 
MAT (No= ref)     
   Yes 2.22***   
 (2.16 - 2.27)   
Referral sources    
   Healthcare provider 
referral 
0.93*** 1.01 0.87*** 
 (0.90 - 0.96) (0.97 - 1.04) (0.83 - 0.92) 
   Institutional referral 1.04* 1.21*** 0.77*** 
 (1.01 - 1.08) (1.17 - 1.26) (0.72 - 0.83) 
   Court/criminal justice 1.87*** 2.14*** 0.74*** 
 (1.82 - 1.92) (2.08 - 2.20) (0.69 - 0.81) 
Frequency of use (No 
past month use= ref)  
   
   Some use 0.72*** 0.70*** 0.85*** 
 (0.70 - 0.74) (0.68 - 0.73) (0.79 - 0.91) 
   Daily use 0.67*** 0.62*** 0.84*** 
 (0.66 - 0.69) (0.60 - 0.64) (0.80 - 0.89) 
Age (18-29= ref)     
   30-44 1.07*** 1.07*** 1.09*** 
 (1.05 - 1.09) (1.04 - 1.10) (1.04 - 1.13) 
   45-64 1.30*** 1.32*** 1.31*** 
 (1.27 - 1.34) (1.27 - 1.36) (1.24 - 1.38) 
Gender (Female=ref)    
   Male 0.90*** 0.89*** 0.92*** 







   
   Non-Hispanic Black 0.94** 0.94** 0.92** 
 (0.91 - 0.98) (0.89 - 0.98) (0.87 - 0.98) 
   Hispanic 1.01 0.94** 1.09** 
 (0.98 - 1.05) (0.90 - 0.98) (1.02 - 1.16) 
   Other 1.00 0.99 0.99 
 (0.95 - 1.06) (0.93 - 1.06) (0.89 - 1.10) 
Education (Less than 
high school= ref)  
   
   Highschool or higher 0.98 1.00 0.96* 
 (0.96 - 1.00) (0.98 - 1.03) (0.92 - 0.99) 
Number of arrests (0= 
ref) 
   
   1 0.97 1.04 0.79*** 
 (0.93 - 1.01) (0.99 - 1.09) (0.73 - 0.86) 
   2 or more 1.18*** 1.17*** 0.86 
 (1.09 - 1.28) (1.07 - 1.28) (0.72 - 1.04) 
Employment status 
(Unemployed= ref)  
   
     Employed 0.79*** 0.78*** 0.83*** 
 (0.77 - 0.81) (0.76 - 0.80) (0.80 - 0.86) 
Comorbidity (No= ref)     
   Yes 0.88*** 0.90*** 0.89*** 
 (0.86 - 0.90) (0.87 - 0.92) (0.86 - 0.93) 
Homeless (No= ref)     
  Yes 0.74*** 0.77*** 0.70*** 
 (0.70 - 0.77) (0.73 - 0.81) (0.65 - 0.76) 
Polysubstance use (no= 
ref)   
   
    One more 0.80*** 0.80*** 0.86*** 
 (0.78 - 0.81) (0.78 - 0.82) (0.82 - 0.89) 
    Two or more 0.73*** 0.76*** 0.76*** 
 (0.71 - 0.74) (0.74 - 0.78) (0.72 - 0.80) 
Unemployment rate     
   Unemployment rate 0.98 0.95*** 1.03 
 (0.96 - 1.00) (0.92 - 0.97) (0.99 - 1.07) 
PMDP (No= ref)    
    Yes 1.06* 1.00 1.39*** 
 (1.01 - 1.12) (0.92 - 1.07) (1.27 - 1.52) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  





Table 3-D2. Sensitivity with added covariates for the DID model for the adjusted association between Medicaid 






DID model  
  MAT 
    
N 225,272 164,420 60,849 
 AOR AOR AOR 
 (95%CI) (95%CI) (95%CI) 
        
Treat    
   Expansion states 2.87*** 1.98** 3.40*** 
    (2.04 - 4.05) (1.19 - 3.28) (2.15 - 5.39) 
Expansion     
   After the ACA implementation (2014)  0.81** 0.91 0.53*** 
 (0.71 - 0.92) (0.78 - 1.06) (0.41 - 0.68) 
Medicaid expansion     
    Expansion  0.95* 0.98 1.15** 
 (0.91 - 1.00) (0.93 - 1.03) (1.05 - 1.27) 
MAT (No= ref)     
   Yes 2.23***   
 (2.18 - 2.29)   
Referral sources    
   Healthcare provider referral 0.93*** 1.01 0.87*** 
 (0.90 - 0.96) (0.98 - 1.05) (0.83 - 0.92) 
   Institutional referral 1.05** 1.22*** 0.79*** 
 (1.02 - 1.09) (1.17 - 1.27) (0.73 - 0.85) 
   Court/criminal justice 1.88*** 2.16*** 0.74*** 
 (1.83 - 1.94) (2.10 - 2.23) (0.68 - 0.80) 
Frequency of use (No past month use= 
ref)  
   
   Some use 0.72*** 0.70*** 0.84*** 
 (0.69 - 0.74) (0.68 - 0.72) (0.78 - 0.90) 
   Daily use 0.67*** 0.62*** 0.84*** 
 (0.65 - 0.69) (0.60 - 0.64) (0.79 - 0.89) 
Age (18-29= ref)     
   30-44 1.07*** 1.07*** 1.09*** 
 (1.05 - 1.10) (1.05 - 1.10) (1.04 - 1.13) 
   45-64 1.30*** 1.32*** 1.30*** 
 (1.27 - 1.34) (1.27 - 1.37) (1.24 - 1.38) 
Gender (Female=ref)    
   Male 0.90*** 0.89*** 0.93*** 
 (0.88 - 0.92) (0.87 - 0.91) (0.89 - 0.96) 
Race/ethnicity (non-Hispanic 
White=ref) 
   





 (0.91 - 0.98) (0.89 - 0.98) (0.87 - 0.99) 
   Hispanic 1.01 0.94** 1.08** 
 (0.97 - 1.05) (0.89 - 0.98) (1.02 - 1.15) 
   Other 1.01 1.00 0.99 
 (0.95 - 1.07) (0.94 - 1.07) (0.89 - 1.11) 
Education (Less than high school= ref)     
   Highschool or higher 0.98* 1.00 0.96* 
 (0.96 - 1.00) (0.98 - 1.03) (0.92 - 0.99) 
Number of arrests (0= ref)    
   1 0.96 1.04 0.79*** 
 (0.92 - 1.00) (0.99 - 1.10) (0.72 - 0.86) 
   2 or more 1.20*** 1.19*** 0.86 
 (1.10 - 1.29) (1.08 - 1.30) (0.71 - 1.04) 
Employment status (Unemployed= ref)     
     Employed 0.80*** 0.79*** 0.83*** 
 (0.78 - 0.82) (0.77 - 0.81) (0.80 - 0.87) 
Comorbidity (No= ref)     
   Yes 0.88*** 0.89*** 0.89*** 
 (0.86 - 0.90) (0.87 - 0.91) (0.86 - 0.93) 
Homeless (No= ref)     
  Yes 0.73*** 0.76*** 0.70*** 
 (0.70 - 0.76) (0.72 - 0.81) (0.64 - 0.75) 
Polysubstance use (no= ref)      
    One more 0.79*** 0.79*** 0.85*** 
 (0.77 - 0.81) (0.77 - 0.82) (0.82 - 0.89) 
    Two or more 0.72*** 0.75*** 0.76*** 
 (0.70 - 0.74) (0.73 - 0.78) (0.72 - 0.80) 
Unemployment rate     
   Unemployment rate 0.97** 0.94*** 1.03 
 (0.95 - 0.99) (0.91 - 0.96) (0.99 - 1.07) 
PMDP (No= ref)    
   Yes 1.07* 1.00 1.40*** 
 (1.01 - 1.13) (0.92 - 1.08) (1.28 - 1.53) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  







Table 3-D3. Sensitivity analysis with added covariates for the 2WFE model for the adjusted associations 
between Medicaid expansion and treatment completion   
  
2 ways fixed effect 
pooled model 
Non-MAT MAT 
     
N 229,288 168,163 61,122 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Medicaid expansion  0.84*** 1.03 0.47*** 
    Expansion  (0.81 - 0.88) (0.99 - 1.09) (0.42 - 0.52) 
    
MAT (No= ref)     
   Yes 0.86***   






   Healthcare provider 
referral 
1.07*** 1.05** 1.14*** 
 (1.04 - 1.10) (1.02 - 1.09) (1.08 - 1.21) 
   Institutional referral 1.30*** 1.32*** 1.15*** 
 (1.26 - 1.34) (1.27 - 1.37) (1.06 - 1.24) 
   Court/criminal justice 2.03*** 2.00*** 1.89*** 
 (1.98 - 2.09) (1.95 - 2.06) (1.73 - 2.06) 
Frequency of use (No 
past month use= ref)  
   
   Some use 0.74*** 0.76*** 0.70*** 
 (0.71 - 0.76) (0.73 - 0.78) (0.65 - 0.76) 
   Daily use 0.77*** 0.85*** 0.59*** 
 (0.75 - 0.79) (0.83 - 0.88) (0.55 - 0.62) 
Age (18-29= ref)     
   30-44 1.06*** 1.07*** 1.04 
 (1.04 - 1.09) (1.04 - 1.09) (0.99 - 1.08) 
   45-64 1.14*** 1.23*** 0.99 
 (1.11 - 1.18) (1.19 - 1.27) (0.93 - 1.05) 
Gender (Female=ref)    
   Male 0.93*** 0.97** 0.81*** 
 (0.92 - 0.95) (0.95 - 0.99) (0.78 - 0.84) 
Race/ethnicity (non-
Hispanic White=ref) 





   Non-Hispanic Black 0.82*** 0.94* 0.68*** 
 (0.79 - 0.86) (0.90 - 0.99) (0.63 - 0.73) 
   Hispanic 0.85*** 0.92*** 0.81*** 
 (0.82 - 0.89) (0.88 - 0.96) (0.75 - 0.87) 
   Other 0.73*** 0.76*** 0.69*** 
 (0.69 - 0.77) (0.72 - 0.81) (0.61 - 0.78) 
Education (Less than 
high school= ref)  
   
   Highschool or higher 1.19*** 1.17*** 1.20*** 
 (1.16 - 1.21) (1.14 - 1.20) (1.15 - 1.25) 
Number of arrests (0= 
ref) 
   
   1 1.15*** 1.19*** 1.03 
 (1.10 - 1.20) (1.13 - 1.24) (0.94 - 1.14) 
   2 or more 0.84*** 0.89** 1.02 
 (0.77 - 0.91) (0.81 - 0.97) (0.82 - 1.28) 
Employment status 
(Unemployed= ref)  
   
     Employed 1.03* 1.06*** 0.97 
 (1.00 - 1.05) (1.03 - 1.09) (0.93 - 1.02) 
Comorbidity (No= ref)     
   Yes 0.89*** 0.87*** 0.95* 
 (0.88 - 0.91) (0.85 - 0.89) (0.91 - 1.00) 
Homeless (No= ref)     
  Yes 1.11*** 1.14*** 1.03 
 (1.06 - 1.15) (1.08 - 1.20) (0.94 - 1.12) 
Polysubstance use (no= 
ref)   
   
    One more 1.12*** 1.14*** 1.02 
 (1.10 - 1.14) (1.11 - 1.17) (0.98 - 1.07) 
    Two or more 1.21*** 1.22*** 1.06* 
 (1.18 - 1.24) (1.18 - 1.25) (1.01 - 1.12) 
Unemployment rate     
   Unemployment rate 0.98* 0.96** 1.06* 
 (0.96 - 1.00) (0.94 - 0.98) (1.01 - 1.11) 
PMDP (No= ref)    
   Yes 1.11*** 1.13** 1.17** 
 (1.05 - 1.18) (1.05 - 1.22) (1.05 - 1.30) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  









Table 3-D4. Sensitivity with added covariates for the DID model for the adjusted association between Medicaid 






DID model  
  MAT 
    
N 225,268 164,418 60,847 
 AOR AOR AOR 
 (95%CI) (95%CI) (95%CI) 
        
Treat    
   Expansion states 2.02*** 1.79* 3.18*** 
    (1.43 - 2.85) (1.09 - 2.93) (1.94 - 5.19) 
Expansion     
   After the ACA implementation (2014)  1.53*** 1.28** 2.87*** 
 (1.34 - 1.74) (1.10 - 1.49) (2.18 - 3.78) 
Medicaid expansion     
    Expansion  0.83*** 1.02 0.47*** 
 (0.79 - 0.86) (0.97 - 1.07) (0.42 - 0.52) 
MAT (No= ref)     
   Yes 0.87***   
 (0.85 - 0.89)   
Referral sources    
   Healthcare provider referral 1.07*** 1.05** 1.14*** 
 (1.04 - 1.10) (1.02 - 1.09) (1.08 - 1.21) 
   Institutional referral 1.31*** 1.32*** 1.16*** 
 (1.27 - 1.35) (1.28 - 1.37) (1.08 - 1.26) 
   Court/criminal justice 2.05*** 2.03*** 1.89*** 
 (2.00 - 2.11) (1.97 - 2.09) (1.73 - 2.07) 
Frequency of use (No past month use= 
ref)  
   
   Some use 0.74*** 0.77*** 0.70*** 
 (0.72 - 0.77) (0.75 - 0.79) (0.65 - 0.76) 
   Daily use 0.79*** 0.88*** 0.59*** 
 (0.77 - 0.81) (0.85 - 0.90) (0.55 - 0.62) 
Age (18-29= ref)     
   30-44 1.06*** 1.07*** 1.04 
 (1.04 - 1.09) (1.04 - 1.09) (0.99 - 1.09) 
   45-64 1.14*** 1.23*** 0.99 
 (1.11 - 1.17) (1.18 - 1.27) (0.94 - 1.05) 
Gender (Female=ref)    
   Male 0.93*** 0.96*** 0.81*** 
 (0.91 - 0.95) (0.94 - 0.98) (0.78 - 0.84) 
Race/ethnicity (non-Hispanic 
White=ref) 





   Non-Hispanic Black 0.82*** 0.94* 0.68*** 
 (0.79 - 0.85) (0.90 - 0.99) (0.63 - 0.73) 
   Hispanic 0.85*** 0.92*** 0.80*** 
 (0.82 - 0.88) (0.88 - 0.97) (0.75 - 0.86) 
   Other 0.74*** 0.78*** 0.68*** 
 (0.70 - 0.78) (0.73 - 0.83) (0.60 - 0.77) 
Education (Less than high school= ref)     
   Highschool or higher 1.19*** 1.17*** 1.20*** 
 (1.16 - 1.21) (1.14 - 1.20) (1.15 - 1.25) 
Number of arrests (0= ref)    
   1 1.16*** 1.20*** 1.03 
 (1.11 - 1.21) (1.14 - 1.26) (0.94 - 1.14) 
   2 or more 0.83*** 0.88** 1.03 
 (0.77 - 0.90) (0.80 - 0.97) (0.83 - 1.29) 
Employment status (Unemployed= ref)     
     Employed 1.03* 1.06*** 0.97 
 (1.01 - 1.05) (1.04 - 1.09) (0.93 - 1.02) 
Comorbidity (No= ref)     
   Yes 0.89*** 0.87*** 0.95* 
 (0.87 - 0.91) (0.85 - 0.89) (0.91 - 1.00) 
Homeless (No= ref)     
  Yes 1.11*** 1.15*** 1.03 
 (1.06 - 1.16) (1.09 - 1.21) (0.94 - 1.12) 
Polysubstance use (no= ref)      
    One more 1.13*** 1.14*** 1.02 
 (1.10 - 1.15) (1.11 - 1.17) (0.98 - 1.07) 
    Two or more 1.22*** 1.22*** 1.07* 
 (1.19 - 1.25) (1.19 - 1.26) (1.01 - 1.13) 
Unemployment rate     
   Unemployment rate 1.00 0.98 1.06** 
 (0.98 - 1.02) (0.96 - 1.01) (1.02 - 1.11) 
PMDP (No= ref)    
   Yes 1.13*** 1.17*** 1.18** 
 (1.07 - 1.20) (1.08 - 1.26) (1.06 - 1.32) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  












Appendix 3-E  
Sensitivity with lagged model 
 
Table 3-E1. Sensitivity with lagged model for the DID model for the adjusted association between Medicaid 






DID model  
  MAT 
    
N 225,272 164,420 60,849 
 AOR AOR AOR 
 (95%CI) (95%CI) (95%CI) 
        
Expansion states 2.87*** 2.07** 3.34*** 
    (2.03 - 4.05) (1.25 - 3.44) (2.08 - 5.38) 
Expansion year (2014) 2.15*** 2.36*** 1.59*** 
 (2.02 - 2.29) (2.20 - 2.53) (1.33 - 1.91) 
Expansion * Post expansion year 0  0.57*** 0.57*** 0.61*** 
     (0.53 - 0.61) (0.53 - 0.62) (0.51 - 0.74) 
Post expansion year 1 0.39*** 0.36*** 0.56***  
(0.36 - 0.42) (0.33 - 0.40) (0.45 - 0.70) 
Expansion* Post expansion year 1 2.48*** 3.00*** 1.45** 
 (2.26 - 2.73) (2.69 - 3.34) (1.15 - 1.83) 
Post expansion year 2 1.49*** 1.57*** 1.38*** 
 (1.38 - 1.62) (1.43 - 1.72) (1.14 - 1.66) 
Expansion* Post expansion year 2 0.62*** 0.59*** 0.72** 
 (0.57 - 0.68) (0.53 - 0.65) (0.59 - 0.88) 
Post expansion year 3 0.70*** 0.99 0.25*** 
 (0.66 - 0.74) (0.93 - 1.07) (0.21 - 0.29) 
Expansion* Post expansion year 3 1.29*** 0.93 3.58*** 
 (1.20 - 1.40) (0.85 - 1.02) (3.04 - 4.23) 
MAT (No= ref)     
   Yes 2.23***   
 (2.17 - 2.28)   
Referral sources    
   Healthcare provider referral 0.93*** 1.01 0.88*** 
 (0.90 - 0.96) (0.98 - 1.05) (0.83 - 0.93) 
   Institutional referral 1.05** 1.22*** 0.79*** 
 (1.01 - 1.08) (1.17 - 1.26) (0.73 - 0.85) 
   Court/criminal justice 1.88*** 2.17*** 0.73*** 
 (1.83 - 1.93) (2.11 - 2.23) (0.68 - 0.80) 
Frequency of use (No past month use= 
ref)  
   
   Some use 0.71*** 0.70*** 0.85*** 
 (0.69 - 0.74) (0.68 - 0.72) (0.79 - 0.91) 





 (0.66 - 0.69) (0.60 - 0.64) (0.81 - 0.91) 
Age (18-29= ref)     
   30-44 1.07*** 1.07*** 1.09*** 
 (1.05 - 1.09) (1.05 - 1.10) (1.04 - 1.13) 
   45-64 1.30*** 1.32*** 1.30*** 
 (1.27 - 1.34) (1.27 - 1.36) (1.23 - 1.37) 
Gender (Female=ref)    
   Male 0.90*** 0.89*** 0.93*** 
 (0.88 - 0.92) (0.87 - 0.91) (0.90 - 0.96) 
Race/ethnicity (non-Hispanic 
White=ref) 
   
   Non-Hispanic Black 0.94** 0.94* 0.94* 
 (0.91 - 0.98) (0.89 - 0.99) (0.88 - 1.00) 
   Hispanic 1.01 0.94** 1.09** 
 (0.97 - 1.05) (0.89 - 0.98) (1.02 - 1.16) 
   Other 1.00 1.00 0.98 
 (0.95 - 1.06) (0.94 - 1.07) (0.88 - 1.10) 
Education (Less than high school= ref)     
   Highschool or higher 0.98 1.00 0.96* 
 (0.96 - 1.00) (0.98 - 1.03) (0.92 - 1.00) 
Number of arrests (0= ref)    
   1 0.96 1.04 0.79*** 
 (0.92 - 1.00) (0.99 - 1.09) (0.72 - 0.86) 
   2 or more 1.20*** 1.17*** 0.89 
 (1.11 - 1.30) (1.07 - 1.28) (0.73 - 1.07) 
Employment status (Unemployed= ref)     
     Employed 0.80*** 0.79*** 0.84*** 
 (0.78 - 0.82) (0.77 - 0.81) (0.80 - 0.87) 
Comorbidity (No= ref)     
   Yes 0.88*** 0.89*** 0.89*** 
 (0.86 - 0.90) (0.87 - 0.92) (0.85 - 0.92) 
Homeless (No= ref)     
  Yes 0.73*** 0.77*** 0.70*** 
 (0.70 - 0.76) (0.72 - 0.81) (0.65 - 0.76) 
Polysubstance use (no= ref)      
    One more 0.79*** 0.79*** 0.85*** 
 (0.78 - 0.81) (0.77 - 0.82) (0.82 - 0.89) 
    Two or more 0.73*** 0.76*** 0.76*** 
 (0.71 - 0.75) (0.73 - 0.78) (0.72 - 0.80) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  









Table 3-E2. Sensitivity with lagged model for the DID model for the adjusted association between Medicaid 






DID model  
  MAT 
    
N 223,557 163,159 60,395 
 AOR AOR AOR 
 (95%CI) (95%CI) (95%CI) 
        
Expansion states 2.15*** 1.91* 3.10*** 
    (1.52 - 3.06) (1.16 - 3.15) (1.87 - 5.13) 
Expansion year (2014) 0.61*** 0.64*** 0.50*** 
 (0.57 - 0.65) (0.60 - 0.68) (0.41 - 0.61) 
Expansion * Post expansion year 0  1.61*** 1.64*** 1.78*** 
     (1.51 - 1.73) (1.52 - 1.76) (1.45 - 2.19) 
Post expansion year 1 1.29*** 1.23*** 2.14***  
(1.19 - 1.39) (1.13 - 1.33) (1.67 - 2.74) 
Expansion* Post expansion year 1 0.68*** 0.75*** 0.36*** 
 (0.62 - 0.75) (0.68 - 0.83) (0.28 - 0.47) 
Post expansion year 2 1.47*** 1.47*** 1.45** 
 (1.36 - 1.58) (1.36 - 1.60) (1.16 - 1.81) 
Expansion* Post expansion year 2 0.72*** 0.72*** 0.78* 
 (0.66 - 0.79) (0.65 - 0.79) (0.61 - 0.99) 
Post expansion year 3 1.93*** 1.56*** 2.15*** 
 (1.81 - 2.05) (1.46 - 1.67) (1.80 - 2.57) 
Expansion* Post expansion year 3 0.59*** 0.74*** 0.54*** 
 (0.54 - 0.64) (0.67 - 0.81) (0.44 - 0.65) 
MAT (No= ref)     
   Yes 0.87***   
 (0.85 - 0.89)   
Referral sources    
   Healthcare provider referral 1.08*** 1.06*** 1.15*** 
 (1.05 - 1.11) (1.03 - 1.10) (1.08 - 1.22) 
   Institutional referral 1.32*** 1.34*** 1.18*** 
 (1.28 - 1.37) (1.29 - 1.39) (1.09 - 1.27) 
   Court/criminal justice 2.08*** 2.04*** 1.91*** 
 (2.02 - 2.13) (1.98 - 2.10) (1.75 - 2.09) 
Frequency of use (No past month use= 
ref)  
   
   Some use 0.74*** 0.77*** 0.70*** 
 (0.72 - 0.77) (0.74 - 0.79) (0.65 - 0.75) 
   Daily use 0.78*** 0.87*** 0.58*** 
 (0.76 - 0.80) (0.84 - 0.89) (0.54 - 0.61) 
Age (18-29= ref)     





 (1.04 - 1.09) (1.04 - 1.10) (0.99 - 1.09) 
   45-64 1.14*** 1.23*** 1.00 
 (1.11 - 1.18) (1.19 - 1.27) (0.94 - 1.06) 
Gender (Female=ref)    
   Male 0.92*** 0.96** 0.80*** 
 (0.91 - 0.94) (0.94 - 0.98) (0.77 - 0.84) 
Race/ethnicity (non-Hispanic 
White=ref) 
   
   Non-Hispanic Black 0.82*** 0.93** 0.67*** 
 (0.78 - 0.85) (0.89 - 0.98) (0.62 - 0.72) 
   Hispanic 0.85*** 0.92** 0.80*** 
 (0.82 - 0.89) (0.88 - 0.97) (0.74 - 0.85) 
   Other 0.76*** 0.79*** 0.68*** 
 (0.72 - 0.80) (0.74 - 0.84) (0.60 - 0.77) 
Education (Less than high school= ref)     
   Highschool or higher 1.18*** 1.17*** 1.20*** 
 (1.16 - 1.21) (1.14 - 1.20) (1.15 - 1.25) 
Number of arrests (0= ref)    
   1 1.15*** 1.20*** 1.03 
 (1.10 - 1.20) (1.14 - 1.26) (0.94 - 1.14) 
   2 or more 0.83*** 0.88** 1.04 
 (0.77 - 0.90) (0.81 - 0.97) (0.84 - 1.30) 
Employment status (Unemployed= ref)     
     Employed 1.03* 1.06*** 0.97 
 (1.00 - 1.05) (1.03 - 1.09) (0.92 - 1.01) 
Comorbidity (No= ref)     
   Yes 0.90*** 0.87*** 0.96 
 (0.88 - 0.92) (0.85 - 0.89) (0.92 - 1.00) 
Homeless (No= ref)     
  Yes 1.10*** 1.14*** 1.01 
 (1.05 - 1.15) (1.08 - 1.21) (0.93 - 1.10) 
Polysubstance use (no= ref)      
    One more 1.11*** 1.13*** 1.02 
 (1.08 - 1.13) (1.10 - 1.16) (0.98 - 1.07) 
    Two or more 1.20*** 1.21*** 1.07* 
 (1.17 - 1.23) (1.17 - 1.24) (1.01 - 1.13) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  







Sensitivity analysis with added Section 1115 Demonstration Waiver 
 
 
Table 3-F1. Sensitivity analysis added Waiver 1115 Demonstrations: Two-ways fixed effects model for the 
adjusted associations between Medicaid expansion and treatment length of stay 
  
2 ways fixed effect 
pooled model 
Non-MAT MAT 
     
N 231,025 169,449 61,573 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Medicaid expansion     
    Expansion  0.93** 0.93** 1.15** 
 (0.90 - 0.98) (0.89 - 0.98) (1.05 - 1.27) 
Waiver 1115 
Demonstration 
   
   Yes 0.93 0.75*** 1.29*** 
 (0.85 - 1.02) (0.65 - 0.87) (1.14 - 1.46) 
    
MAT (No= ref)     
   Yes 2.21***   






   Healthcare provider 
referral 
0.93*** 1.01 0.87*** 
 (0.90 - 0.96) (0.97 - 1.04) (0.83 - 0.92) 
   Institutional referral 1.04* 1.21*** 0.78*** 
 (1.01 - 1.08) (1.17 - 1.26) (0.72 - 0.84) 
   Court/criminal justice 1.87*** 2.14*** 0.74*** 
 (1.82 - 1.92) (2.08 - 2.20) (0.69 - 0.81) 
Frequency of use (No past 
month use= ref)  
   
   Some use 0.72*** 0.70*** 0.85*** 
 (0.70 - 0.74) (0.68 - 0.73) (0.79 - 0.91) 
   Daily use 0.67*** 0.62*** 0.84*** 
 (0.66 - 0.69) (0.60 - 0.64) (0.80 - 0.89) 
Age (18-29= ref)     
   30-44 1.07*** 1.07*** 1.09*** 





   45-64 1.31*** 1.32*** 1.31*** 
 (1.27 - 1.34) (1.27 - 1.36) (1.24 - 1.38) 
Gender (Female=ref)    
   Male 0.90*** 0.89*** 0.92*** 
 (0.88 - 0.91) (0.87 - 0.91) (0.89 - 0.95) 
Race/ethnicity (non-
Hispanic White=ref) 
   
   Non-Hispanic Black 0.94** 0.94** 0.92* 
 (0.91 - 0.98) (0.89 - 0.98) (0.87 - 0.98) 
   Hispanic 1.01 0.94* 1.09** 
 (0.98 - 1.05) (0.90 - 0.99) (1.02 - 1.15) 
   Other 1.00 1.00 0.98 
 (0.95 - 1.06) (0.94 - 1.06) (0.88 - 1.10) 
Education (Less than high 
school= ref)  
   
   Highschool or higher 0.98 1.00 0.96* 
 (0.96 - 1.00) (0.98 - 1.03) (0.92 - 0.99) 
Number of arrests (0= ref)    
   1 0.97 1.04 0.79*** 
 (0.93 - 1.01) (0.99 - 1.09) (0.73 - 0.86) 
   2 or more 1.18*** 1.16*** 0.88 
 (1.09 - 1.28) (1.06 - 1.27) (0.73 - 1.06) 
Employment status 
(Unemployed= ref)  
   
     Employed 0.79*** 0.78*** 0.83*** 
 (0.77 - 0.81) (0.76 - 0.80) (0.80 - 0.86) 
Comorbidity (No= ref)     
   Yes 0.88*** 0.90*** 0.89*** 
 (0.86 - 0.90) (0.87 - 0.92) (0.85 - 0.92) 
Homeless (No= ref)     
  Yes 0.74*** 0.77*** 0.70*** 
 (0.70 - 0.77) (0.73 - 0.81) (0.65 - 0.76) 
Polysubstance use (no= ref)      
    One more 0.79*** 0.80*** 0.86*** 
 (0.78 - 0.81) (0.78 - 0.82) (0.82 - 0.89) 
    Two or more 0.73*** 0.76*** 0.76*** 
 (0.71 - 0.74) (0.73 - 0.78) (0.72 - 0.80) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  









Table 3-F2. Sensitivity analysis added Waiver 1115 Demonstrations: 2WFE model for the adjusted associations 
between Medicaid expansion and treatment completion 
  
2 ways fixed effect 
pooled model 
Non-MAT MAT 
     
N 231,025 169,449 61,573 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Medicaid expansion     
    Expansion  0.85*** 1.02 0.49*** 
 (0.81 - 0.88) (0.97 - 1.07) (0.44 - 0.54) 
Waiver 1115 Demonstration    
   Yes 0.84*** 0.83* 0.93 
 (0.77 - 0.92) (0.72 - 0.96) (0.80 - 1.07) 
    
MAT (No= ref)     
   Yes 0.86***   






   Healthcare provider referral 1.07*** 1.05** 1.15*** 
 (1.04 - 1.10) (1.02 - 1.09) (1.08 - 1.21) 
   Institutional referral 1.30*** 1.32*** 1.15*** 
 (1.26 - 1.34) (1.27 - 1.37) (1.07 - 1.24) 
   Court/criminal justice 2.03*** 2.00*** 1.89*** 
 (1.98 - 2.09) (1.94 - 2.06) (1.73 - 2.06) 
Frequency of use (No past 
month use= ref)  
   
   Some use 0.74*** 0.76*** 0.70*** 
 (0.71 - 0.76) (0.73 - 0.78) (0.65 - 0.76) 
   Daily use 0.77*** 0.85*** 0.59*** 
 (0.75 - 0.79) (0.83 - 0.88) (0.55 - 0.62) 
Age (18-29= ref)     
   30-44 1.06*** 1.07*** 1.04 
 (1.04 - 1.09) (1.04 - 1.09) (0.99 - 1.09) 
   45-64 1.14*** 1.23*** 0.99 
 (1.11 - 1.18) (1.19 - 1.27) (0.93 - 1.05) 
Gender (Female=ref)    





 (0.92 - 0.95) (0.95 - 0.99) (0.78 - 0.84) 
Race/ethnicity (non-
Hispanic White=ref) 
   
   Non-Hispanic Black 0.83*** 0.94* 0.68*** 
 (0.79 - 0.86) (0.90 - 0.99) (0.63 - 0.73) 
   Hispanic 0.85*** 0.92*** 0.81*** 
 (0.82 - 0.89) (0.88 - 0.97) (0.75 - 0.87) 
   Other 0.73*** 0.76*** 0.69*** 
 (0.69 - 0.77) (0.72 - 0.81) (0.61 - 0.78) 
Education (Less than high 
school= ref)  
   
   Highschool or higher 1.19*** 1.17*** 1.20*** 
 (1.16 - 1.21) (1.14 - 1.20) (1.15 - 1.25) 
Number of arrests (0= ref)    
   1 1.15*** 1.19*** 1.04 
 (1.10 - 1.20) (1.13 - 1.24) (0.94 - 1.14) 
   2 or more 0.84*** 0.89* 1.03 
 (0.78 - 0.91) (0.81 - 0.97) (0.83 - 1.29) 
Employment status 
(Unemployed= ref)  
   
     Employed 1.03* 1.06*** 0.98 
 (1.01 - 1.05) (1.03 - 1.09) (0.93 - 1.02) 
Comorbidity (No= ref)     
   Yes 0.89*** 0.87*** 0.95* 
 (0.88 - 0.91) (0.85 - 0.89) (0.91 - 0.99) 
Homeless (No= ref)     
  Yes 1.10*** 1.13*** 1.02 
 (1.06 - 1.15) (1.08 - 1.20) (0.94 - 1.12) 
Polysubstance use (no= ref)      
    One more 1.12*** 1.13*** 1.02 
 (1.09 - 1.14) (1.11 - 1.16) (0.98 - 1.07) 
    Two or more 1.21*** 1.22*** 1.07* 
 (1.18 - 1.25) (1.18 - 1.25) (1.01 - 1.13) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  











Sensitivity analysis for discharges with more than one treatment episode 
 
 
Table 3-G1. 2WFE model for the adjusted associations between Medicaid expansion and length of stay   
  
2 ways fixed effect 
pooled model 
2 ways fixed effect 
Non-MAT 
2 ways fixed effect 
MAT 
     
N 518,154 326,027 192,127 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Medicaid expansion     
    Expansion  0.96* 0.89*** 1.11** 
 (0.93 - 1.00) (0.85 - 0.93) (1.04 - 1.19) 
MAT (No= ref)     
   Yes 2.07***   
 (2.04 - 2.10)   
Referral sources    
   Healthcare provider 
referral 
0.83*** 0.95*** 0.79*** 
 (0.82 - 0.85) (0.93 - 0.97) (0.77 - 0.81) 
   Institutional referral 0.99 1.15*** 0.86*** 
 (0.97 - 1.01) (1.12 - 1.18) (0.83 - 0.90) 
   Court/criminal justice 1.34*** 1.60*** 0.72*** 
 (1.32 - 1.36) (1.56 - 1.63) (0.69 - 0.75) 
Frequency of use (No 
past month use= ref)  
   
   Some use 0.68*** 0.64*** 0.80*** 
 (0.67 - 0.69) (0.63 - 0.65) (0.77 - 0.82) 
   Daily use 0.69*** 0.59*** 0.82*** 
 (0.68 - 0.70) (0.58 - 0.61) (0.80 - 0.84) 
Age (18-29= ref)     
   30-44 1.11*** 1.09*** 1.13*** 
 (1.09 - 1.12) (1.07 - 1.11) (1.11 - 1.16) 
   45-64 1.43*** 1.39*** 1.48*** 
 (1.40 - 1.45) (1.36 - 1.42) (1.44 - 1.53) 
Gender (Female=ref)    





 (0.91 - 0.93) (0.90 - 0.93) (0.90 - 0.94) 
Race/ethnicity (non-
Hispanic White=ref) 
   
   Non-Hispanic Black 0.94*** 0.88*** 1.01 
 (0.92 - 0.97) (0.85 - 0.91) (0.98 - 1.05) 
   Hispanic 1.06*** 0.97 1.14*** 
 (1.04 - 1.08) (0.95 - 1.00) (1.11 - 1.18) 
   Other 0.91*** 0.90*** 0.92** 
 (0.88 - 0.94) (0.87 - 0.94) (0.87 - 0.97) 
Education (Less than 
high school= ref)  
   
   Highschool or higher 1.02* 1.05*** 0.97* 
 (1.00 - 1.03) (1.03 - 1.07) (0.95 - 1.00) 
Number of arrests (0= 
ref) 
   
   1 0.91*** 0.97 0.84*** 
 (0.89 - 0.93) (0.94 - 1.00) (0.81 - 0.88) 
   2 or more 1.15*** 1.10** 1.04 
 (1.08 - 1.21) (1.03 - 1.18) (0.93 - 1.17) 
Employment status 
(Unemployed= ref)  
   
     Employed 0.88*** 0.87*** 0.88*** 
 (0.86 - 0.89) (0.85 - 0.88) (0.86 - 0.90) 
Comorbidity (No= ref)     
   Yes 0.97*** 1.00 0.97** 
 (0.96 - 0.99) (0.98 - 1.02) (0.95 - 0.99) 
Homeless (No= ref)     
  Yes 0.76*** 0.77*** 0.77*** 
 (0.74 - 0.78) (0.75 - 0.80) (0.75 - 0.80) 
Polysubstance use (no= 
ref)   
   
    One more 0.92*** 0.95*** 0.90*** 
 (0.90 - 0.93) (0.94 - 0.97) (0.88 - 0.92) 
    Two or more 0.88*** 0.96*** 0.80*** 
 (0.87 - 0.89) (0.94 - 0.98) (0.78 - 0.82) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  











Table 3-G2. DID model for the adjusted associations between Medicaid expansion and treatment length of stay  





    
N 503,363 313,253 190,110 
 AOR AOR AOR 
 (95%CI) (95%CI) (95%CI) 
     
Treat 2.41*** 1.86* 2.88*** 
   Expansion states (1.76 - 3.29) (1.13 - 3.07) (1.94 - 4.29) 
       
Expansion  0.98 1.20*** 0.72*** 
   After the ACA 
implementation (2014)  
(0.94 - 1.02) (1.14 - 1.26) (0.67 - 0.77) 
    
Medicaid expansion     
    Medicaid expansion  0.99 0.92*** 1.13*** 
 (0.95 - 1.03) (0.88 - 0.97) (1.06 - 1.21) 
MAT (No= ref)     
   Yes 2.08***   
 (2.05 - 2.11)   
Referral sources    
   Healthcare provider referral 0.83*** 0.95*** 0.80*** 
 (0.81 - 0.84) (0.93 - 0.97) (0.78 - 0.82) 
   Institutional referral 1.00 1.15*** 0.88*** 
 (0.97 - 1.02) (1.12 - 1.18) (0.85 - 0.92) 
   Court/criminal justice 1.35*** 1.61*** 0.72*** 
 (1.33 - 1.37) (1.58 - 1.65) (0.69 - 0.75) 
Frequency of use (No past 
month use= ref)  
   
   Some use 0.68*** 0.64*** 0.80*** 
 (0.67 - 0.69) (0.63 - 0.65) (0.77 - 0.82) 
   Daily use 0.69*** 0.59*** 0.82*** 
 (0.68 - 0.70) (0.58 - 0.61) (0.80 - 0.85) 
Age (18-29= ref)     
   30-44 1.11*** 1.10*** 1.14*** 
 (1.09 - 1.13) (1.08 - 1.12) (1.11 - 1.17) 
   45-64 1.43*** 1.39*** 1.49*** 
 (1.40 - 1.45) (1.36 - 1.42) (1.44 - 1.53) 
Gender (Female=ref)    
   Male 0.93*** 0.92*** 0.93*** 
 (0.92 - 0.94) (0.91 - 0.94) (0.91 - 0.94) 
Race/ethnicity (non-
Hispanic White=ref) 
   





 (0.93 - 0.97) (0.86 - 0.92) (0.98 - 1.05) 
   Hispanic 1.06*** 0.97 1.14*** 
 (1.04 - 1.08) (0.95 - 1.00) (1.11 - 1.18) 
   Other 0.91*** 0.91*** 0.92** 
 (0.88 - 0.95) (0.87 - 0.95) (0.87 - 0.97) 
Education (Less than high 
school= ref)  
   
   Highschool or higher 1.01* 1.05*** 0.97* 
 (1.00 - 1.03) (1.03 - 1.07) (0.95 - 1.00) 
Number of arrests (0= ref)    
   1 0.92*** 0.99 0.84*** 
 (0.89 - 0.94) (0.95 - 1.02) (0.81 - 0.88) 
   2 or more 1.17*** 1.13** 1.05 
 (1.10 - 1.24) (1.05 - 1.21) (0.94 - 1.17) 
Employment status 
(Unemployed= ref)  
   
     Employed 0.89*** 0.88*** 0.88*** 
 (0.87 - 0.90) (0.86 - 0.89) (0.86 - 0.90) 
Comorbidity (No= ref)     
   Yes 0.98** 1.01 0.97* 
 (0.97 - 0.99) (0.99 - 1.02) (0.95 - 0.99) 
Homeless (No= ref)     
  Yes 0.76*** 0.77*** 0.77*** 
 (0.74 - 0.78) (0.75 - 0.80) (0.74 - 0.80) 
Polysubstance use (no= ref)      
    One more 0.91*** 0.95*** 0.90*** 
 (0.90 - 0.93) (0.93 - 0.97) (0.88 - 0.92) 
    Two or more 0.88*** 0.96*** 0.79*** 
 (0.86 - 0.89) (0.94 - 0.98) (0.77 - 0.82) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  














Table 3-G3. 2WFE model for the adjusted associations between Medicaid expansion and treatment completion   
  
2 ways fixed effect 
pooled model 
Non-MAT MAT 
     
N 518,146 326,025 192,121 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Medicaid expansion  0.87*** 1.10*** 0.52*** 
    Expansion  (0.84 - 0.90) (1.06 - 1.15) (0.48 - 0.55) 
    
MAT (No= ref)     
   Yes 0.78***   






   Healthcare provider referral 1.38*** 1.32*** 1.42*** 
 (1.35 - 1.40) (1.29 - 1.35) (1.39 - 1.46) 
   Institutional referral 1.30*** 1.32*** 1.21*** 
 (1.27 - 1.33) (1.28 - 1.35) (1.16 - 1.26) 
   Court/criminal justice 2.01*** 1.99*** 1.73*** 
 (1.97 - 2.04) (1.95 - 2.03) (1.66 - 1.80) 
Frequency of use (No past 
month use= ref)  
   
   Some use 0.66*** 0.69*** 0.62*** 
 (0.65 - 0.68) (0.67 - 0.70) (0.60 - 0.65) 
   Daily use 0.69*** 0.86*** 0.51*** 
 (0.68 - 0.70) (0.84 - 0.87) (0.50 - 0.52) 
Age (18-29= ref)     
   30-44 1.05*** 1.08*** 1.00 
 (1.04 - 1.07) (1.06 - 1.10) (0.97 - 1.03) 
   45-64 1.17*** 1.27*** 1.01 
 (1.15 - 1.20) (1.24 - 1.30) (0.98 - 1.04) 
Gender (Female=ref)    
   Male 0.90*** 0.93*** 0.84*** 
 (0.89 - 0.91) (0.92 - 0.95) (0.83 - 0.86) 
Race/ethnicity (non-
Hispanic White=ref) 
   





 (0.94 - 0.99) (1.10 - 1.17) (0.74 - 0.80) 
   Hispanic 0.86*** 0.91*** 0.79*** 
 (0.84 - 0.88) (0.89 - 0.94) (0.76 - 0.82) 
   Other 0.79*** 0.84*** 0.69*** 
 (0.76 - 0.82) (0.81 - 0.88) (0.65 - 0.74) 
Education (Less than high 
school= ref)  
   
   Highschool or higher 1.19*** 1.17*** 1.20*** 
 (1.16 - 1.21) (1.14 - 1.20) (1.15 - 1.25) 
Number of arrests (0= ref)    
   1 1.15*** 1.19*** 1.04 
 (1.10 - 1.20) (1.13 - 1.24) (0.94 - 1.14) 
   2 or more 0.84*** 0.89* 1.03 
 (0.78 - 0.91) (0.81 - 0.97) (0.83 - 1.29) 
Employment status 
(Unemployed= ref)  
   
     Employed 1.11*** 1.12*** 1.10*** 
 (1.10 - 1.13) (1.10 - 1.14) (1.07 - 1.12) 
Comorbidity (No= ref)     
   Yes 0.88*** 0.87*** 0.92*** 
 (0.87 - 0.89) (0.86 - 0.89) (0.90 - 0.94) 
Homeless (No= ref)     
  Yes 0.98 0.98 0.98 
 (0.96 - 1.01) (0.95 - 1.01) (0.94 - 1.02) 
Polysubstance use (no= ref)      
    One more 0.97*** 1.00 0.91*** 
 (0.95 - 0.98) (0.98 - 1.01) (0.89 - 0.94) 
    Two or more 0.99 1.02* 0.93*** 
 (0.97 - 1.00) (1.00 - 1.04) (0.90 - 0.95) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  
























DID model  
  MAT 
    
N 503,355 313,251 190,104 
 AOR AOR AOR 
 (95%CI) (95%CI) (95%CI) 
        
Treat    
   Expansion states 2.79*** 2.95*** 3.28*** 
    (1.96 - 3.98) (1.74 - 4.99) (2.03 - 5.30) 
Expansion     
   After the ACA implementation (2014)  1.40*** 1.26*** 1.76*** 
 (1.34 - 1.45) (1.20 - 1.31) (1.63 - 1.90) 
Medicaid expansion     
    Expansion  0.89*** 1.14*** 0.53*** 
 (0.86 - 0.92) (1.09 - 1.19) (0.49 - 0.57) 
MAT (No= ref)     
   Yes 0.78***   
 (0.77 - 0.79)   
Referral sources    
   Healthcare provider referral 1.38*** 1.32*** 1.43*** 
 (1.36 - 1.41) (1.30 - 1.35) (1.39 - 1.47) 
   Institutional referral 1.29*** 1.30*** 1.21*** 
 (1.26 - 1.32) (1.27 - 1.34) (1.16 - 1.26) 
   Court/criminal justice 2.01*** 1.99*** 1.73*** 
 (1.97 - 2.04) (1.95 - 2.03) (1.66 - 1.81) 
Frequency of use (No past month use= 
ref)  
   
   Some use 0.67*** 0.70*** 0.62*** 
 (0.66 - 0.68) (0.68 - 0.71) (0.60 - 0.64) 
   Daily use 0.70*** 0.88*** 0.51*** 
 (0.69 - 0.71) (0.86 - 0.89) (0.50 - 0.52) 
Age (18-29= ref)     
   30-44 1.06*** 1.08*** 1.00 
 (1.04 - 1.07) (1.06 - 1.10) (0.98 - 1.03) 
   45-64 1.18*** 1.28*** 1.01 
 (1.15 - 1.20) (1.25 - 1.31) (0.98 - 1.05) 
Gender (Female=ref)    
   Male 0.89*** 0.93*** 0.84*** 
 (0.88 - 0.91) (0.91 - 0.94) (0.82 - 0.86) 
Race/ethnicity (non-Hispanic 
White=ref) 
   





 (0.94 - 0.99) (1.10 - 1.17) (0.74 - 0.80) 
   Hispanic 0.86*** 0.91*** 0.79*** 
 (0.84 - 0.88) (0.88 - 0.93) (0.76 - 0.82) 
   Other 0.79*** 0.85*** 0.69*** 
 (0.76 - 0.82) (0.81 - 0.89) (0.65 - 0.74) 
Education (Less than high school= ref)     
   Highschool or higher 1.11*** 1.12*** 1.10*** 
 (1.09 - 1.13) (1.10 - 1.14) (1.07 - 1.12) 
Number of arrests (0= ref)    
   1 1.03 1.07*** 0.93** 
 (1.00 - 1.06) (1.04 - 1.11) (0.89 - 0.98) 
   2 or more 0.76*** 0.79*** 0.85* 
 (0.72 - 0.81) (0.74 - 0.85) (0.74 - 0.96) 
Employment status (Unemployed= ref)     
     Employed 1.02* 1.05*** 0.99 
 (1.00 - 1.03) (1.03 - 1.07) (0.97 - 1.02) 
Comorbidity (No= ref)     
   Yes 0.88*** 0.87*** 0.92*** 
 (0.87 - 0.89) (0.86 - 0.89) (0.90 - 0.94) 
Homeless (No= ref)     
  Yes 0.98 0.99 0.98 
 (0.96 - 1.01) (0.96 - 1.02) (0.94 - 1.02) 
Polysubstance use (no= ref)      
    One more 0.97*** 0.99 0.91*** 
 (0.95 - 0.98) (0.97 - 1.01) (0.89 - 0.94) 
    Two or more 0.98* 1.01 0.92*** 
 (0.96 - 1.00) (0.99 - 1.03) (0.90 - 0.95) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  
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APPENDIX 4. FULL TABLES  
Appendix 4-A  
Full tables from chapter 3 (with details for state and year fixed effects) 







     
N 229,291 229,291 229,291 
 AOR AOR AOR 
 (95%CI) (95%CI) (95%CI) 
Medicaid expansion        
  Yes  1.18*** 2.28*** 1.31*** 
 (1.11 - 1.24) (2.13 - 2.44) (1.24 - 1.38) 
MAT (No= ref)     
   Yes 0.64*** 0.34*** 0.14*** 
  (0.62 - 0.66) (0.33 - 0.36) (0.13 - 0.14) 
Frequency of use (No 
past month use= ref)  
   
   Some use 0.64*** 0.66*** 0.39*** 
 (0.62 - 0.67) (0.63 - 0.68) (0.37 - 0.40) 
   Daily use 0.51*** 0.37*** 0.16*** 
 (0.50 - 0.53) (0.36 - 0.38) (0.16 - 0.17) 
Age (18-29= ref)     
   30-44 1.00 1.01 0.99 
 (0.97 - 1.03) (0.97 - 1.04) (0.97 - 1.02) 
   45-64 1.11*** 0.81*** 0.87*** 
 (1.07 - 1.15) (0.78 - 0.85) (0.84 - 0.90) 
Gender (Female=ref)    
   Male 0.88*** 0.62*** 1.32*** 
 (0.86 - 0.90) (0.61 - 0.64) (1.29 - 1.35) 
Race/ethnicity (non-
Hispanic White=ref) 
   
   Non-Hispanic Black 1.01 1.35*** 1.19*** 
 (0.96 - 1.07) (1.27 - 1.44) (1.13 - 1.26) 
   Hispanic 0.89*** 1.30*** 1.21*** 
 (0.85 - 0.95) (1.23 - 1.37) (1.15 - 1.27) 
   Other 0.87*** 1.03 0.96 
 (0.81 - 0.94) (0.95 - 1.11) (0.90 - 1.03) 
Education (Less than 
high school= ref)  
   
   Highschool or higher 0.96** 0.79*** 0.77*** 





Number of arrests (0= 
ref) 
   
   1 0.85*** 1.18*** 2.71*** 
 (0.80 - 0.91) (1.10 - 1.26) (2.58 - 2.85) 
   2 or more 0.86** 0.96 1.09 
 (0.77 - 0.96) (0.83 - 1.11) (0.99 - 1.20) 
Employment status 
(Not employed= ref)  
   
     Employed 
1.32*** 1.15*** 0.94*** 
 (1.28 - 1.36) (1.11 - 1.19) (0.92 - 0.97) 
Comorbidity (No= ref)     
   Yes 1.48*** 0.91*** 0.65*** 
 (1.44 - 1.52) (0.89 - 0.94) (0.63 - 0.67) 
Homeless (No= ref)     
  Yes 1.31*** 1.37*** 0.61*** 
 (1.25 - 1.38) (1.29 - 1.45) (0.57 - 0.65) 
Polysubstance use 
(no= ref)   
   
    One more 
0.99 1.03 0.85*** 
 (0.96 - 1.02) (0.99 - 1.06) (0.83 - 0.88) 
    Two or more 
0.98 1.07*** 0.95** 
 (0.95 - 1.01) (1.03 - 1.11) (0.92 - 0.98) 
Year (2010= ref)     
   2011 0.96 0.76*** 1.00 
 (0.91 - 1.01) (0.72 - 0.80) (0.95 - 1.05) 
   2012 0.91*** 0.73*** 1.11*** 
 (0.86 - 0.95) (0.69 - 0.78) (1.06 - 1.17) 
   2013 0.86*** 0.68*** 1.18*** 
 (0.82 - 0.91) (0.64 - 0.72) (1.12 - 1.24) 
   2014 0.83*** 0.37*** 0.99 
 (0.78 - 0.89) (0.34 - 0.40) (0.93 - 1.05) 
   2015 0.78*** 0.45*** 1.12* 
 (0.71 - 0.86) (0.40 - 0.50) (1.02 - 1.22) 
   2016 0.66*** 0.47*** 1.14** 
 (0.60 - 0.73) (0.42 - 0.52) (1.05 - 1.25) 
   2017 0.63*** 0.48*** 0.99 
 (0.58 – 0.69) (0.43 – 0.53) (0.91 – 1.08) 
State (Alabama = ref)     
Alaska 0.62 0.53* 1.44 
 (0.35 - 1.08) (0.31 - 0.92) (0.84 - 2.47) 
Arizona 0.48** 0.12*** 0.19*** 
 (0.30 - 0.77) (0.07 - 0.19) (0.11 - 0.31) 
Arkansas 0.40*** 0.54* 0.61 
 (0.24 - 0.68) (0.32 - 0.89) (0.35 - 1.04) 





 (0.29 - 0.77) (0.19 - 0.51) (0.44 - 1.22) 
Connecticut 0.29*** 0.09*** 0.78 
 (0.18 - 0.47) (0.05 - 0.15) (0.47 - 1.29) 
Delaware 1.40 0.06*** 1.12 
 (0.87 - 2.25) (0.04 - 0.10) (0.68 - 1.85) 
District of Columbia 3.26*** 0.36* 0.71 
 (1.79 - 5.94) (0.17 - 0.80) (0.34 - 1.48) 
Florida 0.37*** 0.56* 0.91 
 (0.23 - 0.60) (0.34 - 0.90) (0.55 - 1.50) 
Hawaii 0.36** 0.31*** 1.08 
 (0.18 - 0.74) (0.16 - 0.59) (0.60 - 1.95) 
Idaho 1.71 0.99 5.64*** 
 (0.95 - 3.07) (0.53 - 1.83) (3.19 - 9.96) 
Illinois 0.86 0.16*** 0.73 
 (0.54 - 1.38) (0.10 - 0.26) (0.44 - 1.21) 
Indiana 0.66 0.29*** 0.73 
 (0.40 - 1.06) (0.18 - 0.48) (0.44 - 1.22) 
Iowa 0.84 0.22*** 0.70 
 (0.51 - 1.36) (0.13 - 0.36) (0.42 - 1.17) 
Kansas 0.79 0.37*** 1.12 
 (0.48 - 1.30) (0.22 - 0.63) (0.67 - 1.87) 
Kentucky 0.68 0.55* 1.31 
 (0.43 - 1.09) (0.34 - 0.88) (0.80 - 2.16) 
Louisiana 1.00 1.30 1.25 
 (0.60 - 1.68) (0.78 - 2.15) (0.74 - 2.12) 
Maine 0.77 0.15*** 0.54* 
 (0.48 - 1.24) (0.09 - 0.25) (0.32 - 0.89) 
Maryland 0.31*** 0.21*** 0.85 
 (0.20 - 0.51) (0.13 - 0.34) (0.52 - 1.41) 
Massachusetts 1.08 0.20*** 1.75* 
 (0.67 - 1.75) (0.12 - 0.33) (1.05 - 2.90) 
Michigan 1.68* 0.41*** 0.86 
 (1.05 - 2.69) (0.25 - 0.67) (0.52 - 1.41) 
Minnesota 0.97 0.25*** 0.70 
 (0.58 - 1.61) (0.14 - 0.44) (0.41 - 1.19) 
Missouri 0.29*** 0.28*** 0.96 
 (0.17 - 0.48) (0.17 - 0.46) (0.58 - 1.59) 
Montana 0.92 0.08*** 1.34 
 (0.55 - 1.53) (0.04 - 0.15) (0.79 - 2.26) 
Nebraska 0.75 0.32*** 0.99 
 (0.40 - 1.40) (0.16 - 0.62) (0.55 - 1.80) 
Nevada 0.43 0.33* 0.35 
 (0.14 - 1.35) (0.11 - 0.96) (0.09 - 1.32) 
New Hampshire 1.34 0.10*** 1.36 
 (0.81 - 2.19) (0.06 - 0.18) (0.81 - 2.29) 
New Jersey 0.23*** 0.38*** 1.14 
 (0.14 - 0.36) (0.24 - 0.62) (0.69 - 1.89) 
New Mexico  0.66 0.22* 0.50 





New York  0.73 0.38*** 0.53* 
 (0.46 - 1.18) (0.24 - 0.61) (0.33 - 0.88) 
North Carolina 0.98 0.30*** 0.65 
 (0.61 - 1.57) (0.18 - 0.48) (0.40 - 1.07) 
North Dakota 1.22 0.19* 1.73 
 (0.48 - 3.10) (0.05 - 0.71) (0.74 - 4.06) 
Ohio 0.94 0.39*** 1.55 
 (0.59 - 1.51) (0.24 - 0.64) (0.94 - 2.56) 
Oklahoma 0.25*** 0.62 1.11 
 (0.14 - 0.42) (0.38 - 1.02) (0.67 - 1.86) 
Pennsylvania 4.58*** 1.10 2.51*** 
 (2.78 - 7.53) (0.66 - 1.86) (1.48 - 4.26) 
Rhode Island 0.54* 0.09*** 0.61 
 (0.33 - 0.88) (0.05 - 0.16) (0.36 - 1.01) 
South Carolina 0.67 0.82 0.62 
 (0.41 - 1.11) (0.50 - 1.33) (0.37 - 1.03) 
South Dakota 0.97 0.50 1.48 
 (0.49 - 1.94) (0.23 - 1.05) (0.78 - 2.82) 
Tennessee 1.27 0.37*** 3.14*** 
 (0.76 - 2.12) (0.22 - 0.65) (1.87 - 5.28) 
Utah 0.88 0.57* 2.37*** 
 (0.54 - 1.42) (0.35 - 0.93) (1.43 - 3.91) 
Washington  0.85 0.97 1.06 
 (0.53 - 1.37) (0.60 - 1.57) (0.64 - 1.75) 
Wyoming 0.94 0.38* 0.73 
 (0.46 - 1.92) (0.17 - 0.88) (0.37 - 1.46) 
Reference group for multinomial regression is self-referral. Adjusted Odds Ratio = AOR. Confidence Interval = CI.  



































    
N 225,272 225,272 225,272 
 AOR AOR AOR 
 (95%CI) (95%CI) (95%CI) 
    
Expansion 0.84 0.94 1.06 
    (0.52 - 1.35) (0.58 - 1.52) (0.64 - 1.75) 
Post expansion  0.70*** 0.42*** 0.82*** 
    (0.66 - 0.75) (0.39 - 0.45) (0.78 - 0.87) 
Expansion * Post expansion  1.18*** 2.39*** 1.32*** 
    (1.12 - 1.25) (2.23 - 2.56) (1.25 - 1.39) 
MAT (No= ref)     
   Yes 0.65*** 0.34*** 0.14*** 
 (0.63 - 0.67) (0.32 - 0.35) (0.13 - 0.14) 
Frequency of use     
   Some use 0.64*** 0.66*** 0.39*** 
 (0.62 - 0.67) (0.64 - 0.69) (0.37 - 0.40) 
   Daily use  0.51*** 0.38*** 0.16*** 
 (0.50 - 0.53) (0.36 - 0.39) (0.16 - 0.17) 
Age (18-29= ref)     
   30-44 1.00 1.00 0.99 
 (0.97 - 1.03) (0.97 - 1.03) (0.97 - 1.02) 
   45-64 1.11*** 0.81*** 0.87*** 
 (1.07 - 1.15) (0.77 - 0.85) (0.84 - 0.90) 
Gender    
   Male  0.88*** 0.62*** 1.32*** 
 (0.86 - 0.90) (0.60 - 0.64) (1.29 - 1.35) 
Race/ethnicity     
   Non-Hispanic Black 1.02 1.36*** 1.19*** 
 (0.96 - 1.07) (1.28 - 1.45) (1.13 - 1.26) 
   Hispanic  0.89*** 1.31*** 1.21*** 
 (0.85 - 0.94) (1.24 - 1.39) (1.15 - 1.27) 
   Other 0.88*** 1.04 0.98 
 (0.82 - 0.95) (0.96 - 1.12) (0.92 - 1.06) 
Education     
   Highschool or higher 0.96* 0.81*** 0.78*** 
 (0.94 - 0.99) (0.78 - 0.84) (0.76 - 0.80) 
Number of arrests (0=ref)    
   1 0.83*** 1.20*** 2.73*** 
 (0.78 - 0.89) (1.12 - 1.28) (2.60 - 2.87) 
   2 or more 0.86* 0.96 1.08 
 (0.77 - 0.97) (0.83 - 1.12) (0.98 - 1.20) 
Employment status     





 (1.29 - 1.37) (1.10 - 1.18) (0.91 - 0.96) 
Comorbidity    
   Yes  1.50*** 0.91*** 0.65*** 
 (1.46 - 1.54) (0.88 - 0.94) (0.63 - 0.67) 
Homeless    
  Yes 1.33*** 1.35*** 0.61*** 
 (1.26 - 1.40) (1.27 - 1.43) (0.57 - 0.65) 
Polysubstance use     
    One more 1.00 1.02 0.85*** 
 (0.97 - 1.03) (0.98 - 1.05) (0.82 - 0.87) 
    Two or more 0.99 1.06** 0.94*** 
 (0.95 - 1.02) (1.02 - 1.10) (0.91 - 0.97) 
Year     
   2011 0.96 0.75*** 1.00 
 (0.91 - 1.01) (0.71 - 0.80) (0.95 - 1.05) 
   2012 0.89*** 0.72*** 1.11*** 
 (0.85 - 0.94) (0.68 - 0.76) (1.06 - 1.17) 
   2013 0.85*** 0.66*** 1.18*** 
 (0.81 - 0.90) (0.63 - 0.70) (1.12 - 1.24) 
   2014 1.32*** 0.75*** 0.98 
 (1.21 - 1.44) (0.69 - 0.83) (0.91 - 1.06) 
   2015 1.22*** 0.92** 1.13*** 
 (1.17 - 1.29) (0.87 - 0.97) (1.07 - 1.18) 
   2016 1.04 0.98 1.16*** 
 (0.99 - 1.09) (0.93 - 1.03) (1.11 - 1.21) 
State    
Arizona 0.60*** 0.13*** 0.19*** 
 (0.54 - 0.66) (0.12 - 0.14) (0.17 - 0.21) 
Arkansas 0.48*** 0.55*** 0.58*** 
 (0.37 - 0.62) (0.45 - 0.66) (0.46 - 0.72) 
Colorado 0.55*** 0.33*** 0.71*** 
 (0.48 - 0.63) (0.29 - 0.38) (0.63 - 0.81) 
Connecticut 0.34*** 0.10*** 0.74*** 
 (0.29 - 0.40) (0.08 - 0.12) (0.65 - 0.84) 
Delaware 1.66*** 0.06*** 1.07 
 (1.48 - 1.87) (0.05 - 0.08) (0.95 - 1.20) 
District of Columbia 3.98*** 0.42** 0.76 
 (2.71 - 5.83) (0.22 - 0.80) (0.44 - 1.32) 
Florida 0.38*** 0.55* 0.92 
 (0.23 - 0.61) (0.34 - 0.90) (0.56 - 1.52) 
Hawaii 0.44** 0.34*** 1.02 
 (0.25 - 0.75) (0.22 - 0.52) (0.74 - 1.41) 
Idaho 1.8 1.03 5.85*** 
 (1.00 - 3.25) (0.56 - 1.91) (3.31 - 10.34) 
Illinois 1.03 0.18*** 0.73*** 
 (0.92 - 1.14) (0.16 - 0.20) (0.65 - 0.81) 
Iowa 1.01 0.22*** 0.67*** 
 (0.86 - 1.17) (0.18 - 0.27) (0.57 - 0.78) 





 (0.49 - 1.33) (0.22 - 0.63) (0.68 - 1.90) 
Kentucky 0.82*** 0.55*** 1.24*** 
 (0.75 - 0.89) (0.51 - 0.60) (1.14 - 1.35) 
Maine 0.78 0.15*** 0.54* 
 (0.49 - 1.26) (0.09 - 0.25) (0.32 - 0.89) 
Maryland 0.38*** 0.22*** 0.83*** 
 (0.34 - 0.42) (0.20 - 0.25) (0.75 - 0.92) 
Massachusetts 1.30*** 0.21*** 1.68*** 
 (1.13 - 1.48) (0.17 - 0.25) (1.48 - 1.91) 
Michigan 2.03*** 0.42*** 0.81*** 
 (1.84 - 2.23) (0.38 - 0.47) (0.73 - 0.90) 
Mississippi 1 0.26*** 0.72 
 (0.60 - 1.66) (0.15 - 0.45) (0.42 - 1.21) 
Missouri 0.30*** 0.29*** 0.98 
 (0.18 - 0.50) (0.17 - 0.48) (0.59 - 1.63) 
Nebraska 0.75 0.33** 1.02 
 (0.40 - 1.41) (0.17 - 0.65) (0.56 - 1.84) 
Nevada 0.56 0.36* 0.36 
 (0.19 - 1.61) (0.14 - 0.98) (0.10 - 1.27) 
New Hampshire 1.60*** 0.10*** 1.28** 
 (1.34 - 1.92) (0.07 - 0.14) (1.08 - 1.51) 
New Jersey 0.27*** 0.41*** 1.11 
 (0.23 - 0.30) (0.37 - 0.45) (0.99 - 1.23) 
New Mexico 0.6 0.15* 0.61 
 (0.23 - 1.56) (0.03 - 0.65) (0.18 - 2.00) 
New York 0.88** 0.40*** 0.52*** 
 (0.80 - 0.95) (0.37 - 0.44) (0.48 - 0.56) 
North Carolina 1.01 0.29*** 0.66 
 (0.63 - 1.61) (0.18 - 0.47) (0.40 - 1.07) 
North Dakota 1.43 0.19** 1.61 
 (0.64 - 3.21) (0.05 - 0.66) (0.80 - 3.24) 
Ohio 1.13* 0.40*** 1.46*** 
 (1.02 - 1.25) (0.36 - 0.44) (1.33 - 1.61) 
Oklahoma 0.25*** 0.65 1.14 
 (0.15 - 0.43) (0.40 - 1.07) (0.68 - 1.89) 
Rhode Island 0.66*** 0.09*** 0.53*** 
 (0.57 - 0.76) (0.07 - 0.12) (0.45 - 0.62) 
South Carolina 0.69 0.81 0.62 
 (0.42 - 1.14) (0.50 - 1.32) (0.37 - 1.04) 
South Dakota 1 0.51 1.49 
 (0.50 - 1.98) (0.24 - 1.07) (0.79 - 2.83) 
Tennessee 1.3 0.38*** 3.24*** 
 (0.78 - 2.16) (0.22 - 0.67) (1.93 - 5.43) 
Utah 0.89 0.59* 2.43*** 
 (0.55 - 1.44) (0.36 - 0.96) (1.47 - 4.01) 
Wyoming 0.98 0.39* 0.73 
 (0.48 - 1.99) (0.17 - 0.90) (0.37 - 1.47) 
Reference group for multinomial regression is self-referral. Adjusted Odds Ratio = AOR. Confidence Interval = CI.  














N 168,165 168,165 168,165 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Medicaid expansion     
  Expanded 1.17*** 2.36*** 1.25*** 
 (1.10 - 1.24) (2.19 - 2.54) (1.18 - 1.32) 
Frequency of use (No 
past month use= ref)  
   
   Some use 0.67*** 0.67*** 0.40*** 
 (0.64 - 0.70) (0.64 - 0.70) (0.38 - 0.41) 
   Daily use 0.59*** 0.41*** 0.18*** 
 (0.57 - 0.61) (0.39 - 0.43) (0.17 - 0.19) 
Age (18-29= ref)     
   30-44 1.03 1.00 0.98 
 (0.99 - 1.06) (0.96 - 1.03) (0.96 - 1.01) 
   45-64 1.21*** 0.82*** 0.91*** 
 (1.16 - 1.27) (0.78 - 0.86) (0.88 - 0.95) 
Gender (Female=ref)    
   Male 0.91*** 0.60*** 1.33*** 
 (0.88 - 0.93) (0.58 - 0.62) (1.29 - 1.36) 
Race/ethnicity (non-
Hispanic White=ref) 
   
   Non-Hispanic Black 1.14*** 1.56*** 1.30*** 
 (1.07 - 1.22) (1.45 - 1.67) (1.23 - 1.37) 
   Hispanic 1.02 1.55*** 1.33*** 
 (0.95 - 1.09) (1.45 - 1.66) (1.26 - 1.41) 
   Other 0.90* 1.05 0.97 
 (0.82 - 0.98) (0.96 - 1.14) (0.90 - 1.04) 
Education (Less than high 
school= ref)  
   
   Highschool or higher 0.94*** 0.76*** 0.75*** 
 (0.91 - 0.97) (0.74 - 0.79) (0.73 - 0.77) 
Number of arrests (0= 
ref) 
   
   1 0.79*** 1.13** 2.48*** 





   2 or more 0.69*** 0.93 0.93 
 (0.61 - 0.78) (0.79 - 1.09) (0.84 - 1.04) 
Employment status (Not 
employed= ref)  
   
     Employed 1.30*** 1.12*** 0.92*** 
 (1.25 - 1.35) (1.08 - 1.16) (0.90 - 0.95) 
Comorbidity (No= ref)     
   Yes 1.57*** 0.85*** 0.62*** 
 (1.52 - 1.62) (0.82 - 0.88) (0.60 - 0.64) 
Homeless (No= ref)     
  Yes 1.31*** 1.25*** 0.57*** 
 (1.23 - 1.39) (1.16 - 1.33) (0.53 - 0.61) 
Polysubstance use (no= 
ref)   
   
    One more 0.99 0.92*** 0.78*** 
 (0.95 - 1.02) (0.89 - 0.96) (0.76 - 0.81) 
    Two or more 0.91*** 0.93*** 0.84*** 
 (0.88 - 0.95) (0.89 - 0.97) (0.82 - 0.87) 
Year (2010= ref)     
   2011 0.93* 0.77*** 0.98 
 (0.87 - 0.98) (0.72 - 0.81) (0.93 - 1.04) 
   2012 0.88*** 0.73*** 1.07* 
 (0.83 - 0.93) (0.68 - 0.77) (1.01 - 1.12) 
   2013 0.83*** 0.70*** 1.19*** 
 (0.78 - 0.88) (0.66 - 0.75) (1.13 - 1.25) 
   2014 0.80*** 0.37*** 1.03 
 (0.75 - 0.86) (0.34 - 0.41) (0.97 - 1.10) 
   2015 0.78*** 0.38*** 0.92* 
 (0.73 - 0.84) (0.35 - 0.41) (0.86 - 0.99) 
   2016 0.67*** 0.37*** 0.91** 
 (0.62 - 0.71) (0.34 - 0.40) (0.86 - 0.97) 
   2017 0.69*** 0.36*** 0.75*** 
 (0.65 - 0.74) (0.34 - 0.39) (0.71 - 0.80) 
Alaska 0.66 0.47* 1.5 
 (0.28 - 1.55) (0.23 - 0.95) (0.76 - 2.94) 
Arizona 0.49 0.08*** 0.16*** 
 (0.22 - 1.08) (0.04 - 0.15) (0.09 - 0.31) 
Arkansas 0.37* 0.43* 0.57 
 (0.15 - 0.87) (0.21 - 0.85) (0.29 - 1.13) 
Colorado 0.49 0.26*** 0.71 
 (0.22 - 1.08) (0.14 - 0.51) (0.38 - 1.35) 





 (0.18 - 0.92) (0.06 - 0.25) (0.64 - 2.30) 
Delaware 1.77 0.04*** 1.23 
 (0.80 - 3.91) (0.02 - 0.08) (0.65 - 2.33) 
District of Columbia 1.93 0.20*** 0.48 
 (0.79 - 4.76) (0.08 - 0.49) (0.21 - 1.11) 
Florida 0.75 0.71 1.25 
 (0.34 - 1.66) (0.36 - 1.37) (0.66 - 2.36) 
Hawaii 0.37* 0.24*** 1.08 
 (0.14 - 0.99) (0.11 - 0.53) (0.53 - 2.20) 
Idaho 1.69 0.77 5.27*** 
 (0.71 - 4.03) (0.36 - 1.66) (2.63 - 10.56) 
Illinois 0.7 0.13*** 0.74 
 (0.31 - 1.54) (0.07 - 0.26) (0.39 - 1.40) 
Indiana 0.71 0.22*** 0.73 
 (0.32 - 1.58) (0.11 - 0.43) (0.38 - 1.38) 
Iowa 0.69 0.16*** 0.63 
 (0.31 - 1.55) (0.08 - 0.31) (0.33 - 1.20) 
Kansas 0.78 0.28*** 1.04 
 (0.35 - 1.74) (0.14 - 0.55) (0.55 - 1.99) 
Kentucky 0.62 0.36** 1.1 
 (0.28 - 1.36) (0.19 - 0.69) (0.58 - 2.07) 
 0.99 0.76 1.04 
 (0.44 - 2.25) (0.39 - 1.50) (0.54 - 2.02) 
Maine 0.92 0.16*** 0.64 
 (0.41 - 2.05) (0.08 - 0.32) (0.33 - 1.21) 
Maryland 0.46 0.21*** 1.03 
 (0.21 - 1.02) (0.11 - 0.41) (0.54 - 1.94) 
Massachusetts 0.87 0.16*** 1.66 
 (0.39 - 1.93) (0.08 - 0.31) (0.87 - 3.16) 
Michigan 1.48 0.27*** 0.78 
 (0.67 - 3.25) (0.14 - 0.52) (0.41 - 1.47) 
Mississippi 1.01 0.20*** 0.65 
 (0.45 - 2.27) (0.10 - 0.41) (0.34 - 1.26) 
Missouri 0.25** 0.21*** 0.9 
 (0.11 - 0.58) (0.11 - 0.42) (0.47 - 1.71) 
Montana 0.92 0.06*** 1.25 
 (0.41 - 2.07) (0.03 - 0.13) (0.65 - 2.41) 
Nebraska 0.79 0.24*** 0.83 
 (0.32 - 1.94) (0.11 - 0.55) (0.41 - 1.71) 
Nevada 0.64 0.19 0.55 
 (0.11 - 3.61) (0.04 - 1.03) (0.12 - 2.41) 





 (0.58 - 2.89) (0.03 - 0.14) (0.67 - 2.44) 
New Jersey 0.48 0.54 2.02* 
 (0.21 - 1.07) (0.28 - 1.06) (1.06 - 3.83) 
New Mexico 0 0.51 0.83 
 (0.00 - .) (0.09 - 3.01) (0.14 - 5.03) 
New York 0.79 0.28*** 0.47* 
 (0.36 - 1.74) (0.15 - 0.55) (0.25 - 0.88) 
North Carolina 0.93 0.19*** 0.57 
 (0.43 - 2.05) (0.10 - 0.37) (0.30 - 1.08) 
North Dakota 1.22 0.14** 1.65 
 (0.39 - 3.75) (0.03 - 0.56) (0.65 - 4.20) 
Ohio 0.64 0.27*** 1.26 
 (0.29 - 1.40) (0.14 - 0.52) (0.67 - 2.38) 
Oklahoma 0.26** 0.49* 1.09 
 (0.11 - 0.58) (0.25 - 0.96) (0.57 - 2.08) 
Pennsylvania 5.45*** 0.45* 2.33* 
 (2.41 - 12.31) (0.22 - 0.92) (1.20 - 4.55) 
Rhode Island 1.06 0.12*** 0.86 
 (0.47 - 2.38) (0.06 - 0.25) (0.44 - 1.65) 
South Carolina 0.65 0.53 0.53 
 (0.29 - 1.44) (0.27 - 1.03) (0.28 - 1.01) 
South Dakota 0.87 0.33* 1.16 
 (0.33 - 2.24) (0.14 - 0.81) (0.55 - 2.47) 
Tennessee 1.25 0.27*** 2.86** 
 (0.56 - 2.82) (0.13 - 0.55) (1.50 - 5.48) 
Utah 0.86 0.37** 2.22* 
 (0.39 - 1.91) (0.19 - 0.72) (1.17 - 4.21) 
Washington 0.92 0.74 1.14 
 (0.41 - 2.04) (0.38 - 1.43) (0.60 - 2.16) 
Wyoming 1 0.30* 0.65 
 (0.39 - 2.59) (0.12 - 0.77) (0.29 - 1.44) 
* p<0.05, ** p<0.01, *** p<0.001 
Reference group for multinomial regression is self-referral. Relative Risk Ratio = RRR. 



















N 53,295 48,302 
 AOR AOR 
  (95%CI) (95%CI) 
   
Medicaid expansion    
  Expanded 1.10 1.31 
 (0.97 - 1.25) (1.00 - 1.71) 
Frequency of use (No past month use= ref)    
   Some use 0.58*** 0.36*** 
 (0.53 - 0.63) (0.32 - 0.40) 
   Daily use 0.38*** 0.15*** 
 (0.36 - 0.41) (0.13 - 0.16) 
Age (18-29= ref)    
   30-44 0.91** 0.99 
 (0.86 - 0.96) (0.91 - 1.08) 
   45-64 0.86*** 0.58*** 
 (0.80 - 0.93) (0.51 - 0.66) 
Gender (Female=ref)   
   Male 0.81*** 1.14*** 
 (0.77 - 0.85) (1.06 - 1.24) 
Race/ethnicity (non-Hispanic White=ref)   
   Non-Hispanic Black 0.87** 0.99 
 (0.79 - 0.95) (0.85 - 1.17) 
   Hispanic 0.81*** 0.81** 
 (0.73 - 0.89) (0.69 - 0.93) 
   Other 0.83* 0.91 
 (0.71 - 0.97) (0.71 - 1.15) 
Education (Less than high school= ref)    
   Highschool or higher 0.97 0.87*** 
 (0.92 - 1.02) (0.80 - 0.94) 





   1 0.98 5.34*** 
 (0.86 - 1.13) (4.69 - 6.08) 
   2 or more 1.45** 2.01*** 
 (1.11 - 1.90) (1.38 - 2.93) 
Employment status (Not employed= ref)    
     Employed 1.37*** 0.98 
 (1.29 - 1.46) (0.90 - 1.07) 
Comorbidity (No= ref)    
   Yes 1.20*** 1.01 
 (1.14 - 1.27) (0.93 - 1.10) 
Homeless (No= ref)    
  Yes 1.31*** 0.82* 
 (1.18 - 1.44) (0.68 - 0.98) 
Polysubstance use (no= ref)     
    One more 0.93** 1.57*** 
 (0.88 - 0.98) (1.43 - 1.72) 
    Two or more 1.09* 2.23*** 
 (1.02 - 1.16) (2.02 - 2.46) 
Year (2010= ref)    
   2011 0.98 0.64*** 
 (0.87 - 1.09) (0.55 - 0.75) 
   2012 0.91 0.74*** 
 (0.81 - 1.03) (0.63 - 0.86) 
   2013 0.89* 0.57*** 
 (0.79 - 1.00) (0.48 - 0.67) 
   2014 0.91 0.31*** 
 (0.78 - 1.06) (0.25 - 0.39) 
   2015 1.12 0.45*** 
 (0.93 - 1.36) (0.35 - 0.58) 
   2016 0.95 0.59*** 
 (0.78 - 1.14) (0.46 - 0.75) 
   2017 0.72*** 0.51*** 
 (0.60 - 0.86) (0.40 - 0.65) 
State   
Alaska 0.54 0.40 
 (0.22 - 1.29) (0.10 - 1.62) 
Arizona 0.34*** 0.26** 
 (0.18 - 0.63) (0.10 - 0.67) 
Arkansas 0.44* 0.49 
 (0.22 - 0.87) (0.17 - 1.39) 





 (0.25 - 0.87) (0.24 - 1.64) 
Connecticut 0.23*** 0.06*** 
 (0.12 - 0.43) (0.02 - 0.17) 
Delaware 1.04 0.45 
 (0.56 - 1.92) (0.17 - 1.18) 
District of Columbia 10.76*** 1.43 
 (4.00 - 28.90) (0.14 - 14.32) 
Florida 0.15*** 0.33* 
 (0.08 - 0.29) (0.13 - 0.84) 
Hawaii 0.39 0.50 
 (0.10 - 1.47) (0.05 - 4.60) 
Idaho 2.19 3.53 
 (0.60 - 7.94) (0.71 - 17.56) 
Illinois 1.10 0.27** 
 (0.60 - 2.02) (0.11 - 0.71) 
Indiana 0.31** 0.15** 
 (0.15 - 0.64) (0.04 - 0.48) 
Iowa 2.58** 0.47 
 (1.31 - 5.08) (0.13 - 1.66) 
Kentucky 0.91 1.78 
 (0.50 - 1.67) (0.70 - 4.50) 
Nebraska -  
   
Maine 0.70 0.26** 
 (0.39 - 1.29) (0.10 - 0.66) 
Maryland 0.23*** 0.30* 
 (0.12 - 0.42) (0.12 - 0.77) 
Massachusetts 1.48 0.55 
 (0.80 - 2.77) (0.20 - 1.49) 
Michigan 1.95* 0.37* 
 (1.06 - 3.56) (0.14 - 0.96) 
Mississippi 0.73 1.51 
 (0.20 - 2.60) (0.31 - 7.39) 
Missouri 0.39** 0.60 
 (0.20 - 0.77) (0.22 - 1.62) 
Nebraska 0.55 3.75 
 (0.11 - 2.77) (0.91 - 15.51) 
Nevada 0.28  
 (0.06 - 1.39)  
New Hampshire 2.16 1.63 
 (0.95 - 4.89) (0.50 - 5.34) 
New Jersey 0.20*** 0.42 
 (0.11 - 0.38) (0.16 - 1.06) 





 (0.29 - 2.24) (0.04 - 3.54) 
New York 0.61 0.74 
 (0.33 - 1.11) (0.29 - 1.87) 
North Carolina 1.07 0.16*** 
 (0.59 - 1.94) (0.06 - 0.40) 
Ohio 1.78 1.79 
 (0.97 - 3.26) (0.70 - 4.56) 
Pennsylvania 3.31*** 1.52 
 (1.69 - 6.46) (0.53 - 4.35) 
Rhode Island 0.39** 0.21** 
 (0.21 - 0.72) (0.08 - 0.57) 
South Carolina 0.85 0.51 
 (0.37 - 1.97) (0.16 - 1.63) 
South Dakota 2.57 8.40* 
 (0.50 - 13.23) (1.51 - 46.86) 
Tennessee -  
   
Utah 0.93 0.66 
 (0.50 - 1.74) (0.25 - 1.74) 
Washington 0.73 0.39* 
 (0.39 - 1.34) (0.15 - 1.00) 
* p<0.05, ** p<0.01, *** p<0.001 











Other institutional Court/criminal justice 
referral Referral 
    
N 164,420 164,420 164,420 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Expansion 0.91 0.71 1.14 
    (0.41 - 2.01) (0.37 - 1.38) (0.60 - 2.16) 
Post expansion  0.68*** 0.34*** 0.75*** 
    (0.64 - 0.73) (0.32 - 0.37) (0.70 - 0.80) 
Expansion * Post expansion  1.18*** 2.50*** 1.25*** 
    (1.10 - 1.25) (2.31 - 2.69) (1.18 - 1.32) 
Frequency of use (No 
past month use= ref)  
   
   Some use 0.67*** 0.67*** 0.40*** 
 (0.64 - 0.70) (0.65 - 0.70) (0.38 - 0.41) 
   Daily use 0.59*** 0.41*** 0.18*** 
 (0.57 - 0.61) (0.40 - 0.43) (0.17 - 0.19) 
Age (18-29= ref)     
   30-44 1.02 1.00 0.98 
 (0.99 - 1.06) (0.96 - 1.03) (0.96 - 1.01) 
   45-64 1.21*** 0.82*** 0.91*** 
 (1.16 - 1.27) (0.78 - 0.86) (0.87 - 0.95) 
Gender (Female=ref)    
   Male 0.91*** 0.59*** 1.32*** 
 (0.88 - 0.94) (0.57 - 0.61) (1.29 - 1.36) 
Race/ethnicity (non-
Hispanic White=ref) 
   
   Non-Hispanic Black 1.16*** 1.56*** 1.30*** 
 (1.08 - 1.23) (1.45 - 1.68) (1.22 - 1.37) 
   Hispanic 1.02 1.56*** 1.34*** 
 (0.95 - 1.10) (1.46 - 1.68) (1.26 - 1.42) 
   Other 0.90* 1.06 0.99 
 (0.83 - 0.99) (0.97 - 1.16) (0.92 - 1.07) 
Education (Less than high 
school= ref)  
   
   Highschool or higher 0.94** 0.77*** 0.75*** 
 (0.91 - 0.98) (0.74 - 0.80) (0.73 - 0.78) 
Number of arrests (0= 
ref) 





   1 0.77*** 1.13** 2.48*** 
 (0.71 - 0.84) (1.05 - 1.22) (2.36 - 2.62) 
   2 or more 0.71*** 0.92 0.92 
 (0.62 - 0.80) (0.78 - 1.08) (0.83 - 1.03) 
Employment status (Not 
employed= ref)  
   
     Employed 1.31*** 1.12*** 0.92*** 
 (1.27 - 1.36) (1.08 - 1.16) (0.90 - 0.95) 
Comorbidity (No= ref)     
   Yes 1.59*** 0.85*** 0.62*** 
 (1.54 - 1.64) (0.82 - 0.88) (0.60 - 0.64) 
Homeless (No= ref)     
  Yes 1.34*** 1.24*** 0.56*** 
 (1.26 - 1.42) (1.15 - 1.32) (0.52 - 0.60) 
Polysubstance use (no= 
ref)   
   
    One more 1.00 0.92*** 0.78*** 
 (0.96 - 1.03) (0.88 - 0.95) (0.75 - 0.80) 
    Two or more 0.92*** 0.93*** 0.83*** 
 (0.89 - 0.96) (0.89 - 0.96) (0.80 - 0.86) 
Year (2010= ref)     
   2011 0.92** 0.76*** 0.98 
 (0.87 - 0.98) (0.71 - 0.81) (0.93 - 1.03) 
   2012 0.86*** 0.71*** 1.06* 
 (0.81 - 0.91) (0.67 - 0.76) (1.00 - 1.12) 
   2013 0.83*** 0.68*** 1.18*** 
 (0.78 - 0.88) (0.64 - 0.73) (1.12 - 1.24) 
   2014 1.16*** 1.00 1.36*** 
 (1.10 - 1.23) (0.94 - 1.07) (1.30 - 1.43) 
   2015 1.13*** 1.02 1.22*** 
 (1.06 - 1.20) (0.95 - 1.09) (1.16 - 1.28) 
   2016 0.96 1.02 1.21*** 
 (0.90 - 1.01) (0.95 - 1.08) (1.15 - 1.27) 
State    
Arizona 0.54*** 0.10*** 0.14*** 
 (0.47 - 0.62) (0.09 - 0.12) (0.13 - 0.16) 
Arkansas 0.40*** 0.57*** 0.50*** 
 (0.28 - 0.58) (0.45 - 0.73) (0.39 - 0.65) 
Colorado 0.53*** 0.35*** 0.62*** 
 (0.44 - 0.65) (0.30 - 0.41) (0.54 - 0.72) 
Connecticut 0.45*** 0.17*** 1.06 





Delaware 1.93*** 0.05*** 1.08 
 (1.64 - 2.27) (0.04 - 0.07) (0.94 - 1.24) 
District of Columbia 2.11** 0.26*** 0.42** 
 (1.34 - 3.32) (0.13 - 0.50) (0.24 - 0.74) 
Florida 0.74 0.68 1.24 
 (0.33 - 1.65) (0.35 - 1.32) (0.66 - 2.35) 
Hawaii 0.40** 0.32*** 0.94 
 (0.22 - 0.74) (0.20 - 0.51) (0.67 - 1.32) 
Idaho 1.68 0.76 5.26*** 
 (0.70 - 4.02) (0.35 - 1.64) (2.63 - 10.53) 
Illinois 0.76*** 0.18*** 0.65*** 
 (0.65 - 0.88) (0.15 - 0.21) (0.57 - 0.74) 
Iowa 0.76** 0.21*** 0.55*** 
 (0.63 - 0.91) (0.17 - 0.26) (0.47 - 0.65) 
Kansas 0.77 0.27*** 1.04 
 (0.34 - 1.73) (0.13 - 0.53) (0.54 - 1.99) 
Kentucky 0.68*** 0.48*** 0.96 
 (0.60 - 0.77) (0.44 - 0.53) (0.87 - 1.06) 
Maine 0.92 0.16*** 0.63 
 (0.41 - 2.05) (0.08 - 0.31) (0.33 - 1.21) 
Maryland 0.50*** 0.28*** 0.9 
 (0.43 - 0.59) (0.24 - 0.33) (0.80 - 1.02) 
Massachusetts 0.95 0.21*** 1.46*** 
 (0.79 - 1.14) (0.17 - 0.26) (1.26 - 1.68) 
Michigan 1.62*** 0.36*** 0.68*** 
 (1.42 - 1.86) (0.32 - 0.41) (0.60 - 0.76) 
Mississippi 1.01 0.20*** 0.65 
 (0.45 - 2.28) (0.10 - 0.41) (0.34 - 1.26) 
Missouri 0.25** 0.21*** 0.9 
 (0.11 - 0.58) (0.11 - 0.41) (0.47 - 1.70) 
Nebraska 0.79 0.24*** 0.83 
 (0.32 - 1.94) (0.10 - 0.54) (0.41 - 1.71) 
Nevada 0.7 0.26 0.48 
 (0.15 - 3.28) (0.05 - 1.20) (0.12 - 1.85) 
New Hampshire 1.42*** 0.09*** 1.12 
 (1.15 - 1.74) (0.06 - 0.13) (0.94 - 1.33) 
New Jersey 0.52*** 0.73*** 1.77*** 
 (0.42 - 0.65) (0.62 - 0.85) (1.53 - 2.03) 
New Mexico 0 0.68 0.72 
 (0.00 - .) (0.13 - 3.53) (0.13 - 3.92) 
New York 0.86* 0.38*** 0.41*** 





North Carolina 0.93 0.19*** 0.57 
 (0.42 - 2.05) (0.10 - 0.36) (0.30 - 1.07) 
North Dakota 1.33 0.18** 1.43 
 (0.59 - 2.99) (0.05 - 0.63) (0.71 - 2.87) 
Ohio 0.70*** 0.36*** 1.1 
 (0.60 - 0.80) (0.32 - 0.41) (0.99 - 1.23) 
Oklahoma 0.25** 0.48* 1.09 
 (0.11 - 0.58) (0.25 - 0.95) (0.57 - 2.08) 
Rhode Island 1.16 0.16*** 0.75** 
 (0.93 - 1.46) (0.12 - 0.23) (0.61 - 0.91) 
South Carolina 0.65 0.51* 0.53 
 (0.29 - 1.45) (0.26 - 1.00) (0.28 - 1.01) 
South Dakota 0.86 0.33* 1.15 
 (0.33 - 2.24) (0.13 - 0.79) (0.54 - 2.45) 
Tennessee 1.25 0.27*** 2.86** 
 (0.56 - 2.82) (0.13 - 0.54) (1.49 - 5.48) 
Utah 0.86 0.36** 2.22* 
 (0.39 - 1.90) (0.18 - 0.70) (1.17 - 4.20) 
Wyoming 1.01 0.30* 0.65 
 (0.39 - 2.61) (0.12 - 0.77) (0.29 - 1.44) 
* p<0.05, ** p<0.01, *** p<0.001 













Other institutional  Court/criminal 
justice referral Referral  
    
N 60,852 60,852 60,852 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Expansion 0.79 1.17 0.47 
    (0.43 - 1.44) (0.54 - 2.54) (0.18 - 1.18) 
Post expansion  0.71*** 0.51*** 1.18 
    (0.62 - 0.82) (0.42 - 0.62) (0.89 - 1.57) 
Expansion * Post expansion  1.12 2.22*** 1.33* 
    (0.99 - 1.28) (1.83 - 2.69) (1.02 - 1.74) 
Frequency of use (No past 
month use= ref)  
   
   Some use 0.58*** 0.69*** 0.35*** 
 (0.53 - 0.63) (0.62 - 0.76) (0.32 - 0.39) 
   Daily use 0.38*** 0.40*** 0.15*** 
 (0.35 - 0.41) (0.37 - 0.44) (0.13 - 0.16) 
Age (18-29= ref)     
   30-44 0.92** 0.95 1.02 
 (0.87 - 0.98) (0.88 - 1.02) (0.94 - 1.11) 
   45-64 0.91* 0.69*** 0.61*** 
 (0.84 - 0.98) (0.62 - 0.77) (0.54 - 0.69) 
Gender (Female=ref)    
   Male 0.82*** 0.73*** 1.21*** 
 (0.78 - 0.86) (0.68 - 0.78) (1.12 - 1.30) 
Race/ethnicity (non-Hispanic 
White=ref) 
   
   Non-Hispanic Black 0.88** 1.04 0.97 
 (0.80 - 0.96) (0.91 - 1.19) (0.82 - 1.13) 
   Hispanic 0.82*** 0.93 0.80** 
 (0.74 - 0.90) (0.82 - 1.05) (0.69 - 0.92) 
   Other 0.85* 1.03 0.93 
 (0.73 - 0.99) (0.85 - 1.24) (0.73 - 1.17) 
Education (Less than high 
school= ref)  
   
   Highschool or higher 0.98 0.91* 0.90* 
 (0.93 - 1.03) (0.85 - 0.98) (0.83 - 0.98) 





   1 0.99 1.29** 5.07*** 
 (0.86 - 1.14) (1.09 - 1.52) (4.47 - 5.75) 
   2 or more 1.44** 0.84 2.35*** 
 (1.10 - 1.89) (0.53 - 1.32) (1.64 - 3.38) 
Employment status (Not 
employed= ref)  
   
     Employed 1.40*** 1.21*** 1.00 
 (1.32 - 1.49) (1.12 - 1.31) (0.92 - 1.09) 
Comorbidity (No= ref)     
   Yes 1.21*** 1.26*** 1.07 
 (1.14 - 1.28) (1.18 - 1.35) (0.99 - 1.16) 
Homeless (No= ref)     
  Yes 1.34*** 1.62*** 0.92 
 (1.21 - 1.48) (1.44 - 1.82) (0.77 - 1.10) 
Polysubstance use (no= ref)      
    One more 0.93** 1.36*** 1.59*** 
 (0.88 - 0.98) (1.26 - 1.47) (1.46 - 1.74) 
    Two or more 1.07* 1.47*** 2.15*** 
 (1.00 - 1.14) (1.34 - 1.60) (1.95 - 2.37) 
Year (2010= ref)     
   2011 1.00 0.64*** 1.04 
 (0.90 - 1.12) (0.55 - 0.75) (0.86 - 1.26) 
   2012 0.90 0.68*** 1.61*** 
 (0.81 - 1.01) (0.58 - 0.79) (1.35 - 1.93) 
   2013 0.89* 0.56*** 1.08 
 (0.79 - 1.00) (0.47 - 0.66) (0.89 - 1.32) 
   2014 1.26** 0.57*** 0.59*** 
 (1.09 - 1.45) (0.47 - 0.69) (0.48 - 0.73) 
   2015 1.59*** 0.89* 0.78*** 
 (1.45 - 1.73) (0.79 - 0.99) (0.68 - 0.89) 
   2016 1.32*** 1.13* 0.95 
 (1.21 - 1.44) (1.02 - 1.25) (0.85 - 1.06) 
    
Arizona 0.44*** 0.23*** 0.66* 
 (0.36 - 0.54) (0.18 - 0.29) (0.48 - 0.92) 
Arkansas 0.56** 0.44*** 1.22 
 (0.40 - 0.80) (0.31 - 0.63) (0.72 - 2.05) 
Colorado 0.63*** 0.22*** 1.52** 
 (0.51 - 0.77) (0.17 - 0.29) (1.12 - 2.08) 
Connecticut 0.30*** 0.02*** 0.15*** 
 (0.24 - 0.37) (0.01 - 0.04) (0.09 - 0.25) 





 (1.17 - 1.66) (0.06 - 0.14) (0.83 - 1.57) 
District of Columbia 14.14*** 0.59 2.49 
 (6.39 - 31.31) (0.07 - 4.76) (0.28 - 22.42) 
Florida 0.16*** 0.22*** 0.36* 
 (0.09 - 0.30) (0.10 - 0.49) (0.14 - 0.91) 
Hawaii 0.51 0.29 1.03 
 (0.15 - 1.68) (0.07 - 1.25) (0.13 - 8.00) 
Idaho 2.19 0.69 4.37 
 (0.61 - 7.92) (0.07 - 6.41) (0.93 - 20.51) 
Illinois 1.44*** 0.12*** 0.72 
 (1.24 - 1.68) (0.09 - 0.16) (0.52 - 1.00) 
Iowa 3.31*** 0.11*** 1.34 
 (2.35 - 4.64) (0.04 - 0.30) (0.56 - 3.19) 
Kentucky 1.22** 0.98 4.61*** 
 (1.06 - 1.40) (0.86 - 1.13) (3.68 - 5.76) 
Maine 0.74 0.13*** 0.27** 
 (0.41 - 1.34) (0.06 - 0.29) (0.11 - 0.68) 
Maryland 0.30*** 0.14*** 0.74* 
 (0.26 - 0.36) (0.11 - 0.17) (0.55 - 0.98) 
Massachusetts 1.96*** 0.09*** 1.47 
 (1.60 - 2.40) (0.05 - 0.16) (0.96 - 2.24) 
Michigan 2.58*** 0.50*** 1.08 
 (2.25 - 2.97) (0.42 - 0.59) (0.80 - 1.45) 
Mississippi 0.84 0.39 1.69 
 (0.24 - 2.98) (0.05 - 3.46) (0.35 - 8.06) 
Missouri 0.41* 0.31* 0.73 
 (0.21 - 0.81) (0.13 - 0.76) (0.28 - 1.93) 
Nebraska 0.53 0 4.81* 
 (0.11 - 2.65) (0.00 - .) (1.19 - 19.41) 
Nevada 0.37 0.46 0 
 (0.08 - 1.59) (0.13 - 1.60) (0.00 - .) 
New Hampshire 2.83*** 0.33* 3.79*** 
 (1.61 - 4.98) (0.11 - 0.96) (1.80 - 7.99) 
New Jersey 0.27*** 0.31*** 1.03 
 (0.22 - 0.32) (0.26 - 0.36) (0.79 - 1.35) 
New Mexico 1.05 0.12* 0.67 
 (0.46 - 2.42) (0.02 - 0.87) (0.09 - 5.15) 
New York 0.80*** 0.34*** 1.83*** 
 (0.70 - 0.91) (0.30 - 0.39) (1.46 - 2.30) 
North Carolina 1.14 0.7 0.21*** 
 (0.63 - 2.07) (0.33 - 1.50) (0.09 - 0.53) 





 (2.00 - 2.68) (0.29 - 0.43) (3.80 - 6.20) 
Rhode Island 0.52*** 0.05*** 0.53** 
 (0.42 - 0.63) (0.03 - 0.08) (0.36 - 0.80) 
South Carolina 0.87 2.37 0.63 
 (0.38 - 1.99) (0.97 - 5.78) (0.20 - 1.96) 
South Dakota 2.69 1.58 10.86** 
 (0.53 - 13.64) (0.15 - 16.39) (2.00 - 58.91) 
Tennessee 0 3.39 8.7 
 (0.00 - .) (0.18 - 62.82) (0.45 - 167.87) 
Utah 0.97 1 0.84 
 (0.52 - 1.81) (0.45 - 2.22) (0.33 - 2.17) 
Wyoming 0 0 2.03 
 (0.00 - .) (0.00 - .) (0.16 - 26.26) 
* p<0.05, ** p<0.01, *** p<0.001 




















     
N 231,025 231,025 231,025 
 RRR RRR RRR 
 (95%CI) (95%CI) (95%CI) 
Medicaid expansion        
  Yes  1.10** 2.11*** 1.28*** 
 (1.04 - 1.16) (1.97 - 2.27) (1.22 - 1.35) 
MAT (No= ref)     
   Yes 0.64*** 0.34*** 0.14*** 
  (0.62 - 0.66) (0.33 - 0.35) (0.13 - 0.14) 
Frequency of use (No 
past month use= ref)  
   
   Some use 0.64*** 0.65*** 0.39*** 
 (0.62 - 0.67) (0.63 - 0.68) (0.37 - 0.40) 
   Daily use 0.51*** 0.37*** 0.16*** 
 (0.50 - 0.53) (0.36 - 0.38) (0.16 - 0.17) 
Age (18-29= ref)     
   30-44 1.00 1.00 0.99 
 (0.97 - 1.03) (0.96 - 1.03) (0.96 - 1.01) 
   45-64 1.11*** 0.77*** 0.85*** 
 (1.07 - 1.15) (0.74 - 0.81) (0.82 - 0.88) 
Gender (Female=ref)    
   Male 0.88*** 0.62*** 1.31*** 
 (0.85 - 0.90) (0.60 - 0.64) (1.28 - 1.35) 
Race/ethnicity (non-
Hispanic White=ref) 
   
   Non-Hispanic Black 
1.01 1.36*** 1.19*** 
 (0.96 - 1.07) (1.28 - 1.44) (1.14 - 1.26) 
   Hispanic 0.90*** 1.30*** 1.21*** 
 (0.85 - 0.95) (1.23 - 1.38) (1.15 - 1.27) 
   Other 0.88*** 1.04 0.96 
 (0.82 - 0.95) (0.96 - 1.12) (0.90 - 1.03) 
Education (Less than 
high school= ref)  
   
   Highschool or higher 





 (0.93 - 0.99) (0.78 - 0.83) (0.76 - 0.80) 
Number of arrests (0= 
ref) 
   
   1 0.85*** 1.19*** 2.73*** 
 (0.79 - 0.91) (1.12 - 1.28) (2.60 - 2.86) 
   2 or more 0.83** 0.96 1.10 
 (0.74 - 0.93) (0.83 - 1.11) (1.00 - 1.21) 
Employment status (Not 
employed= ref)  
   
     Employed 
1.32*** 1.14*** 0.93*** 
 (1.28 - 1.36) (1.10 - 1.18) (0.91 - 0.96) 
Comorbidity (No= ref)     
   Yes 1.49*** 0.93*** 0.65*** 
 (1.45 - 1.53) (0.90 - 0.96) (0.63 - 0.67) 
Homeless (No= ref)     
  Yes 1.31*** 1.35*** 0.61*** 
 (1.25 - 1.38) (1.28 - 1.44) (0.58 - 0.65) 
Polysubstance use (no= 
ref)   
   
    One more 
0.99 1.02 0.85*** 
 (0.96 - 1.01) (0.99 - 1.05) (0.83 - 0.88) 
    Two or more 
0.97 1.06** 0.95** 
 (0.94 - 1.01) (1.02 - 1.10) (0.92 - 0.98) 
Unemployment rate    
   Unemployed rate 1.08*** 1.11*** 1.03* 
 (1.05 - 1.11) (1.08 - 1.15) (1.01 - 1.06) 
PMDP (No=ref)    
   Yes 1.24*** 1.44*** 0.84*** 
 (1.13 - 1.36) (1.31 - 1.59) (0.78 - 0.91) 
Year     
2011 0.99 0.77*** 1.04 
 (0.94 - 1.05) (0.72 - 0.82) (0.99 - 1.10) 
2012 0.99 0.82*** 1.19*** 
 (0.92 - 1.06) (0.76 - 0.88) (1.12 - 1.27) 
2013 0.99 0.81*** 1.30*** 
 (0.91 - 1.08) (0.74 - 0.88) (1.20 - 1.41) 
2014 1.13 0.54*** 1.16* 
 (0.99 - 1.29) (0.46 - 0.62) (1.02 - 1.31) 
2015 1.28** 0.66*** 1.13 
 (1.10 - 1.50) (0.56 - 0.79) (0.98 - 1.31) 
2016 1.13 0.72*** 1.18* 
 (0.95 - 1.34) (0.60 - 0.87) (1.01 - 1.38) 
2017 1.13 0.77** 1.04 
 (0.94 - 1.35) (0.64 - 0.94) (0.88 - 1.22) 





Alaska 0.62 0.53* 1.42 
 (0.36 - 1.09) (0.31 - 0.91) (0.83 - 2.45) 
Arizona 0.50** 0.12*** 0.19*** 
 (0.31 - 0.80) (0.08 - 0.20) (0.11 - 0.31) 
Arkansas 0.50** 0.72 0.6 
 (0.29 - 0.85) (0.43 - 1.20) (0.35 - 1.03) 
Colorado 0.56* 0.39*** 0.78 
 (0.34 - 0.91) (0.24 - 0.63) (0.47 - 1.30) 
Connecticut 0.30*** 0.10*** 0.79 
 (0.19 - 0.49) (0.06 - 0.16) (0.47 - 1.31) 
Delaware 1.70* 0.08*** 1.13 
 (1.05 - 2.74) (0.04 - 0.13) (0.68 - 1.87) 
District of Columbia 3.50*** 0.39* 0.66 
 (1.91 - 6.39) (0.18 - 0.86) (0.32 - 1.39) 
Florida 0.39*** 0.60* 0.87 
 (0.24 - 0.63) (0.37 - 0.98) (0.52 - 1.43) 
Hawaii 0.46* 0.42** 1.19 
 (0.23 - 0.94) (0.22 - 0.81) (0.66 - 2.16) 
Idaho 1.93* 1.16 5.95*** 
 (1.07 - 3.49) (0.63 - 2.15) (3.36 - 10.52) 
Illinois 0.87 0.16*** 0.73 
 (0.54 - 1.40) (0.10 - 0.26) (0.44 - 1.21) 
Indiana 0.69 0.31*** 0.75 
 (0.43 - 1.13) (0.19 - 0.51) (0.45 - 1.25) 
Iowa 1.08 0.30*** 0.78 
 (0.66 - 1.77) (0.18 - 0.50) (0.46 - 1.30) 
Kansas 0.99 0.52* 1.17 
 (0.60 - 1.65) (0.31 - 0.88) (0.70 - 1.98) 
Kentucky 0.72 0.57* 1.34 
 (0.45 - 1.15) (0.36 - 0.93) (0.81 - 2.20) 
Louisiana 1.14 1.53 1.33 
 (0.68 - 1.92) (0.92 - 2.54) (0.78 - 2.26) 
Maine 0.87 0.18*** 0.57* 
 (0.54 - 1.40) (0.11 - 0.30) (0.34 - 0.94) 
Maryland 0.41*** 0.30*** 0.84 
 (0.25 - 0.66) (0.19 - 0.49) (0.51 - 1.39) 
Massachusetts 1.25 0.24*** 1.85* 
 (0.77 - 2.03) (0.14 - 0.39) (1.11 - 3.07) 
Michigan 1.67* 0.40*** 0.85 
 (1.04 - 2.68) (0.25 - 0.65) (0.52 - 1.41) 
Mississippi 0.92 0.23*** 0.68 
 (0.55 - 1.52) (0.13 - 0.41) (0.40 - 1.16) 
Missouri 0.39*** 0.44** 0.84 
 (0.23 - 0.65) (0.26 - 0.73) (0.50 - 1.40) 
Montana 1.2 0.11*** 1.39 
 (0.72 - 2.01) (0.06 - 0.22) (0.82 - 2.36) 
Nebraska 1.02 0.49* 1.11 
 (0.54 - 1.92) (0.24 - 0.97) (0.61 - 2.02) 





 (0.13 - 1.34) (0.11 - 0.94) (0.09 - 1.30) 
New Hampshire 1.79* 0.14*** 1.44 
 (1.08 - 2.96) (0.08 - 0.26) (0.85 - 2.43) 
New Jersey 0.24*** 0.42*** 1.14 
 (0.15 - 0.39) (0.26 - 0.68) (0.69 - 1.89) 
New Mexico 0.74 0.25* 0.53 
 (0.29 - 1.90) (0.08 - 0.80) (0.15 - 1.83) 
New York 0.8 0.42*** 0.55* 
 (0.50 - 1.28) (0.26 - 0.67) (0.34 - 0.91) 
North Carolina 0.97 0.29*** 0.65 
 (0.61 - 1.55) (0.18 - 0.46) (0.40 - 1.07) 
North Dakota 1.92 0.33 2.11 
 (0.75 - 4.96) (0.09 - 1.28) (0.89 - 5.03) 
Ohio 1.01 0.42*** 1.6 
 (0.63 - 1.63) (0.26 - 0.68) (0.97 - 2.64) 
Oklahoma 0.29*** 0.76 1.19 
 (0.17 - 0.49) (0.46 - 1.25) (0.71 - 1.98) 
Pennsylvania 4.88*** 1.18 2.50*** 
 (2.96 - 8.03) (0.70 - 1.99) (1.47 - 4.25) 
Rhode Island 0.53* 0.09*** 0.6 
 (0.33 - 0.86) (0.05 - 0.15) (0.36 - 1.00) 
South Carolina 0.67 0.79 0.62 
 (0.41 - 1.10) (0.48 - 1.29) (0.37 - 1.03) 
South Dakota 1.31 0.76 1.62 
 (0.65 - 2.61) (0.36 - 1.62) (0.85 - 3.10) 
Tennessee 1.32 0.39*** 3.20*** 
 (0.79 - 2.20) (0.23 - 0.68) (1.91 - 5.38) 
Utah 1.07 0.74 2.58*** 
 (0.66 - 1.73) (0.45 - 1.22) (1.55 - 4.28) 
Washington 0.93 1.08 1.07 
 (0.58 - 1.50) (0.67 - 1.75) (0.65 - 1.77) 
Wyoming 0.99 0.40* 0.74 
 (0.48 - 2.00) (0.17 - 0.93) (0.37 - 1.49) 
* p<0.05, ** p<0.01, *** p<0.001 
Reference group for multinomial regression is self-referral. Relative Risk Ratio = RRR. Confidence 


























    
N 225,272 225,272 225,272 
 AOR AOR AOR 
 (95%CI) (95%CI) (95%CI) 
    
Expansion 0.92 1.04 1.07 
    (0.57 - 1.48) (0.64 - 1.68) (0.64 - 1.76) 
Post expansion  1.09 0.64*** 1.00 
    (0.91 - 1.31) (0.53 - 0.78) (0.84 - 1.18) 
Expansion * Post expansion  1.11*** 2.25*** 1.29*** 
    (1.04 - 1.17) (2.09 - 2.41) (1.23 - 1.37) 
MAT (No= ref)     
   Yes 0.65*** 0.33*** 0.14*** 
 (0.63 - 0.67) (0.32 - 0.35) (0.13 - 0.14) 
Frequency of use     
   Some use 0.64*** 0.66*** 0.38*** 
 (0.62 - 0.67) (0.63 - 0.69) (0.37 - 0.40) 
   Daily use  0.51*** 0.37*** 0.16*** 
 (0.50 - 0.53) (0.36 - 0.39) (0.16 - 0.17) 
Age (18-29= ref)     
   30-44 1.00 0.99 0.99 
 (0.97 - 1.03) (0.96 - 1.02) (0.96 - 1.01) 
   45-64 1.11*** 0.77*** 0.84*** 
 (1.07 - 1.15) (0.74 - 0.81) (0.81 - 0.88) 
Gender    
   Male  0.88*** 0.62*** 1.31*** 
 (0.86 - 0.90) (0.60 - 0.63) (1.28 - 1.35) 
Race/ethnicity     
   Non-Hispanic Black 1.02 1.36*** 1.19*** 
 (0.97 - 1.07) (1.28 - 1.45) (1.13 - 1.26) 
   Hispanic  0.90*** 1.32*** 1.21*** 
 (0.85 - 0.95) (1.24 - 1.40) (1.15 - 1.27) 
   Other 0.89** 1.04 0.98 
 (0.82 - 0.96) (0.96 - 1.13) (0.92 - 1.06) 
Education     
   Highschool or higher 0.96* 0.81*** 0.78*** 
 (0.94 - 0.99) (0.78 - 0.84) (0.76 - 0.80) 
Number of arrests (0=ref)    
   1 0.83*** 1.20*** 2.73*** 
 (0.78 - 0.89) (1.12 - 1.28) (2.60 - 2.87) 
   2 or more 0.85** 0.96 1.09 
 (0.76 - 0.95) (0.83 - 1.11) (0.99 - 1.21) 
Employment status     





 (1.29 - 1.37) (1.10 - 1.18) (0.91 - 0.96) 
Comorbidity    
   Yes  1.51*** 0.92*** 0.65*** 
 (1.47 - 1.55) (0.89 - 0.95) (0.63 - 0.67) 
Homeless    
  Yes 1.33*** 1.35*** 0.61*** 
 (1.27 - 1.40) (1.27 - 1.43) (0.57 - 0.65) 
Polysubstance use     
    One more 0.99 1.01 0.85*** 
 (0.97 - 1.02) (0.98 - 1.05) (0.82 - 0.87) 
    Two or more 0.98 1.05** 0.94*** 
 (0.95 - 1.02) (1.02 - 1.09) (0.91 - 0.97) 
Unemployment rate     
   Unemployed rate 1.08*** 1.09*** 1.03* 
 (1.05 - 1.11) (1.06 - 1.12) (1.00 - 1.06) 
PMDP ( No= ref)     
   Yes 1.24*** 1.50*** 0.85*** 
 (1.13 - 1.36) (1.36 - 1.65) (0.78 - 0.92) 
Year     
2011 0.99 0.75*** 1.03 
 (0.94 - 1.05) (0.70 - 0.80) (0.98 - 1.09) 
2012 0.97 0.77*** 1.18*** 
 (0.90 - 1.04) (0.71 - 0.83) (1.10 - 1.26) 
2013 0.98 0.74*** 1.28*** 
 (0.90 - 1.07) (0.68 - 0.82) (1.18 - 1.39) 
2014 1 0.70*** 1.12*** 
 (0.93 - 1.08) (0.65 - 0.76) (1.05 - 1.20) 
2015 1.14*** 0.86*** 1.10*** 
 (1.08 - 1.21) (0.81 - 0.91) (1.04 - 1.15) 
2016 1 0.94* 1.14*** 
 (0.95 - 1.05) (0.89 - 1.00) (1.09 - 1.20) 
State    
Arizona 0.54*** 0.11*** 0.17*** 
 (0.49 - 0.60) (0.10 - 0.12) (0.16 - 0.19) 
Arkansas 0.54*** 0.65*** 0.56*** 
 (0.42 - 0.70) (0.53 - 0.79) (0.44 - 0.70) 
Colorado 0.60*** 0.34*** 0.73*** 
 (0.52 - 0.69) (0.30 - 0.39) (0.64 - 0.83) 
Connecticut 0.33*** 0.09*** 0.73*** 
 (0.28 - 0.38) (0.07 - 0.11) (0.65 - 0.83) 
Delaware 1.84*** 0.07*** 1.05 
 (1.63 - 2.07) (0.05 - 0.09) (0.94 - 1.19) 
District of Columbia 3.81*** 0.37** 0.62 
 (2.58 - 5.62) (0.20 - 0.70) (0.36 - 1.08) 
Florida 0.39*** 0.60* 0.87 
 (0.24 - 0.63) (0.37 - 0.97) (0.52 - 1.43) 
Hawaii 0.50* 0.37*** 1.09 
 (0.29 - 0.85) (0.24 - 0.57) (0.79 - 1.52) 





 (1.07 - 3.49) (0.60 - 2.05) (3.34 - 10.44) 
Illinois 0.94 0.15*** 0.69*** 
 (0.84 - 1.05) (0.13 - 0.17) (0.62 - 0.77) 
Iowa 1.16 0.26*** 0.72*** 
 (0.99 - 1.37) (0.21 - 0.32) (0.61 - 0.85) 
Kansas 0.99 0.48** 1.16 
 (0.60 - 1.64) (0.29 - 0.81) (0.69 - 1.96) 
Kentucky 0.78*** 0.53*** 1.25*** 
 (0.71 - 0.85) (0.49 - 0.57) (1.15 - 1.36) 
Maine 0.87 0.17*** 0.56* 
 (0.54 - 1.40) (0.10 - 0.28) (0.34 - 0.93) 
Maryland 0.44*** 0.28*** 0.78*** 
 (0.39 - 0.50) (0.24 - 0.31) (0.70 - 0.87) 
Massachusetts 1.35*** 0.21*** 1.71*** 
 (1.18 - 1.55) (0.17 - 0.26) (1.50 - 1.95) 
Michigan 1.82*** 0.37*** 0.80*** 
 (1.65 - 2.01) (0.33 - 0.41) (0.72 - 0.89) 
Mississippi 0.93 0.24*** 0.69 
 (0.56 - 1.55) (0.13 - 0.41) (0.41 - 1.17) 
Missouri 0.39*** 0.44** 0.83 
 (0.23 - 0.65) (0.26 - 0.73) (0.50 - 1.40) 
Nebraska 1.01 0.44* 1.09 
 (0.53 - 1.91) (0.22 - 0.88) (0.60 - 1.99) 
Nevada 0.46 0.30* 0.32 
 (0.16 - 1.31) (0.11 - 0.79) (0.09 - 1.12) 
New Hampshire 1.94*** 0.13*** 1.33** 
 (1.60 - 2.35) (0.09 - 0.18) (1.11 - 1.58) 
New Jersey 0.26*** 0.39*** 1.07 
 (0.23 - 0.30) (0.35 - 0.43) (0.96 - 1.19) 
New Mexico 0.79 0.23** 0.49 
 (0.35 - 1.80) (0.08 - 0.65) (0.16 - 1.52) 
New York 0.86** 0.38*** 0.51*** 
 (0.79 - 0.94) (0.35 - 0.41) (0.47 - 0.56) 
North Carolina 0.98 0.28*** 0.65 
 (0.61 - 1.56) (0.17 - 0.45) (0.40 - 1.06) 
North Dakota 2.06 0.27* 1.91 
 (0.90 - 4.69) (0.08 - 0.95) (0.94 - 3.90) 
Ohio 1.1 0.38*** 1.49*** 
 (1.00 - 1.22) (0.35 - 0.42) (1.36 - 1.64) 
Oklahoma 0.29*** 0.71 1.18 
 (0.17 - 0.49) (0.43 - 1.18) (0.70 - 1.97) 
Pennsylvania 0.57*** 0.08*** 0.56*** 
 (0.49 - 0.67) (0.06 - 0.11) (0.47 - 0.66) 
Rhode Island 0.67 0.77 0.62 
 (0.41 - 1.11) (0.47 - 1.25) (0.37 - 1.03) 
South Carolina 1.3 0.69 1.59 
 (0.65 - 2.60) (0.33 - 1.48) (0.83 - 3.04) 
South Dakota 1.33 0.38*** 3.20*** 





Utah 1.06 0.68 2.55*** 
 (0.65 - 1.72) (0.42 - 1.12) (1.53 - 4.23) 
Wyoming 1 0.39* 0.74 
Arizona (0.49 - 2.03) (0.17 - 0.91) (0.37 - 1.48) 
* p<0.05, ** p<0.01, *** p<0.001 


















































    
N 225,272 225,272 225,272 
 AOR AOR AOR 
 (95%CI) (95%CI) (95%CI) 
    
Expansion 0.84 0.91 1.03 
    (0.52 - 1.35) (0.57 - 1.48) (0.62 - 1.71) 
Post expansion year 2014  0.91* 0.44*** 1.16*** 
    (0.84 - 0.98) (0.39 - 0.49) (1.07 - 1.26) 
Expansion * Post expansion 
Year 0 (or year 2014)   
1.03 1.78*** 1.04 
    (0.94 - 1.13) (1.57 - 2.01) (0.96 - 1.13) 
Post expansion year 1 1.08 1.09 0.88* 
 (0.98 - 1.20) (0.94 - 1.27) (0.80 - 0.97) 
Expansion* Post expansion year 1 0.98 1.04 1.12 
 (0.87 - 1.10) (0.88 - 1.23) (1.00 - 1.25) 
Post expansion year 2 0.74*** 0.87* 1.00 
 (0.67 - 0.82) (0.76 - 1.00) (0.91 - 1.10) 
Expansion* Post expansion year 2 1.19** 1.26** 1.02 
 (1.06 - 1.33) (1.08 - 1.48) (0.91 - 1.14) 
Post expansion year 3 0.90** 0.83** 0.67*** 
 (0.83 - 0.97) (0.74 - 0.93) (0.62 - 0.72) 
Expansion* Post expansion year 3 1.15** 1.35*** 1.50*** 
 (1.04 - 1.27) (1.19 - 1.54) (1.37 - 1.65) 
MAT (No= ref)     
   Yes 0.65*** 0.33*** 0.14*** 
 (0.63 - 0.67) (0.32 - 0.34) (0.13 - 0.14) 
Frequency of use     
   Some use 0.64*** 0.66*** 0.38*** 
 (0.62 - 0.67) (0.63 - 0.69) (0.37 - 0.40) 
   Daily use  0.51*** 0.38*** 0.16*** 
 (0.50 - 0.53) (0.36 - 0.39) (0.16 - 0.17) 
Age (18-29= ref)     
   30-44 1.00 0.99 0.99 
 (0.97 - 1.03) (0.96 - 1.03) (0.96 - 1.01) 
   45-64 1.11*** 0.77*** 0.84*** 
 (1.07 - 1.15) (0.74 - 0.81) (0.81 - 0.88) 
Gender    
   Male  0.88*** 0.62*** 1.31*** 
 (0.85 - 0.90) (0.60 - 0.63) (1.28 - 1.35) 
Race/ethnicity     
   Non-Hispanic Black 1.02 1.37*** 1.20*** 





   Hispanic  0.89*** 1.31*** 1.21*** 
 (0.84 - 0.94) (1.24 - 1.39) (1.14 - 1.27) 
   Other 0.87*** 1.02 0.97 
 (0.81 - 0.94) (0.95 - 1.11) (0.91 - 1.04) 
Education     
   Highschool or higher 0.96* 0.81*** 0.78*** 
 (0.94 - 0.99) (0.79 - 0.84) (0.76 - 0.80) 
Number of arrests (0=ref)    
   1 0.83*** 1.20*** 2.74*** 
 (0.78 - 0.89) (1.12 - 1.28) (2.61 - 2.87) 
   2 or more 0.86* 0.97 1.09 
 (0.77 - 0.97) (0.83 - 1.12) (0.99 - 1.20) 
Employment status     
     Employed 1.33*** 1.14*** 0.93*** 
 (1.29 - 1.37) (1.10 - 1.18) (0.91 - 0.96) 
Comorbidity    
   Yes  1.50*** 0.91*** 0.65*** 
 (1.46 - 1.54) (0.89 - 0.94) (0.63 - 0.67) 
Homeless    
  Yes 1.33*** 1.35*** 0.61*** 
 (1.27 - 1.41) (1.27 - 1.43) (0.57 - 0.65) 
Polysubstance use     
    One more 1.00 1.02 0.85*** 
 (0.97 - 1.03) (0.99 - 1.06) (0.83 - 0.88) 
    Two or more 0.99 1.07*** 0.95** 
 (0.96 - 1.03) (1.03 - 1.11) (0.92 - 0.98) 
    
Year     
2011 0.96 0.75*** 0.99 
 (0.91 - 1.01) (0.71 - 0.80) (0.95 - 1.05) 
2012 0.89*** 0.72*** 1.11*** 
 (0.84 - 0.93) (0.68 - 0.77) (1.05 - 1.16) 
2013 0.85*** 0.67*** 1.17*** 
 (0.81 – 0.90) (0.63 – 0.71) (1.12 – 1.23) 
State    
Arizona 0.56*** 0.12*** 0.17*** 
 (0.51 - 0.62) (0.11 - 0.13) (0.15 - 0.19) 
Arkansas 0.47*** 0.54*** 0.56*** 
 (0.36 - 0.61) (0.44 - 0.65) (0.45 - 0.71) 
Colorado 0.55*** 0.31*** 0.68*** 
 (0.48 - 0.64) (0.28 - 0.36) (0.60 - 0.77) 
Connecticut 0.33*** 0.09*** 0.71*** 
 (0.28 - 0.39) (0.07 - 0.11) (0.62 - 0.80) 
Delaware 1.63*** 0.06*** 1.04 
 (1.45 - 1.84) (0.05 - 0.08) (0.92 - 1.16) 
District of Columbia 3.81*** 0.36** 0.66 
 (2.60 - 5.60) (0.19 - 0.68) (0.38 - 1.13) 
Florida 0.36*** 0.51** 0.86 





Hawaii 0.42** 0.31*** 0.99 
 (0.25 - 0.73) (0.20 - 0.48) (0.72 - 1.38) 
Idaho 1.66 0.9 5.33*** 
 (0.92 - 2.99) (0.49 - 1.67) (3.02 - 9.41) 
Illinois 1 0.16*** 0.67*** 
 (0.89 - 1.11) (0.14 - 0.18) (0.60 - 0.74) 
Iowa 0.98 0.22*** 0.65*** 
 (0.84 - 1.14) (0.18 - 0.26) (0.55 - 0.75) 
Kansas 0.79 0.35*** 1.09 
 (0.48 - 1.30) (0.21 - 0.59) (0.65 - 1.83) 
Kentucky 0.80*** 0.55*** 1.21*** 
 (0.73 - 0.87) (0.51 - 0.59) (1.11 - 1.32) 
Maine 0.74 0.14*** 0.50** 
 (0.46 - 1.20) (0.08 - 0.23) (0.30 - 0.83) 
Maryland 0.37*** 0.21*** 0.80*** 
 (0.33 - 0.42) (0.19 - 0.24) (0.72 - 0.89) 
Massachusetts 1.27*** 0.20*** 1.62*** 
 (1.11 - 1.45) (0.16 - 0.24) (1.43 - 1.84) 
Michigan 1.96*** 0.41*** 0.79*** 
 (1.78 - 2.15) (0.37 - 0.45) (0.71 - 0.87) 
Mississippi 0.97 0.25*** 0.69 
 (0.58 - 1.62) (0.14 - 0.43) (0.41 - 1.17) 
Missouri 0.28*** 0.25*** 0.9 
 (0.17 - 0.47) (0.15 - 0.42) (0.54 - 1.50) 
Nebraska 0.73 0.29*** 0.93 
 (0.39 - 1.37) (0.14 - 0.57) (0.51 - 1.69) 
Nevada 0.5 0.33* 0.32 
 (0.17 - 1.44) (0.12 - 0.87) (0.09 - 1.12) 
New Hampshire 1.56*** 0.10*** 1.25** 
 (1.31 - 1.87) (0.07 - 0.14) (1.06 - 1.48) 
New Jersey 0.26*** 0.38*** 1.04 
 (0.23 - 0.30) (0.34 - 0.42) (0.94 - 1.16) 
New Mexico 0.76 0.22** 0.45 
 (0.34 - 1.73) (0.08 - 0.64) (0.14 - 1.41) 
New York 0.86*** 0.38*** 0.50*** 
 (0.79 - 0.94) (0.35 - 0.41) (0.46 - 0.54) 
North Carolina 0.98 0.28*** 0.62 
 (0.61 - 1.56) (0.17 - 0.45) (0.38 - 1.02) 
North Dakota 1.44 0.19** 1.6 
 (0.64 - 3.23) (0.05 - 0.65) (0.80 - 3.22) 
Ohio 1.11* 0.40*** 1.44*** 
 (1.00 - 1.23) (0.36 - 0.44) (1.31 - 1.58) 
Oklahoma 0.24*** 0.58* 1.06 
 (0.14 - 0.41) (0.35 - 0.95) (0.63 - 1.76) 
Rhode Island 0.63*** 0.09*** 0.56*** 
 (0.55 - 0.73) (0.07 - 0.12) (0.47 - 0.66) 
South Carolina 0.67 0.76 0.59* 
 (0.41 - 1.10) (0.46 - 1.24) (0.35 - 0.98) 





 (0.48 - 1.90) (0.21 - 0.97) (0.73 - 2.64) 
Tennessee 1.25 0.34*** 2.97*** 
 (0.75 - 2.08) (0.20 - 0.59) (1.77 - 4.98) 
Utah 0.85 0.52** 2.22** 
 (0.52 - 1.37) (0.32 - 0.85) (1.34 - 3.67) 
Wyoming 0.93 0.36* 0.7 
 (0.46 - 1.89) (0.16 - 0.83) (0.35 - 1.40) 
* p<0.05, ** p<0.01, *** p<0.001 









Table 4-A10. Sensitivity analysis that added Waiver 1115 Demonstrations: 2WFE model for non-intensive 







     
N 231,025 231,025 231,025 
 RRR RRR RRR 
 (95%CI) (95%CI) (95%CI) 
Medicaid expansion        
  Yes  1.17*** 2.26*** 1.31*** 
 (1.11 - 1.24) (2.11 - 2.42) (1.24 - 1.38) 
Waiver 1115 
Demonstrations 
   
   Yes  1.04 1.21* 1.03 
 (0.88 - 1.23) (1.04 - 1.41) (0.89 - 1.18) 
MAT (No= ref)     
   Yes 0.64*** 0.34*** 0.14*** 
  (0.62 - 0.66) (0.33 - 0.35) (0.13 - 0.14) 
Frequency of use (No 
past month use= ref)  
   
   Some use 0.64*** 0.65*** 0.39*** 
 (0.62 - 0.67) (0.63 - 0.68) (0.37 - 0.40) 
   Daily use 0.51*** 0.37*** 0.16*** 
 (0.50 - 0.53) (0.36 - 0.38) (0.16 - 0.17) 
Age (18-29= ref)     
   30-44 1.00 1.00 0.99 
 (0.97 - 1.03) (0.97 - 1.03) (0.96 - 1.01) 
   45-64 1.11*** 0.77*** 0.85*** 
 (1.07 - 1.15) (0.74 - 0.81) (0.82 - 0.88) 
Gender (Female=ref)    
   Male 0.88*** 0.62*** 1.31*** 
 (0.85 - 0.90) (0.60 - 0.64) (1.28 - 1.35) 
Race/ethnicity (non-
Hispanic White=ref) 
   
   Non-Hispanic Black 1.01 1.35*** 1.19*** 
 (0.96 - 1.07) (1.27 - 1.44) (1.13 - 1.26) 
   Hispanic 0.89*** 1.30*** 1.21*** 
 (0.85 - 0.95) (1.22 - 1.37) (1.15 - 1.27) 
   Other 0.87*** 1.03 0.96 
 (0.81 - 0.94) (0.95 - 1.11) (0.90 - 1.03) 
Education (Less than 
high school= ref)  
   





 (0.93 - 0.99) (0.78 - 0.83) (0.76 - 0.80) 
Number of arrests (0= 
ref) 
   
   1 0.85*** 1.19*** 2.73*** 
 (0.79 - 0.91) (1.11 - 1.27) (2.60 - 2.86) 
   2 or more 0.85** 0.97 1.09 
 (0.76 - 0.95) (0.84 - 1.12) (0.99 - 1.20) 
Employment status 
(Not employed= ref)  
   
     Employed 
1.32*** 1.14*** 0.93*** 
 (1.28 - 1.36) (1.10 - 1.18) (0.91 - 0.96) 
Comorbidity (No= ref)     
   Yes 1.49*** 0.92*** 0.65*** 
 (1.45 - 1.53) (0.89 - 0.95) (0.63 - 0.67) 
Homeless (No= ref)     
  Yes 1.31*** 1.35*** 0.61*** 
 (1.25 - 1.38) (1.28 - 1.43) (0.58 - 0.65) 
Polysubstance use 
(no= ref)   
   
    One more 0.99 1.02 0.85*** 
 (0.96 - 1.02) (0.99 - 1.06) (0.83 - 0.88) 
    Two or more 0.98 1.07*** 0.95** 
 (0.95 - 1.01) (1.03 - 1.11) (0.92 - 0.98) 
Year     
2011 0.96 0.76*** 1 
 (0.91 - 1.01) (0.72 - 0.80) (0.95 - 1.05) 
2012 0.90*** 0.73*** 1.11*** 
 (0.85 - 0.95) (0.69 - 0.77) (1.06 - 1.16) 
2013 0.86*** 0.68*** 1.18*** 
 (0.81 - 0.90) (0.64 - 0.72) (1.12 - 1.23) 
2014 0.83*** 0.37*** 0.98 
 (0.78 - 0.88) (0.34 - 0.40) (0.93 - 1.04) 
2015 0.88*** 0.41*** 0.93* 
 (0.82 - 0.93) (0.38 - 0.44) (0.88 - 0.99) 
2016 0.74*** 0.43*** 0.96 
 (0.70 - 0.79) (0.40 - 0.46) (0.90 - 1.02) 
2017 0.71*** 0.44*** 0.83*** 
 (0.67 - 0.75) (0.41 - 0.47) (0.78 - 0.87) 
State    
Alaska 0.62 0.54* 1.44 
 (0.35 - 1.08) (0.31 - 0.92) (0.84 - 2.48) 
Arizona 0.48** 0.12*** 0.19*** 
 (0.30 - 0.77) (0.07 - 0.19) (0.11 - 0.31) 
Arkansas 0.39*** 0.48** 0.6 





Colorado 0.47** 0.32*** 0.74 
 (0.29 - 0.77) (0.19 - 0.52) (0.44 - 1.22) 
Connecticut 0.29*** 0.09*** 0.78 
 (0.18 - 0.47) (0.05 - 0.15) (0.47 - 1.29) 
Delaware 1.34 0.05*** 1.09 
 (0.81 - 2.22) (0.03 - 0.09) (0.65 - 1.84) 
District of Columbia 3.26*** 0.37* 0.71 
 (1.79 - 5.95) (0.17 - 0.80) (0.34 - 1.49) 
Florida 0.37*** 0.55* 0.91 
 (0.23 - 0.60) (0.34 - 0.90) (0.55 - 1.50) 
Hawaii 0.36** 0.31*** 1.08 
 (0.18 - 0.74) (0.16 - 0.59) (0.60 - 1.95) 
Idaho 1.71 0.99 5.64*** 
 (0.95 - 3.07) (0.53 - 1.83) (3.19 - 9.96) 
Illinois 0.86 0.16*** 0.73 
 (0.54 - 1.39) (0.10 - 0.26) (0.44 - 1.21) 
Indiana 0.65 0.29*** 0.73 
 (0.40 - 1.06) (0.18 - 0.48) (0.44 - 1.22) 
Iowa 0.84 0.22*** 0.7 
 (0.52 - 1.36) (0.13 - 0.36) (0.42 - 1.17) 
Kansas 0.79 0.37*** 1.11 
 (0.48 - 1.30) (0.22 - 0.62) (0.66 - 1.87) 
Kentucky 0.68 0.55* 1.32 
 (0.43 - 1.09) (0.34 - 0.88) (0.80 - 2.16) 
 1 1.3 1.25 
 (0.60 - 1.68) (0.78 - 2.15) (0.74 - 2.12) 
Maine 0.77 0.15*** 0.54* 
 (0.48 - 1.24) (0.09 - 0.25) (0.32 - 0.89) 
Maryland 0.30*** 0.17*** 0.83 
 (0.18 - 0.50) (0.10 - 0.29) (0.50 - 1.40) 
Massachusetts 1.04 0.16*** 1.70* 
 (0.62 - 1.73) (0.10 - 0.28) (1.01 - 2.88) 
Michigan 1.68* 0.41*** 0.86 
 (1.05 - 2.69) (0.26 - 0.67) (0.52 - 1.42) 
Mississippi 0.97 0.25*** 0.7 
 (0.58 - 1.61) (0.14 - 0.44) (0.41 - 1.19) 
Missouri 0.29*** 0.28*** 0.96 
 (0.17 - 0.48) (0.17 - 0.46) (0.58 - 1.59) 
Montana 0.92 0.08*** 1.34 
 (0.55 - 1.53) (0.04 - 0.15) (0.79 - 2.26) 
Nebraska 0.75 0.31*** 0.99 
 (0.40 - 1.40) (0.16 - 0.62) (0.55 - 1.80) 
Nevada 0.43 0.33* 0.35 
 (0.14 - 1.35) (0.11 - 0.97) (0.09 - 1.32) 
New Hampshire 1.34 0.10*** 1.37 
 (0.81 - 2.20) (0.06 - 0.18) (0.81 - 2.29) 
New Jersey 0.22*** 0.33*** 1.13 
 (0.13 - 0.36) (0.20 - 0.55) (0.68 - 1.88) 





 (0.26 - 1.69) (0.07 - 0.71) (0.14 - 1.71) 
New York 0.74 0.38*** 0.53* 
 (0.46 - 1.18) (0.24 - 0.62) (0.33 - 0.88) 
North Carolina 0.98 0.30*** 0.65 
 (0.61 - 1.57) (0.18 - 0.47) (0.40 - 1.07) 
North Dakota 1.22 0.19* 1.73 
 (0.48 - 3.10) (0.05 - 0.71) (0.74 - 4.06) 
Ohio 0.94 0.39*** 1.55 
 (0.59 - 1.51) (0.24 - 0.64) (0.94 - 2.56) 
Oklahoma 0.25*** 0.62 1.11 
 (0.14 - 0.42) (0.38 - 1.02) (0.67 - 1.86) 
Pennsylvania 4.50*** 1.02 2.48*** 
 (2.72 - 7.44) (0.60 - 1.72) (1.46 - 4.22) 
Rhode Island 0.52* 0.08*** 0.59 
 (0.31 - 0.87) (0.04 - 0.13) (0.35 - 1.01) 
South Carolina 0.67 0.82 0.62 
 (0.41 - 1.11) (0.50 - 1.33) (0.37 - 1.03) 
South Dakota 0.97 0.5 1.48 
 (0.49 - 1.94) (0.23 - 1.05) (0.78 - 2.82) 
Tennessee 1.27 0.37*** 3.14*** 
 (0.76 - 2.12) (0.22 - 0.65) (1.87 - 5.28) 
Utah 0.88 0.57* 2.37*** 
 (0.54 - 1.42) (0.35 - 0.93) (1.43 - 3.91) 
Washington 0.85 0.97 1.06 
 (0.53 - 1.37) (0.60 - 1.57) (0.64 - 1.75) 
Wyoming  0.94 0.38* 
  (0.46 - 1.92) (0.17 - 0.88) 
* p<0.05, ** p<0.01, *** p<0.001 
Reference group for multinomial regression is self-referral. Adjusted Odds Ratio = AOR. 























Table 4-A11. Sensitivity analysis that added Waiver 1115 Demonstrations: DID model for non-intensive 








    
N 225,272 225,272 225,272 
 RRR RRR RRR 
 (95%CI) (95%CI) (95%CI) 
    
Expansion 0.84 0.94 1.06 
    (0.52 - 1.36) (0.58 - 1.52) (0.64 - 1.75) 
Post expansion  0.70*** 0.42*** 0.82*** 
    (0.66 - 0.74) (0.39 - 0.45) (0.77 - 0.87) 
Expansion * Post expansion  1.18*** 2.38*** 1.31*** 
    (1.12 - 1.24) (2.22 - 2.54) (1.25 - 1.38) 
Waiver 1115 Demonstrations    
   Yes 1.21 1.16 1.02 
 (0.97 - 1.50) (0.98 - 1.36) (0.88 - 1.19) 
MAT (No= ref)     
   Yes 0.65*** 0.33*** 0.14*** 
 (0.63 - 0.67) (0.32 - 0.35) (0.13 - 0.14) 
Frequency of use     
   Some use 0.64*** 0.66*** 0.38*** 
 (0.62 - 0.67) (0.63 - 0.69) (0.37 - 0.40) 
   Daily use  0.51*** 0.38*** 0.16*** 
 (0.50 - 0.53) (0.36 - 0.39) (0.16 - 0.17) 
Age (18-29= ref)     
   30-44 1.00 0.99 0.99 
 (0.97 - 1.03) (0.96 - 1.03) (0.96 - 1.01) 
   45-64 1.11*** 0.77*** 0.84*** 
 (1.07 - 1.15) (0.74 - 0.81) (0.81 - 0.88) 
Gender    
   Male  0.88*** 0.62*** 1.31*** 
 (0.85 - 0.90) (0.60 - 0.63) (1.28 - 1.35) 
Race/ethnicity     
   Non-Hispanic Black 1.02 1.36*** 1.19*** 
 (0.96 - 1.07) (1.28 - 1.45) (1.13 - 1.26) 
   Hispanic  0.89*** 1.31*** 1.21*** 
 (0.84 - 0.94) (1.24 - 1.39) (1.15 - 1.27) 
   Other 0.88*** 1.04 0.98 
 (0.82 - 0.95) (0.96 - 1.12) (0.92 - 1.06) 
Education     
   Highschool or higher 0.96* 0.81*** 0.78*** 
 (0.94 - 0.99) (0.78 - 0.84) (0.76 - 0.80) 
Number of arrests (0=ref)    
   1 0.83*** 1.20*** 2.73*** 
 (0.78 - 0.89) (1.12 - 1.28) (2.60 - 2.87) 





 (0.77 - 0.97) (0.83 - 1.12) (0.98 - 1.20) 
Employment status     
     Employed 1.33*** 1.14*** 0.93*** 
 (1.29 - 1.37) (1.10 - 1.18) (0.91 - 0.96) 
Comorbidity    
   Yes  1.50*** 0.91*** 0.65*** 
 (1.46 - 1.54) (0.89 - 0.94) (0.63 - 0.67) 
Homeless    
  Yes 1.33*** 1.35*** 0.61*** 
 (1.26 - 1.40) (1.27 - 1.43) (0.57 - 0.65) 
Polysubstance use     
    One more 1.00 1.02 0.85*** 
 (0.97 - 1.03) (0.98 - 1.05) (0.82 - 0.87) 
    Two or more 0.99 1.06** 0.94*** 
 (0.95 - 1.02) (1.02 - 1.10) (0.91 - 0.97) 
Year     
2011 0.95 0.75*** 0.99 
 (0.91 - 1.00) (0.71 - 0.80) (0.95 - 1.04) 
2012 0.88*** 0.72*** 1.10*** 
 (0.84 - 0.93) (0.68 - 0.76) (1.05 - 1.16) 
2013 0.85*** 0.66*** 1.17*** 
 (0.81 - 0.90) (0.63 - 0.70) (1.11 - 1.23) 
2014 1.17*** 0.83*** 1.19*** 
 (1.11 - 1.22) (0.78 - 0.88) (1.13 - 1.24) 
2015 1.23*** 0.93** 1.13*** 
 (1.17 - 1.29) (0.88 - 0.98) (1.07 - 1.18) 
2016 1.04 0.98 1.16*** 
 (0.99 - 1.09) (0.93 - 1.04) (1.11 - 1.21) 
State     
Arizona 0.57*** 0.12*** 0.17*** 
 (0.52 - 0.63) (0.11 - 0.13) (0.16 - 0.19) 
Arkansas 0.43*** 0.50*** 0.56*** 
 (0.32 - 0.57) (0.40 - 0.62) (0.44 - 0.72) 
Colorado 0.56*** 0.32*** 0.69*** 
 (0.49 - 0.65) (0.28 - 0.37) (0.61 - 0.78) 
Connecticut 0.34*** 0.09*** 0.73*** 
 (0.29 - 0.40) (0.08 - 0.11) (0.64 - 0.83) 
Delaware 1.37* 0.05*** 1.03 
 (1.07 - 1.75) (0.04 - 0.07) (0.85 - 1.25) 
District of Columbia  3.88*** 0.37** 0.67 
 (2.64 - 5.69) (0.20 - 0.69) (0.39 - 1.16) 
Florida 0.37*** 0.54* 0.91 
 (0.23 - 0.60) (0.33 - 0.87) (0.55 - 1.50) 
Hawaii 0.43** 0.32*** 1.01 
 (0.25 - 0.73) (0.21 - 0.49) (0.73 - 1.40) 
Idaho 1.71 0.97 5.64*** 
 (0.95 - 3.08) (0.53 - 1.80) (3.20 - 9.97) 
Illinois 1.02 0.16*** 0.69*** 





Iowa 0.99 0.22*** 0.66*** 
 (0.85 - 1.16) (0.18 - 0.27) (0.56 - 0.77) 
Kansas 0.79 0.36*** 1.12 
 (0.48 - 1.30) (0.22 - 0.60) (0.67 - 1.87) 
Kentucky 0.81*** 0.56*** 1.24*** 
 (0.74 - 0.89) (0.52 - 0.61) (1.14 - 1.34) 
Maine 0.77 0.15*** 0.53* 
 (0.48 - 1.24) (0.09 - 0.25) (0.32 - 0.89) 
Maryland 0.31*** 0.19*** 0.79* 
 (0.24 - 0.39) (0.15 - 0.23) (0.65 - 0.95) 
Massachusetts 1.06 0.17*** 1.61*** 
 (0.82 - 1.37) (0.14 - 0.22) (1.32 - 1.96) 
Michigan 1.99*** 0.42*** 0.81*** 
 (1.81 - 2.19) (0.38 - 0.46) (0.73 - 0.89) 
Mississippi 0.98 0.25*** 0.7 
 (0.59 - 1.63) (0.14 - 0.44) (0.41 - 1.19) 
Missouri 0.29*** 0.27*** 0.96 
 (0.18 - 0.48) (0.16 - 0.45) (0.58 - 1.59) 
Nebraska 0.75 0.31*** 0.99 
 (0.40 - 1.41) (0.16 - 0.61) (0.55 - 1.80) 
Nevada 0.51 0.33* 0.33 
 (0.18 - 1.45) (0.13 - 0.89) (0.09 - 1.14) 
New Hampshire 1.60*** 0.10*** 1.29** 
 (1.33 - 1.91) (0.07 - 0.14) (1.09 - 1.52) 
New Jersey 0.23*** 0.35*** 1.06 
 (0.19 - 0.29) (0.30 - 0.41) (0.91 - 1.24) 
New Mexico 0.77 0.23** 0.46 
 (0.34 - 1.76) (0.08 - 0.65) (0.15 - 1.44) 
New York 0.87** 0.39*** 0.50*** 
 (0.80 - 0.95) (0.36 - 0.42) (0.46 - 0.55) 
North Carolina 0.99 0.29*** 0.65 
 (0.62 - 1.58) (0.18 - 0.46) (0.40 - 1.06) 
North Dakota  1.45 0.19** 1.62 
 (0.64 - 3.25) (0.05 - 0.66) (0.81 - 3.26) 
Ohio  1.12* 0.40*** 1.46*** 
 (1.01 - 1.24) (0.36 - 0.44) (1.33 - 1.60) 
Oklahoma  0.25*** 0.61 1.12 
 (0.15 - 0.42) (0.37 - 1.00) (0.67 - 1.86) 
Rhode Island 0.53*** 0.08*** 0.56*** 
 (0.41 - 0.69) (0.06 - 0.11) (0.44 - 0.69) 
South Carolina  0.68 0.79 0.62 
 (0.41 - 1.11) (0.48 - 1.29) (0.37 - 1.03) 
South Dakota 0.98 0.49 1.48 
 (0.49 - 1.95) (0.23 - 1.03) (0.78 - 2.81) 
Tennessee 1.28 0.37*** 3.15*** 
 (0.77 - 2.13) (0.21 - 0.64) (1.88 - 5.30) 
Utah  0.88 0.56* 2.37*** 
 (0.54 - 1.42) (0.34 - 0.91) (1.43 - 3.92) 





 (0.47 - 1.94) (0.16 - 0.87) (0.37 - 1.46) 
* p<0.05, ** p<0.01, *** p<0.001 

















     
N 518,154 518,154 518,154 
 RRR RRR RRR 
 (95%CI) (95%CI) (95%CI) 
Medicaid expansion        
  Yes  0.91*** 1.34*** 0.96 
 (0.88 - 0.95) (1.26 - 1.42) (0.92 - 1.01) 
MAT (No= ref)     
   Yes 0.53*** 0.29*** 0.13*** 
  (0.52 - 0.54) (0.28 - 0.30) (0.13 - 0.13) 
Frequency of use (No 
past month use= ref)  
   
   Some use 0.52*** 0.57*** 0.36*** 
 (0.51 - 0.53) (0.55 - 0.58) (0.35 - 0.37) 
   Daily use 0.49*** 0.38*** 0.19*** 
 (0.49 - 0.50) (0.37 - 0.39) (0.19 - 0.20) 
Age (18-29= ref)     
   30-44 0.94*** 1.04** 0.90*** 
 (0.92 - 0.95) (1.02 - 1.07) (0.88 - 0.92) 
   45-64 0.92*** 0.86*** 0.67*** 
 (0.89 - 0.94) (0.84 - 0.89) (0.65 - 0.69) 
Gender (Female=ref)    
   Male 0.96*** 0.74*** 1.40*** 
 (0.94 - 0.97) (0.72 - 0.75) (1.37 - 1.42) 
Race/ethnicity (non-
Hispanic White=ref) 
   
   Non-Hispanic Black 1.22*** 1.36*** 1.01 
 (1.18 - 1.25) (1.31 - 1.42) (0.97 - 1.04) 
   Hispanic 0.90*** 1.24*** 1.11*** 
 (0.87 - 0.92) (1.20 - 1.28) (1.08 - 1.14) 
   Other 0.80*** 0.84*** 0.87*** 
 (0.77 - 0.84) (0.80 - 0.89) (0.83 - 0.91) 
Education (Less than 
high school= ref)  
   
   Highschool or higher 1.00 0.83*** 0.86*** 





Number of arrests (0= 
ref) 
   
   1 0.79*** 1.11*** 2.35*** 
 (0.76 - 0.82) (1.06 - 1.17) (2.27 - 2.43) 
   2 or more 0.67*** 0.77*** 1.33*** 
 (0.62 - 0.73) (0.69 - 0.87) (1.24 - 1.44) 
Employment status 
(Not employed= ref)  
   
     Employed 
1.32*** 1.24*** 0.95*** 
 (1.29 - 1.35) (1.21 - 1.27) (0.93 - 0.97) 
Comorbidity (No= ref)     
   Yes 1.22*** 0.97** 0.76*** 
 (1.20 - 1.24) (0.95 - 0.99) (0.75 - 0.77) 
Homeless (No= ref)     
  Yes 1.07*** 1.39*** 0.65*** 
 (1.04 - 1.11) (1.34 - 1.44) (0.63 - 0.68) 
Polysubstance use 
(no= ref)   
   
    One more 1.00 1.11*** 1.06*** 
 (0.98 - 1.01) (1.09 - 1.14) (1.04 - 1.08) 
    Two or more 1.06*** 1.24*** 1.18*** 
 (1.04 - 1.08) (1.21 - 1.27) (1.15 - 1.20) 
Year     
2011 0.94*** 0.86*** 0.97 
 (0.91 - 0.97) (0.83 - 0.90) (0.94 - 1.00) 
2012 0.85*** 0.84*** 0.96* 
 (0.82 - 0.88) (0.81 - 0.88) (0.92 - 0.99) 
2013 0.84*** 0.85*** 1.04* 
 (0.81 - 0.86) (0.82 - 0.89) (1.01 - 1.08) 
2014 0.87*** 0.66*** 1.21*** 
 (0.83 - 0.91) (0.62 - 0.71) (1.15 - 1.27) 
2015 0.90*** 0.78*** 1.15*** 
 (0.86 - 0.95) (0.73 - 0.84) (1.09 - 1.21) 
2016 0.83*** 0.80*** 1.23*** 
 (0.79 - 0.87) (0.75 - 0.86) (1.17 - 1.30) 
2017 0.80*** 0.82*** 1.22*** 
 (0.76 - 0.84) (0.77 - 0.87) (1.16 - 1.29) 
State    
Alaska 0.97 1.51 0.84 
 (0.59 - 1.58) (0.81 - 2.83) (0.54 - 1.32) 
Arizona 0.46*** 0.26*** 0.12*** 
 (0.29 - 0.73) (0.14 - 0.47) (0.08 - 0.19) 
Arkansas 0.72 1.09 0.30*** 
 (0.44 - 1.17) (0.58 - 2.05) (0.19 - 0.48) 
Colorado 0.93 0.81 0.59* 





Connecticut 0.55** 0.24*** 0.27*** 
 (0.35 - 0.86) (0.13 - 0.44) (0.18 - 0.41) 
Delaware 1.54 0.17*** 0.63* 
 (0.97 - 2.44) (0.09 - 0.32) (0.41 - 0.96) 
District of Columbia 3.23*** 0.47* 0.43** 
 (1.97 - 5.28) (0.23 - 0.97) (0.26 - 0.73) 
Florida 0.35*** 1.4 0.53** 
 (0.22 - 0.56) (0.76 - 2.57) (0.35 - 0.82) 
Hawaii 0.65 0.8 1.1 
 (0.33 - 1.29) (0.37 - 1.76) (0.64 - 1.89) 
Idaho 1.64 2.71** 3.48*** 
 (0.97 - 2.78) (1.41 - 5.22) (2.18 - 5.56) 
Illinois 8.67*** 0.66 1.23 
 (5.50 - 13.67) (0.36 - 1.22) (0.81 - 1.88) 
Indiana 1.12 1.14 0.60* 
 (0.71 - 1.77) (0.62 - 2.09) (0.39 - 0.92) 
Iowa 1.14 0.56 0.58* 
 (0.72 - 1.82) (0.30 - 1.03) (0.37 - 0.88) 
Kansas 0.85 0.65 0.65 
 (0.50 - 1.44) (0.33 - 1.31) (0.40 - 1.05) 
Kentucky 0.99 1.88* 0.89 
 (0.63 - 1.56) (1.03 - 3.43) (0.58 - 1.36) 
Louisiana 1.39 2.86*** 0.7 
 (0.86 - 2.24) (1.54 - 5.29) (0.45 - 1.09) 
Maine 1.21 0.38** 0.42*** 
 (0.76 - 1.90) (0.21 - 0.70) (0.27 - 0.64) 
Maryland 0.58* 0.48* 0.68 
 (0.37 - 0.91) (0.26 - 0.87) (0.45 - 1.04) 
Massachusetts 2.99*** 0.49* 1.25 
 (1.90 - 4.71) (0.27 - 0.89) (0.82 - 1.91) 
Michigan 2.24*** 0.86 0.56** 
 (1.42 - 3.53) (0.47 - 1.56) (0.37 - 0.85) 
Mississippi 0.71 0.41** 0.32*** 
 (0.43 - 1.17) (0.21 - 0.80) (0.20 - 0.50) 
Missouri 0.29*** 0.46* 0.88 
 (0.19 - 0.47) (0.25 - 0.84) (0.58 - 1.35) 
Montana 2.00** 0.10*** 1.39 
 (1.24 - 3.23) (0.05 - 0.23) (0.89 - 2.16) 
Nebraska 1.25 1.11 0.44** 
 (0.74 - 2.12) (0.57 - 2.19) (0.27 - 0.72) 
Nevada 1.36 0.13 0.91 
 (0.60 - 3.06) (0.02 - 1.07) (0.41 - 2.01) 
New Hampshire 1.42 0.26*** 0.51** 
 (0.89 - 2.27) (0.13 - 0.49) (0.33 - 0.79) 
New Jersey 0.41*** 0.98 0.93 
 (0.26 - 0.65) (0.53 - 1.78) (0.61 - 1.42) 
New Mexico 1 0.71 0.34* 
 (0.49 - 2.06) (0.26 - 1.93) (0.14 - 0.86) 





 (0.94 - 2.34) (0.65 - 2.15) (0.29 - 0.67) 
North Carolina 0.93 0.52* 0.19*** 
 (0.59 - 1.46) (0.29 - 0.95) (0.13 - 0.29) 
North Dakota 2.34** 0.59 1.48 
 (1.23 - 4.44) (0.23 - 1.52) (0.82 - 2.65) 
Ohio 1.16 0.96 1.2 
 (0.73 - 1.82) (0.52 - 1.75) (0.79 - 1.83) 
Oklahoma 0.16*** 1.06 0.75 
 (0.09 - 0.30) (0.56 - 2.00) (0.48 - 1.18) 
Pennsylvania 4.24*** 2.12* 1.82** 
 (2.66 - 6.76) (1.14 - 3.93) (1.18 - 2.82) 
Rhode Island 0.67 0.13*** 0.32*** 
 (0.42 - 1.06) (0.07 - 0.25) (0.21 - 0.49) 
South Carolina 0.65 1.38 0.33*** 
 (0.41 - 1.04) (0.75 - 2.54) (0.21 - 0.51) 
South Dakota 1.80* 0.72 1.77* 
 (1.04 - 3.12) (0.33 - 1.54) (1.08 - 2.90) 
Tennessee 1.38 0.35** 1.47 
 (0.85 - 2.25) (0.18 - 0.71) (0.94 - 2.29) 
Utah 1.4 1.73 1.74* 
 (0.89 - 2.22) (0.95 - 3.17) (1.14 - 2.66) 
Washington 0.94 2.49** 0.79 
 (0.60 - 1.49) (1.36 - 4.55) (0.52 - 1.21) 
Wyoming 0.97 0.68 0.38*** 
 (0.53 - 1.78) (0.31 - 1.50) (0.22 - 0.65) 
* p<0.05, ** p<0.01, *** p<0.001 
Reference group for multinomial regression is self-referral. Adjusted Odds Ratio = AOR. 





























N 225,272 225,272 225,272 
 RRR RRR RRR 
 (95%CI) (95%CI) (95%CI) 
    
Expansion 0.86 2.32** 0.82 
    (0.55 - 1.33) (1.30 - 4.16) (0.54 - 1.24) 
Post expansion  0.78*** 0.79*** 1.42*** 
    (0.74 - 0.83) (0.73 - 0.85) (1.33 - 1.51) 
Expansion * Post expansion  0.90*** 1.36*** 0.93** 
    (0.86 - 0.94) (1.28 - 1.44) (0.88 - 0.97) 
MAT (No= ref)     
   Yes 0.54*** 0.29*** 0.13*** 
 (0.53 - 0.55) (0.29 - 0.30) (0.13 - 0.14) 
Frequency of use     
   Some use 0.52*** 0.57*** 0.36*** 
 (0.50 - 0.53) (0.56 - 0.59) (0.35 - 0.37) 
   Daily use  0.49*** 0.39*** 0.19*** 
 (0.49 - 0.50) (0.38 - 0.39) (0.19 - 0.20) 
Age (18-29= ref)     
   30-44 0.94*** 1.07*** 0.91*** 
 (0.92 - 0.96) (1.04 - 1.09) (0.89 - 0.93) 
   45-64 0.94*** 0.96** 0.68*** 
 (0.92 - 0.96) (0.93 - 0.99) (0.67 - 0.70) 
Gender    
   Male  0.95*** 0.75*** 1.40*** 
 (0.94 - 0.97) (0.73 - 0.76) (1.37 - 1.42) 
Race/ethnicity     
   Non-Hispanic Black 1.10*** 1.04 0.86*** 
 (1.05 - 1.14) (0.98 - 1.10) (0.81 - 0.90) 
   Hispanic  0.99 1.00 1.13*** 
 (0.95 - 1.03) (0.95 - 1.05) (1.08 - 1.18) 
   Other 0.73*** 0.75*** 0.82*** 
 (0.69 - 0.78) (0.70 - 0.81) (0.77 - 0.87) 
Education     
   Highschool or higher 1.00 0.81*** 0.86*** 
 (0.98 - 1.02) (0.79 - 0.83) (0.84 - 0.88) 
Number of arrests (0=ref)    
   1 0.79*** 1.12*** 2.35*** 
 (0.76 - 0.82) (1.06 - 1.17) (2.27 - 2.43) 
   2 or more 0.68*** 0.77*** 1.34*** 
 (0.62 - 0.74) (0.68 - 0.87) (1.24 - 1.44) 
Employment status     
     Employed 1.33*** 1.27*** 0.96*** 
 (1.31 - 1.36) (1.24 - 1.31) (0.94 - 0.98) 





   Yes  1.21*** 0.96*** 0.76*** 
 (1.19 - 1.23) (0.94 - 0.98) (0.75 - 0.78) 
Homeless    
  Yes 1.08*** 1.42*** 0.65*** 
 (1.05 - 1.12) (1.37 - 1.47) (0.63 - 0.68) 
Polysubstance use     
    One more 1.00 1.11*** 1.04*** 
 (0.98 - 1.02) (1.08 - 1.14) (1.02 - 1.07) 
    Two or more 1.07*** 1.24*** 1.17*** 
 (1.05 - 1.09) (1.21 - 1.27) (1.14 - 1.19) 
    
Year     
2011 0.94*** 0.86*** 0.96* 
 (0.91 - 0.97) (0.83 - 0.90) (0.93 - 1.00) 
2012 0.85*** 0.83*** 0.95** 
 (0.82 - 0.87) (0.80 - 0.87) (0.92 - 0.99) 
2013 0.84*** 0.84*** 1.05** 
 (0.81 - 0.86) (0.80 - 0.87) (1.02 - 1.09) 
2014 1.12*** 0.81*** 0.88*** 
 (1.07 - 1.17) (0.77 - 0.86) (0.84 - 0.93) 
2015 1.14*** 0.98 0.95** 
 (1.11 - 1.18) (0.94 - 1.02) (0.92 - 0.98) 
2016 1.04** 1.00 1.01 
 (1.01 - 1.08) (0.96 - 1.04) (0.97 - 1.04) 
State    
Arizona 0.51*** 0.12*** 0.16*** 
 (0.46 - 0.55) (0.10 - 0.13) (0.15 - 0.18) 
Arkansas 0.79* 0.45*** 0.39*** 
 (0.65 - 0.95) (0.37 - 0.54) (0.32 - 0.47) 
Colorado 0.98 0.35*** 0.76*** 
 (0.91 - 1.06) (0.32 - 0.38) (0.71 - 0.82) 
Connecticut 0.59*** 0.10*** 0.34*** 
 (0.55 - 0.64) (0.09 - 0.11) (0.32 - 0.37) 
Delaware 1.68*** 0.07*** 0.80*** 
 (1.52 - 1.85) (0.06 - 0.09) (0.73 - 0.88) 
District of Columbia 3.95*** 0.22*** 0.58*** 
 (3.24 - 4.82) (0.15 - 0.33) (0.43 - 0.80) 
Florida 0.32*** 1.32 0.55** 
 (0.20 - 0.50) (0.74 - 2.38) (0.36 - 0.84) 
Hawaii 0.65 0.33*** 1.43* 
 (0.39 - 1.11) (0.20 - 0.55) (1.01 - 2.02) 
Idaho 1.51 2.63** 3.59*** 
 (0.91 - 2.52) (1.39 - 4.97) (2.26 - 5.69) 
Illinois 10.06*** 0.30*** 1.64*** 
 (9.43 - 10.73) (0.28 - 0.33) (1.53 - 1.75) 
Indiana 1.25*** 0.23*** 0.74*** 
 (1.13 - 1.39) (0.20 - 0.26) (0.67 - 0.81) 
Kansas 0.78 0.64 0.67 





Kentucky 1.07* 0.76*** 1.13*** 
 (1.00 - 1.15) (0.72 - 0.80) (1.06 - 1.20) 
Maine 1.11 0.36*** 0.42*** 
 (0.72 - 1.71) (0.20 - 0.64) (0.28 - 0.64) 
Maryland 0.65*** 0.21*** 0.87*** 
 (0.61 - 0.70) (0.19 - 0.22) (0.82 - 0.93) 
Massachusetts 3.22*** 0.20*** 1.61*** 
 (3.03 - 3.42) (0.18 - 0.22) (1.51 - 1.71) 
Michigan 2.47*** 0.35*** 0.72*** 
 (2.33 - 2.62) (0.33 - 0.37) (0.67 - 0.76) 
Mississippi 0.66 0.40** 0.32*** 
 (0.41 - 1.07) (0.21 - 0.76) (0.21 - 0.50) 
Missouri 0.28*** 0.46** 0.91 
 (0.18 - 0.44) (0.25 - 0.82) (0.60 - 1.38) 
Montana 1.13 1.07 0.44*** 
 (0.67 - 1.88) (0.56 - 2.07) (0.27 - 0.72) 
Nebraska 1.52 0.06** 1.21 
 (0.77 - 3.00) (0.01 - 0.44) (0.61 - 2.40) 
New Hampshire 1.55*** 0.11*** 0.66*** 
 (1.36 - 1.78) (0.08 - 0.14) (0.58 - 0.75) 
New Jersey 0.45*** 0.42*** 1.20*** 
 (0.42 - 0.49) (0.39 - 0.45) (1.13 - 1.28) 
New Mexico 1.15 0.36* 0.52 
 (0.61 - 2.17) (0.15 - 0.86) (0.21 - 1.27) 
New York 1.60*** 0.50*** 0.57*** 
 (1.52 - 1.69) (0.48 - 0.53) (0.54 - 0.60) 
North Carolina 0.87 0.50* 0.19*** 
 (0.56 - 1.34) (0.28 - 0.90) (0.13 - 0.29) 
North Dakota 2.43*** 0.23*** 1.83** 
 (1.54 - 3.84) (0.11 - 0.49) (1.22 - 2.76) 
Ohio 1.26*** 0.39*** 1.53*** 
 (1.18 - 1.35) (0.37 - 0.42) (1.44 - 1.62) 
Oklahoma 0.15*** 0.99 0.75 
 (0.08 - 0.28) (0.54 - 1.85) (0.48 - 1.18) 
Rhode Island 0.73*** 0.06*** 0.39*** 
 (0.67 - 0.79) (0.05 - 0.07) (0.36 - 0.43) 
South Carolina 0.61* 1.32 0.34*** 
 (0.39 - 0.95) (0.73 - 2.37) (0.22 - 0.52) 
South Dakota 1.66 0.69 1.78* 
 (0.97 - 2.82) (0.33 - 1.45) (1.09 - 2.90) 
Tennessee 1.27 0.34** 1.51 
 (0.80 - 2.03) (0.17 - 0.67) (0.98 - 2.34) 
Utah 1.28 1.68 1.79** 
 (0.83 - 1.98) (0.93 - 3.01) (1.18 - 2.71) 
Wyoming 0.9 0.67 0.38*** 
 (0.50 - 1.62) (0.31 - 1.45) (0.22 - 0.65) 
* p<0.05, ** p<0.01, *** p<0.001 















N 169,449 169,449 169,449 
 RRR RRR RRR 
  (95%CI) (95%CI) (95%CI) 
    
Medicaid expansion     
  Expanded 0.89*** 1.26*** 0.86*** 
 (0.85 - 0.94) (1.17 - 1.35) (0.82 - 0.91) 
Frequency of use (No 
past month use= ref)  
   
   Some use 0.58*** 0.59*** 0.38*** 
 (0.57 - 0.60) (0.57 - 0.61) (0.37 - 0.39) 
   Daily use 0.70*** 0.42*** 0.23*** 
 (0.68 - 0.71) (0.41 - 0.44) (0.22 - 0.23) 
Age (18-29= ref)     
   30-44 0.96*** 1.11*** 0.94*** 
 (0.93 - 0.98) (1.08 - 1.14) (0.92 - 0.96) 
   45-64 1.00 0.94** 0.76*** 
 (0.97 - 1.03) (0.91 - 0.98) (0.74 - 0.78) 
Gender (Female=ref)    
   Male 0.98* 0.71*** 1.39*** 
 (0.96 - 1.00) (0.70 - 0.73) (1.36 - 1.41) 
Race/ethnicity (non-
Hispanic White=ref) 
   
   Non-Hispanic Black 1.40*** 1.48*** 1.06** 
 (1.35 - 1.46) (1.41 - 1.56) (1.02 - 1.10) 
   Hispanic 1.02 1.45*** 1.25*** 
 (0.99 - 1.06) (1.39 - 1.51) (1.20 - 1.29) 
   Other 0.83*** 0.86*** 0.87*** 
 (0.79 - 0.88) (0.80 - 0.92) (0.83 - 0.92) 
Education (Less than high 
school= ref)  
   
   Highschool or higher 0.96*** 0.78*** 0.82*** 
 (0.94 - 0.98) (0.76 - 0.80) (0.80 - 0.83) 
Number of arrests (0= 
ref) 
   
   1 0.72*** 1.07* 1.96*** 





   2 or more 0.59*** 0.69*** 1.12** 
 (0.53 - 0.65) (0.61 - 0.79) (1.03 - 1.22) 
Employment status (Not 
employed= ref)  
   
     Employed 1.38*** 1.24*** 0.95*** 
 (1.35 - 1.42) (1.21 - 1.28) (0.93 - 0.97) 
Comorbidity (No= ref)     
   Yes 1.20*** 0.85*** 0.70*** 
 (1.18 - 1.23) (0.83 - 0.88) (0.68 - 0.71) 
Homeless (No= ref)     
  Yes 1.10*** 1.43*** 0.61*** 
 (1.05 - 1.14) (1.37 - 1.50) (0.58 - 0.64) 
Polysubstance use (no= 
ref)   
   
    One more 0.92*** 1.02 0.96*** 
 (0.89 - 0.94) (0.99 - 1.05) (0.94 - 0.98) 
    Two or more 0.94*** 1.09*** 1.03** 
 (0.91 - 0.96) (1.06 - 1.12) (1.01 - 1.06) 
Year     
2011 0.93*** 0.88*** 0.98 
 (0.90 - 0.97) (0.84 - 0.93) (0.95 - 1.02) 
2012 0.85*** 0.86*** 0.97 
 (0.81 - 0.88) (0.83 - 0.91) (0.93 - 1.01) 
2013 0.82*** 0.88*** 1.06** 
 (0.79 - 0.86) (0.84 - 0.92) (1.02 - 1.10) 
2014 0.85*** 0.69*** 1.32*** 
 (0.80 - 0.91) (0.64 - 0.75) (1.24 - 1.39) 
2015 0.82*** 0.76*** 1.13*** 
 (0.78 - 0.88) (0.70 - 0.82) (1.07 - 1.20) 
2016 0.79*** 0.75*** 1.19*** 
 (0.74 - 0.83) (0.70 - 0.81) (1.12 - 1.26) 
2017 0.78*** 0.74*** 1.13*** 
State    
Alaska 0.42* 1.05 0.62 
 (0.18 - 0.95) (0.40 - 2.73) (0.31 - 1.25) 
Arizona 0.17*** 0.13*** 0.08*** 
 (0.08 - 0.38) (0.05 - 0.34) (0.04 - 0.15) 
Arkansas 0.29** 0.71 0.18*** 
 (0.13 - 0.65) (0.27 - 1.85) (0.09 - 0.36) 
Colorado 0.33** 0.59 0.44* 
 (0.15 - 0.73) (0.23 - 1.51) (0.22 - 0.87) 





 (0.17 - 0.82) (0.12 - 0.81) (0.15 - 0.58) 
Delaware 0.73 0.10*** 0.47* 
 (0.33 - 1.62) (0.04 - 0.26) (0.24 - 0.93) 
District of Columbia 0.79 0.23** 0.20*** 
 (0.35 - 1.78) (0.08 - 0.65) (0.09 - 0.42) 
Florida 0.27** 1.45 0.52 
 (0.12 - 0.60) (0.56 - 3.73) (0.26 - 1.04) 
Hawaii 0.34* 0.53 0.82 
 (0.13 - 0.89) (0.18 - 1.58) (0.38 - 1.79) 
Idaho 0.71 1.59 2.18* 
 (0.31 - 1.64) (0.60 - 4.24) (1.07 - 4.44) 
Illinois 2.69* 0.33* 0.66 
 (1.22 - 5.92) (0.13 - 0.85) (0.33 - 1.30) 
Indiana 0.53 0.8 0.45* 
 (0.24 - 1.17) (0.31 - 2.05) (0.23 - 0.89) 
Iowa 0.41* 0.35* 0.37** 
 (0.19 - 0.91) (0.13 - 0.89) (0.19 - 0.74) 
Kansas 0.34* 0.4 0.42* 
 (0.15 - 0.80) (0.15 - 1.08) (0.20 - 0.86) 
Kentucky 0.34** 0.96 0.49* 
 (0.16 - 0.76) (0.37 - 2.45) (0.25 - 0.96) 
Louisiana 0.59 1.4 0.40* 
 (0.26 - 1.32) (0.54 - 3.63) (0.20 - 0.81) 
Maine 0.34** 0.22** 0.28*** 
 (0.15 - 0.76) (0.09 - 0.58) (0.14 - 0.56) 
Maryland 0.32** 0.38* 0.55 
 (0.14 - 0.69) (0.15 - 0.97) (0.28 - 1.08) 
Massachusetts 1.05 0.28** 0.86 
 (0.47 - 2.30) (0.11 - 0.73) (0.43 - 1.70) 
Michigan 0.79 0.36* 0.34** 
 (0.36 - 1.75) (0.14 - 0.93) (0.17 - 0.68) 
Mississippi 0.30** 0.26** 0.21*** 
 (0.13 - 0.67) (0.10 - 0.69) (0.10 - 0.42) 
Missouri 0.11*** 0.20*** 0.51 
 (0.05 - 0.24) (0.08 - 0.51) (0.26 - 1.02) 
Montana 0.91 0.06*** 0.91 
 (0.41 - 2.02) (0.02 - 0.18) (0.45 - 1.82) 
Nebraska 0.53 0.55 0.24*** 
 (0.23 - 1.24) (0.20 - 1.48) (0.11 - 0.49) 
Nevada 0.28 0.17 0.81 
 (0.05 - 1.65) (0.02 - 1.66) (0.26 - 2.56) 





 (0.25 - 1.26) (0.05 - 0.38) (0.17 - 0.67) 
New Jersey 0.34** 0.91 1.16 
 (0.15 - 0.74) (0.35 - 2.33) (0.58 - 2.29) 
New Mexico 0 0.47 0.29 
 (0.00 - .) (0.09 - 2.48) (0.08 - 1.03) 
New York 0.7 0.79 0.28*** 
 (0.32 - 1.54) (0.31 - 2.02) (0.14 - 0.55) 
North Carolina 0.37* 0.29* 0.12*** 
 (0.17 - 0.81) (0.11 - 0.75) (0.06 - 0.23) 
North Dakota 1.07 0.37 1 
 (0.43 - 2.66) (0.11 - 1.23) (0.45 - 2.21) 
Ohio 0.33** 0.51 0.63 
 (0.15 - 0.73) (0.20 - 1.32) (0.32 - 1.26) 
Oklahoma 0.08*** 0.68 0.51 
 (0.03 - 0.18) (0.26 - 1.78) (0.25 - 1.02) 
Pennsylvania 2.17 0.69 1.24 
 (0.97 - 4.85) (0.26 - 1.82) (0.62 - 2.48) 
Rhode Island 0.79 0.24** 0.41* 
 (0.35 - 1.74) (0.09 - 0.62) (0.20 - 0.81) 
South Carolina 0.27** 0.73 0.19*** 
 (0.12 - 0.59) (0.28 - 1.88) (0.10 - 0.38) 
South Dakota 0.86 0.4 1.04 
 (0.37 - 2.01) (0.14 - 1.15) (0.50 - 2.15) 
Tennessee 0.57 0.21** 0.91 
 (0.25 - 1.28) (0.08 - 0.58) (0.45 - 1.82) 
Utah 0.57 0.99 1.2 
 (0.26 - 1.26) (0.39 - 2.56) (0.61 - 2.38) 
Washington 0.45* 1.44 0.6 
 (0.20 - 1.00) (0.56 - 3.70) (0.30 - 1.18) 
Wyoming 0.42 0.45 0.25*** 
 (0.17 - 1.04) (0.16 - 1.32) (0.12 - 0.54) 
* p<0.05, ** p<0.01, *** p<0.001 
Reference group for multinomial regression is self-referral. Relative Risk Ratio = RRR. 






    







Table 4-A15. 2WFE model for the associations among MAT, non-intensive outpatient treatment for OUD with 











N 166,400 141,859 141,885 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Medicaid expansion     
  Expanded 0.88** 1.59*** 1.15* 
 (0.81 - 0.95) (1.38 - 1.82) (1.01 - 1.32) 
Frequency of use (No past month 




   Some use 0.42*** 0.61*** 0.39*** 
 (0.41 - 0.44) (0.58 - 0.65) (0.37 - 0.41) 
   Daily use 0.32*** 0.41*** 0.19*** 
 (0.31 - 0.33) (0.39 - 0.43) (0.18 - 0.20) 
Age (18-29= ref)     
   30-44 0.91*** 0.91*** 0.74*** 
 (0.88 - 0.94) (0.87 - 0.96) (0.70 - 0.77) 
   45-64 0.81*** 0.75*** 0.44*** 
 (0.78 - 0.84) (0.71 - 0.80) (0.42 - 0.47) 
Gender (Female=ref)    
   Male 0.93*** 0.81*** 1.45*** 






   Non-Hispanic Black 0.95* 1.18*** 0.99 
 (0.91 - 1.00) (1.11 - 1.26) (0.92 - 1.07) 
   Hispanic 0.83*** 1.05 0.83*** 
 (0.79 - 0.86) (0.99 - 1.12) (0.77 - 0.88) 
   Other 0.74*** 0.83*** 0.95 
 (0.68 - 0.79) (0.75 - 0.92) (0.84 - 1.07) 





   Highschool or higher 1.03* 0.91*** 1.01 
 (1.00 - 1.06) (0.87 - 0.95) (0.97 - 1.06) 
Number of arrests (0= ref)  
 
 
   1 0.88*** 1.05 4.31*** 





   2 or more 0.85 0.91 2.64*** 
 (0.71 - 1.00) (0.72 - 1.16) (2.20 - 3.17) 
Employment status (Not 




     Employed 1.25*** 1.29*** 0.99 
 (1.21 - 1.29) (1.23 - 1.36) (0.94 - 1.04) 
Comorbidity (No= ref)     
   Yes 1.15*** 1.23*** 1.01 
 (1.12 - 1.18) (1.18 - 1.28) (0.97 - 1.05) 
Homeless (No= ref)     
  Yes 1.05* 1.32*** 0.82*** 
 (1.00 - 1.10) (1.24 - 1.41) (0.76 - 0.90) 
Polysubstance use (no= ref)    
 
 
    One more 1.10*** 1.25*** 1.29*** 
 (1.06 - 1.13) (1.19 - 1.31) (1.23 - 1.35) 
    Two or more 1.27*** 1.45*** 1.61*** 
 (1.23 - 1.31) (1.37 - 1.52) (1.52 - 1.69) 
Year     
2011 0.98 0.82*** 0.85** 
 (0.93 - 1.04) (0.74 - 0.90) (0.77 - 0.95) 
2012 0.91*** 0.76*** 0.86** 
 (0.86 - 0.96) (0.70 - 0.84) (0.77 - 0.95) 
2013 0.91** 0.77*** 0.97 
 (0.86 - 0.96) (0.70 - 0.85) (0.88 - 1.07) 
2014 0.97 0.56*** 0.98 
 (0.89 - 1.07) (0.48 - 0.66) (0.84 - 1.14) 
2015 1.08 0.76*** 1.14 
 (0.99 - 1.18) (0.65 - 0.88) (0.98 - 1.32) 
2016 0.93 0.81** 1.25** 
 (0.85 - 1.02) (0.70 - 0.94) (1.08 - 1.45) 
2017 0.86** 0.79** 1.39*** 
 (0.79 - 0.94) (0.68 - 0.91) (1.20 - 1.61) 
State    
Alaska 1.7 1.04 0.36* 
 (0.81 - 3.55) (0.39 - 2.75) (0.14 - 0.90) 
Arizona 0.94 0.6 0.24*** 
 (0.49 - 1.80) (0.25 - 1.43) (0.12 - 0.49) 
Arkansas 1.2 0.85 0.51 
 (0.60 - 2.39) (0.33 - 2.14) (0.24 - 1.08) 
Colorado 1.76 0.58 0.42* 
 (0.93 - 3.30) (0.25 - 1.38) (0.22 - 0.82) 





 (0.35 - 1.25) (0.04 - 0.20) (0.05 - 0.21) 
Delaware 2.02* 0.25** 0.40** 
 (1.06 - 3.83) (0.10 - 0.65) (0.20 - 0.80) 
District of Columbia 16.07*** 0.25 1.29 
 (7.69 - 33.60) (0.03 - 2.18) (0.42 - 3.94) 
Florida 0.29*** 0.44 0.21*** 
 (0.15 - 0.56) (0.18 - 1.07) (0.10 - 0.42) 
Hawaii 0.33 0.84 0.32 
 (0.04 - 2.72) (0.16 - 4.48) (0.04 - 2.67) 
Idaho 2.3 5.61** 5.58*** 
 (0.80 - 6.66) (1.77 - 17.80) (2.18 - 14.28) 
Illinois 23.88*** 0.82 0.95 
 (12.70 - 44.91) (0.34 - 1.96) (0.48 - 1.85) 
Indiana 1.07 0.74 0.40** 
 (0.55 - 2.08) (0.30 - 1.81) (0.20 - 0.80) 
Iowa 5.21*** 0.39 0.8 
 (2.69 - 10.08) (0.14 - 1.08) (0.38 - 1.69) 
Kentucky 2.30** 3.21** 1.67 
 (1.23 - 4.33) (1.37 - 7.51) (0.87 - 3.22) 
Louisiana 0.83 16.71*** 2.83* 
 (0.24 - 2.86) (6.43 - 43.39) (1.11 - 7.21) 
Maine 1.83 0.43* 0.37** 
 (0.98 - 3.44) (0.18 - 1.00) (0.19 - 0.71) 
Maryland 0.74 0.36* 0.42** 
 (0.39 - 1.38) (0.15 - 0.83) (0.22 - 0.80) 
Massachusetts 5.61*** 0.46 0.47* 
 (2.99 - 10.52) (0.20 - 1.08) (0.24 - 0.91) 
Michigan 4.17*** 1.33 0.33*** 
 (2.22 - 7.81) (0.57 - 3.12) (0.17 - 0.63) 
Mississippi 1.08  0.25 
 (0.27 - 4.38)  (0.03 - 2.19) 
Missouri 0.65 1.02 1.27 
 (0.34 - 1.24) (0.44 - 2.41) (0.66 - 2.44) 
Nebraska 1.68 4.04* 1.76 
 (0.60 - 4.75) (1.30 - 12.60) (0.65 - 4.81) 
Nevada 2.61  0.32 
 (0.98 - 6.96)  (0.08 - 1.38) 
New Hampshire 3.40*** 0.63 0.95 
 (1.70 - 6.80) (0.22 - 1.75) (0.44 - 2.05) 
New Jersey 0.62 0.97 0.39** 
 (0.33 - 1.16) (0.41 - 2.27) (0.20 - 0.75) 
New Mexico 2.17 0.71 0.15 
 (0.93 - 5.09) (0.19 - 2.70) (0.02 - 1.23) 





 (1.09 - 3.81) (0.41 - 2.23) (0.33 - 1.21) 
North Carolina 1.26 0.91 0.23*** 
 (0.67 - 2.36) (0.39 - 2.13) (0.12 - 0.45) 
North Dakota 3.16*** 0.99 1.77 
 (1.68 - 5.93) (0.42 - 2.32) (0.92 - 3.40) 
Pennsylvania 4.89*** 4.20** 1.38 
 (2.55 - 9.36) (1.76 - 9.98) (0.69 - 2.75) 
Rhode Island 0.76 0.06*** 0.18*** 
 (0.40 - 1.42) (0.03 - 0.15) (0.09 - 0.36) 
South Carolina 1.4 3.86** 0.77 
 (0.69 - 2.85) (1.59 - 9.38) (0.37 - 1.60) 
South Dakota 1.9 2.48 7.25*** 
 (0.49 - 7.37) (0.51 - 12.03) (2.54 - 20.72) 
Tennessee 3.66  30.54*** 
 (0.52 - 25.60)  (6.67 - 139.79) 
Utah 2.40** 2.14 0.78 
 (1.27 - 4.53) (0.91 - 5.03) (0.40 - 1.52) 
Washington 1.29 2.71* 0.41** 
 (0.68 - 2.42) (1.16 - 6.34) (0.21 - 0.79) 
Wyoming 2.46  0.33 
 (0.61 - 9.98)  (0.04 - 3.17) 
* p<0.05, ** p<0.01, *** p<0.001 


























Other institutional Court/criminal justice 
referral Referral 
    
N 313,253 313,253 313,253 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Expansion 0.45* 1.39 0.61 
    (0.20 - 0.99) (0.54 - 3.56) (0.31 - 1.21) 
Post expansion  0.77*** 0.70*** 1.15*** 
    (0.72 - 0.81) (0.65 - 0.76) (1.09 - 1.22) 
Expansion * Post expansion  0.87*** 1.29*** 0.82*** 
    (0.83 - 0.92) (1.20 - 1.38) (0.78 - 0.86) 
Frequency of use (No 
past month use= ref)  
   
   Some use 0.58*** 0.59*** 0.37*** 
 (0.56 - 0.60) (0.57 - 0.61) (0.36 - 0.38) 
   Daily use 0.70*** 0.43*** 0.22*** 
 (0.69 - 0.72) (0.42 - 0.44) (0.22 - 0.23) 
Age (18-29= ref)     
   30-44 0.96*** 1.12*** 0.95*** 
 (0.94 - 0.98) (1.09 - 1.15) (0.93 - 0.97) 
   45-64 0.99 0.97 0.76*** 
 (0.96 - 1.02) (0.93 - 1.00) (0.74 - 0.78) 
Gender (Female=ref)    
   Male 0.98 0.72*** 1.38*** 
 (0.96 - 1.00) (0.70 - 0.74) (1.35 - 1.41) 
Race/ethnicity (non-
Hispanic White=ref) 
   
   Non-Hispanic Black 1.43*** 1.47*** 1.06** 
 (1.37 - 1.48) (1.40 - 1.55) (1.02 - 1.10) 
   Hispanic 1.03 1.45*** 1.25*** 
 (0.99 - 1.07) (1.39 - 1.51) (1.21 - 1.29) 
   Other 0.86*** 0.86*** 0.89*** 
 (0.81 - 0.91) (0.80 - 0.92) (0.84 - 0.94) 
Education (Less than high 
school= ref)  
   
   Highschool or higher 0.96*** 0.78*** 0.82*** 
 (0.93 - 0.98) (0.76 - 0.81) (0.80 - 0.84) 
Number of arrests (0= 
ref) 





   1 0.72*** 1.08** 1.95*** 
 (0.68 - 0.76) (1.02 - 1.14) (1.87 - 2.02) 
   2 or more 0.60*** 0.68*** 1.11* 
 (0.54 - 0.67) (0.59 - 0.78) (1.02 - 1.20) 
Employment status (Not 
employed= ref)  
   
     Employed 1.40*** 1.26*** 0.96*** 
 (1.37 - 1.44) (1.22 - 1.30) (0.94 - 0.99) 
Comorbidity (No= ref)     
   Yes 1.21*** 0.86*** 0.70*** 
 (1.18 - 1.24) (0.84 - 0.88) (0.68 - 0.71) 
Homeless (No= ref)     
  Yes 1.10*** 1.43*** 0.61*** 
 (1.06 - 1.15) (1.36 - 1.50) (0.58 - 0.64) 
Polysubstance use (no= 
ref)   
   
    One more 0.91*** 1.01 0.94*** 
 (0.89 - 0.94) (0.98 - 1.04) (0.92 - 0.96) 
    Two or more 0.94*** 1.08*** 1.01 
 (0.92 - 0.97) (1.05 - 1.12) (0.99 - 1.04) 
Year     
2011 0.94*** 0.89*** 0.98 
 (0.90 - 0.97) (0.85 - 0.94) (0.94 - 1.02) 
2012 0.85*** 0.87*** 0.97 
 (0.82 - 0.88) (0.83 - 0.91) (0.93 - 1.01) 
2013 0.82*** 0.86*** 1.06** 
 (0.79 - 0.85) (0.82 - 0.91) (1.02 - 1.11) 
2014 1.13*** 0.94* 1.20*** 
 (1.09 - 1.18) (0.90 - 0.99) (1.16 - 1.25) 
2015 1.09*** 1.04 1.03 
 (1.04 - 1.14) (0.99 - 1.09) (0.99 - 1.07) 
2016 1.03 1.03 1.07*** 
 (0.99 - 1.08) (0.98 - 1.08) (1.03 - 1.11) 
State    
Arizona 0.39*** 0.09*** 0.13*** 
 (0.34 - 0.43) (0.08 - 0.11) (0.12 - 0.14) 
Arkansas 0.64*** 0.49*** 0.30*** 
 (0.50 - 0.82) (0.39 - 0.61) (0.24 - 0.37) 
Colorado 0.75*** 0.41*** 0.74*** 
 (0.66 - 0.84) (0.37 - 0.46) (0.68 - 0.81) 
Connecticut 0.85** 0.22*** 0.50*** 





Delaware 1.63*** 0.07*** 0.80*** 
 (1.43 - 1.87) (0.05 - 0.09) (0.72 - 0.89) 
District of Columbia 1.75*** 0.16*** 0.33*** 
 (1.38 - 2.21) (0.11 - 0.24) (0.24 - 0.46) 
Florida 0.27** 1.39 0.53 
 (0.12 - 0.59) (0.54 - 3.59) (0.27 - 1.06) 
Hawaii 0.76 0.37*** 1.38 
 (0.44 - 1.32) (0.21 - 0.64) (0.95 - 2.00) 
Idaho 0.7 1.56 2.18* 
 (0.30 - 1.62) (0.59 - 4.15) (1.07 - 4.45) 
Illinois 5.99*** 0.23*** 1.11* 
 (5.45 - 6.59) (0.20 - 0.25) (1.02 - 1.21) 
Indiana 0.92 0.24*** 0.63*** 
 (0.81 - 1.05) (0.21 - 0.28) (0.56 - 0.70) 
Kansas 0.34* 0.39 0.42* 
 (0.15 - 0.79) (0.14 - 1.06) (0.21 - 0.86) 
Kentucky 0.77*** 0.66*** 0.82*** 
 (0.70 - 0.85) (0.61 - 0.72) (0.76 - 0.88) 
Maine 0.34** 0.22** 0.29*** 
 (0.15 - 0.75) (0.08 - 0.57) (0.14 - 0.57) 
Maryland 0.70*** 0.26*** 0.91* 
 (0.63 - 0.77) (0.24 - 0.29) (0.84 - 0.99) 
Massachusetts 2.32*** 0.20*** 1.45*** 
 (2.11 - 2.55) (0.18 - 0.22) (1.34 - 1.57) 
Michigan 1.77*** 0.25*** 0.58*** 
 (1.62 - 1.94) (0.23 - 0.28) (0.54 - 0.62) 
Mississippi 0.30** 0.26** 0.21*** 
 (0.13 - 0.67) (0.10 - 0.69) (0.10 - 0.42) 
Missouri 0.11*** 0.20*** 0.52 
 (0.05 - 0.24) (0.08 - 0.50) (0.26 - 1.02) 
Montana 0.53 0.54 0.24*** 
 (0.23 - 1.23) (0.20 - 1.45) (0.11 - 0.50) 
Nebraska 0.64 0.12* 1.38 
 (0.13 - 3.11) (0.01 - 0.96) (0.55 - 3.51) 
New Hampshire 1.27** 0.10*** 0.57*** 
 (1.09 - 1.49) (0.08 - 0.13) (0.50 - 0.66) 
New Jersey 0.76*** 0.63*** 1.95*** 
 (0.67 - 0.86) (0.57 - 0.71) (1.79 - 2.13) 
New Mexico 0 0.33 0.48 
 (0.00 - .) (0.08 - 1.29) (0.16 - 1.43) 
New York 1.56*** 0.55*** 0.47*** 





North Carolina 0.36* 0.28** 0.12*** 
 (0.17 - 0.80) (0.11 - 0.73) (0.06 - 0.23) 
North Dakota 2.38*** 0.26*** 1.67* 
 (1.50 - 3.77) (0.12 - 0.54) (1.11 - 2.51) 
Ohio 0.74*** 0.36*** 1.07 
 (0.67 - 0.82) (0.33 - 0.39) (0.99 - 1.15) 
Oklahoma 0.07*** 0.65 0.51 
 (0.03 - 0.18) (0.25 - 1.71) (0.25 - 1.03) 
Rhode Island 1.77*** 0.16*** 0.68*** 
 (1.53 - 2.05) (0.13 - 0.21) (0.60 - 0.78) 
South Carolina 0.27** 0.71 0.19*** 
 (0.12 - 0.59) (0.28 - 1.83) (0.10 - 0.38) 
South Dakota 0.85 0.39 1.04 
 (0.36 - 2.00) (0.14 - 1.14) (0.50 - 2.16) 
Tennessee 0.56 0.21** 0.91 
 (0.25 - 1.26) (0.08 - 0.56) (0.45 - 1.83) 
Utah 0.56 0.97 1.21 
 (0.26 - 1.25) (0.38 - 2.49) (0.61 - 2.39) 
Wyoming 0.43 0.45 0.25*** 
 (0.17 - 1.04) (0.16 - 1.32) (0.12 - 0.54) 
* p<0.05, ** p<0.01, *** p<0.001 


























Table 4-A17. DID model for the associations among MAT, non-intensive outpatient treatment for OUD with 




Other institutional  Court/criminal 
justice referral Referral  
    
N 60,852 60,852 60,852 
 RRR RRR RRR 
  (95%CI) (95%CI) (95%CI) 
    
Expansion 1.28 2.68* 0.40** 
    (0.68 - 2.41) (1.15 - 6.28) (0.21 - 0.78) 
Post expansion  0.86*** 0.77*** 1.37*** 
    (0.79 - 0.94) (0.66 - 0.89) (1.18 - 1.59) 
Expansion * Post expansion  0.89** 1.61*** 1.17* 
    (0.82 - 0.96) (1.40 - 1.85) (1.02 - 1.35) 
Frequency of use (No past 
month use= ref)  
   
   Some use 0.42*** 0.62*** 0.39*** 
 (0.40 - 0.44) (0.58 - 0.65) (0.37 - 0.41) 
   Daily use 0.31*** 0.41*** 0.19*** 
 (0.30 - 0.32) (0.39 - 0.43) (0.18 - 0.20) 
Age (18-29= ref)     
   30-44 0.91*** 0.91*** 0.74*** 
 (0.88 - 0.94) (0.87 - 0.95) (0.71 - 0.78) 
   45-64 0.81*** 0.75*** 0.44*** 
 (0.78 - 0.84) (0.71 - 0.80) (0.42 - 0.47) 
Gender (Female=ref)    
   Male 0.92*** 0.81*** 1.45*** 
 (0.90 - 0.95) (0.78 - 0.84) (1.39 - 1.51) 
Race/ethnicity (non-Hispanic 
White=ref) 
   
   Non-Hispanic Black 0.96 1.18*** 0.99 
 (0.91 - 1.00) (1.11 - 1.26) (0.92 - 1.07) 
   Hispanic 0.83*** 1.06 0.82*** 
 (0.79 - 0.86) (0.99 - 1.12) (0.77 - 0.88) 
   Other 0.74*** 0.82*** 0.96 
 (0.68 - 0.79) (0.74 - 0.91) (0.85 - 1.07) 
Education (Less than high 
school= ref)  
   
   Highschool or higher 1.03* 0.91*** 1.02 
 (1.00 - 1.06) (0.87 - 0.95) (0.97 - 1.06) 





   1 0.88*** 1.05 4.29*** 
 (0.82 - 0.94) (0.95 - 1.16) (4.02 - 4.58) 
   2 or more 0.84 0.94 2.67*** 
 (0.71 - 1.00) (0.74 - 1.19) (2.22 - 3.21) 
Employment status (Not 
employed= ref)  
   
     Employed 1.25*** 1.30*** 0.99 
 (1.21 - 1.30) (1.23 - 1.37) (0.95 - 1.04) 
Comorbidity (No= ref)     
   Yes 1.14*** 1.22*** 1.00 
 (1.11 - 1.18) (1.17 - 1.27) (0.96 - 1.04) 
Homeless (No= ref)     
  Yes 1.05* 1.33*** 0.82*** 
 (1.00 - 1.10) (1.24 - 1.42) (0.76 - 0.90) 
Polysubstance use (no= ref)      
    One more 1.09*** 1.25*** 1.28*** 
 (1.06 - 1.12) (1.19 - 1.31) (1.22 - 1.35) 
    Two or more 1.27*** 1.45*** 1.61*** 
 (1.23 - 1.31) (1.38 - 1.53) (1.52 - 1.69) 
Year     
2011 0.98 0.81*** 0.85** 
 (0.93 - 1.04) (0.74 - 0.89) (0.77 - 0.95) 
2012 0.91*** 0.75*** 0.86** 
 (0.86 - 0.96) (0.69 - 0.83) (0.77 - 0.95) 
2013 0.91** 0.77*** 0.98 
 (0.86 - 0.97) (0.70 - 0.85) (0.89 - 1.08) 
2014 1.12*** 0.72*** 0.70*** 
 (1.07 - 1.18) (0.66 - 0.77) (0.64 - 0.75) 
2015 1.24*** 0.97 0.82*** 
 (1.19 - 1.30) (0.90 - 1.03) (0.76 - 0.88) 
2016 1.07** 1.03 0.89*** 
 (1.02 - 1.12) (0.97 - 1.10) (0.84 - 0.95) 
State    
Arizona 0.73*** 0.22*** 0.60*** 
 (0.62 - 0.87) (0.18 - 0.27) (0.46 - 0.78) 
Arkansas 0.93 0.31*** 1.25 
 (0.69 - 1.25) (0.21 - 0.46) (0.84 - 1.86) 
Colorado 1.37*** 0.22*** 1.04 
 (1.23 - 1.52) (0.18 - 0.25) (0.87 - 1.24) 
Connecticut 0.52*** 0.03*** 0.26*** 
 (0.47 - 0.57) (0.03 - 0.04) (0.22 - 0.31) 





 (1.35 - 1.82) (0.06 - 0.14) (0.75 - 1.28) 
District of Columbia 12.48*** 0.09* 3.17* 
 (8.41 - 18.52) (0.01 - 0.68) (1.27 - 7.91) 
Florida 0.29*** 0.44 0.21*** 
 (0.15 - 0.57) (0.18 - 1.06) (0.10 - 0.42) 
Hawaii 0.26 0.31 0.79 
 (0.03 - 1.93) (0.07 - 1.32) (0.10 - 5.91) 
Idaho 2.3 5.60** 5.55*** 
 (0.80 - 6.66) (1.77 - 17.75) (2.17 - 14.22) 
Illinois 18.53*** 0.30*** 2.32*** 
 (16.73 - 20.53) (0.25 - 0.37) (1.89 - 2.85) 
Kansas 4.06*** 0.14*** 1.97*** 
 (3.26 - 5.06) (0.08 - 0.26) (1.34 - 2.89) 
Kentucky 1.79*** 1.19*** 4.13*** 
 (1.61 - 1.98) (1.08 - 1.31) (3.59 - 4.75) 
Maine 1.84 0.43* 0.37** 
 (0.98 - 3.44) (0.18 - 1.00) (0.19 - 0.71) 
Maryland 0.57*** 0.13*** 1.02 
 (0.52 - 0.63) (0.12 - 0.15) (0.89 - 1.18) 
Massachusetts 4.38*** 0.17*** 1.15 
 (4.02 - 4.76) (0.15 - 0.20) (0.98 - 1.36) 
Michigan 3.24*** 0.49*** 0.81** 
 (2.99 - 3.52) (0.45 - 0.54) (0.70 - 0.93) 
Mississippi 1.09  0.25 
 (0.27 - 4.42)  (0.03 - 2.21) 
Missouri 0.66 1.03 1.27 
 (0.34 - 1.25) (0.44 - 2.41) (0.66 - 2.45) 
Montana 1.68 4.03* 1.76 
 (0.59 - 4.74) (1.29 - 12.54) (0.64 - 4.79) 
Nebraska 2.03  0.79 
 (0.95 - 4.33)  (0.21 - 2.92) 
New Hampshire 2.64*** 0.23*** 2.34*** 
 (1.95 - 3.59) (0.13 - 0.42) (1.53 - 3.59) 
New Jersey 0.48*** 0.36*** 0.96 
 (0.44 - 0.53) (0.33 - 0.39) (0.84 - 1.11) 
New Mexico 1.69 0.26* 0.37 
 (0.95 - 3.02) (0.09 - 0.73) (0.05 - 2.73) 
New York 1.58*** 0.35*** 1.56*** 
 (1.47 - 1.71) (0.33 - 0.38) (1.38 - 1.76) 
North Carolina 1.26 0.92 0.23*** 
 (0.67 - 2.36) (0.39 - 2.14) (0.12 - 0.45) 





 (2.24 - 2.69) (0.32 - 0.41) (3.80 - 4.96) 
Oklahoma 0.59*** 0.02*** 0.45*** 
 (0.53 - 0.65) (0.02 - 0.03) (0.38 - 0.54) 
South Carolina 1.41 3.87** 0.78 
 (0.69 - 2.86) (1.59 - 9.40) (0.38 - 1.61) 
South Dakota 1.9 2.48 7.28*** 
 (0.49 - 7.37) (0.51 - 12.02) (2.55 - 20.77) 
Tennessee 3.67  30.76*** 
 (0.53 - 25.70)  (6.72 - 140.78) 
Utah 2.41** 2.14 0.78 
 (1.28 - 4.56) (0.91 - 5.04) (0.40 - 1.53) 
Wyoming 2.46  0.34 
 (0.60 - 9.97)  (0.04 - 3.20) 
* p<0.05, ** p<0.01, *** p<0.001 





























FULL TABLES  
Appendix 4-B 
Full tables from Chapter 4 (with details for state and year fixed effects) 
 
Table 4-B1. 2WFE model for the adjusted associations between Medicaid expansion and length of stay   
  
2 ways fixed effect 
pooled model 
2 ways fixed effect 
non-MAT 
2 ways fixed effect 
MAT 
     
N 231,025 169,449 61,573 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Medicaid expansion     
    Expansion  0.93*** 0.92** 1.19*** 
 (0.89 - 0.97) (0.88 - 0.97) (1.08 - 1.30) 
MAT (No= ref)     
   Yes 2.22***   
 (2.16 - 2.27)   
Referral sources    
   Healthcare provider 
referral 
0.93*** 1.01 0.87*** 
 (0.90 - 0.96) (0.97 - 1.04) (0.83 - 0.92) 
   Institutional referral 1.04* 1.21*** 0.78*** 
 (1.01 - 1.08) (1.17 - 1.26) (0.72 - 0.84) 
   Court/criminal justice 1.87*** 2.14*** 0.74*** 
 (1.82 - 1.92) (2.07 - 2.20) (0.69 - 0.81) 
Frequency of use (No 
past month use= ref)  
   
   Some use 0.72*** 0.70*** 0.85*** 
 (0.70 - 0.74) (0.68 - 0.73) (0.79 - 0.91) 
   Daily use 0.67*** 0.62*** 0.84*** 
 (0.66 - 0.69) (0.60 - 0.64) (0.80 - 0.89) 
Age (18-29= ref)     
   30-44 1.07*** 1.07*** 1.09*** 
 (1.05 - 1.09) (1.04 - 1.10) (1.04 - 1.13) 
   45-64 1.31*** 1.32*** 1.31*** 
 (1.27 - 1.34) (1.27 - 1.36) (1.25 - 1.38) 
Gender (Female=ref)    
   Male 0.90*** 0.89*** 0.92*** 







   
   Non-Hispanic Black 0.94** 0.94** 0.93* 
 (0.91 - 0.98) (0.89 - 0.98) (0.87 - 0.98) 
   Hispanic 1.01 0.94* 1.09** 
 (0.98 - 1.05) (0.90 - 0.99) (1.03 - 1.16) 
   Other 1.00 1.00 0.99 
 (0.95 - 1.06) (0.94 - 1.06) (0.88 - 1.10) 
Education (Less than 
high school= ref)  
   
   Highschool or higher 0.98 1.00 0.96* 
 (0.96 - 1.00) (0.98 - 1.03) (0.92 - 0.99) 
Number of arrests (0= 
ref) 
   
   1 0.97 1.04 0.79*** 
 (0.93 - 1.01) (0.99 - 1.09) (0.73 - 0.86) 
   2 or more 1.18*** 1.17*** 0.88 
 (1.09 - 1.28) (1.07 - 1.27) (0.73 - 1.06) 
Employment status 
(Unemployed= ref)  
   
     Employed 0.79*** 0.78*** 0.83*** 
 (0.77 - 0.81) (0.76 - 0.80) (0.80 - 0.87) 
Comorbidity (No= ref)     
   Yes 0.88*** 0.90*** 0.89*** 
 (0.86 - 0.90) (0.87 - 0.92) (0.85 - 0.92) 
Homeless (No= ref)     
  Yes 0.74*** 0.77*** 0.70*** 
 (0.70 - 0.77) (0.73 - 0.81) (0.65 - 0.76) 
Polysubstance use (no= 
ref)   
   
    One more 0.80*** 0.80*** 0.86*** 
 (0.78 - 0.81) (0.78 - 0.82) (0.82 - 0.89) 
    Two or more 0.73*** 0.76*** 0.76*** 
 (0.71 - 0.74) (0.73 - 0.78) (0.72 - 0.80) 
Year    
2011 1.16*** 1.21*** 1.08* 
 (1.12 - 1.21) (1.16 - 1.27) (1.00 - 1.16) 
2012 1.14*** 1.21*** 1.06 
 (1.10 - 1.19) (1.16 - 1.27) (0.98 - 1.15) 
2013 1.18*** 1.26*** 1.06 
 (1.13 - 1.23) (1.20 - 1.31) (0.98 - 1.15) 
2014 1.48*** 1.68*** 0.90* 





2015 1.15*** 1.36*** 0.69*** 
 (1.09 - 1.21) (1.28 - 1.44) (0.62 - 0.76) 
2016 1.19*** 1.41*** 0.71*** 
 (1.13 - 1.25) (1.33 - 1.49) (0.64 - 0.79) 
2017 0.98 1.33*** 0.51*** 
 (0.93 - 1.02) (1.26 - 1.40) (0.46 - 0.56) 
State    
Alaska 4.21*** 3.41*** 3.10*** 
 (2.87 - 6.19) (1.99 - 5.85) (1.65 - 5.83) 
Arizona 5.23*** 4.47*** 4.43*** 
 (3.72 - 7.35) (2.70 - 7.40) (2.78 - 7.06) 
Arkansas 1.16 1.06 1 
 (0.81 - 1.67) (0.62 - 1.82) (0.62 - 1.64) 
Colorado 2.37*** 1.83* 2.19*** 
 (1.68 - 3.35) (1.10 - 3.04) (1.38 - 3.49) 
Connecticut 1.55* 0.72 2.28*** 
 (1.10 - 2.20) (0.43 - 1.21) (1.44 - 3.63) 
Delaware 1.56* 1.49 0.96 
 (1.11 - 2.20) (0.90 - 2.48) (0.61 - 1.53) 
District of Columbia 4.66*** 3.75*** 4.18** 
 (2.86 - 7.61) (1.98 - 7.08) (1.62 - 10.81) 
Florida 1.65** 0.99 2.04** 
 (1.17 - 2.32) (0.60 - 1.64) (1.29 - 3.22) 
Hawaii 0.82 0.40** 5.68*** 
 (0.53 - 1.27) (0.22 - 0.74) (2.11 - 15.32) 
Idaho 2.56*** 1.88* 1.91 
 (1.73 - 3.76) (1.10 - 3.22) (0.66 - 5.47) 
Illinois 1.29 1.04 1.21 
 (0.92 - 1.82) (0.62 - 1.72) (0.76 - 1.91) 
Indiana 1.88*** 1.56 1.79* 
 (1.33 - 2.67) (0.94 - 2.60) (1.07 - 2.98) 
Iowa 2.23*** 1.77* 2.34** 
 (1.57 - 3.17) (1.06 - 2.96) (1.35 - 4.03) 
Kansas 3.37*** 2.69***  
 (2.35 - 4.82) (1.61 - 4.51)  
Kentucky 0.17*** 0.13*** 0.22*** 
 (0.12 - 0.24) (0.08 - 0.21) (0.14 - 0.35) 
Louisiana 2.18*** 1.97* 0.55 
 (1.52 - 3.13) (1.17 - 3.31) (0.26 - 1.16) 
Maine 2.30*** 1.58 2.51*** 
 (1.63 - 3.24) (0.95 - 2.65) (1.59 - 3.96) 





 (1.24 - 2.46) (0.86 - 2.37) (0.93 - 2.32) 
Massachusetts 2.17*** 1.87* 1.89** 
 (1.54 - 3.08) (1.12 - 3.12) (1.18 - 3.03) 
Michigan 1.44* 1.06 1.65* 
 (1.03 - 2.03) (0.64 - 1.75) (1.04 - 2.60) 
Mississippi 1.16 0.83 1.96 
 (0.80 - 1.67) (0.49 - 1.40) (0.78 - 4.89) 
Missouri 1.67** 1.1 2.86*** 
 (1.18 - 2.37) (0.66 - 1.84) (1.76 - 4.66) 
Montana 2.14*** 1.70*  
 (1.48 - 3.08) (1.01 - 2.87)  
Nebraska 1.02 0.83 0.74 
 (0.66 - 1.58) (0.46 - 1.48) (0.27 - 2.02) 
Nevada 3.20** 1.45 5.36** 
 (1.53 - 6.71) (0.46 - 4.52) (1.79 - 16.04) 
New Hampshire 1.24 0.9 2.09* 
 (0.87 - 1.78) (0.54 - 1.52) (1.07 - 4.06) 
New Jersey 1.90*** 1.22 1.85** 
 (1.35 - 2.68) (0.74 - 2.03) (1.18 - 2.92) 
New Mexico 1.09 0.2 1.05 
 (0.57 - 2.09) (0.02 - 1.77) (0.49 - 2.22) 
New York 1.95*** 1.61 1.85** 
 (1.39 - 2.73) (0.97 - 2.65) (1.18 - 2.92) 
North Carolina 0.59** 0.49** 0.54** 
 (0.42 - 0.83) (0.30 - 0.82) (0.35 - 0.85) 
North Dakota 2.46** 1.99  
 (1.27 - 4.75) (0.93 - 4.26)  
Ohio 2.19*** 1.82* 1.93** 
 (1.56 - 3.08) (1.10 - 3.02) (1.22 - 3.05) 
Oklahoma 4.69*** 3.52***  
 (3.29 - 6.70) (2.11 - 5.89)  
Pennsylvania 1.14 0.87 1.26 
 (0.80 - 1.64) (0.51 - 1.46) (0.76 - 2.09) 
Rhode Island 2.60*** 1.27 3.08*** 
 (1.83 - 3.68) (0.75 - 2.14) (1.93 - 4.89) 
South Carolina 2.09*** 1.80* 1.57 
 (1.47 - 2.97) (1.08 - 3.00) (0.87 - 2.83) 
South Dakota 1.62* 1.31 1.27 
 (1.01 - 2.60) (0.72 - 2.41) (0.38 - 4.17) 
Tennessee 1.50* 1.14 1.08 
 (1.05 - 2.15) (0.68 - 1.90) (0.09 - 12.77) 





 (1.96 - 3.89) (1.51 - 4.14) (1.11 - 2.85) 
Washington 2.93*** 2.10** 3.26*** 
 (2.08 - 4.13) (1.27 - 3.49) (2.06 - 5.17) 
Wyoming 2.90*** 2.10*  
 (1.73 - 4.86) (1.11 - 3.98)  
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  














Table 4-B2. DID model for the adjusted associations between Medicaid expansion and treatment length of stay  





    
N 225,272 164,420 60,849 
 AOR AOR AOR 
 (95%CI) (95%CI) (95%CI) 
     
Treat 2.91*** 2.09** 3.25*** 
   Expansion states (2.07 - 4.10) (1.26 - 3.46) (2.05 - 5.15) 
       
Expansion  0.97 1.33*** 0.51*** 
   After the ACA 
implementation (2014)  
(0.93 - 1.02) (1.26 - 1.41) (0.46 - 0.56) 
    
Medicaid expansion     
    Medicaid expansion  0.94** 0.94** 1.19*** 
 (0.90 - 0.98) (0.89 - 0.98) (1.08 - 1.31) 
MAT (No= ref)     
   Yes 2.23***   
 (2.18 - 2.29)   
Referral sources    
   Healthcare provider referral 0.93*** 1.01 0.88*** 
 (0.90 - 0.96) (0.97 - 1.05) (0.83 - 0.92) 
   Institutional referral 1.05** 1.22*** 0.79*** 
 (1.02 - 1.09) (1.17 - 1.26) (0.74 - 0.85) 
   Court/criminal justice 1.88*** 2.16*** 0.74*** 
 (1.83 - 1.94) (2.10 - 2.23) (0.68 - 0.80) 
Frequency of use (No past 
month use= ref)  
   
   Some use 0.72*** 0.70*** 0.84*** 
 (0.69 - 0.74) (0.68 - 0.72) (0.78 - 0.90) 
   Daily use 0.67*** 0.62*** 0.84*** 
 (0.65 - 0.69) (0.60 - 0.64) (0.79 - 0.89) 
Age (18-29= ref)     
   30-44 1.07*** 1.07*** 1.09*** 
 (1.05 - 1.10) (1.05 - 1.10) (1.04 - 1.14) 
   45-64 1.30*** 1.32*** 1.31*** 
 (1.27 - 1.34) (1.27 - 1.37) (1.24 - 1.38) 
Gender (Female=ref)    
   Male 0.90*** 0.89*** 0.93*** 
 (0.88 - 0.92) (0.87 - 0.92) (0.89 - 0.96) 
Race/ethnicity (non-
Hispanic White=ref) 
   





 (0.91 - 0.98) (0.89 - 0.99) (0.87 - 0.99) 
   Hispanic 1.01 0.94** 1.09** 
 (0.97 - 1.05) (0.89 - 0.98) (1.02 - 1.16) 
   Other 1.01 1.01 0.99 
 (0.96 - 1.07) (0.94 - 1.08) (0.88 - 1.10) 
Education (Less than high 
school= ref)  
   
   Highschool or higher 0.98 1.00 0.96* 
 (0.96 - 1.00) (0.98 - 1.03) (0.92 - 0.99) 
Number of arrests (0= ref)    
   1 0.96 1.04 0.79*** 
 (0.92 - 1.00) (0.99 - 1.09) (0.72 - 0.86) 
   2 or more 1.20*** 1.18*** 0.88 
 (1.11 - 1.30) (1.08 - 1.30) (0.73 - 1.06) 
Employment status 
(Unemployed= ref)  
   
     Employed 0.80*** 0.79*** 0.84*** 
 (0.78 - 0.82) (0.77 - 0.81) (0.80 - 0.87) 
Comorbidity (No= ref)     
   Yes 0.88*** 0.89*** 0.89*** 
 (0.86 - 0.90) (0.87 - 0.92) (0.85 - 0.92) 
Homeless (No= ref)     
  Yes 0.73*** 0.76*** 0.70*** 
 (0.70 - 0.76) (0.72 - 0.81) (0.64 - 0.75) 
Polysubstance use (no= ref)      
    One more 0.79*** 0.79*** 0.85*** 
 (0.77 - 0.81) (0.77 - 0.81) (0.82 - 0.89) 
    Two or more 0.72*** 0.75*** 0.76*** 
 (0.70 - 0.74) (0.73 - 0.77) (0.73 - 0.80) 
Year    
2011 1.18*** 1.23*** 1.09* 
 (1.13 - 1.22) (1.18 - 1.29) (1.01 - 1.17) 
2012 1.15*** 1.23*** 1.06 
 (1.11 - 1.20) (1.17 - 1.28) (0.98 - 1.15) 
2013 1.18*** 1.26*** 1.06 
 (1.14 - 1.23) (1.20 - 1.32) (0.98 - 1.15) 
2014 1.51*** 1.25*** 1.76*** 
 (1.45 - 1.57) (1.20 - 1.31) (1.64 - 1.88) 
2015 1.18*** 1.02 1.35*** 
 (1.14 - 1.23) (0.97 - 1.07) (1.27 - 1.44) 
2016 1.22*** 1.05* 1.41*** 
 (1.17 - 1.26) (1.01 - 1.10) (1.32 - 1.49) 
2017 - - - 
    
State    





 (1.67 - 1.92) (1.95 - 2.32) (1.18 - 1.58) 
Arkansas 0.40*** 0.51*** 0.31*** 
 (0.34 - 0.46) (0.41 - 0.62) (0.25 - 0.38) 
Colorado 0.81*** 0.87* 0.68*** 
 (0.74 - 0.89) (0.78 - 0.98) (0.59 - 0.78) 
Connecticut 0.53*** 0.34*** 0.70*** 
 (0.48 - 0.58) (0.30 - 0.39) (0.61 - 0.81) 
Delaware 0.53*** 0.70*** 0.30*** 
 (0.49 - 0.58) (0.63 - 0.78) (0.26 - 0.34) 
District of Columbia 1.59* 1.78** 1.28 
 (1.11 - 2.28) (1.19 - 2.65) (0.55 - 2.97) 
Florida 1.64** 0.99 2.04** 
 (1.16 - 2.31) (0.59 - 1.63) (1.29 - 3.21) 
Hawaii 0.28*** 0.19*** 1.74 
 (0.21 - 0.37) (0.13 - 0.27) (0.72 - 4.24) 
Idaho 2.56*** 1.88* 1.9 
 (1.74 - 3.77) (1.10 - 3.21) (0.66 - 5.45) 
Illinois 0.44*** 0.49*** 0.37*** 
 (0.41 - 0.48) (0.44 - 0.54) (0.33 - 0.42) 
Iowa 0.76*** 0.85** 0.72* 
 (0.68 - 0.86) (0.75 - 0.96) (0.52 - 0.99) 
Kansas 3.37*** 2.69***  
 (2.35 - 4.82) (1.61 - 4.50)  
Kentucky 0.06*** 0.06*** 0.07*** 
 (0.05 - 0.06) (0.06 - 0.07) (0.06 - 0.08) 
Maine 2.30*** 1.58 2.51*** 
 (1.63 - 3.24) (0.95 - 2.64) (1.59 - 3.96) 
Maryland 0.60*** 0.68*** 0.45*** 
 (0.55 - 0.64) (0.62 - 0.75) (0.41 - 0.51) 
Massachusetts 0.74*** 0.89 0.58*** 
 (0.67 - 0.82) (0.79 - 1.00) (0.49 - 0.69) 
Michigan 0.49*** 0.50*** 0.51*** 
 (0.46 - 0.53) (0.46 - 0.55) (0.45 - 0.57) 
Mississippi 1.16 0.83 1.96 
 (0.80 - 1.68) (0.49 - 1.40) (0.79 - 4.90) 
Missouri 1.67** 1.1 2.86*** 
 (1.18 - 2.37) (0.66 - 1.83) (1.76 - 4.65) 
Nebraska 1.02 0.82 0.74 
 (0.66 - 1.58) (0.46 - 1.47) (0.27 - 2.02) 
Nevada 1.09 0.68 1.64 
 (0.56 - 2.11) (0.25 - 1.91) (0.60 - 4.47) 
New Hampshire 0.42*** 0.43*** 0.64 
 (0.37 - 0.49) (0.37 - 0.50) (0.39 - 1.05) 
New Jersey 0.65*** 0.58*** 0.57*** 
 (0.60 - 0.70) (0.52 - 0.64) (0.51 - 0.63) 





 (0.21 - 0.65) (0.01 - 0.79) (0.18 - 0.59) 
New York 0.67*** 0.77*** 0.57*** 
 (0.63 - 0.71) (0.71 - 0.83) (0.52 - 0.63) 
North Carolina 0.59** 0.49** 0.54** 
 (0.42 - 0.83) (0.30 - 0.81) (0.35 - 0.85) 
North Dakota 0.84 0.95  
 (0.47 - 1.48) (0.53 - 1.69)  
Ohio 0.75*** 0.87*** 0.59*** 
 (0.70 - 0.80) (0.80 - 0.94) (0.53 - 0.67) 
Oklahoma 4.70*** 3.52***  
 (3.29 - 6.71) (2.11 - 5.89)  
Rhode Island 0.89* 0.60*** 0.95 
 (0.80 - 0.98) (0.51 - 0.71) (0.82 - 1.09) 
South Carolina 2.08*** 1.79* 1.57 
 (1.47 - 2.96) (1.08 - 2.99) (0.87 - 2.82) 
South Dakota 1.62* 1.31 1.27 
 (1.01 - 2.60) (0.71 - 2.41) (0.39 - 4.17) 
Tennessee 1.50* 1.13 1.07 
 (1.05 - 2.15) (0.68 - 1.90) (0.09 - 12.71) 
Utah 2.76*** 2.49*** 1.78* 
 (1.96 - 3.89) (1.50 - 4.13) (1.11 - 2.84) 
Washington - - - 
    
Wyoming 2.92*** 2.11*  
 (1.74 - 4.89) (1.11 - 4.00)  
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  













Table 4-B3. 2WFE model for the adjusted associations between Medicaid expansion and treatment completion   
  Pooled model Non-MAT MAT 
     
N 231,021 169,447 61,571 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Medicaid expansion  0.84*** 1.02 0.48*** 
    Expansion  (0.80 - 0.87) (0.97 - 1.06) (0.43 - 0.54) 
    
MAT (No= ref)     
   Yes 0.86***   






   Healthcare provider 
referral 
1.07*** 1.05** 1.14*** 
 (1.04 - 1.10) (1.02 - 1.09) (1.08 - 1.21) 
   Institutional referral 1.30*** 1.32*** 1.15*** 
 (1.26 - 1.34) (1.27 - 1.37) (1.07 - 1.24) 
   Court/criminal justice 2.03*** 2.00*** 1.89*** 
 (1.98 - 2.09) (1.94 - 2.06) (1.73 - 2.06) 
Frequency of use (No 
past month use= ref)  
   
   Some use 0.74*** 0.76*** 0.70*** 
 (0.71 - 0.76) (0.73 - 0.78) (0.65 - 0.76) 
   Daily use 0.77*** 0.85*** 0.59*** 
 (0.75 - 0.79) (0.83 - 0.88) (0.55 - 0.62) 
Age (18-29= ref)     
   30-44 1.06*** 1.07*** 1.04 
 (1.04 - 1.09) (1.04 - 1.09) (0.99 - 1.08) 
   45-64 1.14*** 1.23*** 0.99 
 (1.11 - 1.18) (1.19 - 1.27) (0.93 - 1.05) 
Gender (Female=ref)    
   Male 0.93*** 0.97** 0.81*** 
 (0.92 - 0.95) (0.95 - 0.99) (0.78 - 0.84) 
Race/ethnicity (non-
Hispanic White=ref) 
   





 (0.79 - 0.86) (0.90 - 0.99) (0.63 - 0.73) 
   Hispanic 0.85*** 0.92*** 0.81*** 
 (0.82 - 0.89) (0.88 - 0.97) (0.75 - 0.86) 
   Other 0.73*** 0.76*** 0.69*** 
 (0.69 - 0.77) (0.72 - 0.81) (0.61 - 0.78) 
Education (Less than 
high school= ref)  
   
   Highschool or higher 1.19*** 1.17*** 1.20*** 
 (1.16 - 1.21) (1.14 - 1.20) (1.15 - 1.25) 
Number of arrests (0= 
ref) 
   
   1 1.15*** 1.19*** 1.04 
 (1.10 - 1.20) (1.13 - 1.24) (0.94 - 1.14) 
   2 or more 0.84*** 0.89* 1.03 
 (0.78 - 0.91) (0.81 - 0.97) (0.83 - 1.29) 
Employment status 
(Unemployed= ref)  
   
     Employed 1.03* 1.06*** 0.97 
 (1.01 - 1.05) (1.03 - 1.09) (0.93 - 1.02) 
Comorbidity (No= ref)     
   Yes 0.89*** 0.87*** 0.95* 
 (0.88 - 0.91) (0.85 - 0.89) (0.91 - 0.99) 
Homeless (No= ref)     
  Yes 1.10*** 1.14*** 1.02 
 (1.06 - 1.15) (1.08 - 1.20) (0.94 - 1.12) 
Polysubstance use (no= 
ref)   
   
    One more 1.12*** 1.13*** 1.02 
 (1.10 - 1.14) (1.11 - 1.16) (0.98 - 1.07) 
    Two or more 1.21*** 1.22*** 1.07* 
 (1.18 - 1.24) (1.18 - 1.25) (1.01 - 1.13) 
Year    
2011 1.02 1.04 0.95 
 (0.98 - 1.06) (0.99 - 1.08) (0.87 - 1.03) 
2012 1 1.03 0.96 
 (0.96 - 1.04) (0.99 - 1.08) (0.88 - 1.04) 
2013 0.93*** 0.96 0.87*** 
 (0.89 - 0.96) (0.92 - 1.01) (0.79 - 0.94) 
2014 0.97 0.88*** 1.56*** 
 (0.92 - 1.01) (0.83 - 0.92) (1.38 - 1.77) 
2015 0.96 0.90*** 1.40*** 
 (0.92 - 1.01) (0.85 - 0.95) (1.24 - 1.59) 





 (1.06 - 1.17) (1.01 - 1.12) (1.43 - 1.83) 
2017 1.55*** 1.42*** 2.12*** 
 (1.49 - 1.63) (1.35 - 1.49) (1.88 - 2.38) 
State    
Alaska 1.51* 1.53 0.94 
 (1.03 - 2.21) (0.91 - 2.59) (0.47 - 1.91) 
Arizona 0.64* 0.49** 1.45 
 (0.45 - 0.90) (0.30 - 0.81) (0.88 - 2.38) 
Arkansas 1.87*** 2.23** 1.91* 
 (1.30 - 2.70) (1.32 - 3.76) (1.13 - 3.22) 
Colorado 2.66*** 2.17** 4.38*** 
 (1.88 - 3.76) (1.32 - 3.58) (2.68 - 7.17) 
Connecticut 4.01*** 3.23*** 6.53*** 
 (2.83 - 5.68) (1.95 - 5.33) (3.99 - 10.70) 
Delaware 1.64** 1.24 3.27*** 
 (1.16 - 2.32) (0.75 - 2.03) (2.00 - 5.36) 
District of Columbia 3.07*** 1.99* 7.60*** 
 (1.92 - 4.92) (1.08 - 3.68) (3.26 - 17.73) 
Florida 8.54*** 3.41*** 43.97*** 
 (6.04 - 12.06) (2.08 - 5.59) (26.61 - 72.64) 
Hawaii 5.05*** 5.02*** 4.04*** 
 (3.23 - 7.88) (2.79 - 9.05) (1.77 - 9.18) 
Idaho 2.06*** 2.09** 2.16 
 (1.39 - 3.03) (1.24 - 3.54) (0.74 - 6.29) 
Illinois 1.03 0.96 1.6 
 (0.73 - 1.45) (0.59 - 1.57) (0.98 - 2.61) 
Indiana 0.66* 0.65 0.45* 
 (0.47 - 0.94) (0.39 - 1.07) (0.25 - 0.83) 
Iowa 1.28 1.26 0.41* 
 (0.89 - 1.82) (0.76 - 2.07) (0.20 - 0.82) 
Kansas 1.61** 1.53  
 (1.12 - 2.31) (0.92 - 2.52)  
Kentucky 13.44*** 12.31*** 16.20*** 
 (9.55 - 18.90) (7.54 - 20.10) (9.95 - 26.36) 
Louisiana 1.4 1.19 6.40*** 
 (0.97 - 2.01) (0.72 - 1.97) (2.98 - 13.74) 
Maine 0.91 0.83 1.01 
 (0.64 - 1.28) (0.51 - 1.38) (0.62 - 1.63) 
Maryland 1.34 1.36 1.80* 
 (0.95 - 1.89) (0.83 - 2.23) (1.11 - 2.93) 
Massachusetts 1.21 1.15 1.34 





Michigan 1.37 1.12 2.31*** 
 (0.97 - 1.93) (0.68 - 1.82) (1.42 - 3.76) 
Mississippi 1.50* 1.52 0.32 
 (1.04 - 2.17) (0.91 - 2.53) (0.10 - 1.04) 
Missouri 1.84*** 2.08** 1.45 
 (1.30 - 2.62) (1.26 - 3.43) (0.87 - 2.42) 
Montana 1.70** 1.59  
 (1.18 - 2.46) (0.96 - 2.65)  
Nebraska 4.95*** 4.74*** 6.73*** 
 (3.11 - 7.85) (2.63 - 8.56) (2.26 - 20.06) 
Nevada 2.27* 2.73 2.72* 
 (1.11 - 4.61) (0.88 - 8.51) (1.05 - 7.08) 
New Hampshire 6.37*** 5.70*** 5.71*** 
 (4.40 - 9.21) (3.42 - 9.51) (2.85 - 11.45) 
New Jersey 1.09 1.75* 1.18 
 (0.77 - 1.53) (1.06 - 2.87) (0.73 - 1.92) 
New Mexico 8.61*** 1.82 18.17*** 
 (4.20 - 17.65) (0.44 - 7.46) (7.52 - 43.91) 
New York 0.85 0.8 1.14 
 (0.60 - 1.19) (0.49 - 1.30) (0.70 - 1.86) 
North Carolina 4.50*** 3.83*** 12.85*** 
 (3.20 - 6.31) (2.35 - 6.24) (7.95 - 20.78) 
North Dakota 2.58** 2.39*  
 (1.33 - 5.01) (1.13 - 5.05)  
Ohio 0.91 0.94 0.66 
 (0.64 - 1.27) (0.57 - 1.53) (0.40 - 1.08) 
Oklahoma 1.44* 1.43  
 (1.01 - 2.05) (0.87 - 2.36)  
Pennsylvania 1.17 1.29 0.75 
 (0.82 - 1.68) (0.77 - 2.14) (0.43 - 1.32) 
Rhode Island 1.74** 1.38 2.73*** 
 (1.22 - 2.46) (0.83 - 2.30) (1.67 - 4.46) 
South Carolina 1.58* 1.5 1.35 
 (1.11 - 2.25) (0.91 - 2.46) (0.73 - 2.49) 
South Dakota 2.53*** 2.54** 2.71 
 (1.57 - 4.08) (1.39 - 4.64) (0.78 - 9.47) 
Tennessee 0.77 0.76  
 (0.54 - 1.11) (0.46 - 1.25)  
Utah 2.17*** 2.30*** 1.68* 
 (1.53 - 3.06) (1.40 - 3.77) (1.02 - 2.76) 
Washington 1.98*** 1.77* 3.00*** 





Wyoming 2.16** 2.16* 1.68 
 (1.29 - 3.62) (1.15 - 4.04) (0.14 - 19.57) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  

















DID model  
  MAT 
    
N 225,268 164,418 60,847 
 AOR AOR AOR 
 (95%CI) (95%CI) (95%CI) 
        
Treat    
   Expansion states 1.58*** 1.45*** 2.12*** 
    (1.51 - 1.65) (1.38 - 1.52) (1.89 - 2.39) 
Expansion     
   After the ACA implementation (2014)  2.00*** 1.78* 3.01*** 
 (1.42 - 2.82) (1.09 - 2.91) (1.85 - 4.91) 
Medicaid expansion     
    Expansion  0.83*** 1.02 0.48*** 
 (0.80 - 0.87) (0.97 - 1.07) (0.43 - 0.54) 
MAT (No= ref)     
   Yes 0.87***   
 (0.85 - 0.89)   
Referral sources    
   Healthcare provider referral 1.07*** 1.06*** 1.15*** 
 (1.04 - 1.10) (1.02 - 1.09) (1.09 - 1.22) 
   Institutional referral 1.30*** 1.32*** 1.16*** 
 (1.26 - 1.34) (1.27 - 1.37) (1.07 - 1.25) 
   Court/criminal justice 2.05*** 2.03*** 1.89*** 
 (2.00 - 2.11) (1.97 - 2.09) (1.73 - 2.07) 
Frequency of use (No past month use= 
ref)  
   
   Some use 0.74*** 0.77*** 0.70*** 
 (0.72 - 0.76) (0.74 - 0.79) (0.65 - 0.75) 
   Daily use 0.79*** 0.87*** 0.58*** 
 (0.77 - 0.81) (0.85 - 0.90) (0.55 - 0.62) 
Age (18-29= ref)     
   30-44 1.06*** 1.07*** 1.03 
 (1.04 - 1.08) (1.04 - 1.09) (0.98 - 1.08) 
   45-64 1.11*** 1.22*** 0.91** 
 (1.08 - 1.14) (1.18 - 1.27) (0.86 - 0.96) 
Gender (Female=ref)    
   Male 0.92*** 0.96*** 0.80*** 
 (0.90 - 0.94) (0.94 - 0.98) (0.77 - 0.84) 
Race/ethnicity (non-Hispanic 
White=ref) 





   Non-Hispanic Black 0.82*** 0.94* 0.68*** 
 (0.79 - 0.86) (0.90 - 0.99) (0.63 - 0.73) 
   Hispanic 0.85*** 0.92** 0.80*** 
 (0.82 - 0.88) (0.88 - 0.97) (0.75 - 0.86) 
   Other 0.74*** 0.78*** 0.68*** 
 (0.70 - 0.78) (0.73 - 0.83) (0.60 - 0.77) 
Education (Less than high school= ref)     
   Highschool or higher 1.19*** 1.17*** 1.20*** 
 (1.16 - 1.21) (1.14 - 1.20) (1.15 - 1.25) 
Number of arrests (0= ref)    
   1 1.16*** 1.20*** 1.03 
 (1.11 - 1.21) (1.14 - 1.26) (0.94 - 1.14) 
   2 or more 0.84*** 0.89* 1.04 
 (0.77 - 0.91) (0.81 - 0.97) (0.83 - 1.30) 
Employment status (Unemployed= ref)     
     Employed 1.03* 1.06*** 0.97 
 (1.01 - 1.05) (1.04 - 1.09) (0.93 - 1.02) 
Comorbidity (No= ref)     
   Yes 0.89*** 0.87*** 0.95* 
 (0.87 - 0.91) (0.85 - 0.89) (0.91 - 0.99) 
Homeless (No= ref)     
  Yes 1.11*** 1.15*** 1.02 
 (1.06 - 1.16) (1.09 - 1.21) (0.94 - 1.12) 
Polysubstance use (no= ref)      
    One more 1.13*** 1.14*** 1.02 
 (1.10 - 1.15) (1.11 - 1.17) (0.98 - 1.07) 
    Two or more 1.22*** 1.22*** 1.07* 
 (1.19 - 1.25) (1.19 - 1.26) (1.01 - 1.13) 
Year  
   
2011 1.01 1.03 0.96 
 (0.98 - 1.05) (0.99 - 1.08) (0.88 - 1.04) 
2012 1 1.04 0.96 
 (0.96 - 1.04) (0.99 - 1.08) (0.88 - 1.05) 
2013 0.92*** 0.97 0.85*** 
 (0.89 - 0.96) (0.92 - 1.01) (0.78 - 0.93) 
2014 0.62*** 0.61*** 0.74*** 
 (0.60 - 0.64) (0.59 - 0.64) (0.68 - 0.80) 
2015 0.61*** 0.63*** 0.66*** 
 (0.59 - 0.64) (0.60 - 0.65) (0.61 - 0.71) 
2016 0.71*** 0.74*** 0.77*** 
 (0.68 - 0.73) (0.71 - 0.77) (0.72 - 0.82) 
2017 - - - 
    
State    





 (0.30 - 0.35) (0.25 - 0.30) (0.42 - 0.55) 
Arkansas 0.94 1.26* 0.64*** 
 (0.82 - 1.09) (1.03 - 1.53) (0.51 - 0.79) 
Colorado 1.34*** 1.23*** 1.46*** 
 (1.23 - 1.46) (1.10 - 1.38) (1.28 - 1.67) 
Connecticut 2.03*** 1.82*** 2.18*** 
 (1.85 - 2.22) (1.59 - 2.08) (1.91 - 2.49) 
Delaware 0.83*** 0.70*** 1.09 
 (0.76 - 0.90) (0.63 - 0.78) (0.95 - 1.25) 
District of Columbia 1.56** 1.12 2.53** 
 (1.12 - 2.17) (0.77 - 1.64) (1.25 - 5.10) 
Florida 8.60*** 3.44*** 44.04*** 
 (6.09 - 12.16) (2.10 - 5.64) (26.65 - 72.78) 
Hawaii 2.55*** 2.81*** 1.35 
 (1.90 - 3.41) (2.01 - 3.94) (0.69 - 2.64) 
Idaho 2.07*** 2.10** 2.16 
 (1.40 - 3.05) (1.24 - 3.55) (0.74 - 6.29) 
Illinois 0.52*** 0.54*** 0.53*** 
 (0.48 - 0.56) (0.49 - 0.60) (0.47 - 0.60) 
Iowa 0.64*** 0.71*** 0.14*** 
 (0.58 - 0.72) (0.63 - 0.80) (0.08 - 0.23) 
Kansas 1.62** 1.53  
 (1.13 - 2.33) (0.93 - 2.53)  
Kentucky 6.81*** 6.97*** 5.38*** 
 (6.40 - 7.24) (6.44 - 7.54) (4.81 - 6.00) 
Maine 0.91 0.84 1.01 
 (0.65 - 1.29) (0.51 - 1.39) (0.62 - 1.64) 
Maryland 0.68*** 0.77*** 0.60*** 
 (0.63 - 0.73) (0.70 - 0.85) (0.54 - 0.67) 
Massachusetts 0.61*** 0.64*** 0.45*** 
 (0.55 - 0.67) (0.57 - 0.72) (0.37 - 0.54) 
Michigan 0.69*** 0.63*** 0.77*** 
 (0.64 - 0.74) (0.57 - 0.68) (0.69 - 0.86) 
Mississippi 1.50* 1.51 0.32 
 (1.04 - 2.16) (0.91 - 2.51) (0.10 - 1.04) 
Missouri 1.86*** 2.11** 1.45 
 (1.31 - 2.64) (1.28 - 3.48) (0.87 - 2.43) 
Nebraska 4.98*** 4.76*** 6.74*** 
 (3.14 - 7.91) (2.64 - 8.60) (2.26 - 20.11) 
Nevada 1.14 1.52 0.91 
 (0.61 - 2.13) (0.54 - 4.26) (0.40 - 2.08) 
New Hampshire 3.22*** 3.21*** 1.90* 
 (2.77 - 3.75) (2.72 - 3.79) (1.14 - 3.16) 
New Jersey 0.55*** 0.99 0.39*** 
 (0.51 - 0.59) (0.89 - 1.10) (0.35 - 0.44) 





 (2.30 - 8.19) (0.27 - 3.86) (2.89 - 12.79) 
New York 0.43*** 0.45*** 0.38*** 
 (0.41 - 0.46) (0.42 - 0.49) (0.35 - 0.42) 
North Carolina 4.53*** 3.84*** 12.87*** 
 (3.22 - 6.36) (2.36 - 6.27) (7.96 - 20.81) 
North Dakota 1.3 1.35  
 (0.74 - 2.31) (0.76 - 2.39)  
Ohio 0.46*** 0.53*** 0.22*** 
 (0.43 - 0.49) (0.49 - 0.58) (0.19 - 0.25) 
Oklahoma 1.45* 1.44  
 (1.01 - 2.07) (0.87 - 2.37)  
Rhode Island 0.88** 0.78** 0.91 
 (0.79 - 0.97) (0.67 - 0.92) (0.80 - 1.04) 
South Carolina 1.60** 1.51 1.34 
 (1.12 - 2.28) (0.92 - 2.49) (0.73 - 2.48) 
South Dakota 2.56*** 2.57** 2.71 
 (1.59 - 4.13) (1.41 - 4.69) (0.77 - 9.45) 
Tennessee 0.78 0.76  
 (0.54 - 1.12) (0.46 - 1.26)  
Utah 2.18*** 2.30*** 1.68* 
 (1.54 - 3.08) (1.41 - 3.77) (1.02 - 2.77) 
Washington - - - 
    
Wyoming 2.17** 2.16* 1.68 
 (1.30 - 3.64) (1.16 - 4.05) (0.14 - 19.60) 
Arizona 0.32*** 0.28*** 0.48*** 
 (0.30 - 0.35) (0.25 - 0.30) (0.42 - 0.55) 
Arkansas 0.94 1.26* 0.64*** 
 (0.82 - 1.09) (1.03 - 1.53) (0.51 - 0.79) 
Colorado 1.34*** 1.23*** 1.46*** 
 (1.23 - 1.46) (1.10 - 1.38) (1.28 - 1.67) 
Connecticut 2.03*** 1.82*** 2.18*** 
 (1.85 - 2.22) (1.59 - 2.08) (1.91 - 2.49) 
Delaware 0.83*** 0.70*** 1.09 
 (0.76 - 0.90) (0.63 - 0.78) (0.95 - 1.25) 
District of Columbia 1.56** 1.12 2.53** 
 (1.12 - 2.17) (0.77 - 1.64) (1.25 - 5.10) 
Florida 8.60*** 3.44*** 44.04*** 
 (6.09 - 12.16) (2.10 - 5.64) (26.65 - 72.78) 
Hawaii 2.55*** 2.81*** 1.35 
 (1.90 - 3.41) (2.01 - 3.94) (0.69 - 2.64) 
Idaho 2.07*** 2.10** 2.16 
 (1.40 - 3.05) (1.24 - 3.55) (0.74 - 6.29) 
Illinois 0.52*** 0.54*** 0.53*** 
 (0.48 - 0.56) (0.49 - 0.60) (0.47 - 0.60) 





 (0.58 - 0.72) (0.63 - 0.80) (0.08 - 0.23) 
Kansas 1.62** 1.53  
 (1.13 - 2.33) (0.93 - 2.53)  
Kentucky 6.81*** 6.97*** 5.38*** 
 (6.40 - 7.24) (6.44 - 7.54) (4.81 - 6.00) 
Maine 0.91 0.84 1.01 
 (0.65 - 1.29) (0.51 - 1.39) (0.62 - 1.64) 
Maryland 0.68*** 0.77*** 0.60*** 
 (0.63 - 0.73) (0.70 - 0.85) (0.54 - 0.67) 
Massachusetts 0.61*** 0.64*** 0.45*** 
 (0.55 - 0.67) (0.57 - 0.72) (0.37 - 0.54) 
Michigan 0.69*** 0.63*** 0.77*** 
 (0.64 - 0.74) (0.57 - 0.68) (0.69 - 0.86) 
Mississippi 1.50* 1.51 0.32 
 (1.04 - 2.16) (0.91 - 2.51) (0.10 - 1.04) 
Missouri 1.86*** 2.11** 1.45 
 (1.31 - 2.64) (1.28 - 3.48) (0.87 - 2.43) 
Nebraska 4.98*** 4.76*** 6.74*** 
 (3.14 - 7.91) (2.64 - 8.60) (2.26 - 20.11) 
Nevada 1.14 1.52 0.91 
 (0.61 - 2.13) (0.54 - 4.26) (0.40 - 2.08) 
New Hampshire 3.22*** 3.21*** 1.90* 
 (2.77 - 3.75) (2.72 - 3.79) (1.14 - 3.16) 
New Jersey 0.55*** 0.99 0.39*** 
 (0.51 - 0.59) (0.89 - 1.10) (0.35 - 0.44) 
New Mexico 4.35*** 1.02 6.07*** 
 (2.30 - 8.19) (0.27 - 3.86) (2.89 - 12.79) 
New York 0.43*** 0.45*** 0.38*** 
 (0.41 - 0.46) (0.42 - 0.49) (0.35 - 0.42) 
North Carolina 4.53*** 3.84*** 12.87*** 
 (3.22 - 6.36) (2.36 - 6.27) (7.96 - 20.81) 
North Dakota 1.3 1.35  
 (0.74 - 2.31) (0.76 - 2.39)  
Ohio 0.46*** 0.53*** 0.22*** 
 (0.43 - 0.49) (0.49 - 0.58) (0.19 - 0.25) 
Oklahoma 1.45* 1.44  
 (1.01 - 2.07) (0.87 - 2.37)  
Rhode Island 0.88** 0.78** 0.91 
 (0.79 - 0.97) (0.67 - 0.92) (0.80 - 1.04) 
South Carolina 1.60** 1.51 1.34 
 (1.12 - 2.28) (0.92 - 2.49) (0.73 - 2.48) 
South Dakota 2.56*** 2.57** 2.71 
 (1.59 - 4.13) (1.41 - 4.69) (0.77 - 9.45) 
Tennessee 0.78 0.76  
 (0.54 - 1.12) (0.46 - 1.26)  





 (1.54 - 3.08) (1.41 - 3.77) (1.02 - 2.77) 
Washington - - - 
    
Wyoming 2.17** 2.16* 1.68 
 (1.30 - 3.64) (1.16 - 4.05) (0.14 - 19.60) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  










Table 4-B5. DID model for the adjusted associations between Medicaid expansion and length of stay (without 
controlling for referral sources) 
  DID pooled model DID Non-MAT DID MAT 
    
N 228,239 166,465 61,771 
 AOR AOR AOR 
 (95%CI) (95%CI) (95%CI) 
     
Treat    
   Expansion states 2.96*** 2.09** 3.35*** 
    (2.10 - 4.15) (1.27 - 3.45) (2.12 - 5.30) 
Expansion  0.98 1.30*** 0.52*** 
   After the ACA 
implementation (2014)  
(0.93 - 1.02) (1.23 - 1.37) (0.47 - 0.58) 
    
Medicaid expansion     
    Expansion  0.96 0.96 1.17*** 
 (0.92 - 1.00) (0.92 - 1.01) (1.07 - 1.29) 
MAT (No= ref)     
   Yes 1.95***   
 (1.90 - 1.99)   
Frequency of use (No past 
month use= ref)  
   
   Some use 0.65*** 0.61*** 0.87*** 
 (0.63 - 0.66) (0.59 - 0.63) (0.81 - 0.93) 
   Daily use 0.57*** 0.49*** 0.88*** 
 (0.55 - 0.58) (0.48 - 0.51) (0.84 - 0.93) 
Age (18-29= ref)     
   30-44 1.06*** 1.06*** 1.09*** 
 (1.04 - 1.09) (1.04 - 1.09) (1.05 - 1.14) 
   45-64 1.27*** 1.28*** 1.33*** 
 (1.24 - 1.31) (1.24 - 1.32) (1.26 - 1.40) 
Gender (Female=ref)    
   Male 0.93*** 0.93*** 0.93*** 
 (0.91 - 0.95) (0.91 - 0.95) (0.89 - 0.96) 
Race/ethnicity (non-Hispanic 
White=ref) 
   
   Non-Hispanic Black 0.96 0.97 0.93* 
 (0.93 - 1.00) (0.93 - 1.02) (0.88 - 0.99) 
   Hispanic 1.03 0.97 1.09** 
 (0.99 - 1.07) (0.92 - 1.01) (1.03 - 1.16) 
   Other 1.01 1.01 0.97 





Education (Less than high 
school= ref)  
   
   Highschool or higher 0.96*** 0.97** 0.96* 
 (0.94 - 0.98) (0.94 - 0.99) (0.92 - 1.00) 
Number of arrests (0= ref)    
   1 1.07*** 1.20*** 0.75*** 
 (1.03 - 1.12) (1.14 - 1.25) (0.69 - 0.82) 
   2 or more 1.21*** 1.17*** 0.86 
 (1.12 - 1.31) (1.07 - 1.28) (0.71 - 1.04) 
Employment status 
(Unemployed= ref)  
   
     Employed 0.79*** 0.78*** 0.83*** 
 (0.77 - 0.81) (0.76 - 0.80) (0.80 - 0.87) 
Comorbidity (No= ref)     
   Yes 0.83*** 0.82*** 0.88*** 
 (0.82 - 0.85) (0.80 - 0.84) (0.85 - 0.92) 
Homeless (No= ref)     
  Yes 0.70*** 0.72*** 0.68*** 
 (0.67 - 0.73) (0.68 - 0.76) (0.63 - 0.74) 
Polysubstance use (no= ref)      
    One more 0.78*** 0.77*** 0.85*** 
 (0.76 - 0.80) (0.75 - 0.79) (0.81 - 0.88) 
    Two or more 0.72*** 0.74*** 0.75*** 
 (0.70 - 0.74) (0.72 - 0.76) (0.72 - 0.79) 
    
Year     
2011 1.19*** 1.23*** 1.11** 
 (1.14 - 1.23) (1.18 - 1.29) (1.03 - 1.19) 
2012 1.17*** 1.24*** 1.08 
 (1.12 - 1.21) (1.18 - 1.30) (1.00 - 1.16) 
2013 1.21*** 1.29*** 1.09* 
 (1.16 - 1.26) (1.23 - 1.35) (1.01 - 1.18) 
2014 1.51*** 1.29*** 1.77*** 
 (1.46 - 1.57) (1.23 - 1.34) (1.65 - 1.89) 
2015 1.18*** 1.04 1.35*** 
 (1.14 - 1.22) (0.99 - 1.09) (1.26 - 1.44) 
2016 1.22*** 1.08** 1.40*** 
 (1.18 - 1.26) (1.03 - 1.12) (1.32 - 1.48) 
2017 - - - 
    
State    
Arizona 1.59*** 1.75*** 1.43*** 
 (1.48 - 1.70) (1.62 - 1.90) (1.24 - 1.64) 
Arkansas 0.39*** 0.49*** 0.32*** 





Colorado 0.81*** 0.85** 0.70*** 
 (0.75 - 0.89) (0.76 - 0.95) (0.61 - 0.80) 
Connecticut 0.55*** 0.39*** 0.75*** 
 (0.50 - 0.60) (0.34 - 0.44) (0.65 - 0.85) 
Delaware 0.55*** 0.73*** 0.31*** 
 (0.50 - 0.59) (0.65 - 0.81) (0.27 - 0.35) 
District of Columbia 1.44* 1.58* 1.14 
 (1.02 - 2.04) (1.07 - 2.33) (0.52 - 2.53) 
Florida 1.70** 1.02 2.19*** 
 (1.21 - 2.38) (0.62 - 1.68) (1.39 - 3.45) 
Hawaii 0.30*** 0.21*** 1.8 
 (0.23 - 0.40) (0.15 - 0.29) (0.74 - 4.36) 
Idaho 3.14*** 2.33** 1.89 
 (2.13 - 4.61) (1.37 - 3.96) (0.66 - 5.41) 
Illinois 0.44*** 0.49*** 0.38*** 
 (0.41 - 0.47) (0.44 - 0.54) (0.34 - 0.43) 
Iowa 0.75*** 0.81*** 0.73* 
 (0.67 - 0.83) (0.72 - 0.92) (0.53 - 1.00) 
Kansas 3.49*** 2.73***  
 (2.44 - 4.99) (1.64 - 4.54)  
Kentucky 0.06*** 0.06*** 0.07*** 
 (0.06 - 0.06) (0.06 - 0.07) (0.06 - 0.07) 
Maine 2.30*** 1.51 2.68*** 
 (1.64 - 3.24) (0.91 - 2.51) (1.70 - 4.22) 
Maryland 0.61*** 0.71*** 0.47*** 
 (0.57 - 0.66) (0.65 - 0.78) (0.42 - 0.53) 
Massachusetts 0.79*** 0.96 0.61*** 
 (0.72 - 0.87) (0.86 - 1.08) (0.52 - 0.72) 
Michigan 0.48*** 0.48*** 0.51*** 
 (0.45 - 0.51) (0.44 - 0.53) (0.46 - 0.57) 
Mississippi 1.14 0.79 2.18 
 (0.79 - 1.65) (0.47 - 1.32) (0.88 - 5.36) 
Missouri 1.75** 1.13 3.01*** 
 (1.24 - 2.48) (0.68 - 1.87) (1.86 - 4.89) 
Nebraska 1.07 0.83 0.75 
 (0.69 - 1.66) (0.47 - 1.48) (0.28 - 2.04) 
Nevada 0.99 0.59 1.71 
 (0.52 - 1.90) (0.22 - 1.62) (0.63 - 4.63) 
New Hampshire 0.44*** 0.45*** 0.61* 
 (0.39 - 0.51) (0.39 - 0.52) (0.37 - 1.00) 
New Jersey 0.69*** 0.65*** 0.59*** 
 (0.64 - 0.74) (0.59 - 0.73) (0.53 - 0.66) 
New Mexico 0.25*** 0.05** 0.26*** 
 (0.15 - 0.42) (0.01 - 0.37) (0.15 - 0.47) 
New York 0.64*** 0.70*** 0.58*** 





North Carolina 0.60** 0.48** 0.57* 
 (0.43 - 0.84) (0.29 - 0.79) (0.36 - 0.89) 
North Dakota 0.9 1.01  
 (0.52 - 1.58) (0.58 - 1.78)  
Ohio 0.79*** 0.90* 0.59*** 
 (0.74 - 0.84) (0.83 - 0.98) (0.52 - 0.66) 
Oklahoma 4.94*** 3.64***  
 (3.47 - 7.04) (2.19 - 6.04)  
Rhode Island 0.89* 0.60*** 0.99 
 (0.80 - 0.98) (0.51 - 0.71) (0.86 - 1.14) 
South Carolina 1.99*** 1.65 1.53 
 (1.41 - 2.82) (1.00 - 2.73) (0.85 - 2.74) 
South Dakota 1.75* 1.37 1.19 
 (1.10 - 2.79) (0.75 - 2.49) (0.36 - 3.93) 
Tennessee 1.80** 1.36 0.99 
 (1.26 - 2.57) (0.81 - 2.25) (0.08 - 11.95) 
Utah 3.13*** 2.84*** 1.86** 
 (2.22 - 4.40) (1.72 - 4.68) (1.16 - 2.97) 
Washington - - - 
    
Wyoming 2.80*** 1.95*  
 (1.68 - 4.66) (1.04 - 3.67)  
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  

























Table 4-B6. DID model for the adjusted associations of Medicaid expansion and treatment completion (without 
controlling for referral sources)  
  DID pooled model DID non-MAT DID MAT 
    
N 228,235 166,463 61,769 
 AOR AOR AOR 
 (95%CI) (95%CI) (95%CI) 
     
Treat    
   Expansion states 2.02*** 1.78* 3.00*** 
    (1.43 - 2.84) (1.09 - 2.91) (1.84 - 4.87) 
Expansion  1.56*** 1.40*** 2.14*** 
   After the ACA 
implementation (2014)  
(1.50 - 1.64) (1.33 - 1.47) (1.90 - 2.40) 
    
Medicaid expansion     
    Expansion  0.87*** 1.06* 0.49*** 
 (0.83 - 0.91) (1.01 - 1.11) (0.44 - 0.55) 
MAT (No= ref)     
   Yes 0.74***   
 (0.72 - 0.76)   
Frequency of use (No past 
month use= ref)  
   
   Some use 0.67*** 0.69*** 0.66*** 
 (0.65 - 0.69) (0.67 - 0.71) (0.62 - 0.71) 
   Daily use 0.65*** 0.71*** 0.53*** 
 (0.63 - 0.66) (0.70 - 0.73) (0.50 - 0.56) 
Age (18-29= ref)     
   30-44 1.06*** 1.06*** 1.03 
 (1.04 - 1.08) (1.04 - 1.09) (0.99 - 1.08) 
   45-64 1.12*** 1.20*** 0.98 
 (1.09 - 1.15) (1.16 - 1.25) (0.93 - 1.04) 
Gender (Female=ref)    
   Male 0.95*** 0.99 0.81*** 
 (0.94 - 0.97) (0.97 - 1.02) (0.78 - 0.85) 
Race/ethnicity (non-Hispanic 
White=ref) 
   
   Non-Hispanic Black 0.84*** 0.97 0.68*** 
 (0.81 - 0.87) (0.92 - 1.01) (0.63 - 0.73) 
   Hispanic 0.86*** 0.94* 0.78*** 
 (0.83 - 0.89) (0.90 - 0.99) (0.73 - 0.84) 
   Other 0.74*** 0.77*** 0.68*** 





Education (Less than high 
school= ref)  
   
   Highschool or higher 1.16*** 1.13*** 1.19*** 
 (1.13 - 1.18) (1.10 - 1.16) (1.14 - 1.24) 
Number of arrests (0= ref)    
   1 1.28*** 1.33*** 1.11* 
 (1.23 - 1.34) (1.27 - 1.39) (1.01 - 1.23) 
   2 or more 0.84*** 0.87** 1.08 
 (0.77 - 0.91) (0.79 - 0.95) (0.87 - 1.34) 
Employment status 
(Unemployed= ref)  
   
     Employed 1.02 1.05*** 0.98 
 (1.00 - 1.04) (1.02 - 1.07) (0.94 - 1.02) 
Comorbidity (No= ref)     
   Yes 0.85*** 0.81*** 0.95* 
 (0.83 - 0.87) (0.79 - 0.83) (0.91 - 0.99) 
Homeless (No= ref)     
  Yes 1.08** 1.09** 1.02 
 (1.03 - 1.12) (1.04 - 1.15) (0.94 - 1.12) 
Polysubstance use (no= ref)      
    One more 1.11*** 1.11*** 1.03 
 (1.08 - 1.13) (1.08 - 1.14) (0.99 - 1.08) 
    Two or more 1.21*** 1.20*** 1.10*** 
 (1.18 - 1.24) (1.16 - 1.23) (1.04 - 1.16) 
Year     
2011 1.02 1.03 0.96 
 (0.98 - 1.05) (0.99 - 1.08) (0.89 - 1.05) 
2012 1.01 1.04* 0.98 
 (0.97 - 1.05) (1.00 - 1.09) (0.90 - 1.07) 
2013 0.95** 0.99 0.87** 
 (0.91 - 0.98) (0.95 - 1.04) (0.80 - 0.94) 
2014 0.62*** 0.63*** 0.73*** 
 (0.60 - 0.65) (0.61 - 0.66) (0.67 - 0.78) 
2015 0.62*** 0.64*** 0.66*** 
 (0.60 - 0.64) (0.61 - 0.67) (0.61 - 0.71) 
2016 0.72*** 0.77*** 0.78*** 
 (0.70 - 0.75) (0.73 - 0.80) (0.73 - 0.83) 
2017 - - - 
State    
Arizona 0.29*** 0.24*** 0.48*** 
 (0.27 - 0.31) (0.22 - 0.26) (0.42 - 0.55) 
Arkansas 0.91 1.2 0.63*** 
 (0.79 - 1.05) (0.98 - 1.45) (0.50 - 0.78) 
Colorado 1.30*** 1.18** 1.45*** 





Connecticut 1.92*** 1.82*** 2.04*** 
 (1.75 - 2.10) (1.60 - 2.07) (1.79 - 2.32) 
Delaware 0.84*** 0.72*** 1.07 
 (0.77 - 0.91) (0.65 - 0.80) (0.94 - 1.22) 
District of Columbia 1.34 0.92 2.66** 
 (0.97 - 1.85) (0.64 - 1.33) (1.35 - 5.27) 
Florida 8.46*** 3.46*** 42.23*** 
 (6.00 - 11.93) (2.11 - 5.65) (25.63 - 69.59) 
Hawaii 2.54*** 2.82*** 1.33 
 (1.90 - 3.39) (2.02 - 3.92) (0.68 - 2.60) 
Idaho 2.52*** 2.52*** 2.4 
 (1.72 - 3.71) (1.50 - 4.25) (0.83 - 6.92) 
Illinois 0.50*** 0.53*** 0.52*** 
 (0.47 - 0.54) (0.48 - 0.58) (0.46 - 0.59) 
Iowa 0.61*** 0.67*** 0.14*** 
 (0.55 - 0.68) (0.59 - 0.76) (0.08 - 0.23) 
Kansas 1.65** 1.55  
 (1.15 - 2.36) (0.94 - 2.55)  
Kentucky 6.71*** 6.84*** 5.63*** 
 (6.32 - 7.13) (6.34 - 7.38) (5.05 - 6.27) 
Maine 0.89 0.81 0.98 
 (0.63 - 1.25) (0.49 - 1.33) (0.61 - 1.59) 
Maryland 0.68*** 0.80*** 0.59*** 
 (0.63 - 0.73) (0.72 - 0.87) (0.53 - 0.65) 
Massachusetts 0.64*** 0.68*** 0.47*** 
 (0.58 - 0.70) (0.61 - 0.77) (0.39 - 0.56) 
Michigan 0.66*** 0.60*** 0.77*** 
 (0.62 - 0.71) (0.55 - 0.65) (0.69 - 0.86) 
Mississippi 1.45* 1.46 0.31* 
 (1.01 - 2.09) (0.88 - 2.41) (0.10 - 1.00) 
Missouri 1.89*** 2.10** 1.43 
 (1.33 - 2.68) (1.28 - 3.45) (0.86 - 2.38) 
Nebraska 4.99*** 4.65*** 7.20*** 
 (3.15 - 7.89) (2.59 - 8.34) (2.45 - 21.18) 
Nevada 0.99 1.19 0.85 
 (0.53 - 1.83) (0.45 - 3.16) (0.37 - 1.95) 
New Hampshire 3.14*** 3.11*** 2.03** 
 (2.71 - 3.64) (2.65 - 3.65) (1.23 - 3.36) 
New Jersey 0.55*** 1.09 0.38*** 
 (0.52 - 0.59) (0.98 - 1.21) (0.34 - 0.42) 
New Mexico 5.10*** 2.44 7.22*** 
 (2.86 - 9.10) (0.92 - 6.52) (3.47 - 15.03) 
New York 0.41*** 0.42*** 0.38*** 
 (0.38 - 0.43) (0.39 - 0.45) (0.35 - 0.42) 
North Carolina 4.28*** 3.57*** 12.63*** 





North Dakota 1.37 1.41  
 (0.77 - 2.41) (0.80 - 2.48)  
Ohio 0.49*** 0.57*** 0.24*** 
 (0.46 - 0.53) (0.53 - 0.62) (0.21 - 0.27) 
Oklahoma 1.52* 1.5  
 (1.06 - 2.16) (0.91 - 2.46)  
Rhode Island 0.84*** 0.77*** 0.88 
 (0.77 - 0.93) (0.65 - 0.90) (0.77 - 1.00) 
South Carolina 1.55* 1.43 1.32 
 (1.09 - 2.20) (0.87 - 2.35) (0.72 - 2.42) 
South Dakota 2.67*** 2.60** 3.24 
 (1.67 - 4.29) (1.43 - 4.72) (0.94 - 11.09) 
Tennessee 0.91 0.87  
 (0.64 - 1.31) (0.53 - 1.44)  
Utah 2.42*** 2.56*** 1.69* 
 (1.72 - 3.42) (1.57 - 4.18) (1.03 - 2.78) 
Washington - - - 
    
Wyoming 2.04** 2.00* 1.81 
 (1.22 - 3.39) (1.07 - 3.71) (0.16 - 21.01) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  





















Table 4-B7. Sensitivity analysis with added covariates for the 2WFE model for the adjusted associations 
between Medicaid expansion and length of stay   
  
2 ways fixed effect 
pooled model 
2 ways fixed effect 
Non-MAT 
2 ways fixed effect 
MAT 
     
N 231,025 169,449 61,573 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Medicaid expansion     
    Expansion  0.94** 0.95 1.15** 
 (0.90 - 0.98) (0.91 - 1.00) (1.04 - 1.26) 
MAT (No= ref)     
   Yes 2.22***   
 (2.16 - 2.27)   
Referral sources    
   Healthcare provider 
referral 
0.93*** 1.01 0.87*** 
 (0.90 - 0.96) (0.97 - 1.04) (0.83 - 0.92) 
   Institutional referral 1.04* 1.21*** 0.77*** 
 (1.01 - 1.08) (1.17 - 1.26) (0.72 - 0.83) 
   Court/criminal justice 1.87*** 2.14*** 0.74*** 
 (1.82 - 1.92) (2.08 - 2.20) (0.69 - 0.81) 
Frequency of use (No 
past month use= ref)  
   
   Some use 0.72*** 0.70*** 0.85*** 
 (0.70 - 0.74) (0.68 - 0.73) (0.79 - 0.91) 
   Daily use 0.67*** 0.62*** 0.84*** 
 (0.66 - 0.69) (0.60 - 0.64) (0.80 - 0.89) 
Age (18-29= ref)     
   30-44 1.07*** 1.07*** 1.09*** 
 (1.05 - 1.09) (1.04 - 1.10) (1.04 - 1.13) 
   45-64 1.30*** 1.32*** 1.31*** 
 (1.27 - 1.34) (1.27 - 1.36) (1.24 - 1.38) 
Gender (Female=ref)    
   Male 0.90*** 0.89*** 0.92*** 
 (0.88 - 0.91) (0.87 - 0.91) (0.89 - 0.95) 
Race/ethnicity (non-
Hispanic White=ref) 
   
   Non-Hispanic Black 0.94** 0.94** 0.92** 





   Hispanic 1.01 0.94** 1.09** 
 (0.98 - 1.05) (0.90 - 0.98) (1.02 - 1.16) 
   Other 1.00 0.99 0.99 
 (0.95 - 1.06) (0.93 - 1.06) (0.89 - 1.10) 
Education (Less than 
high school= ref)  
   
   Highschool or higher 0.98 1.00 0.96* 
 (0.96 - 1.00) (0.98 - 1.03) (0.92 - 0.99) 
Number of arrests (0= 
ref) 
   
   1 0.97 1.04 0.79*** 
 (0.93 - 1.01) (0.99 - 1.09) (0.73 - 0.86) 
   2 or more 1.18*** 1.17*** 0.86 
 (1.09 - 1.28) (1.07 - 1.28) (0.72 - 1.04) 
Employment status 
(Unemployed= ref)  
   
     Employed 0.79*** 0.78*** 0.83*** 
 (0.77 - 0.81) (0.76 - 0.80) (0.80 - 0.86) 
Comorbidity (No= ref)     
   Yes 0.88*** 0.90*** 0.89*** 
 (0.86 - 0.90) (0.87 - 0.92) (0.86 - 0.93) 
Homeless (No= ref)     
  Yes 0.74*** 0.77*** 0.70*** 
 (0.70 - 0.77) (0.73 - 0.81) (0.65 - 0.76) 
Polysubstance use (no= 
ref)   
   
    One more 0.80*** 0.80*** 0.86*** 
 (0.78 - 0.81) (0.78 - 0.82) (0.82 - 0.89) 
    Two or more 0.73*** 0.76*** 0.76*** 
 (0.71 - 0.74) (0.74 - 0.78) (0.72 - 0.80) 
Unemployment rate     
   Unemployment rate 0.98 0.95*** 1.03 
 (0.96 - 1.00) (0.92 - 0.97) (0.99 - 1.07) 
PMDP (No= ref)    
    Yes 1.06* 1.00 1.39*** 
 (1.01 - 1.12) (0.92 - 1.07) (1.27 - 1.52) 
Year     
2011 1.13*** 1.16*** 0.99 
 (1.09 - 1.18) (1.11 - 1.22) (0.91 - 1.08) 
2012 1.10*** 1.12*** 0.99 
 (1.05 - 1.16) (1.06 - 1.19) (0.90 - 1.10) 
2013 1.12*** 1.12** 0.96 





2014 1.36*** 1.36*** 0.87 
 (1.24 - 1.49) (1.21 - 1.51) (0.72 - 1.05) 
2015 1.04 1.04 0.70** 
 (0.93 - 1.16) (0.92 - 1.19) (0.56 - 0.87) 
2016 1.06 1.06 0.74* 
 (0.94 - 1.19) (0.92 - 1.21) (0.58 - 0.93) 
2017 0.87* 0.97 0.54*** 
 (0.76 - 0.98) (0.84 - 1.13) (0.42 - 0.69) 
State    
Alaska 4.25*** 3.42*** 3.15*** 
 (2.89 - 6.24) (2.00 - 5.88) (1.68 - 5.91) 
Arizona 5.21*** 4.38*** 4.51*** 
 (3.71 - 7.33) (2.65 - 7.25) (2.83 - 7.18) 
Arkansas 1.16 0.98 1.14 
 (0.80 - 1.67) (0.57 - 1.67) (0.70 - 1.86) 
Colorado 2.29*** 1.64 2.29*** 
 (1.62 - 3.24) (0.98 - 2.73) (1.43 - 3.66) 
Connecticut 1.55* 0.7 2.34*** 
 (1.09 - 2.18) (0.42 - 1.17) (1.47 - 3.72) 
Delaware 1.54* 1.37 1.09 
 (1.09 - 2.18) (0.82 - 2.28) (0.69 - 1.74) 
District of Columbia 4.84*** 3.85*** 5.31*** 
 (2.96 - 7.91) (2.04 - 7.28) (2.05 - 13.78) 
Florida 1.68** 1 2.15** 
 (1.20 - 2.37) (0.60 - 1.66) (1.36 - 3.40) 
Hawaii 0.78 0.34*** 6.11*** 
 (0.50 - 1.21) (0.19 - 0.63) (2.25 - 16.58) 
Idaho 2.49*** 1.73* 1.96 
 (1.69 - 3.66) (1.01 - 2.96) (0.68 - 5.64) 
Illinois 1.3 1.04 1.21 
 (0.92 - 1.82) (0.62 - 1.72) (0.77 - 1.92) 
Indiana 1.86*** 1.51 1.80* 
 (1.31 - 2.64) (0.91 - 2.52) (1.08 - 3.02) 
Iowa 2.11*** 1.5 2.50** 
 (1.48 - 3.01) (0.89 - 2.51) (1.44 - 4.34) 
Kansas 3.26*** 2.36**  
 (2.27 - 4.68) (1.41 - 3.97)  
Kentucky 0.17*** 0.12*** 0.22*** 
 (0.12 - 0.23) (0.07 - 0.20) (0.14 - 0.35) 
Louisiana 2.11*** 1.80* 0.56 
 (1.46 - 3.03) (1.07 - 3.03) (0.26 - 1.17) 





 (1.58 - 3.15) (0.87 - 2.44) (1.63 - 4.06) 
Maryland 1.74** 1.29 1.81* 
 (1.24 - 2.45) (0.77 - 2.14) (1.14 - 2.87) 
Massachusetts 2.11*** 1.71* 1.99** 
 (1.49 - 2.99) (1.02 - 2.84) (1.24 - 3.22) 
Michigan 1.45* 1.07 1.64* 
 (1.03 - 2.04) (0.65 - 1.77) (1.04 - 2.59) 
Mississippi 1.17 0.86 1.91 
 (0.81 - 1.70) (0.51 - 1.45) (0.76 - 4.77) 
Missouri 1.75** 1.04 4.06*** 
 (1.23 - 2.49) (0.62 - 1.75) (2.48 - 6.65) 
Montana 2.08*** 1.49  
 (1.44 - 3.01) (0.88 - 2.52)  
Nebraska 0.96 0.69 0.87 
 (0.61 - 1.50) (0.38 - 1.24) (0.31 - 2.39) 
Nevada 3.23** 1.45 5.40** 
 (1.54 - 6.78) (0.46 - 4.52) (1.80 - 16.15) 
New Hampshire 1.2 0.77 2.47** 
 (0.83 - 1.72) (0.46 - 1.30) (1.26 - 4.84) 
New Jersey 1.91*** 1.2 1.94** 
 (1.36 - 2.68) (0.72 - 1.98) (1.23 - 3.05) 
New Mexico 1.06 0.2 1.04 
 (0.56 - 2.03) (0.02 - 1.76) (0.49 - 2.21) 
New York 1.92*** 1.53 1.89** 
 (1.37 - 2.70) (0.93 - 2.53) (1.20 - 2.98) 
North Carolina 0.59** 0.50** 0.53** 
 (0.42 - 0.83) (0.30 - 0.82) (0.34 - 0.84) 
North Dakota 2.21* 1.47  
 (1.13 - 4.32) (0.68 - 3.19)  
Ohio 2.16*** 1.75* 1.97** 
 (1.54 - 3.03) (1.06 - 2.89) (1.24 - 3.11) 
Oklahoma 4.54*** 3.18***  
 (3.17 - 6.49) (1.90 - 5.33)  
Pennsylvania 1.15 0.85 1.32 
 (0.80 - 1.64) (0.50 - 1.43) (0.79 - 2.19) 
Rhode Island 2.62*** 1.31 3.02*** 
 (1.85 - 3.71) (0.78 - 2.20) (1.90 - 4.81) 
South Carolina 2.09*** 1.82* 1.58 
 (1.47 - 2.97) (1.09 - 3.03) (0.87 - 2.84) 
South Dakota 1.54 1.09 1.36 
 (0.96 - 2.47) (0.59 - 2.01) (0.41 - 4.50) 





 (1.04 - 2.13) (0.66 - 1.85) (0.09 - 12.74) 
Utah 2.63*** 2.17** 1.87* 
 (1.86 - 3.72) (1.31 - 3.62) (1.16 - 3.01) 
Washington 2.91*** 2.02** 3.42*** 
 (2.07 - 4.10) (1.22 - 3.35) (2.16 - 5.42) 
Wyoming 2.87*** 2.03*  
 (1.71 - 4.81) (1.07 - 3.85)  
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  






Table 4-B8. Sensitivity with added covariates for the DID model for the adjusted association between Medicaid 






DID model  
  MAT 
    
N 225,272 164,420 60,849 
 AOR AOR AOR 
 (95%CI) (95%CI) (95%CI) 
        
Treat    
   Expansion states 2.87*** 1.98** 3.40*** 
    (2.04 - 4.05) (1.19 - 3.28) (2.15 - 5.39) 
Expansion     
   After the ACA implementation (2014)  0.81** 0.91 0.53*** 
 (0.71 - 0.92) (0.78 - 1.06) (0.41 - 0.68) 
Medicaid expansion     
    Expansion  0.95* 0.98 1.15** 
 (0.91 - 1.00) (0.93 - 1.03) (1.05 - 1.27) 
MAT (No= ref)     
   Yes 2.23***   
 (2.18 - 2.29)   
Referral sources    
   Healthcare provider referral 0.93*** 1.01 0.87*** 
 (0.90 - 0.96) (0.98 - 1.05) (0.83 - 0.92) 
   Institutional referral 1.05** 1.22*** 0.79*** 
 (1.02 - 1.09) (1.17 - 1.27) (0.73 - 0.85) 
   Court/criminal justice 1.88*** 2.16*** 0.74*** 
 (1.83 - 1.94) (2.10 - 2.23) (0.68 - 0.80) 
Frequency of use (No past month use= 
ref)  
   
   Some use 0.72*** 0.70*** 0.84*** 
 (0.69 - 0.74) (0.68 - 0.72) (0.78 - 0.90) 
   Daily use 0.67*** 0.62*** 0.84*** 
 (0.65 - 0.69) (0.60 - 0.64) (0.79 - 0.89) 
Age (18-29= ref)     
   30-44 1.07*** 1.07*** 1.09*** 
 (1.05 - 1.10) (1.05 - 1.10) (1.04 - 1.13) 
   45-64 1.30*** 1.32*** 1.30*** 
 (1.27 - 1.34) (1.27 - 1.37) (1.24 - 1.38) 
Gender (Female=ref)    
   Male 0.90*** 0.89*** 0.93*** 
 (0.88 - 0.92) (0.87 - 0.91) (0.89 - 0.96) 
Race/ethnicity (non-Hispanic 
White=ref) 
   





 (0.91 - 0.98) (0.89 - 0.98) (0.87 - 0.99) 
   Hispanic 1.01 0.94** 1.08** 
 (0.97 - 1.05) (0.89 - 0.98) (1.02 - 1.15) 
   Other 1.01 1.00 0.99 
 (0.95 - 1.07) (0.94 - 1.07) (0.89 - 1.11) 
Education (Less than high school= ref)     
   Highschool or higher 0.98* 1.00 0.96* 
 (0.96 - 1.00) (0.98 - 1.03) (0.92 - 0.99) 
Number of arrests (0= ref)    
   1 0.96 1.04 0.79*** 
 (0.92 - 1.00) (0.99 - 1.10) (0.72 - 0.86) 
   2 or more 1.20*** 1.19*** 0.86 
 (1.10 - 1.29) (1.08 - 1.30) (0.71 - 1.04) 
Employment status (Unemployed= ref)     
     Employed 0.80*** 0.79*** 0.83*** 
 (0.78 - 0.82) (0.77 - 0.81) (0.80 - 0.87) 
Comorbidity (No= ref)     
   Yes 0.88*** 0.89*** 0.89*** 
 (0.86 - 0.90) (0.87 - 0.91) (0.86 - 0.93) 
Homeless (No= ref)     
  Yes 0.73*** 0.76*** 0.70*** 
 (0.70 - 0.76) (0.72 - 0.81) (0.64 - 0.75) 
Polysubstance use (no= ref)      
    One more 0.79*** 0.79*** 0.85*** 
 (0.77 - 0.81) (0.77 - 0.82) (0.82 - 0.89) 
    Two or more 0.72*** 0.75*** 0.76*** 
 (0.70 - 0.74) (0.73 - 0.78) (0.72 - 0.80) 
Unemployment rate     
   Unemployment rate 0.97** 0.94*** 1.03 
 (0.95 - 0.99) (0.91 - 0.96) (0.99 - 1.07) 
PMDP (No= ref)    
   Yes 1.07* 1.00 1.40*** 
 (1.01 - 1.13) (0.92 - 1.08) (1.28 - 1.53) 
Year     
2011 1.14*** 1.17*** 1 
 (1.09 - 1.19) (1.12 - 1.24) (0.92 - 1.09) 
2012 1.09*** 1.12*** 0.99 
 (1.04 - 1.15) (1.05 - 1.19) (0.90 - 1.10) 
2013 1.09** 1.10* 0.95 
 (1.03 - 1.16) (1.02 - 1.18) (0.84 - 1.08) 
2014 1.59*** 1.41*** 1.63*** 
 (1.51 - 1.68) (1.32 - 1.50) (1.46 - 1.81) 
2015 1.21*** 1.08** 1.31*** 
 (1.16 - 1.27) (1.03 - 1.14) (1.21 - 1.41) 





 (1.19 - 1.28) (1.04 - 1.14) (1.30 - 1.47) 
2017 - - - 
    
State     
Arizona 1.80*** 2.19*** 1.32*** 
 (1.68 - 1.94) (2.00 - 2.38) (1.14 - 1.53) 
Arkansas 0.39*** 0.48*** 0.33*** 
 (0.34 - 0.46) (0.39 - 0.59) (0.27 - 0.41) 
Colorado 0.78*** 0.80*** 0.67*** 
 (0.71 - 0.86) (0.71 - 0.90) (0.58 - 0.78) 
Connecticut 0.53*** 0.35*** 0.69*** 
 (0.49 - 0.58) (0.30 - 0.40) (0.60 - 0.79) 
Delaware 0.52*** 0.67*** 0.32*** 
 (0.48 - 0.57) (0.60 - 0.75) (0.28 - 0.37) 
District of Columbia 1.69** 1.94** 1.56 
 (1.18 - 2.42) (1.30 - 2.89) (0.67 - 3.64) 
Florida 1.68** 0.99 2.15*** 
 (1.19 - 2.37) (0.60 - 1.65) (1.36 - 3.40) 
Hawaii 0.26*** 0.16*** 1.79 
 (0.20 - 0.35) (0.12 - 0.23) (0.73 - 4.36) 
Idaho 2.45*** 1.69 1.95 
 (1.66 - 3.61) (0.99 - 2.90) (0.68 - 5.61) 
Illinois 0.45*** 0.52*** 0.36*** 
 (0.41 - 0.48) (0.47 - 0.57) (0.32 - 0.40) 
Iowa 0.71*** 0.73*** 0.73 
 (0.63 - 0.80) (0.63 - 0.83) (0.53 - 1.02) 
Kansas 3.19*** 2.29**  
 (2.22 - 4.57) (1.36 - 3.85)  
Kentucky 0.06*** 0.06*** 0.07*** 
 (0.05 - 0.06) (0.06 - 0.07) (0.06 - 0.07) 
Maine 2.20*** 1.43 2.57*** 
 (1.56 - 3.10) (0.85 - 2.39) (1.62 - 4.06) 
Maryland 0.59*** 0.63*** 0.53*** 
 (0.55 - 0.64) (0.57 - 0.70) (0.47 - 0.60) 
Massachusetts 0.72*** 0.84** 0.59*** 
 (0.65 - 0.80) (0.74 - 0.95) (0.49 - 0.70) 
Michigan 0.50*** 0.54*** 0.48*** 
 (0.47 - 0.54) (0.49 - 0.59) (0.43 - 0.54) 
Mississippi 1.18 0.86 1.91 
 (0.82 - 1.72) (0.51 - 1.46) (0.77 - 4.79) 
Missouri 1.74** 1.03 4.08*** 
 (1.22 - 2.48) (0.61 - 1.73) (2.49 - 6.69) 
Nebraska 0.93 0.66 0.87 
 (0.59 - 1.45) (0.36 - 1.18) (0.31 - 2.39) 
Nevada 1.12 0.72 1.58 





New Hampshire 0.40*** 0.37*** 0.72 
 (0.35 - 0.47) (0.32 - 0.43) (0.44 - 1.20) 
New Jersey 0.66*** 0.59*** 0.57*** 
 (0.61 - 0.71) (0.53 - 0.66) (0.51 - 0.63) 
New Mexico 0.36*** 0.10* 0.31*** 
 (0.21 - 0.63) (0.01 - 0.82) (0.17 - 0.56) 
New York 0.66*** 0.76*** 0.56*** 
 (0.62 - 0.70) (0.70 - 0.82) (0.50 - 0.61) 
North Carolina 0.59** 0.50** 0.53** 
 (0.42 - 0.83) (0.30 - 0.82) (0.34 - 0.84) 
North Dakota 0.72 0.69  
 (0.41 - 1.29) (0.38 - 1.24)  
Ohio 0.74*** 0.86*** 0.58*** 
 (0.69 - 0.79) (0.79 - 0.94) (0.51 - 0.65) 
Oklahoma 4.46*** 3.11***  
 (3.12 - 6.38) (1.86 - 5.21)  
Rhode Island 0.91 0.66*** 0.89 
 (0.82 - 1.01) (0.56 - 0.78) (0.76 - 1.03) 
South Carolina 2.09*** 1.81* 1.57 
 (1.47 - 2.97) (1.09 - 3.02) (0.87 - 2.82) 
South Dakota 1.49 1.05 1.36 
 (0.92 - 2.39) (0.57 - 1.93) (0.41 - 4.49) 
Tennessee 1.48* 1.1 1.07 
 (1.04 - 2.12) (0.66 - 1.84) (0.09 - 12.68) 
Utah 2.57*** 2.10** 1.86* 
 (1.81 - 3.63) (1.26 - 3.50) (1.15 - 3.00) 
Washington - - - 
    
Wyoming 2.87*** 2.03*  
 (1.71 - 4.82) (1.07 - 3.84)  
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  







Table 4-B9. Sensitivity analysis with added covariates for the 2WFE model for the adjusted associations 
between Medicaid expansion and treatment completion   
  
2 ways fixed effect 
pooled model 
Non-MAT MAT 
     
N 229,288 168,163 61,122 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Medicaid expansion  0.84*** 1.03 0.47*** 
    Expansion  (0.81 - 0.88) (0.99 - 1.09) (0.42 - 0.52) 
    
MAT (No= ref)     
   Yes 0.86***   






   Healthcare provider 
referral 
1.07*** 1.05** 1.14*** 
 (1.04 - 1.10) (1.02 - 1.09) (1.08 - 1.21) 
   Institutional referral 1.30*** 1.32*** 1.15*** 
 (1.26 - 1.34) (1.27 - 1.37) (1.06 - 1.24) 
   Court/criminal justice 2.03*** 2.00*** 1.89*** 
 (1.98 - 2.09) (1.95 - 2.06) (1.73 - 2.06) 
Frequency of use (No 
past month use= ref)  
   
   Some use 0.74*** 0.76*** 0.70*** 
 (0.71 - 0.76) (0.73 - 0.78) (0.65 - 0.76) 
   Daily use 0.77*** 0.85*** 0.59*** 
 (0.75 - 0.79) (0.83 - 0.88) (0.55 - 0.62) 
Age (18-29= ref)     
   30-44 1.06*** 1.07*** 1.04 
 (1.04 - 1.09) (1.04 - 1.09) (0.99 - 1.08) 
   45-64 1.14*** 1.23*** 0.99 
 (1.11 - 1.18) (1.19 - 1.27) (0.93 - 1.05) 
Gender (Female=ref)    
   Male 0.93*** 0.97** 0.81*** 
 (0.92 - 0.95) (0.95 - 0.99) (0.78 - 0.84) 
Race/ethnicity (non-
Hispanic White=ref) 





   Non-Hispanic Black 0.82*** 0.94* 0.68*** 
 (0.79 - 0.86) (0.90 - 0.99) (0.63 - 0.73) 
   Hispanic 0.85*** 0.92*** 0.81*** 
 (0.82 - 0.89) (0.88 - 0.96) (0.75 - 0.87) 
   Other 0.73*** 0.76*** 0.69*** 
 (0.69 - 0.77) (0.72 - 0.81) (0.61 - 0.78) 
Education (Less than 
high school= ref)  
   
   Highschool or higher 1.19*** 1.17*** 1.20*** 
 (1.16 - 1.21) (1.14 - 1.20) (1.15 - 1.25) 
Number of arrests (0= 
ref) 
   
   1 1.15*** 1.19*** 1.03 
 (1.10 - 1.20) (1.13 - 1.24) (0.94 - 1.14) 
   2 or more 0.84*** 0.89** 1.02 
 (0.77 - 0.91) (0.81 - 0.97) (0.82 - 1.28) 
Employment status 
(Unemployed= ref)  
   
     Employed 1.03* 1.06*** 0.97 
 (1.00 - 1.05) (1.03 - 1.09) (0.93 - 1.02) 
Comorbidity (No= ref)     
   Yes 0.89*** 0.87*** 0.95* 
 (0.88 - 0.91) (0.85 - 0.89) (0.91 - 1.00) 
Homeless (No= ref)     
  Yes 1.11*** 1.14*** 1.03 
 (1.06 - 1.15) (1.08 - 1.20) (0.94 - 1.12) 
Polysubstance use (no= 
ref)   
   
    One more 1.12*** 1.14*** 1.02 
 (1.10 - 1.14) (1.11 - 1.17) (0.98 - 1.07) 
    Two or more 1.21*** 1.22*** 1.06* 
 (1.18 - 1.24) (1.18 - 1.25) (1.01 - 1.12) 
Unemployment rate     
   Unemployment rate 0.98* 0.96** 1.06* 
 (0.96 - 1.00) (0.94 - 0.98) (1.01 - 1.11) 
PMDP (No= ref)    
   Yes 1.11*** 1.13** 1.17** 
 (1.05 - 1.18) (1.05 - 1.22) (1.05 - 1.30) 
Year     
2011 0.99 0.99 0.95 
 (0.95 - 1.03) (0.95 - 1.04) (0.86 - 1.04) 





 (0.91 - 1.00) (0.91 - 1.02) (0.88 - 1.10) 
2013 0.87*** 0.87*** 0.9 
 (0.81 - 0.92) (0.81 - 0.93) (0.79 - 1.03) 
2014 0.88** 0.74*** 1.80*** 
 (0.80 - 0.96) (0.66 - 0.82) (1.47 - 2.22) 
2015 0.86** 0.73*** 1.74*** 
 (0.77 - 0.96) (0.64 - 0.83) (1.37 - 2.21) 
2016 0.98 0.85* 2.07*** 
 (0.87 - 1.11) (0.74 - 0.97) (1.59 - 2.68) 
2017 1.36*** 1.12 2.78*** 
 (1.20 - 1.54) (0.97 - 1.29) (2.11 - 3.65) 
State    
Alaska 1.53* 1.55 0.94 
 (1.04 - 2.24) (0.92 - 2.61) (0.47 - 1.92) 
Arizona 0.64* 0.49** 1.47 
 (0.45 - 0.90) (0.30 - 0.80) (0.90 - 2.41) 
Arkansas 1.89*** 2.22** 2.14** 
 (1.31 - 2.73) (1.31 - 3.75) (1.27 - 3.63) 
Colorado 2.57*** 2.02** 4.80*** 
 (1.81 - 3.64) (1.23 - 3.33) (2.92 - 7.89) 
Connecticut 4.00*** 3.18*** 6.68*** 
 (2.82 - 5.67) (1.92 - 5.25) (4.07 - 10.95) 
Delaware 1.64** 1.21 3.71*** 
 (1.16 - 2.32) (0.73 - 1.98) (2.26 - 6.10) 
District of Columbia 3.26*** 2.12* 8.37*** 
 (2.03 - 5.24) (1.15 - 3.93) (3.57 - 19.61) 
Florida 8.84*** 3.54*** 44.30*** 
 (6.25 - 12.50) (2.16 - 5.81) (26.75 - 73.39) 
Hawaii 4.79*** 4.50*** 4.70*** 
 (3.06 - 7.49) (2.49 - 8.14) (2.05 - 10.79) 
Idaho 1.99*** 1.97* 2.34 
 (1.35 - 2.94) (1.16 - 3.34) (0.80 - 6.80) 
Illinois 1.03 0.96 1.59 
 (0.73 - 1.46) (0.58 - 1.57) (0.97 - 2.60) 
Indiana 0.65* 0.63 0.47* 
 (0.46 - 0.93) (0.38 - 1.04) (0.25 - 0.86) 
Iowa 1.2 1.11 0.46* 
 (0.84 - 1.73) (0.67 - 1.85) (0.23 - 0.94) 
Kansas 1.56* 1.42  
 (1.09 - 2.25) (0.86 - 2.35)  
Kentucky 13.36*** 12.08*** 16.53*** 





Louisiana 1.35 1.11 6.91*** 
 (0.94 - 1.94) (0.67 - 1.84) (3.21 - 14.87) 
Maine 0.88 0.78 1.08 
 (0.62 - 1.24) (0.47 - 1.30) (0.66 - 1.76) 
Maryland 1.37 1.35 2.15** 
 (0.97 - 1.93) (0.82 - 2.22) (1.32 - 3.53) 
Massachusetts 1.17 1.08 1.46 
 (0.83 - 1.67) (0.65 - 1.78) (0.87 - 2.44) 
Michigan 1.38 1.13 2.28*** 
 (0.98 - 1.94) (0.69 - 1.84) (1.40 - 3.71) 
Mississippi 1.52* 1.55 0.31* 
 (1.05 - 2.19) (0.93 - 2.59) (0.09 - 1.00) 
Missouri 2.00*** 2.26** 1.77* 
 (1.40 - 2.86) (1.36 - 3.75) (1.05 - 2.99) 
Montana 1.67** 1.5  
 (1.15 - 2.42) (0.90 - 2.50)  
Nebraska 4.65*** 4.19*** 8.92*** 
 (2.91 - 7.43) (2.31 - 7.61) (2.92 - 27.19) 
Nevada 2.30* 2.75 2.65* 
 (1.13 - 4.69) (0.88 - 8.58) (1.02 - 6.89) 
New Hampshire 6.20*** 5.28*** 7.00*** 
 (4.27 - 9.01) (3.15 - 8.84) (3.46 - 14.16) 
New Jersey 1.09 1.74* 1.22 
 (0.78 - 1.54) (1.06 - 2.86) (0.75 - 1.99) 
New Mexico 8.31*** 1.79 19.34*** 
 (4.06 - 17.04) (0.44 - 7.32) (7.98 - 46.84) 
New York 0.84 0.77 1.19 
 (0.59 - 1.18) (0.47 - 1.26) (0.73 - 1.93) 
North Carolina 4.50*** 3.84*** 12.70*** 
 (3.21 - 6.32) (2.36 - 6.26) (7.85 - 20.55) 
North Dakota 2.30* 1.92  
 (1.17 - 4.52) (0.90 - 4.11)  
Ohio 0.89 0.91 0.68 
 (0.63 - 1.26) (0.56 - 1.49) (0.42 - 1.12) 
Oklahoma 1.38 1.33  
 (0.97 - 1.98) (0.80 - 2.19)  
Pennsylvania 1.18 1.28 0.77 
 (0.82 - 1.69) (0.77 - 2.13) (0.44 - 1.36) 
Rhode Island 1.75** 1.41 2.64*** 
 (1.24 - 2.49) (0.85 - 2.35) (1.61 - 4.32) 
South Carolina 1.58* 1.5 1.36 





South Dakota 2.40*** 2.26** 3.17 
 (1.48 - 3.88) (1.24 - 4.15) (0.90 - 11.18) 
Tennessee 0.77 0.74  
 (0.53 - 1.10) (0.45 - 1.23)  
Utah 2.06*** 2.08** 1.88* 
 (1.45 - 2.92) (1.26 - 3.42) (1.13 - 3.13) 
Washington 1.98*** 1.74* 3.15*** 
 (1.40 - 2.79) (1.06 - 2.85) (1.93 - 5.15) 
Wyoming 2.14** 2.11* 1.7 
 (1.28 - 3.58) (1.13 - 3.95) (0.15 - 19.85) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  











Table 4-B10. Sensitivity with added covariates for the DID model for the adjusted association between 






DID model  
  MAT 
    
N 225,268 164,418 60,847 
 AOR AOR AOR 
 (95%CI) (95%CI) (95%CI) 
        
Treat    
   Expansion states 2.02*** 1.79* 3.18*** 
    (1.43 - 2.85) (1.09 - 2.93) (1.94 - 5.19) 
Expansion     
   After the ACA implementation (2014)  1.53*** 1.28** 2.87*** 
 (1.34 - 1.74) (1.10 - 1.49) (2.18 - 3.78) 
Medicaid expansion     
    Expansion  0.83*** 1.02 0.47*** 
 (0.79 - 0.86) (0.97 - 1.07) (0.42 - 0.52) 
MAT (No= ref)     
   Yes 0.87***   
 (0.85 - 0.89)   
Referral sources    
   Healthcare provider referral 1.07*** 1.05** 1.14*** 
 (1.04 - 1.10) (1.02 - 1.09) (1.08 - 1.21) 
   Institutional referral 1.31*** 1.32*** 1.16*** 
 (1.27 - 1.35) (1.28 - 1.37) (1.08 - 1.26) 
   Court/criminal justice 2.05*** 2.03*** 1.89*** 
 (2.00 - 2.11) (1.97 - 2.09) (1.73 - 2.07) 
Frequency of use (No past month use= 
ref)  
   
   Some use 0.74*** 0.77*** 0.70*** 
 (0.72 - 0.77) (0.75 - 0.79) (0.65 - 0.76) 
   Daily use 0.79*** 0.88*** 0.59*** 
 (0.77 - 0.81) (0.85 - 0.90) (0.55 - 0.62) 
Age (18-29= ref)     
   30-44 1.06*** 1.07*** 1.04 
 (1.04 - 1.09) (1.04 - 1.09) (0.99 - 1.09) 
   45-64 1.14*** 1.23*** 0.99 
 (1.11 - 1.17) (1.18 - 1.27) (0.94 - 1.05) 
Gender (Female=ref)    
   Male 0.93*** 0.96*** 0.81*** 







   
   Non-Hispanic Black 0.82*** 0.94* 0.68*** 
 (0.79 - 0.85) (0.90 - 0.99) (0.63 - 0.73) 
   Hispanic 0.85*** 0.92*** 0.80*** 
 (0.82 - 0.88) (0.88 - 0.97) (0.75 - 0.86) 
   Other 0.74*** 0.78*** 0.68*** 
 (0.70 - 0.78) (0.73 - 0.83) (0.60 - 0.77) 
Education (Less than high school= ref)     
   Highschool or higher 1.19*** 1.17*** 1.20*** 
 (1.16 - 1.21) (1.14 - 1.20) (1.15 - 1.25) 
Number of arrests (0= ref)    
   1 1.16*** 1.20*** 1.03 
 (1.11 - 1.21) (1.14 - 1.26) (0.94 - 1.14) 
   2 or more 0.83*** 0.88** 1.03 
 (0.77 - 0.90) (0.80 - 0.97) (0.83 - 1.29) 
Employment status (Unemployed= ref)     
     Employed 1.03* 1.06*** 0.97 
 (1.01 - 1.05) (1.04 - 1.09) (0.93 - 1.02) 
Comorbidity (No= ref)     
   Yes 0.89*** 0.87*** 0.95* 
 (0.87 - 0.91) (0.85 - 0.89) (0.91 - 1.00) 
Homeless (No= ref)     
  Yes 1.11*** 1.15*** 1.03 
 (1.06 - 1.16) (1.09 - 1.21) (0.94 - 1.12) 
Polysubstance use (no= ref)      
    One more 1.13*** 1.14*** 1.02 
 (1.10 - 1.15) (1.11 - 1.17) (0.98 - 1.07) 
    Two or more 1.22*** 1.22*** 1.07* 
 (1.19 - 1.25) (1.19 - 1.26) (1.01 - 1.13) 
Unemployment rate     
   Unemployment rate 1.00 0.98 1.06** 
 (0.98 - 1.02) (0.96 - 1.01) (1.02 - 1.11) 
PMDP (No= ref)    
   Yes 1.13*** 1.17*** 1.18** 
 (1.07 - 1.20) (1.08 - 1.26) (1.06 - 1.32) 
Year     
2011 0.99 1 0.96 
 (0.95 - 1.04) (0.95 - 1.05) (0.87 - 1.05) 
2012 0.98 0.99 0.99 
 (0.93 - 1.03) (0.94 - 1.05) (0.89 - 1.11) 
2013 0.89*** 0.91** 0.89 
 (0.84 - 0.95) (0.84 - 0.97) (0.78 - 1.03) 
2014 0.62*** 0.63*** 0.64*** 





2015 0.62*** 0.63*** 0.62*** 
 (0.59 - 0.64) (0.60 - 0.67) (0.57 - 0.67) 
2016 0.71*** 0.74*** 0.74*** 
 (0.68 - 0.74) (0.71 - 0.78) (0.69 - 0.80) 
2017 - - - 
    
State    
Arizona 0.32*** 0.28*** 0.46*** 
 (0.30 - 0.35) (0.25 - 0.30) (0.40 - 0.53) 
Arkansas 0.98 1.31** 0.68*** 
 (0.84 - 1.13) (1.07 - 1.60) (0.55 - 0.85) 
Colorado 1.32*** 1.19** 1.53*** 
 (1.21 - 1.45) (1.05 - 1.33) (1.33 - 1.77) 
Connecticut 2.01*** 1.81*** 2.12*** 
 (1.83 - 2.21) (1.58 - 2.07) (1.85 - 2.42) 
Delaware 0.85*** 0.71*** 1.19* 
 (0.78 - 0.92) (0.63 - 0.79) (1.03 - 1.36) 
District of Columbia 1.63** 1.19 2.66** 
 (1.17 - 2.28) (0.82 - 1.75) (1.31 - 5.40) 
Florida 8.92*** 3.59*** 44.38*** 
 (6.31 - 12.61) (2.19 - 5.89) (26.78 - 73.55) 
Hawaii 2.50*** 2.67*** 1.51 
 (1.86 - 3.36) (1.90 - 3.75) (0.77 - 2.98) 
Idaho 2.06*** 2.04** 2.36 
 (1.40 - 3.04) (1.21 - 3.46) (0.81 - 6.86) 
Illinois 0.51*** 0.54*** 0.50*** 
 (0.48 - 0.55) (0.49 - 0.59) (0.44 - 0.57) 
Iowa 0.63*** 0.67*** 0.15*** 
 (0.56 - 0.72) (0.58 - 0.77) (0.09 - 0.25) 
Kansas 1.65** 1.51  
 (1.15 - 2.37) (0.91 - 2.50)  
Kentucky 6.74*** 6.89*** 5.21*** 
 (6.34 - 7.18) (6.37 - 7.46) (4.66 - 5.82) 
Maine 0.91 0.82 1.09 
 (0.64 - 1.28) (0.49 - 1.35) (0.67 - 1.78) 
Maryland 0.71*** 0.81*** 0.69*** 
 (0.66 - 0.77) (0.73 - 0.89) (0.61 - 0.78) 
Massachusetts 0.60*** 0.62*** 0.47*** 
 (0.54 - 0.66) (0.55 - 0.70) (0.38 - 0.56) 
Michigan 0.68*** 0.63*** 0.72*** 
 (0.64 - 0.73) (0.57 - 0.69) (0.64 - 0.81) 
Mississippi 1.50* 1.52 0.30* 
 (1.04 - 2.17) (0.92 - 2.53) (0.09 - 0.99) 
Missouri 2.10*** 2.42*** 1.81* 
 (1.47 - 2.99) (1.46 - 4.01) (1.07 - 3.05) 





 (3.13 - 7.98) (2.50 - 8.25) (3.01 - 28.07) 
Nevada 1.14 1.53 0.83 
 (0.61 - 2.13) (0.55 - 4.28) (0.36 - 1.91) 
New Hampshire 3.28*** 3.18*** 2.25** 
 (2.80 - 3.84) (2.68 - 3.78) (1.34 - 3.77) 
New Jersey 0.55*** 1 0.39*** 
 (0.51 - 0.59) (0.90 - 1.11) (0.35 - 0.43) 
New Mexico 4.24*** 1.01 6.17*** 
 (2.25 - 8.01) (0.27 - 3.81) (2.93 - 13.01) 
New York 0.42*** 0.44*** 0.38*** 
 (0.40 - 0.45) (0.41 - 0.48) (0.34 - 0.42) 
North Carolina 4.52*** 3.84*** 12.71*** 
 (3.22 - 6.35) (2.36 - 6.26) (7.85 - 20.56) 
North Dakota 1.26 1.21  
 (0.71 - 2.26) (0.67 - 2.17)  
Ohio 0.45*** 0.52*** 0.22*** 
 (0.42 - 0.48) (0.48 - 0.57) (0.19 - 0.25) 
Oklahoma 1.44* 1.39  
 (1.00 - 2.06) (0.84 - 2.29)  
Rhode Island 0.87** 0.79** 0.83** 
 (0.78 - 0.96) (0.67 - 0.93) (0.72 - 0.96) 
South Carolina 1.60** 1.51 1.35 
 (1.12 - 2.27) (0.92 - 2.49) (0.73 - 2.50) 
South Dakota 2.57*** 2.47** 3.22 
 (1.59 - 4.17) (1.35 - 4.53) (0.91 - 11.35) 
Tennessee 0.78 0.75  
 (0.54 - 1.12) (0.45 - 1.24)  
Utah 2.16*** 2.20** 1.91* 
 (1.52 - 3.06) (1.34 - 3.62) (1.15 - 3.18) 
Washington - - - 
    
Wyoming 2.17** 2.14* 1.7 
 (1.30 - 3.63) (1.14 - 4.01) (0.15 - 19.91) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  










Table 4-B11. Sensitivity with lagged model for the DID model for the adjusted association between Medicaid 






DID model  
  MAT 
    
N 225,272 164,420 60,849 
 AOR AOR AOR 
 (95%CI) (95%CI) (95%CI) 
        
Expansion states 2.87*** 2.07** 3.34*** 
    (2.03 - 4.05) (1.25 - 3.44) (2.08 - 5.38) 
Expansion year (2014) 2.15*** 2.36*** 1.59*** 
 (2.02 - 2.29) (2.20 - 2.53) (1.33 - 1.91) 
Expansion * Post expansion year 0  0.57*** 0.57*** 0.61*** 
     (0.53 - 0.61) (0.53 - 0.62) (0.51 - 0.74) 
Post expansion year 1 0.39*** 0.36*** 0.56***  
(0.36 - 0.42) (0.33 - 0.40) (0.45 - 0.70) 
Expansion* Post expansion year 1 2.48*** 3.00*** 1.45** 
 (2.26 - 2.73) (2.69 - 3.34) (1.15 - 1.83) 
Post expansion year 2 1.49*** 1.57*** 1.38*** 
 (1.38 - 1.62) (1.43 - 1.72) (1.14 - 1.66) 
Expansion* Post expansion year 2 0.62*** 0.59*** 0.72** 
 (0.57 - 0.68) (0.53 - 0.65) (0.59 - 0.88) 
Post expansion year 3 0.70*** 0.99 0.25*** 
 (0.66 - 0.74) (0.93 - 1.07) (0.21 - 0.29) 
Expansion* Post expansion year 3 1.29*** 0.93 3.58*** 
 (1.20 - 1.40) (0.85 - 1.02) (3.04 - 4.23) 
MAT (No= ref)     
   Yes 2.23***   
 (2.17 - 2.28)   
Referral sources    
   Healthcare provider referral 0.93*** 1.01 0.88*** 
 (0.90 - 0.96) (0.98 - 1.05) (0.83 - 0.93) 
   Institutional referral 1.05** 1.22*** 0.79*** 
 (1.01 - 1.08) (1.17 - 1.26) (0.73 - 0.85) 
   Court/criminal justice 1.88*** 2.17*** 0.73*** 
 (1.83 - 1.93) (2.11 - 2.23) (0.68 - 0.80) 
Frequency of use (No past month use= 
ref)  
   
   Some use 0.71*** 0.70*** 0.85*** 
 (0.69 - 0.74) (0.68 - 0.72) (0.79 - 0.91) 
   Daily use 0.67*** 0.62*** 0.86*** 
 (0.66 - 0.69) (0.60 - 0.64) (0.81 - 0.91) 
Age (18-29= ref)     





 (1.05 - 1.09) (1.05 - 1.10) (1.04 - 1.13) 
   45-64 1.30*** 1.32*** 1.30*** 
 (1.27 - 1.34) (1.27 - 1.36) (1.23 - 1.37) 
Gender (Female=ref)    
   Male 0.90*** 0.89*** 0.93*** 
 (0.88 - 0.92) (0.87 - 0.91) (0.90 - 0.96) 
Race/ethnicity (non-Hispanic 
White=ref) 
   
   Non-Hispanic Black 0.94** 0.94* 0.94* 
 (0.91 - 0.98) (0.89 - 0.99) (0.88 - 1.00) 
   Hispanic 1.01 0.94** 1.09** 
 (0.97 - 1.05) (0.89 - 0.98) (1.02 - 1.16) 
   Other 1.00 1.00 0.98 
 (0.95 - 1.06) (0.94 - 1.07) (0.88 - 1.10) 
Education (Less than high school= ref)     
   Highschool or higher 0.98 1.00 0.96* 
 (0.96 - 1.00) (0.98 - 1.03) (0.92 - 1.00) 
Number of arrests (0= ref)    
   1 0.96 1.04 0.79*** 
 (0.92 - 1.00) (0.99 - 1.09) (0.72 - 0.86) 
   2 or more 1.20*** 1.17*** 0.89 
 (1.11 - 1.30) (1.07 - 1.28) (0.73 - 1.07) 
Employment status (Unemployed= ref)     
     Employed 0.80*** 0.79*** 0.84*** 
 (0.78 - 0.82) (0.77 - 0.81) (0.80 - 0.87) 
Comorbidity (No= ref)     
   Yes 0.88*** 0.89*** 0.89*** 
 (0.86 - 0.90) (0.87 - 0.92) (0.85 - 0.92) 
Homeless (No= ref)     
  Yes 0.73*** 0.77*** 0.70*** 
 (0.70 - 0.76) (0.72 - 0.81) (0.65 - 0.76) 
Polysubstance use (no= ref)      
    One more 0.79*** 0.79*** 0.85*** 
 (0.78 - 0.81) (0.77 - 0.82) (0.82 - 0.89) 
    Two or more 0.73*** 0.76*** 0.76*** 
 (0.71 - 0.75) (0.73 - 0.78) (0.72 - 0.80) 
Year     
2011 1.18*** 1.23*** 1.09* 
 (1.14 - 1.23) (1.18 - 1.29) (1.01 - 1.17) 
2012 1.16*** 1.23*** 1.06 
 (1.11 - 1.20) (1.17 - 1.29) (0.98 - 1.14) 
2013 1.19*** 1.27*** 1.05 
 (1.14 - 1.23) (1.21 - 1.33) (0.97 - 1.14) 
State    





 (1.63 - 1.88) (1.92 - 2.28) (1.12 - 1.50) 
Arkansas 0.39*** 0.50*** 0.30*** 
 (0.34 - 0.45) (0.41 - 0.62) (0.24 - 0.37) 
Colorado 0.80*** 0.87* 0.65*** 
 (0.74 - 0.88) (0.77 - 0.97) (0.56 - 0.74) 
Connecticut 0.51*** 0.33*** 0.67*** 
 (0.47 - 0.56) (0.29 - 0.37) (0.58 - 0.76) 
Delaware 0.53*** 0.70*** 0.29*** 
 (0.48 - 0.57) (0.63 - 0.78) (0.25 - 0.33) 
District of Columbia 1.57* 1.76** 1.24 
 (1.10 - 2.26) (1.18 - 2.63) (0.54 - 2.88) 
Florida 1.67** 1.04 1.91** 
 (1.18 - 2.36) (0.62 - 1.72) (1.19 - 3.07) 
Hawaii 0.28*** 0.19*** 1.7 
 (0.21 - 0.37) (0.13 - 0.26) (0.70 - 4.13) 
Idaho 2.59*** 1.98* 1.86 
 (1.76 - 3.83) (1.15 - 3.39) (0.64 - 5.38) 
Illinois 0.43*** 0.49*** 0.35*** 
 (0.40 - 0.47) (0.44 - 0.54) (0.31 - 0.40) 
Iowa 0.76*** 0.84** 0.67* 
 (0.68 - 0.85) (0.74 - 0.95) (0.49 - 0.92) 
Kansas 3.35*** 2.70***  
 (2.34 - 4.81) (1.61 - 4.53)  
Kentucky 0.06*** 0.06*** 0.07*** 
 (0.05 - 0.06) (0.06 - 0.07) (0.06 - 0.07) 
Maine 2.26*** 1.61 2.26*** 
 (1.60 - 3.19) (0.96 - 2.69) (1.41 - 3.62) 
Maryland 0.60*** 0.69*** 0.44*** 
 (0.56 - 0.65) (0.63 - 0.77) (0.40 - 0.49) 
Massachusetts 0.74*** 0.89 0.56*** 
 (0.67 - 0.82) (0.79 - 1.00) (0.47 - 0.66) 
Michigan 0.49*** 0.50*** 0.48*** 
 (0.45 - 0.52) (0.46 - 0.55) (0.43 - 0.54) 
Mississippi 1.23 0.91 1.61 
 (0.85 - 1.79) (0.54 - 1.53) (0.62 - 4.18) 
Missouri 1.68** 1.12 2.57*** 
 (1.18 - 2.39) (0.67 - 1.88) (1.56 - 4.26) 
Nebraska 1 0.84 0.67 
 (0.64 - 1.56) (0.47 - 1.52) (0.24 - 1.86) 
Nevada 1.07 0.65 1.62 
 (0.55 - 2.06) (0.23 - 1.82) (0.60 - 4.40) 
New Hampshire 0.42*** 0.42*** 0.63 
 (0.36 - 0.48) (0.36 - 0.49) (0.38 - 1.03) 
New Jersey 0.64*** 0.57*** 0.54*** 
 (0.59 - 0.68) (0.51 - 0.63) (0.49 - 0.60) 





 (0.21 - 0.63) (0.01 - 0.75) (0.17 - 0.56) 
New York 0.67*** 0.77*** 0.55*** 
 (0.63 - 0.71) (0.71 - 0.83) (0.50 - 0.61) 
North Carolina 0.57** 0.48** 0.65 
 (0.41 - 0.81) (0.29 - 0.79) (0.41 - 1.04) 
North Dakota 0.84 0.95  
 (0.47 - 1.48) (0.53 - 1.69)  
Ohio 0.74*** 0.86*** 0.58*** 
 (0.70 - 0.80) (0.79 - 0.94) (0.52 - 0.66) 
Oklahoma 4.69*** 3.62***  
 (3.28 - 6.72) (2.16 - 6.06)  
Rhode Island 0.87** 0.60*** 0.91 
 (0.79 - 0.97) (0.51 - 0.70) (0.79 - 1.05) 
South Carolina 2.01*** 1.74* 1.47 
 (1.41 - 2.86) (1.04 - 2.91) (0.80 - 2.73) 
South Dakota 1.58 1.32 1.07 
 (0.98 - 2.53) (0.72 - 2.43) (0.31 - 3.69) 
Tennessee 1.47* 1.15 0.91 
 (1.03 - 2.11) (0.68 - 1.92) (0.08 - 10.64) 
Utah 2.74*** 2.55*** 1.62 
 (1.94 - 3.87) (1.54 - 4.24) (0.99 - 2.63) 
Washington - - - 
    
Wyoming 3.21*** 2.48**  
 (1.91 - 5.41) (1.30 - 4.71)  
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  












Table 4-B12. Sensitivity with lagged model for the DID model for the adjusted association between Medicaid 






DID model  
  MAT 
    
N 223,557 163,159 60,395 
 AOR AOR AOR 
 (95%CI) (95%CI) (95%CI) 
        
Expansion states 2.15*** 1.91* 3.10*** 
    (1.52 - 3.06) (1.16 - 3.15) (1.87 - 5.13) 
Expansion year (2014) 0.61*** 0.64*** 0.50*** 
 (0.57 - 0.65) (0.60 - 0.68) (0.41 - 0.61) 
Expansion * Post expansion year 0  1.61*** 1.64*** 1.78*** 
     (1.51 - 1.73) (1.52 - 1.76) (1.45 - 2.19) 
Post expansion year 1 1.29*** 1.23*** 2.14***  
(1.19 - 1.39) (1.13 - 1.33) (1.67 - 2.74) 
Expansion* Post expansion year 1 0.68*** 0.75*** 0.36*** 
 (0.62 - 0.75) (0.68 - 0.83) (0.28 - 0.47) 
Post expansion year 2 1.47*** 1.47*** 1.45** 
 (1.36 - 1.58) (1.36 - 1.60) (1.16 - 1.81) 
Expansion* Post expansion year 2 0.72*** 0.72*** 0.78* 
 (0.66 - 0.79) (0.65 - 0.79) (0.61 - 0.99) 
Post expansion year 3 1.93*** 1.56*** 2.15*** 
 (1.81 - 2.05) (1.46 - 1.67) (1.80 - 2.57) 
Expansion* Post expansion year 3 0.59*** 0.74*** 0.54*** 
 (0.54 - 0.64) (0.67 - 0.81) (0.44 - 0.65) 
MAT (No= ref)     
   Yes 0.87***   
 (0.85 - 0.89)   
Referral sources    
   Healthcare provider referral 1.08*** 1.06*** 1.15*** 
 (1.05 - 1.11) (1.03 - 1.10) (1.08 - 1.22) 
   Institutional referral 1.32*** 1.34*** 1.18*** 
 (1.28 - 1.37) (1.29 - 1.39) (1.09 - 1.27) 
   Court/criminal justice 2.08*** 2.04*** 1.91*** 
 (2.02 - 2.13) (1.98 - 2.10) (1.75 - 2.09) 
Frequency of use (No past month use= 
ref)  
   
   Some use 0.74*** 0.77*** 0.70*** 
 (0.72 - 0.77) (0.74 - 0.79) (0.65 - 0.75) 





 (0.76 - 0.80) (0.84 - 0.89) (0.54 - 0.61) 
Age (18-29= ref)     
   30-44 1.06*** 1.07*** 1.04 
 (1.04 - 1.09) (1.04 - 1.10) (0.99 - 1.09) 
   45-64 1.14*** 1.23*** 1.00 
 (1.11 - 1.18) (1.19 - 1.27) (0.94 - 1.06) 
Gender (Female=ref)    
   Male 0.92*** 0.96** 0.80*** 
 (0.91 - 0.94) (0.94 - 0.98) (0.77 - 0.84) 
Race/ethnicity (non-Hispanic 
White=ref) 
   
   Non-Hispanic Black 0.82*** 0.93** 0.67*** 
 (0.78 - 0.85) (0.89 - 0.98) (0.62 - 0.72) 
   Hispanic 0.85*** 0.92** 0.80*** 
 (0.82 - 0.89) (0.88 - 0.97) (0.74 - 0.85) 
   Other 0.76*** 0.79*** 0.68*** 
 (0.72 - 0.80) (0.74 - 0.84) (0.60 - 0.77) 
Education (Less than high school= ref)     
   Highschool or higher 1.18*** 1.17*** 1.20*** 
 (1.16 - 1.21) (1.14 - 1.20) (1.15 - 1.25) 
Number of arrests (0= ref)    
   1 1.15*** 1.20*** 1.03 
 (1.10 - 1.20) (1.14 - 1.26) (0.94 - 1.14) 
   2 or more 0.83*** 0.88** 1.04 
 (0.77 - 0.90) (0.81 - 0.97) (0.84 - 1.30) 
Employment status (Unemployed= ref)     
     Employed 1.03* 1.06*** 0.97 
 (1.00 - 1.05) (1.03 - 1.09) (0.92 - 1.01) 
Comorbidity (No= ref)     
   Yes 0.90*** 0.87*** 0.96 
 (0.88 - 0.92) (0.85 - 0.89) (0.92 - 1.00) 
Homeless (No= ref)     
  Yes 1.10*** 1.14*** 1.01 
 (1.05 - 1.15) (1.08 - 1.21) (0.93 - 1.10) 
Polysubstance use (no= ref)      
    One more 1.11*** 1.13*** 1.02 
 (1.08 - 1.13) (1.10 - 1.16) (0.98 - 1.07) 
    Two or more 1.20*** 1.21*** 1.07* 
 (1.17 - 1.23) (1.17 - 1.24) (1.01 - 1.13) 
Year     
2011 1.01 1.03 0.96 
 (0.97 - 1.05) (0.99 - 1.08) (0.88 - 1.04) 
2012 1 1.04 0.96 
 (0.96 - 1.04) (0.99 - 1.08) (0.88 - 1.05) 





 (0.89 - 0.96) (0.92 - 1.01) (0.78 - 0.93) 
State    
Arizona 0.35*** 0.30*** 0.51*** 
 (0.32 - 0.37) (0.27 - 0.32) (0.45 - 0.59) 
Arkansas 1 1.32** 0.66*** 
 (0.87 - 1.15) (1.08 - 1.61) (0.53 - 0.82) 
Colorado 1.41*** 1.29*** 1.52*** 
 (1.29 - 1.53) (1.15 - 1.44) (1.33 - 1.73) 
Connecticut 2.22*** 1.97*** 2.33*** 
 (2.02 - 2.44) (1.72 - 2.25) (2.04 - 2.67) 
Delaware 0.87*** 0.73*** 1.12 
 (0.80 - 0.94) (0.65 - 0.81) (0.98 - 1.28) 
District of Columbia 1.63** 1.19 2.61** 
 (1.17 - 2.27) (0.81 - 1.73) (1.29 - 5.26) 
Florida 9.71*** 3.75*** 48.02*** 
 (6.83 - 13.80) (2.28 - 6.18) (28.64 - 80.51) 
Hawaii 2.63*** 2.94*** 1.35 
 (1.97 - 3.52) (2.10 - 4.11) (0.69 - 2.65) 
Idaho 2.42*** 2.36** 2.43 
 (1.63 - 3.59) (1.39 - 4.01) (0.83 - 7.09) 
Illinois 0.56*** 0.58*** 0.57*** 
 (0.52 - 0.61) (0.52 - 0.64) (0.50 - 0.64) 
Iowa 0.68*** 0.74*** 0.15*** 
 (0.60 - 0.76) (0.65 - 0.83) (0.09 - 0.25) 
Kansas 1.72** 1.62  
 (1.19 - 2.48) (0.97 - 2.68)  
Kentucky 7.09*** 7.21*** 5.66*** 
 (6.67 - 7.55) (6.67 - 7.80) (5.07 - 6.32) 
Maine 1.06 0.94 1.19 
 (0.74 - 1.50) (0.57 - 1.57) (0.72 - 1.97) 
Maryland 0.69*** 0.78*** 0.61*** 
 (0.64 - 0.74) (0.70 - 0.85) (0.55 - 0.68) 
Massachusetts 0.63*** 0.66*** 0.47*** 
 (0.57 - 0.70) (0.58 - 0.74) (0.39 - 0.56) 
Michigan 0.73*** 0.65*** 0.81*** 
 (0.68 - 0.78) (0.60 - 0.71) (0.73 - 0.91) 
Mississippi 1.50* 1.52 0.31 
 (1.03 - 2.19) (0.91 - 2.54) (0.09 - 1.04) 
Missouri 2.17*** 2.37*** 1.74* 
 (1.51 - 3.10) (1.43 - 3.93) (1.02 - 2.95) 
Nebraska 5.93*** 5.42*** 8.32*** 
 (3.71 - 9.47) (2.99 - 9.83) (2.74 - 25.25) 
Nevada 1.18 1.71 0.9 
 (0.64 - 2.21) (0.61 - 4.78) (0.39 - 2.07) 
New Hampshire 3.39*** 3.39*** 1.96** 





New Jersey 0.60*** 1.06 0.42*** 
 (0.55 - 0.64) (0.95 - 1.18) (0.38 - 0.47) 
New Mexico 4.61*** 1.11 6.40*** 
 (2.44 - 8.68) (0.29 - 4.19) (3.04 - 13.46) 
New York 0.45*** 0.46*** 0.40*** 
 (0.42 - 0.47) (0.43 - 0.50) (0.36 - 0.44) 
North Carolina 5.05*** 4.27*** 11.96*** 
 (3.57 - 7.14) (2.61 - 6.98) (7.29 - 19.63) 
North Dakota 1.32 1.36  
 (0.75 - 2.35) (0.77 - 2.42)  
Ohio 0.47*** 0.55*** 0.22*** 
 (0.44 - 0.50) (0.50 - 0.60) (0.19 - 0.25) 
Oklahoma 1.63** 1.58  
 (1.13 - 2.34) (0.95 - 2.61)  
Rhode Island 0.93 0.81* 0.95 
 (0.84 - 1.02) (0.69 - 0.95) (0.83 - 1.08) 
South Carolina 1.78** 1.67* 1.18 
 (1.25 - 2.55) (1.01 - 2.77) (0.63 - 2.21) 
South Dakota 3.00*** 2.91*** 2.98 
 (1.85 - 4.87) (1.59 - 5.34) (0.83 - 10.69) 
Tennessee 0.89 0.84  
 (0.62 - 1.29) (0.51 - 1.40)  
Utah 2.56*** 2.63*** 1.86* 
 (1.80 - 3.64) (1.60 - 4.34) (1.11 - 3.11) 
Washington - - - 
    
Wyoming 2.36** 2.31** 1.13 
 (1.40 - 3.99) (1.23 - 4.34) (0.10 - 13.26) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  






Table 4-B13. Sensitivity analysis added Waiver 1115 Demonstrations: 2WFE model for the adjusted 
associations between Medicaid expansion and treatment length of stay 
  
2 ways fixed effect 
pooled model 
Non-MAT MAT 
     
N 231,025 169,449 61,573 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Medicaid expansion     
    Expansion  0.93** 0.93** 1.15** 
 (0.90 - 0.98) (0.89 - 0.98) (1.05 - 1.27) 
Waiver 1115 
Demonstration 
   
   Yes 0.93 0.75*** 1.29*** 
 (0.85 - 1.02) (0.65 - 0.87) (1.14 - 1.46) 
    
MAT (No= ref)     
   Yes 2.21***   






   Healthcare provider 
referral 
0.93*** 1.01 0.87*** 
 (0.90 - 0.96) (0.97 - 1.04) (0.83 - 0.92) 
   Institutional referral 1.04* 1.21*** 0.78*** 
 (1.01 - 1.08) (1.17 - 1.26) (0.72 - 0.84) 
   Court/criminal justice 1.87*** 2.14*** 0.74*** 
 (1.82 - 1.92) (2.08 - 2.20) (0.69 - 0.81) 
Frequency of use (No past 
month use= ref)  
   
   Some use 0.72*** 0.70*** 0.85*** 
 (0.70 - 0.74) (0.68 - 0.73) (0.79 - 0.91) 
   Daily use 0.67*** 0.62*** 0.84*** 
 (0.66 - 0.69) (0.60 - 0.64) (0.80 - 0.89) 
Age (18-29= ref)     
   30-44 1.07*** 1.07*** 1.09*** 
 (1.05 - 1.09) (1.04 - 1.10) (1.04 - 1.13) 
   45-64 1.31*** 1.32*** 1.31*** 
 (1.27 - 1.34) (1.27 - 1.36) (1.24 - 1.38) 





   Male 0.90*** 0.89*** 0.92*** 
 (0.88 - 0.91) (0.87 - 0.91) (0.89 - 0.95) 
Race/ethnicity (non-
Hispanic White=ref) 
   
   Non-Hispanic Black 0.94** 0.94** 0.92* 
 (0.91 - 0.98) (0.89 - 0.98) (0.87 - 0.98) 
   Hispanic 1.01 0.94* 1.09** 
 (0.98 - 1.05) (0.90 - 0.99) (1.02 - 1.15) 
   Other 1.00 1.00 0.98 
 (0.95 - 1.06) (0.94 - 1.06) (0.88 - 1.10) 
Education (Less than high 
school= ref)  
   
   Highschool or higher 0.98 1.00 0.96* 
 (0.96 - 1.00) (0.98 - 1.03) (0.92 - 0.99) 
Number of arrests (0= ref)    
   1 0.97 1.04 0.79*** 
 (0.93 - 1.01) (0.99 - 1.09) (0.73 - 0.86) 
   2 or more 1.18*** 1.16*** 0.88 
 (1.09 - 1.28) (1.06 - 1.27) (0.73 - 1.06) 
Employment status 
(Unemployed= ref)  
   
     Employed 0.79*** 0.78*** 0.83*** 
 (0.77 - 0.81) (0.76 - 0.80) (0.80 - 0.86) 
Comorbidity (No= ref)     
   Yes 0.88*** 0.90*** 0.89*** 
 (0.86 - 0.90) (0.87 - 0.92) (0.85 - 0.92) 
Homeless (No= ref)     
  Yes 0.74*** 0.77*** 0.70*** 
 (0.70 - 0.77) (0.73 - 0.81) (0.65 - 0.76) 
Polysubstance use (no= ref)      
    One more 0.79*** 0.80*** 0.86*** 
 (0.78 - 0.81) (0.78 - 0.82) (0.82 - 0.89) 
    Two or more 0.73*** 0.76*** 0.76*** 
 (0.71 - 0.74) (0.73 - 0.78) (0.72 - 0.80) 
Year     
2011 1.16*** 1.21*** 1.07 
 (1.12 - 1.21) (1.16 - 1.27) (1.00 - 1.16) 
2012 1.15*** 1.22*** 1.02 
 (1.10 - 1.19) (1.17 - 1.28) (0.95 - 1.11) 
2013 1.18*** 1.26*** 1.02 
 (1.14 - 1.23) (1.21 - 1.32) (0.94 - 1.11) 





 (1.41 - 1.55) (1.59 - 1.77) (0.80 - 0.99) 
2015 1.15*** 1.36*** 0.68*** 
 (1.09 - 1.21) (1.28 - 1.44) (0.61 - 0.75) 
2016 1.19*** 1.41*** 0.70*** 
 (1.13 - 1.25) (1.33 - 1.49) (0.63 - 0.78) 
2017 0.98 1.34*** 0.50*** 
 (0.93 - 1.03) (1.27 - 1.41) (0.45 - 0.55) 
State    
Alaska 4.20*** 3.40*** 3.15*** 
 (2.86 - 6.17) (1.98 - 5.83) (1.68 - 5.91) 
Arizona 5.21*** 4.45*** 4.53*** 
 (3.71 - 7.33) (2.69 - 7.36) (2.84 - 7.22) 
Arkansas 1.21 1.24 0.85 
 (0.84 - 1.75) (0.72 - 2.13) (0.52 - 1.39) 
Colorado 2.37*** 1.82* 2.22*** 
 (1.68 - 3.34) (1.09 - 3.02) (1.40 - 3.53) 
Connecticut 1.55* 0.72 2.34*** 
 (1.10 - 2.19) (0.43 - 1.20) (1.47 - 3.72) 
Delaware 1.67** 1.99* 0.75 
 (1.17 - 2.39) (1.17 - 3.37) (0.47 - 1.22) 
District of Columbia 4.65*** 3.72*** 4.26** 
 (2.85 - 7.59) (1.97 - 7.04) (1.65 - 11.01) 
Florida 1.65** 0.99 2.01** 
 (1.17 - 2.32) (0.60 - 1.65) (1.28 - 3.18) 
Hawaii 0.82 0.40** 5.74*** 
 (0.53 - 1.27) (0.22 - 0.73) (2.13 - 15.48) 
Idaho 2.56*** 1.88* 1.9 
 (1.74 - 3.76) (1.10 - 3.22) (0.66 - 5.46) 
Illinois 1.29 1.03 1.23 
 (0.92 - 1.82) (0.62 - 1.71) (0.78 - 1.95) 
Indiana 1.89*** 1.57 1.74* 
 (1.33 - 2.67) (0.94 - 2.61) (1.04 - 2.91) 
Iowa 2.22*** 1.77* 2.39** 
 (1.56 - 3.16) (1.06 - 2.95) (1.39 - 4.13) 
Kansas 3.37*** 2.70***  
 (2.35 - 4.82) (1.61 - 4.52)  
Kentucky 0.17*** 0.13*** 0.23*** 
 (0.12 - 0.24) (0.08 - 0.21) (0.14 - 0.36) 
Louisiana 2.18*** 1.97* 0.55 
 (1.52 - 3.13) (1.17 - 3.31) (0.26 - 1.15) 
Maine 2.30*** 1.59 2.51*** 





Maryland 1.87*** 1.91* 1.15 
 (1.32 - 2.67) (1.13 - 3.23) (0.72 - 1.84) 
Massachusetts 2.33*** 2.49*** 1.5 
 (1.63 - 3.33) (1.47 - 4.24) (0.92 - 2.44) 
Michigan 1.44* 1.06 1.67* 
 (1.02 - 2.02) (0.64 - 1.75) (1.06 - 2.64) 
Mississippi 1.16 0.83 1.95 
 (0.80 - 1.67) (0.49 - 1.40) (0.78 - 4.88) 
Missouri 1.67** 1.1 2.87*** 
 (1.18 - 2.37) (0.66 - 1.84) (1.76 - 4.66) 
Montana 2.14*** 1.70*  
 (1.48 - 3.08) (1.01 - 2.87)  
Nebraska 1.02 0.83 0.73 
 (0.66 - 1.58) (0.46 - 1.48) (0.27 - 2.01) 
Nevada 3.19** 1.44 5.49** 
 (1.52 - 6.69) (0.46 - 4.48) (1.83 - 16.41) 
New Hampshire 1.24 0.9 2.12* 
 (0.86 - 1.77) (0.54 - 1.51) (1.09 - 4.13) 
New Jersey 2.00*** 1.52 1.56 
 (1.42 - 2.83) (0.90 - 2.55) (0.98 - 2.48) 
New Mexico 1.09 0.2 1.04 
 (0.57 - 2.09) (0.02 - 1.76) (0.49 - 2.21) 
New York 1.95*** 1.6 1.89** 
 (1.39 - 2.73) (0.97 - 2.65) (1.20 - 2.97) 
North Carolina 0.59** 0.50** 0.54** 
 (0.42 - 0.83) (0.30 - 0.82) (0.35 - 0.85) 
North Dakota 2.46** 1.99  
 (1.27 - 4.75) (0.93 - 4.26)  
Ohio 2.19*** 1.82* 1.95** 
 (1.56 - 3.07) (1.10 - 3.01) (1.24 - 3.09) 
Oklahoma 4.69*** 3.53***  
 (3.29 - 6.71) (2.11 - 5.89)  
Pennsylvania 1.17 0.95 1.11 
 (0.82 - 1.69) (0.56 - 1.61) (0.67 - 1.86) 
Rhode Island 2.78*** 1.69 2.42*** 
 (1.94 - 3.99) (0.99 - 2.91) (1.50 - 3.90) 
South Carolina 2.09*** 1.80* 1.57 
 (1.47 - 2.96) (1.08 - 3.00) (0.87 - 2.83) 
South Dakota 1.62* 1.32 1.27 
 (1.01 - 2.60) (0.72 - 2.41) (0.39 - 4.18) 
Tennessee 1.50* 1.14 1.07 





Utah 2.76*** 2.50*** 1.77* 
 (1.96 - 3.89) (1.51 - 4.15) (1.11 - 2.84) 
Washington 2.93*** 2.10** 3.31*** 
 (2.08 - 4.12) (1.27 - 3.49) (2.09 - 5.24) 
Wyoming 2.90*** 2.11*  
 (1.73 - 4.86) (1.11 - 3.99)  
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  










Table 4-B14. Sensitivity analysis added Waiver 1115 Demonstrations: 2WFE model for the adjusted 
associations between Medicaid expansion and treatment completion 
  
2 ways fixed effect 
pooled model 
Non-MAT MAT 
     
N 231,025 169,449 61,573 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Medicaid expansion     
    Expansion  0.85*** 1.02 0.49*** 
 (0.81 - 0.88) (0.97 - 1.07) (0.44 - 0.54) 
Waiver 1115 Demonstration    
   Yes 0.84*** 0.83* 0.93 
 (0.77 - 0.92) (0.72 - 0.96) (0.80 - 1.07) 
    
MAT (No= ref)     
   Yes 0.86***   






   Healthcare provider referral 1.07*** 1.05** 1.15*** 
 (1.04 - 1.10) (1.02 - 1.09) (1.08 - 1.21) 
   Institutional referral 1.30*** 1.32*** 1.15*** 
 (1.26 - 1.34) (1.27 - 1.37) (1.07 - 1.24) 
   Court/criminal justice 2.03*** 2.00*** 1.89*** 
 (1.98 - 2.09) (1.94 - 2.06) (1.73 - 2.06) 
Frequency of use (No past 
month use= ref)  
   
   Some use 0.74*** 0.76*** 0.70*** 
 (0.71 - 0.76) (0.73 - 0.78) (0.65 - 0.76) 
   Daily use 0.77*** 0.85*** 0.59*** 
 (0.75 - 0.79) (0.83 - 0.88) (0.55 - 0.62) 
Age (18-29= ref)     
   30-44 1.06*** 1.07*** 1.04 
 (1.04 - 1.09) (1.04 - 1.09) (0.99 - 1.09) 
   45-64 1.14*** 1.23*** 0.99 
 (1.11 - 1.18) (1.19 - 1.27) (0.93 - 1.05) 





   Male 0.93*** 0.97** 0.81*** 
 (0.92 - 0.95) (0.95 - 0.99) (0.78 - 0.84) 
Race/ethnicity (non-
Hispanic White=ref) 
   
   Non-Hispanic Black 0.83*** 0.94* 0.68*** 
 (0.79 - 0.86) (0.90 - 0.99) (0.63 - 0.73) 
   Hispanic 0.85*** 0.92*** 0.81*** 
 (0.82 - 0.89) (0.88 - 0.97) (0.75 - 0.87) 
   Other 0.73*** 0.76*** 0.69*** 
 (0.69 - 0.77) (0.72 - 0.81) (0.61 - 0.78) 
Education (Less than high 
school= ref)  
   
   Highschool or higher 1.19*** 1.17*** 1.20*** 
 (1.16 - 1.21) (1.14 - 1.20) (1.15 - 1.25) 
Number of arrests (0= ref)    
   1 1.15*** 1.19*** 1.04 
 (1.10 - 1.20) (1.13 - 1.24) (0.94 - 1.14) 
   2 or more 0.84*** 0.89* 1.03 
 (0.78 - 0.91) (0.81 - 0.97) (0.83 - 1.29) 
Employment status 
(Unemployed= ref)  
   
     Employed 1.03* 1.06*** 0.98 
 (1.01 - 1.05) (1.03 - 1.09) (0.93 - 1.02) 
Comorbidity (No= ref)     
   Yes 0.89*** 0.87*** 0.95* 
 (0.88 - 0.91) (0.85 - 0.89) (0.91 - 0.99) 
Homeless (No= ref)     
  Yes 1.10*** 1.13*** 1.02 
 (1.06 - 1.15) (1.08 - 1.20) (0.94 - 1.12) 
Polysubstance use (no= ref)      
    One more 1.12*** 1.13*** 1.02 
 (1.09 - 1.14) (1.11 - 1.16) (0.98 - 1.07) 
    Two or more 1.21*** 1.22*** 1.07* 
 (1.18 - 1.25) (1.18 - 1.25) (1.01 - 1.13) 
Year     
2011 1.02 1.04 0.95 
 (0.98 - 1.06) (0.99 - 1.08) (0.88 - 1.04) 
2012 1.01 1.04 0.97 
 (0.97 - 1.05) (0.99 - 1.08) (0.89 - 1.05) 
2013 0.93*** 0.97 0.87** 
 (0.90 - 0.97) (0.93 - 1.01) (0.80 - 0.95) 





 (0.92 - 1.01) (0.83 - 0.92) (1.38 - 1.78) 
2015 0.97 0.90*** 1.41*** 
 (0.92 - 1.01) (0.85 - 0.95) (1.24 - 1.60) 
2016 1.12*** 1.06* 1.63*** 
 (1.06 - 1.17) (1.01 - 1.12) (1.44 - 1.84) 
2017 1.02 1.04 0.95 
 (0.98 - 1.06) (0.99 - 1.08) (0.88 - 1.04) 
State    
Alaska 1.50* 1.53 0.94 
 (1.03 - 2.20) (0.90 - 2.58) (0.46 - 1.91) 
Arizona 0.64** 0.49** 1.44 
 (0.45 - 0.90) (0.30 - 0.80) (0.88 - 2.36) 
Arkansas 2.08*** 2.45*** 2.01* 
 (1.44 - 3.01) (1.44 - 4.15) (1.18 - 3.42) 
Colorado 2.65*** 2.17** 4.37*** 
 (1.87 - 3.74) (1.32 - 3.56) (2.67 - 7.14) 
Connecticut 3.98*** 3.21*** 6.49*** 
 (2.81 - 5.64) (1.94 - 5.30) (3.96 - 10.64) 
Delaware 1.95*** 1.48 3.53*** 
 (1.36 - 2.78) (0.88 - 2.48) (2.11 - 5.88) 
District of Columbia 3.05*** 1.98* 7.57*** 
 (1.90 - 4.89) (1.07 - 3.66) (3.24 - 17.65) 
Florida 8.57*** 3.41*** 44.14*** 
 (6.06 - 12.11) (2.08 - 5.60) (26.72 - 72.93) 
Hawaii 5.03*** 5.01*** 4.03*** 
 (3.22 - 7.84) (2.78 - 9.03) (1.77 - 9.17) 
Idaho 2.06*** 2.09** 2.16 
 (1.39 - 3.03) (1.24 - 3.54) (0.74 - 6.29) 
Illinois 1.03 0.96 1.59 
 (0.73 - 1.45) (0.59 - 1.57) (0.98 - 2.60) 
Indiana 0.66* 0.65 0.46* 
 (0.47 - 0.94) (0.39 - 1.07) (0.25 - 0.84) 
Iowa 1.27 1.25 0.41* 
 (0.89 - 1.81) (0.76 - 2.07) (0.20 - 0.82) 
Kansas 1.61** 1.53  
 (1.12 - 2.31) (0.92 - 2.52)  
Kentucky 13.37*** 12.28*** 16.13*** 
 (9.50 - 18.81) (7.52 - 20.05) (9.91 - 26.25) 
Louisiana 1.4 1.19 6.41*** 
 (0.97 - 2.02) (0.72 - 1.98) (2.99 - 13.76) 
Maine 0.91 0.84 1.01 





Maryland 1.60* 1.63 1.95** 
 (1.12 - 2.28) (0.98 - 2.73) (1.17 - 3.23) 
Massachusetts 1.43 1.37 1.44 
 (0.99 - 2.05) (0.82 - 2.30) (0.85 - 2.44) 
Michigan 1.36 1.11 2.30*** 
 (0.97 - 1.92) (0.68 - 1.82) (1.41 - 3.75) 
Mississippi 1.50* 1.52 0.32 
 (1.04 - 2.17) (0.91 - 2.53) (0.10 - 1.04) 
Missouri 1.84*** 2.08** 1.45 
 (1.30 - 2.62) (1.26 - 3.43) (0.87 - 2.42) 
Montana 1.70** 1.59  
 (1.18 - 2.46) (0.96 - 2.65)  
Nebraska 4.95*** 4.75*** 6.74*** 
 (3.12 - 7.86) (2.63 - 8.57) (2.26 - 20.09) 
Nevada 2.25* 2.72 2.71* 
 (1.11 - 4.58) (0.87 - 8.47) (1.04 - 7.04) 
New Hampshire 6.33*** 5.68*** 5.69*** 
 (4.38 - 9.15) (3.41 - 9.48) (2.84 - 11.41) 
New Jersey 1.23 2.00** 1.25 
 (0.87 - 1.74) (1.20 - 3.32) (0.76 - 2.05) 
New Mexico 8.63*** 1.81 18.20*** 
 (4.21 - 17.68) (0.44 - 7.44) (7.53 - 43.97) 
New York 0.85 0.8 1.14 
 (0.60 - 1.19) (0.49 - 1.30) (0.70 - 1.85) 
North Carolina 4.50*** 3.83*** 12.86*** 
 (3.21 - 6.32) (2.35 - 6.25) (7.95 - 20.79) 
North Dakota 2.58** 2.39*  
 (1.33 - 5.01) (1.13 - 5.05)  
Ohio 0.9 0.94 0.66 
 (0.64 - 1.27) (0.57 - 1.53) (0.40 - 1.08) 
Oklahoma 1.44* 1.43  
 (1.01 - 2.05) (0.87 - 2.36)  
Pennsylvania 1.25 1.37 0.78 
 (0.87 - 1.80) (0.82 - 2.28) (0.44 - 1.38) 
Rhode Island 2.06*** 1.65 2.94*** 
 (1.43 - 2.95) (0.97 - 2.80) (1.76 - 4.90) 
South Carolina 1.58* 1.5 1.35 
 (1.11 - 2.25) (0.91 - 2.46) (0.73 - 2.49) 
South Dakota 2.53*** 2.55** 2.71 
 (1.57 - 4.09) (1.40 - 4.64) (0.78 - 9.47) 
Tennessee 0.78 0.76  





Utah 2.17*** 2.30*** 1.68* 
 (1.54 - 3.07) (1.40 - 3.77) (1.02 - 2.76) 
Washington 1.98*** 1.77* 3.00*** 
 (1.40 - 2.79) (1.08 - 2.90) (1.84 - 4.88) 
Wyoming 2.16** 2.16* 1.68 
 (1.29 - 3.62) (1.16 - 4.04) (0.14 - 19.57) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  







Table 4-B15. 2WFE model for the adjusted associations between Medicaid expansion and length of stay   
  
2 ways fixed effect 
pooled model 
2 ways fixed effect 
Non-MAT 
2 ways fixed effect 
MAT 
     
N 518,154 326,027 192,127 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Medicaid expansion     
    Expansion  0.96* 0.89*** 1.11** 
 (0.93 - 1.00) (0.85 - 0.93) (1.04 - 1.19) 
MAT (No= ref)     
   Yes 2.07***   
 (2.04 - 2.10)   
Referral sources    
   Healthcare provider 
referral 
0.83*** 0.95*** 0.79*** 
 (0.82 - 0.85) (0.93 - 0.97) (0.77 - 0.81) 
   Institutional referral 0.99 1.15*** 0.86*** 
 (0.97 - 1.01) (1.12 - 1.18) (0.83 - 0.90) 
   Court/criminal justice 1.34*** 1.60*** 0.72*** 
 (1.32 - 1.36) (1.56 - 1.63) (0.69 - 0.75) 
Frequency of use (No 
past month use= ref)  
   
   Some use 0.68*** 0.64*** 0.80*** 
 (0.67 - 0.69) (0.63 - 0.65) (0.77 - 0.82) 
   Daily use 0.69*** 0.59*** 0.82*** 
 (0.68 - 0.70) (0.58 - 0.61) (0.80 - 0.84) 
Age (18-29= ref)     
   30-44 1.11*** 1.09*** 1.13*** 
 (1.09 - 1.12) (1.07 - 1.11) (1.11 - 1.16) 
   45-64 1.43*** 1.39*** 1.48*** 
 (1.40 - 1.45) (1.36 - 1.42) (1.44 - 1.53) 
Gender (Female=ref)    
   Male 0.92*** 0.92*** 0.92*** 
 (0.91 - 0.93) (0.90 - 0.93) (0.90 - 0.94) 
Race/ethnicity (non-
Hispanic White=ref) 
   
   Non-Hispanic Black 0.94*** 0.88*** 1.01 





   Hispanic 1.06*** 0.97 1.14*** 
 (1.04 - 1.08) (0.95 - 1.00) (1.11 - 1.18) 
   Other 0.91*** 0.90*** 0.92** 
 (0.88 - 0.94) (0.87 - 0.94) (0.87 - 0.97) 
Education (Less than 
high school= ref)  
   
   Highschool or higher 1.02* 1.05*** 0.97* 
 (1.00 - 1.03) (1.03 - 1.07) (0.95 - 1.00) 
Number of arrests (0= 
ref) 
   
   1 0.91*** 0.97 0.84*** 
 (0.89 - 0.93) (0.94 - 1.00) (0.81 - 0.88) 
   2 or more 1.15*** 1.10** 1.04 
 (1.08 - 1.21) (1.03 - 1.18) (0.93 - 1.17) 
Employment status 
(Unemployed= ref)  
   
     Employed 0.88*** 0.87*** 0.88*** 
 (0.86 - 0.89) (0.85 - 0.88) (0.86 - 0.90) 
Comorbidity (No= ref)     
   Yes 0.97*** 1.00 0.97** 
 (0.96 - 0.99) (0.98 - 1.02) (0.95 - 0.99) 
Homeless (No= ref)     
  Yes 0.76*** 0.77*** 0.77*** 
 (0.74 - 0.78) (0.75 - 0.80) (0.75 - 0.80) 
Polysubstance use (no= 
ref)   
   
    One more 0.92*** 0.95*** 0.90*** 
 (0.90 - 0.93) (0.94 - 0.97) (0.88 - 0.92) 
    Two or more 0.88*** 0.96*** 0.80*** 
 (0.87 - 0.89) (0.94 - 0.98) (0.78 - 0.82) 
Year     
2011 1.03** 1.05*** 0.97 
 (1.01 - 1.06) (1.02 - 1.09) (0.93 - 1.01) 
2012 1.12*** 1.12*** 1.09*** 
 (1.09 - 1.15) (1.09 - 1.16) (1.04 - 1.14) 
2013 1.13*** 1.13*** 1.10*** 
 (1.10 - 1.16) (1.09 - 1.16) (1.05 - 1.15) 
2014 1.25*** 1.42*** 0.95 
 (1.20 - 1.30) (1.35 - 1.49) (0.88 - 1.02) 
2015 1.12*** 1.42*** 0.74*** 
 (1.07 - 1.16) (1.35 - 1.49) (0.69 - 0.80) 
2016 1.05** 1.26*** 0.76*** 





2017 1.02 1.28*** 0.73*** 
 (0.99 - 1.06) (1.22 - 1.34) (0.68 - 0.78) 
State    
Alaska 3.86*** 3.38*** 3.11*** 
 (2.76 - 5.40) (2.02 - 5.67) (1.90 - 5.09) 
Arizona 4.96*** 5.07*** 3.87*** 
 (3.62 - 6.80) (3.08 - 8.36) (2.57 - 5.83) 
Arkansas 1.12 1.02 1.17 
 (0.80 - 1.57) (0.60 - 1.72) (0.76 - 1.82) 
Colorado 2.00*** 1.61 2.17*** 
 (1.46 - 2.74) (0.98 - 2.65) (1.45 - 3.23) 
Connecticut 1.56** 0.94 1.96*** 
 (1.14 - 2.13) (0.57 - 1.55) (1.31 - 2.91) 
Delaware 1.57** 1.72* 1.03 
 (1.15 - 2.16) (1.04 - 2.84) (0.69 - 1.55) 
District of Columbia 4.77*** 4.35*** 6.48*** 
 (3.31 - 6.86) (2.54 - 7.46) (3.43 - 12.26) 
Florida 1.51* 1.08 1.89** 
 (1.10 - 2.08) (0.65 - 1.79) (1.26 - 2.83) 
Hawaii 0.58* 0.31*** 3.29** 
 (0.37 - 0.90) (0.17 - 0.59) (1.34 - 8.10) 
Idaho 3.09*** 2.38*** 2.64** 
 (2.20 - 4.32) (1.42 - 3.98) (1.34 - 5.19) 
Illinois 0.44*** 0.48** 0.25*** 
 (0.32 - 0.60) (0.29 - 0.79) (0.17 - 0.37) 
Indiana 2.25*** 1.88* 2.13*** 
 (1.65 - 3.09) (1.14 - 3.10) (1.40 - 3.24) 
Iowa 2.20*** 1.97** 1.82** 
 (1.60 - 3.03) (1.19 - 3.25) (1.17 - 2.82) 
Kansas 3.02*** 2.56***  
 (2.10 - 4.35) (1.50 - 4.35)  
Kentucky 0.20*** 0.18*** 0.22*** 
 (0.15 - 0.27) (0.11 - 0.29) (0.15 - 0.32) 
Louisiana 2.21*** 2.18** 0.63 
 (1.59 - 3.06) (1.32 - 3.63) (0.36 - 1.09) 
Maine 1.78*** 1.68* 1.95*** 
 (1.30 - 2.44) (1.02 - 2.78) (1.31 - 2.89) 
Maryland 1.82*** 1.56 1.83** 
 (1.33 - 2.48) (0.95 - 2.56) (1.23 - 2.72) 
Massachusetts 1.75*** 1.71* 1.68* 
 (1.28 - 2.40) (1.04 - 2.81) (1.13 - 2.50) 





 (1.09 - 2.03) (0.68 - 1.84) (1.30 - 2.87) 
Mississippi 1.14 0.89 1.31 
 (0.81 - 1.61) (0.53 - 1.50) (0.51 - 3.39) 
Missouri 1.65** 1.14 2.76*** 
 (1.21 - 2.26) (0.69 - 1.87) (1.85 - 4.12) 
Montana 2.22*** 1.81*  
 (1.61 - 3.08) (1.09 - 3.00)  
Nebraska 1.14 0.98 1.03 
 (0.79 - 1.66) (0.57 - 1.69) (0.52 - 2.02) 
Nevada 1.87* 0.86 3.10** 
 (1.03 - 3.39) (0.33 - 2.28) (1.40 - 6.89) 
New Hampshire 1.32 1.07 1.86* 
 (0.95 - 1.82) (0.64 - 1.77) (1.16 - 2.99) 
New Jersey 1.79*** 1.39 1.82** 
 (1.31 - 2.45) (0.84 - 2.28) (1.22 - 2.70) 
New Mexico 1.1 0.43 1.2 
 (0.65 - 1.85) (0.13 - 1.48) (0.66 - 2.20) 
New York 1.86*** 1.6 2.02*** 
 (1.37 - 2.54) (0.98 - 2.64) (1.36 - 3.01) 
North Carolina 0.38*** 0.37*** 0.29*** 
 (0.28 - 0.51) (0.22 - 0.60) (0.20 - 0.43) 
North Dakota 2.52*** 2.09*  
 (1.64 - 3.87) (1.17 - 3.73)  
Ohio 1.99*** 1.82* 1.92** 
 (1.46 - 2.72) (1.11 - 2.99) (1.29 - 2.86) 
Oklahoma 3.79*** 3.14***  
 (2.68 - 5.36) (1.87 - 5.27)  
Pennsylvania 1.29 1.08 1.42 
 (0.94 - 1.78) (0.65 - 1.79) (0.93 - 2.15) 
Rhode Island 2.28*** 1.19 2.66*** 
 (1.66 - 3.12) (0.72 - 1.98) (1.78 - 3.96) 
South Carolina 1.95*** 1.86* 1.33 
 (1.42 - 2.68) (1.13 - 3.08) (0.85 - 2.07) 
South Dakota 2.26*** 1.76* 2.23* 
 (1.58 - 3.24) (1.03 - 2.99) (1.05 - 4.73) 
Tennessee 1.89*** 1.52 18.45** 
 (1.36 - 2.63) (0.91 - 2.53) (2.28 - 149.58) 
Utah 2.73*** 2.89*** 1.62* 
 (2.00 - 3.74) (1.75 - 4.76) (1.08 - 2.42) 
Washington 2.47*** 1.93** 2.92*** 
 (1.81 - 3.38) (1.17 - 3.17) (1.96 - 4.35) 





 (2.37 - 5.59) (1.57 - 5.05) (0.67 - 7.30) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  











Table 4-B16. DID model for the adjusted associations between Medicaid expansion and treatment length of stay  





    
N 503,363 313,253 190,110 
 AOR AOR AOR 
 (95%CI) (95%CI) (95%CI) 
     
Treat 2.41*** 1.86* 2.88*** 
   Expansion states (1.76 - 3.29) (1.13 - 3.07) (1.94 - 4.29) 
       
Expansion  0.98 1.20*** 0.72*** 
   After the ACA 
implementation (2014)  
(0.94 - 1.02) (1.14 - 1.26) (0.67 - 0.77) 
    
Medicaid expansion     
    Medicaid expansion  0.99 0.92*** 1.13*** 
 (0.95 - 1.03) (0.88 - 0.97) (1.06 - 1.21) 
MAT (No= ref)     
   Yes 2.08***   
 (2.05 - 2.11)   
Referral sources    
   Healthcare provider referral 0.83*** 0.95*** 0.80*** 
 (0.81 - 0.84) (0.93 - 0.97) (0.78 - 0.82) 
   Institutional referral 1.00 1.15*** 0.88*** 
 (0.97 - 1.02) (1.12 - 1.18) (0.85 - 0.92) 
   Court/criminal justice 1.35*** 1.61*** 0.72*** 
 (1.33 - 1.37) (1.58 - 1.65) (0.69 - 0.75) 
Frequency of use (No past 
month use= ref)  
   
   Some use 0.68*** 0.64*** 0.80*** 
 (0.67 - 0.69) (0.63 - 0.65) (0.77 - 0.82) 
   Daily use 0.69*** 0.59*** 0.82*** 
 (0.68 - 0.70) (0.58 - 0.61) (0.80 - 0.85) 
Age (18-29= ref)     
   30-44 1.11*** 1.10*** 1.14*** 
 (1.09 - 1.13) (1.08 - 1.12) (1.11 - 1.17) 
   45-64 1.43*** 1.39*** 1.49*** 
 (1.40 - 1.45) (1.36 - 1.42) (1.44 - 1.53) 
Gender (Female=ref)    
   Male 0.93*** 0.92*** 0.93*** 
 (0.92 - 0.94) (0.91 - 0.94) (0.91 - 0.94) 
Race/ethnicity (non-
Hispanic White=ref) 
   





 (0.93 - 0.97) (0.86 - 0.92) (0.98 - 1.05) 
   Hispanic 1.06*** 0.97 1.14*** 
 (1.04 - 1.08) (0.95 - 1.00) (1.11 - 1.18) 
   Other 0.91*** 0.91*** 0.92** 
 (0.88 - 0.95) (0.87 - 0.95) (0.87 - 0.97) 
Education (Less than high 
school= ref)  
   
   Highschool or higher 1.01* 1.05*** 0.97* 
 (1.00 - 1.03) (1.03 - 1.07) (0.95 - 1.00) 
Number of arrests (0= ref)    
   1 0.92*** 0.99 0.84*** 
 (0.89 - 0.94) (0.95 - 1.02) (0.81 - 0.88) 
   2 or more 1.17*** 1.13** 1.05 
 (1.10 - 1.24) (1.05 - 1.21) (0.94 - 1.17) 
Employment status 
(Unemployed= ref)  
   
     Employed 0.89*** 0.88*** 0.88*** 
 (0.87 - 0.90) (0.86 - 0.89) (0.86 - 0.90) 
Comorbidity (No= ref)     
   Yes 0.98** 1.01 0.97* 
 (0.97 - 0.99) (0.99 - 1.02) (0.95 - 0.99) 
Homeless (No= ref)     
  Yes 0.76*** 0.77*** 0.77*** 
 (0.74 - 0.78) (0.75 - 0.80) (0.74 - 0.80) 
Polysubstance use (no= ref)      
    One more 0.91*** 0.95*** 0.90*** 
 (0.90 - 0.93) (0.93 - 0.97) (0.88 - 0.92) 
    Two or more 0.88*** 0.96*** 0.79*** 
 (0.86 - 0.89) (0.94 - 0.98) (0.77 - 0.82) 
    
Year     
2011 1.04** 1.06*** 0.97 
 (1.01 - 1.06) (1.03 - 1.09) (0.93 - 1.02) 
2012 1.13*** 1.12*** 1.09*** 
 (1.10 - 1.16) (1.09 - 1.16) (1.05 - 1.14) 
2013 1.12*** 1.11*** 1.10*** 
 (1.09 - 1.14) (1.07 - 1.14) (1.05 - 1.15) 
2014 1.24*** 1.14*** 1.29*** 
 (1.21 - 1.27) (1.10 - 1.17) (1.24 - 1.34) 
2015 1.11*** 1.15*** 1.01 
 (1.08 - 1.14) (1.11 - 1.18) (0.98 - 1.05) 
2016 1.07*** 1.06*** 1.04** 
 (1.05 - 1.10) (1.03 - 1.10) (1.01 - 1.08) 
2017 - - - 
    





Arizona 2.02*** 2.65*** 1.33*** 
 (1.90 - 2.14) (2.45 - 2.85) (1.18 - 1.50) 
Arkansas 0.46*** 0.53*** 0.40*** 
 (0.40 - 0.52) (0.45 - 0.63) (0.33 - 0.49) 
Colorado 0.81*** 0.84*** 0.74*** 
 (0.77 - 0.86) (0.78 - 0.90) (0.69 - 0.81) 
Connecticut 0.63*** 0.48*** 0.67*** 
 (0.60 - 0.66) (0.45 - 0.52) (0.63 - 0.71) 
Delaware 0.64*** 0.89** 0.35*** 
 (0.59 - 0.68) (0.81 - 0.97) (0.32 - 0.40) 
District of Columbia 1.93*** 2.25*** 2.22** 
 (1.59 - 2.34) (1.82 - 2.79) (1.34 - 3.68) 
Florida 1.48* 1.05 1.87** 
 (1.08 - 2.03) (0.63 - 1.74) (1.25 - 2.81) 
Hawaii 0.23*** 0.16*** 1.13 
 (0.17 - 0.32) (0.11 - 0.24) (0.50 - 2.54) 
Idaho 3.07*** 2.35** 2.62** 
 (2.19 - 4.30) (1.41 - 3.93) (1.33 - 5.15) 
Illinois 0.18*** 0.25*** 0.09*** 
 (0.17 - 0.19) (0.24 - 0.27) (0.08 - 0.09) 
Iowa 0.89** 1.02 0.62*** 
 (0.83 - 0.96) (0.94 - 1.11) (0.51 - 0.76) 
Kansas 3.00*** 2.52***  
 (2.09 - 4.33) (1.48 - 4.29)  
Kentucky 0.08*** 0.09*** 0.07*** 
 (0.08 - 0.09) (0.09 - 0.10) (0.07 - 0.08) 
Maine 1.76*** 1.66* 1.95*** 
 (1.29 - 2.41) (1.00 - 2.73) (1.31 - 2.89) 
Maryland 0.74*** 0.81*** 0.63*** 
 (0.71 - 0.77) (0.76 - 0.86) (0.59 - 0.67) 
Massachusetts 0.71*** 0.89*** 0.57*** 
 (0.68 - 0.74) (0.84 - 0.94) (0.54 - 0.61) 
Michigan 0.60*** 0.58*** 0.66*** 
 (0.58 - 0.63) (0.55 - 0.62) (0.62 - 0.70) 
Mississippi 1.14 0.89 1.32 
 (0.81 - 1.61) (0.53 - 1.49) (0.51 - 3.42) 
Missouri 1.64** 1.12 2.76*** 
 (1.20 - 2.25) (0.68 - 1.84) (1.85 - 4.12) 
Nebraska 1.14 0.97 1.02 
 (0.78 - 1.65) (0.56 - 1.67) (0.52 - 2.01) 
Nevada 0.75 0.45 1.06 
 (0.45 - 1.25) (0.19 - 1.03) (0.53 - 2.13) 
New Hampshire 0.53*** 0.55*** 0.64*** 
 (0.48 - 0.59) (0.49 - 0.62) (0.49 - 0.83) 
New Jersey 0.73*** 0.72*** 0.62*** 





New Mexico 0.44*** 0.23** 0.41*** 
 (0.29 - 0.67) (0.07 - 0.69) (0.26 - 0.65) 
New York 0.76*** 0.84*** 0.69*** 
 (0.73 - 0.78) (0.79 - 0.88) (0.66 - 0.73) 
North Carolina 0.38*** 0.37*** 0.29*** 
 (0.28 - 0.51) (0.22 - 0.60) (0.20 - 0.43) 
North Dakota 1.03 1.09  
 (0.76 - 1.38) (0.80 - 1.47)  
Ohio 0.81*** 0.94* 0.66*** 
 (0.77 - 0.84) (0.89 - 1.00) (0.61 - 0.71) 
Oklahoma 3.74*** 3.06***  
 (2.65 - 5.28) (1.82 - 5.15)  
Rhode Island 0.92** 0.62*** 0.91* 
 (0.87 - 0.97) (0.56 - 0.69) (0.85 - 0.98) 
South Carolina 1.93*** 1.84* 1.33 
 (1.41 - 2.66) (1.11 - 3.03) (0.85 - 2.08) 
South Dakota 2.26*** 1.74* 2.23* 
 (1.58 - 3.23) (1.02 - 2.95) (1.05 - 4.74) 
Tennessee 1.87*** 1.49 18.53** 
 (1.35 - 2.61) (0.90 - 2.48) (2.29 - 150.29) 
Utah 2.71*** 2.84*** 1.61* 
 (1.98 - 3.71) (1.72 - 4.67) (1.08 - 2.41) 
Washington - - - 
    
Wyoming 3.68*** 2.83*** 2.23 
 (2.40 - 5.65) (1.58 - 5.07) (0.68 - 7.35) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  














Table 4-B17. 2WFE model for the adjusted associations between Medicaid expansion and treatment completion   
  
2 ways fixed effect 
pooled model 
Non-MAT MAT 
     
N 518,146 326,025 192,121 
 AOR AOR AOR 
  (95%CI) (95%CI) (95%CI) 
    
Medicaid expansion  0.87*** 1.10*** 0.52*** 
    Expansion  (0.84 - 0.90) (1.06 - 1.15) (0.48 - 0.55) 
    
MAT (No= ref)     
   Yes 0.78***   






   Healthcare provider referral 1.38*** 1.32*** 1.42*** 
 (1.35 - 1.40) (1.29 - 1.35) (1.39 - 1.46) 
   Institutional referral 1.30*** 1.32*** 1.21*** 
 (1.27 - 1.33) (1.28 - 1.35) (1.16 - 1.26) 
   Court/criminal justice 2.01*** 1.99*** 1.73*** 
 (1.97 - 2.04) (1.95 - 2.03) (1.66 - 1.80) 
Frequency of use (No past 
month use= ref)  
   
   Some use 0.66*** 0.69*** 0.62*** 
 (0.65 - 0.68) (0.67 - 0.70) (0.60 - 0.65) 
   Daily use 0.69*** 0.86*** 0.51*** 
 (0.68 - 0.70) (0.84 - 0.87) (0.50 - 0.52) 
Age (18-29= ref)     
   30-44 1.05*** 1.08*** 1.00 
 (1.04 - 1.07) (1.06 - 1.10) (0.97 - 1.03) 
   45-64 1.17*** 1.27*** 1.01 
 (1.15 - 1.20) (1.24 - 1.30) (0.98 - 1.04) 
Gender (Female=ref)    
   Male 0.90*** 0.93*** 0.84*** 
 (0.89 - 0.91) (0.92 - 0.95) (0.83 - 0.86) 
Race/ethnicity (non-
Hispanic White=ref) 
   





 (0.94 - 0.99) (1.10 - 1.17) (0.74 - 0.80) 
   Hispanic 0.86*** 0.91*** 0.79*** 
 (0.84 - 0.88) (0.89 - 0.94) (0.76 - 0.82) 
   Other 0.79*** 0.84*** 0.69*** 
 (0.76 - 0.82) (0.81 - 0.88) (0.65 - 0.74) 
Education (Less than high 
school= ref)  
   
   Highschool or higher 1.19*** 1.17*** 1.20*** 
 (1.16 - 1.21) (1.14 - 1.20) (1.15 - 1.25) 
Number of arrests (0= ref)    
   1 1.15*** 1.19*** 1.04 
 (1.10 - 1.20) (1.13 - 1.24) (0.94 - 1.14) 
   2 or more 0.84*** 0.89* 1.03 
 (0.78 - 0.91) (0.81 - 0.97) (0.83 - 1.29) 
Employment status 
(Unemployed= ref)  
   
     Employed 1.11*** 1.12*** 1.10*** 
 (1.10 - 1.13) (1.10 - 1.14) (1.07 - 1.12) 
Comorbidity (No= ref)     
   Yes 0.88*** 0.87*** 0.92*** 
 (0.87 - 0.89) (0.86 - 0.89) (0.90 - 0.94) 
Homeless (No= ref)     
  Yes 0.98 0.98 0.98 
 (0.96 - 1.01) (0.95 - 1.01) (0.94 - 1.02) 
Polysubstance use (no= ref)      
    One more 0.97*** 1.00 0.91*** 
 (0.95 - 0.98) (0.98 - 1.01) (0.89 - 0.94) 
    Two or more 0.99 1.02* 0.93*** 
 (0.97 - 1.00) (1.00 - 1.04) (0.90 - 0.95) 
Year     
2011 0.99 1.03* 0.87*** 
 (0.96 - 1.01) (1.00 - 1.06) (0.83 - 0.91) 
2012 0.99 1.03* 0.92*** 
 (0.97 - 1.02) (1.00 - 1.06) (0.87 - 0.96) 
2013 0.95*** 1.01 0.85*** 
 (0.93 - 0.98) (0.98 - 1.04) (0.81 - 0.89) 
2014 1.09*** 0.93** 1.58*** 
 (1.05 - 1.13) (0.89 - 0.97) (1.46 - 1.71) 
2015 1.11*** 1.00 1.47*** 
 (1.06 - 1.15) (0.95 - 1.05) (1.36 - 1.59) 
2016 1.16*** 1.02 1.61*** 





2017 1.38*** 1.23*** 1.78*** 
 (1.33 - 1.43) (1.18 - 1.29) (1.65 - 1.93) 
State    
Alaska 2.47*** 2.50*** 1.83* 
 (1.70 - 3.59) (1.46 - 4.30) (1.02 - 3.28) 
Arizona 1.07 0.81 2.16** 
 (0.75 - 1.53) (0.48 - 1.37) (1.32 - 3.53) 
Arkansas 2.78*** 2.65*** 3.35*** 
 (1.91 - 4.04) (1.53 - 4.57) (2.00 - 5.61) 
Colorado 4.54*** 3.80*** 6.65*** 
 (3.18 - 6.48) (2.24 - 6.43) (4.11 - 10.76) 
Connecticut 6.22*** 3.67*** 10.18*** 
 (4.37 - 8.87) (2.16 - 6.21) (6.30 - 16.45) 
Delaware 2.87*** 2.20** 5.10*** 
 (2.01 - 4.11) (1.29 - 3.73) (3.13 - 8.31) 
District of Columbia 3.88*** 2.47** 9.44*** 
 (2.62 - 5.74) (1.41 - 4.32) (5.20 - 17.16) 
Florida 14.81*** 6.29*** 66.07*** 
 (10.32 - 21.26) (3.70 - 10.72) (39.74 - 109.87) 
Hawaii 6.36*** 6.42*** 5.08*** 
 (4.02 - 10.04) (3.46 - 11.90) (2.12 - 12.18) 
Idaho 3.51*** 3.76*** 3.99*** 
 (2.41 - 5.11) (2.19 - 6.46) (1.95 - 8.16) 
Illinois 9.53*** 7.04*** 18.85*** 
 (6.69 - 13.59) (4.16 - 11.90) (11.63 - 30.55) 
Indiana 0.73 0.68 0.79 
 (0.51 - 1.04) (0.40 - 1.15) (0.47 - 1.32) 
Iowa 1.83*** 1.87* 0.66 
 (1.28 - 2.62) (1.10 - 3.17) (0.37 - 1.17) 
Kansas 3.57*** 3.51***  
 (2.39 - 5.32) (2.01 - 6.12)  
Kentucky 12.69*** 11.53*** 16.75*** 
 (8.90 - 18.08) (6.82 - 19.50) (10.34 - 27.12) 
Louisiana 2.54*** 2.22** 7.89*** 
 (1.76 - 3.66) (1.30 - 3.78) (4.27 - 14.57) 
Maine 1.41 1.51 1.23 
 (0.99 - 2.01) (0.89 - 2.57) (0.76 - 1.98) 
Maryland 2.78*** 2.39** 3.80*** 
 (1.95 - 3.95) (1.41 - 4.04) (2.35 - 6.14) 
Massachusetts 1.98*** 1.68 2.59*** 
 (1.39 - 2.82) (0.99 - 2.84) (1.60 - 4.18) 





 (1.53 - 3.10) (1.08 - 3.09) (1.92 - 5.00) 
Mississippi 2.25*** 2.42** 0.69 
 (1.54 - 3.29) (1.41 - 4.16) (0.21 - 2.29) 
Missouri 3.22*** 3.91*** 2.48*** 
 (2.26 - 4.60) (2.31 - 6.62) (1.53 - 4.02) 
Montana 3.96*** 3.95***  
 (2.74 - 5.72) (2.32 - 6.74)  
Nebraska 6.99*** 7.36*** 5.81*** 
 (4.61 - 10.60) (4.14 - 13.10) (2.76 - 12.21) 
Nevada 1.69 2.34 1.54 
 (0.88 - 3.24) (0.90 - 6.06) (0.59 - 4.03) 
New Hampshire 10.21*** 9.52*** 10.42*** 
 (7.05 - 14.78) (5.56 - 16.31) (5.99 - 18.13) 
New Jersey 2.15*** 3.43*** 2.01** 
 (1.51 - 3.06) (2.03 - 5.81) (1.25 - 3.25) 
New Mexico 16.75*** 7.04** 26.62*** 
 (9.20 - 30.51) (2.18 - 22.71) (12.87 - 55.07) 
New York 1.47* 1.37 1.95** 
 (1.03 - 2.09) (0.81 - 2.32) (1.21 - 3.15) 
North Carolina 11.60*** 9.44*** 31.32*** 
 (8.15 - 16.51) (5.59 - 15.94) (19.35 - 50.68) 
North Dakota 3.23*** 3.12***  
 (2.04 - 5.11) (1.71 - 5.69)  
Ohio 1.31 1.38 1.11 
 (0.92 - 1.87) (0.81 - 2.33) (0.69 - 1.80) 
Oklahoma 2.39*** 2.46**  
 (1.64 - 3.50) (1.43 - 4.23)  
Pennsylvania 2.51*** 2.81*** 2.09** 
 (1.75 - 3.60) (1.65 - 4.79) (1.27 - 3.45) 
Rhode Island 3.00*** 1.88* 4.29*** 
 (2.10 - 4.28) (1.11 - 3.21) (2.65 - 6.93) 
South Carolina 2.27*** 2.34** 1.6 
 (1.58 - 3.25) (1.38 - 3.97) (0.95 - 2.71) 
South Dakota 3.26*** 3.52*** 3.92** 
 (2.19 - 4.84) (2.02 - 6.15) (1.72 - 8.95) 
Tennessee 1.3 1.32 8.80** 
 (0.90 - 1.89) (0.77 - 2.26) (2.15 - 36.00) 
Utah 4.19*** 5.03*** 2.63*** 
 (2.94 - 5.98) (2.97 - 8.52) (1.62 - 4.26) 
Washington 2.80*** 2.95*** 3.31*** 
 (1.96 - 3.99) (1.74 - 5.00) (2.05 - 5.36) 





 (2.86 - 7.20) (2.72 - 9.17) (1.29 - 16.85) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  
























DID model  
  MAT 
    
N 503,355 313,251 190,104 
 AOR AOR AOR 
 (95%CI) (95%CI) (95%CI) 
        
Treat    
   Expansion states 2.79*** 2.95*** 3.28*** 
    (1.96 - 3.98) (1.74 - 4.99) (2.03 - 5.30) 
Expansion     
   After the ACA implementation (2014)  1.40*** 1.26*** 1.76*** 
 (1.34 - 1.45) (1.20 - 1.31) (1.63 - 1.90) 
Medicaid expansion     
    Expansion  0.89*** 1.14*** 0.53*** 
 (0.86 - 0.92) (1.09 - 1.19) (0.49 - 0.57) 
MAT (No= ref)     
   Yes 0.78***   
 (0.77 - 0.79)   
Referral sources    
   Healthcare provider referral 1.38*** 1.32*** 1.43*** 
 (1.36 - 1.41) (1.30 - 1.35) (1.39 - 1.47) 
   Institutional referral 1.29*** 1.30*** 1.21*** 
 (1.26 - 1.32) (1.27 - 1.34) (1.16 - 1.26) 
   Court/criminal justice 2.01*** 1.99*** 1.73*** 
 (1.97 - 2.04) (1.95 - 2.03) (1.66 - 1.81) 
Frequency of use (No past month use= 
ref)  
   
   Some use 0.67*** 0.70*** 0.62*** 
 (0.66 - 0.68) (0.68 - 0.71) (0.60 - 0.64) 
   Daily use 0.70*** 0.88*** 0.51*** 
 (0.69 - 0.71) (0.86 - 0.89) (0.50 - 0.52) 
Age (18-29= ref)     
   30-44 1.06*** 1.08*** 1.00 
 (1.04 - 1.07) (1.06 - 1.10) (0.98 - 1.03) 
   45-64 1.18*** 1.28*** 1.01 
 (1.15 - 1.20) (1.25 - 1.31) (0.98 - 1.05) 
Gender (Female=ref)    
   Male 0.89*** 0.93*** 0.84*** 
 (0.88 - 0.91) (0.91 - 0.94) (0.82 - 0.86) 
Race/ethnicity (non-Hispanic 
White=ref) 
   





 (0.94 - 0.99) (1.10 - 1.17) (0.74 - 0.80) 
   Hispanic 0.86*** 0.91*** 0.79*** 
 (0.84 - 0.88) (0.88 - 0.93) (0.76 - 0.82) 
   Other 0.79*** 0.85*** 0.69*** 
 (0.76 - 0.82) (0.81 - 0.89) (0.65 - 0.74) 
Education (Less than high school= ref)     
   Highschool or higher 1.11*** 1.12*** 1.10*** 
 (1.09 - 1.13) (1.10 - 1.14) (1.07 - 1.12) 
Number of arrests (0= ref)    
   1 1.03 1.07*** 0.93** 
 (1.00 - 1.06) (1.04 - 1.11) (0.89 - 0.98) 
   2 or more 0.76*** 0.79*** 0.85* 
 (0.72 - 0.81) (0.74 - 0.85) (0.74 - 0.96) 
Employment status (Unemployed= ref)     
     Employed 1.02* 1.05*** 0.99 
 (1.00 - 1.03) (1.03 - 1.07) (0.97 - 1.02) 
Comorbidity (No= ref)     
   Yes 0.88*** 0.87*** 0.92*** 
 (0.87 - 0.89) (0.86 - 0.89) (0.90 - 0.94) 
Homeless (No= ref)     
  Yes 0.98 0.99 0.98 
 (0.96 - 1.01) (0.96 - 1.02) (0.94 - 1.02) 
Polysubstance use (no= ref)      
    One more 0.97*** 0.99 0.91*** 
 (0.95 - 0.98) (0.97 - 1.01) (0.89 - 0.94) 
    Two or more 0.98* 1.01 0.92*** 
 (0.96 - 1.00) (0.99 - 1.03) (0.90 - 0.95) 
Year     
2011 0.98 1.03 0.87*** 
 (0.96 - 1.01) (1.00 - 1.06) (0.83 - 0.91) 
2012 0.98 1.02 0.91*** 
 (0.96 - 1.01) (0.99 - 1.05) (0.87 - 0.96) 
2013 0.95*** 1.00 0.84*** 
 (0.92 - 0.97) (0.97 - 1.03) (0.80 - 0.88) 
2014 0.77*** 0.72*** 0.88*** 
 (0.75 - 0.78) (0.70 - 0.74) (0.84 - 0.91) 
2015 0.78*** 0.78*** 0.81*** 
 (0.76 - 0.80) (0.75 - 0.80) (0.78 - 0.85) 
2016 0.82*** 0.80*** 0.90*** 
 (0.81 - 0.84) (0.78 - 0.83) (0.87 - 0.93) 
2017 - - - 
    
State    
Arizona 0.38*** 0.27*** 0.65*** 





Arkansas 0.99 0.89 1.01 
 (0.87 - 1.12) (0.75 - 1.04) (0.82 - 1.23) 
Colorado 1.61*** 1.27*** 2.00*** 
 (1.53 - 1.70) (1.18 - 1.37) (1.85 - 2.16) 
Connecticut 2.19*** 1.22*** 3.06*** 
 (2.09 - 2.29) (1.13 - 1.31) (2.86 - 3.26) 
Delaware 1.02 0.74*** 1.53*** 
 (0.95 - 1.10) (0.67 - 0.81) (1.37 - 1.72) 
District of Columbia 1.37*** 0.82 2.84*** 
 (1.15 - 1.63) (0.67 - 1.00) (1.98 - 4.08) 
Florida 14.81*** 6.32*** 65.49*** 
 (10.31 - 21.25) (3.71 - 10.76) (39.38 - 108.89) 
Hawaii 2.26*** 2.16*** 1.53 
 (1.69 - 3.03) (1.55 - 3.00) (0.74 - 3.19) 
Idaho 3.54*** 3.81*** 3.96*** 
 (2.43 - 5.15) (2.22 - 6.55) (1.94 - 8.11) 
Illinois 3.36*** 2.33*** 5.66*** 
 (3.20 - 3.52) (2.19 - 2.47) (5.19 - 6.18) 
Iowa 0.65*** 0.63*** 0.20*** 
 (0.60 - 0.70) (0.57 - 0.68) (0.14 - 0.27) 
Kansas 3.55*** 3.48***  
 (2.38 - 5.30) (2.00 - 6.08)  
Kentucky 4.50*** 3.87*** 5.03*** 
 (4.29 - 4.71) (3.64 - 4.11) (4.63 - 5.45) 
Maine 1.42 1.53 1.23 
 (0.99 - 2.02) (0.90 - 2.59) (0.76 - 1.98) 
Maryland 0.99 0.81*** 1.15*** 
 (0.95 - 1.04) (0.76 - 0.86) (1.08 - 1.22) 
Massachusetts 0.70*** 0.56*** 0.78*** 
 (0.67 - 0.73) (0.52 - 0.59) (0.73 - 0.84) 
Michigan 0.77*** 0.61*** 0.93* 
 (0.74 - 0.80) (0.57 - 0.64) (0.87 - 0.99) 
Mississippi 2.24*** 2.40** 0.69 
 (1.53 - 3.28) (1.40 - 4.13) (0.21 - 2.29) 
Missouri 3.25*** 3.97*** 2.49*** 
 (2.28 - 4.63) (2.35 - 6.72) (1.54 - 4.03) 
Nebraska 7.01*** 7.42*** 5.78*** 
 (4.62 - 10.64) (4.17 - 13.20) (2.75 - 12.16) 
Nevada 0.6 0.77 0.46 
 (0.35 - 1.03) (0.35 - 1.70) (0.20 - 1.07) 
New Hampshire 3.61*** 3.17*** 3.14*** 
 (3.21 - 4.06) (2.78 - 3.62) (2.36 - 4.17) 
New Jersey 0.76*** 1.16*** 0.61*** 
 (0.73 - 0.80) (1.08 - 1.23) (0.57 - 0.65) 
New Mexico 5.97*** 2.36 8.02*** 





New York 0.52*** 0.46*** 0.59*** 
 (0.51 - 0.54) (0.44 - 0.49) (0.55 - 0.62) 
North Carolina 11.53*** 9.35*** 31.25*** 
 (8.10 - 16.41) (5.54 - 15.80) (19.31 - 50.56) 
North Dakota 1.15 1.06  
 (0.86 - 1.55) (0.78 - 1.42)  
Ohio 0.47*** 0.46*** 0.34*** 
 (0.45 - 0.49) (0.44 - 0.49) (0.31 - 0.36) 
Oklahoma 2.42*** 2.49***  
 (1.65 - 3.53) (1.45 - 4.29)  
Rhode Island 1.06* 0.63*** 1.29*** 
 (1.01 - 1.12) (0.57 - 0.70) (1.20 - 1.39) 
South Carolina 2.27*** 2.36** 1.6 
 (1.59 - 3.26) (1.39 - 4.00) (0.95 - 2.71) 
South Dakota 3.28*** 3.58*** 3.90** 
 (2.21 - 4.89) (2.05 - 6.25) (1.71 - 8.91) 
Tennessee 1.31 1.33 8.82** 
 (0.90 - 1.90) (0.78 - 2.28) (2.16 - 36.06) 
Utah 4.21*** 5.07*** 2.63*** 
 (2.95 - 6.00) (3.00 - 8.59) (1.62 - 4.27) 
Washington - - - 
    
Wyoming 4.54*** 5.03*** 4.65* 
 (2.86 - 7.21) (2.74 - 9.24) (1.29 - 16.79) 
Adjusted Odds Ratio = AOR. Confidence Interval = CI.  
* p<0.05, ** p<0.01, *** p<0.001 
 
 
